<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>ES2916601T3 - 
  Compositions comprising bacterial strains
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/ES2916601T3/en">
    <meta name="description" content="
   
    A composition comprising a bacterial strain of the genus Megasphaera, for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO : 1.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Compositions comprising bacterial strains
 
     ">
    <meta name="DC.date" content="2019-05-13" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    A composition comprising a bacterial strain of the genus Megasphaera, for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO : 1.
   
 
   ">
    <meta name="citation_patent_application_number" content="ES:19725068T">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/88/f4/67/3cf6561673245d/ES2916601T3.pdf">
    <meta name="citation_patent_number" content="ES:2916601:T3">
    <meta name="DC.date" content="2022-07-04" scheme="issue">
    <meta name="DC.contributor" content="Imke Elisabeth MULDER" scheme="inventor">
    <meta name="DC.contributor" content="Parthena Fotiadou" scheme="inventor">
    <meta name="DC.contributor" content="Amy Beth HOLT" scheme="inventor">
    <meta name="DC.contributor" content="Suaad Ahmed" scheme="inventor">
    <meta name="DC.contributor" content="Anna Ettorre" scheme="inventor">
    <meta name="DC.contributor" content="Samantha Yuille" scheme="inventor">
    <meta name="DC.contributor" content="Ted Dinan" scheme="inventor">
    <meta name="DC.contributor" content="John Cryan" scheme="inventor">
    <meta name="DC.contributor" content="4D Pharma Research Ltd" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Compositions comprising bacterial strains
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA514275047" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composicin que comprende una cepa bacteriana del gnero Megasphaera, para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16S que es por lo menos un 97% idntica a la SEQ ID NO: 1.</span>A composition comprising a bacterial strain of the genus Megasphaera, for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO : 1.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/66"><a id="link" href="#" class="style-scope state-modifier">A61K35/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms or materials therefrom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K35/74"><a id="link" href="#" class="style-scope state-modifier">A61K35/74</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L"><a id="link" href="#" class="style-scope state-modifier">A23L</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/00"><a id="link" href="#" class="style-scope state-modifier">A23L33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/10"><a id="link" href="#" class="style-scope state-modifier">A23L33/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/135"><a id="link" href="#" class="style-scope state-modifier">A23L33/135</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria or derivatives thereof, e.g. probiotics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L"><a id="link" href="#" class="style-scope state-modifier">A23L</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/00"><a id="link" href="#" class="style-scope state-modifier">A23L33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/40"><a id="link" href="#" class="style-scope state-modifier">A23L33/40</a></state-modifier>
                  <span class="description style-scope classification-tree">Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/12"><a id="link" href="#" class="style-scope state-modifier">A61K35/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/14"><a id="link" href="#" class="style-scope state-modifier">A61K35/14</a></state-modifier>
                  <span class="description style-scope classification-tree">Blood; Artificial blood</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/17"><a id="link" href="#" class="style-scope state-modifier">A61K35/17</a></state-modifier>
                  <span class="description style-scope classification-tree">Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/12"><a id="link" href="#" class="style-scope state-modifier">A61K35/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/28"><a id="link" href="#" class="style-scope state-modifier">A61K35/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/66"><a id="link" href="#" class="style-scope state-modifier">A61K35/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms or materials therefrom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/74"><a id="link" href="#" class="style-scope state-modifier">A61K35/74</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/741"><a id="link" href="#" class="style-scope state-modifier">A61K35/741</a></state-modifier>
                  <span class="description style-scope classification-tree">Probiotics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/00"><a id="link" href="#" class="style-scope state-modifier">A61K9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by special physical form</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/0012"><a id="link" href="#" class="style-scope state-modifier">A61K9/0012</a></state-modifier>
                  <span class="description style-scope classification-tree">Galenical forms characterised by the site of application</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/0053"><a id="link" href="#" class="style-scope state-modifier">A61K9/0053</a></state-modifier>
                  <span class="description style-scope classification-tree">Mouth and digestive tract, i.e. intraoral and peroral administration</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/00"><a id="link" href="#" class="style-scope state-modifier">A61K9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by special physical form</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/14"><a id="link" href="#" class="style-scope state-modifier">A61K9/14</a></state-modifier>
                  <span class="description style-scope classification-tree">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/19"><a id="link" href="#" class="style-scope state-modifier">A61K9/19</a></state-modifier>
                  <span class="description style-scope classification-tree">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/00"><a id="link" href="#" class="style-scope state-modifier">A61P1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/00"><a id="link" href="#" class="style-scope state-modifier">A61P11/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the respiratory system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/06"><a id="link" href="#" class="style-scope state-modifier">A61P11/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Antiasthmatics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P17/00"><a id="link" href="#" class="style-scope state-modifier">A61P17/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for dermatological disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P17/06"><a id="link" href="#" class="style-scope state-modifier">A61P17/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Antipsoriatics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P19/00"><a id="link" href="#" class="style-scope state-modifier">A61P19/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for skeletal disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P19/02"><a id="link" href="#" class="style-scope state-modifier">A61P19/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P29/00"><a id="link" href="#" class="style-scope state-modifier">A61P29/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/00"><a id="link" href="#" class="style-scope state-modifier">A61P3/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/08"><a id="link" href="#" class="style-scope state-modifier">A61P3/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism for glucose homeostasis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/10"><a id="link" href="#" class="style-scope state-modifier">A61P3/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/02"><a id="link" href="#" class="style-scope state-modifier">A61P37/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunomodulators</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/06"><a id="link" href="#" class="style-scope state-modifier">A61P37/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunosuppressants, e.g. drugs for graft rejection</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N"><a id="link" href="#" class="style-scope state-modifier">C12N</a></state-modifier>
                  <span class="description style-scope classification-tree">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N1/00"><a id="link" href="#" class="style-scope state-modifier">C12N1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N1/20"><a id="link" href="#" class="style-scope state-modifier">C12N1/20</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria; Culture media therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V"><a id="link" href="#" class="style-scope state-modifier">A23V</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A23V2002/00"><a id="link" href="#" class="style-scope state-modifier">A23V2002/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Food compositions, function of food ingredients or processes for food or foodstuffs</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V"><a id="link" href="#" class="style-scope state-modifier">A23V</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/00"><a id="link" href="#" class="style-scope state-modifier">A23V2200/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Function of food ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/30"><a id="link" href="#" class="style-scope state-modifier">A23V2200/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A23V2200/308"><a id="link" href="#" class="style-scope state-modifier">A23V2200/308</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V"><a id="link" href="#" class="style-scope state-modifier">A23V</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/00"><a id="link" href="#" class="style-scope state-modifier">A23V2200/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Function of food ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/30"><a id="link" href="#" class="style-scope state-modifier">A23V2200/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A23V2200/324"><a id="link" href="#" class="style-scope state-modifier">A23V2200/324</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health having an effect on the immune system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K45/00"><a id="link" href="#" class="style-scope state-modifier">A61K45/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing active ingredients not provided for in groups A61K31/00&nbsp;-&nbsp;A61K41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K45/06"><a id="link" href="#" class="style-scope state-modifier">A61K45/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12R"><a id="link" href="#" class="style-scope state-modifier">C12R</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12R2001/00"><a id="link" href="#" class="style-scope state-modifier">C12R2001/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms ; Processes using microorganisms</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12R2001/01"><a id="link" href="#" class="style-scope state-modifier">C12R2001/01</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria or Actinomycetales ; using bacteria or Actinomycetales</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02"><a id="link" href="#" class="style-scope state-modifier">Y02</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A"><a id="link" href="#" class="style-scope state-modifier">Y02A</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A50/00"><a id="link" href="#" class="style-scope state-modifier">Y02A50/00</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y02A50/30"><a id="link" href="#" class="style-scope state-modifier">Y02A50/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 24 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">ES2916601T3</h2>
                  <p class="tagline style-scope patent-result">Spain</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Translation of granted European patent ( former B3)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/88/f4/67/3cf6561673245d/ES2916601T3.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;cancer&quot;,&quot;compositions&quot;,&quot;bacterial strain&quot;,&quot;treatment&quot;,&quot;composition&quot;]" data-before="20180511"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/ES2916601T3"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2916601T3/es"><a id="link" href="#" class="style-scope state-modifier">Spanish</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Imke Elisabeth MULDER"><a id="link" href="#" class="style-scope state-modifier">Imke Elisabeth MULDER</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Parthena Fotiadou"><a id="link" href="#" class="style-scope state-modifier">Parthena Fotiadou</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Amy Beth HOLT"><a id="link" href="#" class="style-scope state-modifier">Amy Beth HOLT</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Suaad Ahmed"><a id="link" href="#" class="style-scope state-modifier">Suaad Ahmed</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Anna Ettorre"><a id="link" href="#" class="style-scope state-modifier">Anna Ettorre</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Samantha Yuille"><a id="link" href="#" class="style-scope state-modifier">Samantha Yuille</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Ted Dinan"><a id="link" href="#" class="style-scope state-modifier">Ted Dinan</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="John Cryan"><a id="link" href="#" class="style-scope state-modifier">John Cryan</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    4D Pharma Research Ltd
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2019</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TW202014513A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW108116449A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2019267170A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2019267170A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP4056192A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP22162255.8A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SI3743086T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SI</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SI201930216T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RS63273B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">RS</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RS20220465A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2019215346A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2019/062238</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Search and Examination</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3099209A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3099209A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR20210008393A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020207035244A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BR112020022833A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BR112020022833-8A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/LT3743086T/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">LT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: LTEPPCT/EP2019/062238T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HRP20220578T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HRP20220578TT</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2019267171A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2019267171A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MD3743086T2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MD</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MDE20201221T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP7058449B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2020545563A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2021523895A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2020562128A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PL3743086T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PL19725068T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3790564A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP19725067.3A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG11202011031UA/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG11202011031UA</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP4066845A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP22162425.7A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2019215345A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2019/062236</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Search and Examination</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK3743086T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK19725068.1T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TW202011975A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW108116469A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR20210008391A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020207035242A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Application Discontinuation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN112512539A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201980031512.5A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MX2020012061A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MX2020012061A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3743086B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP19725068.1A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG11202011028SA/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG11202011028SA</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2916601T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES19725068T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN112601534A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201980031147.8A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3098971A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3098971A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2020</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US11419902B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/013,026</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-04</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL278471B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL278471A</div>
                <div class="style-scope application-timeline">Filing date: 2020-11-03</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20210275605A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/095,427</div>
                <div class="style-scope application-timeline">Filing date: 2020-11-11</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2022</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2022088631A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2022062741A</div>
                <div class="style-scope application-timeline">Filing date: 2022-04-05</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CY1125211T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CY20221100367T</div>
                <div class="style-scope application-timeline">Filing date: 2022-05-27</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20230158083A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/847,336</div>
                <div class="style-scope application-timeline">Filing date: 2022-06-23</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2023</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2023200562A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2023200562A</div>
                <div class="style-scope application-timeline">Filing date: 2023-02-03</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application ES19725068T events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2019-05-13</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="4D Pharma Research Ltd"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by 4D Pharma Research Ltd</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2022-07-04</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2022-07-04</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2916601T3/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of ES2916601T3</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2039-05-13</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      
        <div class="event layout horizontal expand style-scope application-timeline">
          Show all events <iron-icon style="height: 15px; width: 15px;" icon="expand-more" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M16.59 8.59L12 13.17 7.41 8.59 6 10l6 6 6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope application-timeline"></template>
          <template is="dom-if" class="style-scope application-timeline"></template>
        </div>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (36)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (10)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=ES&amp;NR=2916601T3&amp;KC=T3&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/ES/2916601/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/ES2916601T3">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES335314204" lang="EN" load-source="google" class="style-scope patent-text">
  
  <p class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCIN</span>DESCRIPTION</span>
    </b>
  </p>
  <p id="p0001" num="0001" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones que comprenden cepas bacterianas</span>Compositions comprising bacterial strains</span>
  </p>
  <p id="p0002" num="0002" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CAMPO TCNICO</span>TECHNICAL FIELD</span>
    </b>
  </p>
  <p id="p0003" num="0003" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esta invencin pertenece al campo de las composiciones que comprenden cepas bacterianas aisladas del tracto digestivo de mamferos y el uso de tales composiciones en el tratamiento de enfermedades, en particular cncer, y en particular para estimular el sistema inmunitario en el tratamiento de enfermedades, como se define en las reivindicaciones.</span>This invention belongs to the field of compositions comprising bacterial strains isolated from the digestive tract of mammals and the use of such compositions in the treatment of diseases, in particular cancer, and in particular to stimulate the immune system in the treatment of diseases, such as defined in the claims.</span>
  </p>
  <p id="p0004" num="0004" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ANTECEDENTES DE LA INVENCIN</span>BACKGROUND OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0005" num="0005" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cree que el intestino humano es estril <i class="style-scope patent-text">in utero</i>, pero est expuesto a una gran variedad de microbios maternos y ambientales inmediatamente despus del nacimiento. A partir de entonces, se produce un perodo dinmico de colonizacin y sucesin microbiana, que est influenciado por factores como el modo de administracin, el medio ambiente, la dieta y el genotipo del husped, todos los cuales impactan en la composicin del microbiota intestinal, particularmente durante los primeros aos de vida. Posteriormente, el microbiota se estabiliza y se vuelve similar a la adulta [1] El microbiota intestinal humana contiene ms de 500-1000 filotipos diferentes que pertenecen esencialmente a dos divisiones bacterianas principales, Bacteroidetes y Firmicutes [2] Las relaciones simbiticas con xito que surgen de la colonizacin bacteriana del intestino humano han proporcionado una amplia variedad de funciones metablicas, estructurales, protectoras y otras funciones beneficiosas. Las actividades metablicas mejoradas del intestino colonizado aseguran que los componentes dietticos que de otro modo no seran digeribles se degraden con la liberacin de subproductos que proporcionan una importante fuente de nutrientes para el husped. De manera similar, la importancia inmunolgica del microbiota intestinal est bien reconocida y se ejemplifica en animales libres de grmenes que tienen un sistema inmunitario deteriorado que se reconstituye funcionalmente despus de la introduccin de bacterias comensales [3-5].</span>The human intestine is believed to be sterile <i class="style-scope patent-text">in utero</i> , but is exposed to a wide variety of maternal and environmental microbes immediately after birth. Thereafter, a dynamic period of microbial colonization and succession ensues, which is influenced by factors such as mode of administration, environment, diet, and host genotype, all of which impact the composition of the gut microbiota. particularly during the first years of life. Subsequently, the microbiota stabilizes and becomes adult-like [1] The human gut microbiota contains more than 500-1000 different phylotypes essentially belonging to two main bacterial divisions, Bacteroidetes and Firmicutes [2] Successful symbiotic relationships that arise from bacterial colonization of the human intestine have provided a wide variety of metabolic, structural, protective, and other beneficial functions. The enhanced metabolic activities of the colonized intestine ensure that otherwise indigestible dietary components are degraded with the release of by-products that provide an important source of nutrients for the host. Similarly, the immunological importance of the gut microbiota is well recognized and is exemplified in germ-free animals that have an impaired immune system that is functionally reconstituted after the introduction of commensal bacteria [3-5].</span>
  </p>
  <p id="p0006" num="0006" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se han documentado cambios drsticos en la composicin del microbiota en trastornos gastrointestinales como la enfermedad inflamatoria intestinal (IBD). Por ejemplo, los niveles de bacterias <i class="style-scope patent-text">Clostridium </i>clster XlVa se reducen en pacientes con IBD, mientras que el nmero de <i class="style-scope patent-text">E. coli </i>aumenta, lo que sugiere un cambio en el equilibrio de simbiontes y patobiontes dentro del intestino [6-9]. Curiosamente, esta disbiosis microbiana tambin se asocia con desequilibrios en las poblaciones de clulas T efectoras.</span>Drastic changes in the composition of the microbiota have been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, the levels of <i class="style-scope patent-text">Clostridium</i> cluster XlVa bacteria are reduced in IBD patients, while the number of <i class="style-scope patent-text">E. coli</i> is increased, suggesting a shift in the balance of symbionts and pathobionts within the gut [6-9]. Interestingly, this microbial dysbiosis is also associated with imbalances in effector T cell populations.</span>
  </p>
  <p id="p0007" num="0007" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En reconocimiento del efecto positivo potencial que ciertas cepas bacterianas pueden tener en el intestino animal, se han propuesto varias cepas para su uso en el tratamiento de varias enfermedades (ver, por ejemplo, [10 13]). Adems, ciertas cepas, incluyendo principalmente las cepas de <i class="style-scope patent-text">Lactobacillus </i>y <i class="style-scope patent-text">Bifidobacterium, </i>se han propuesto para su uso en el tratamiento de varias enfermedades inflamatorias y autoinmunes que no estn directamente relacionadas con los intestinos (ver [14] y [15] para revisiones). Sin embargo, la relacin entre diferentes enfermedades y diferentes cepas bacterianas, y los efectos precisos de cepas bacterianas particulares en el intestino y a nivel sistmico y en cualquier tipo particular de enfermedad, estn pobremente caracterizados.</span>In recognition of the potential positive effect that certain bacterial strains may have on the animal gut, several strains have been proposed for use in the treatment of various diseases (see, eg, [10-13]). In addition, certain strains, including primarily <i class="style-scope patent-text">Lactobacillus</i> and <i class="style-scope patent-text">Bifidobacterium strains,</i> have been proposed for use in the treatment of various inflammatory and autoimmune diseases that are not directly related to the intestines (see [14] and [15] for reviews). However, the relationship between different diseases and different bacterial strains, and the precise effects of particular bacterial strains at the gut and systemic level and on any particular type of disease, are poorly characterized.</span>
  </p>
  <p id="p0008" num="0008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La WO2015038731 analiza un mtodo para tratar el cncer de colon mediante la alteracin de una biopelcula colnica mediante la administracin de un agente antimicrobiano o un agente probitico. La solicitud enumera una gran cantidad de bacterias que pueden usarse en un probitico, pero no proporciona ninguna demostracin de la eficacia de ninguna de las bacterias en el tratamiento del cncer de colon. En cambio, esta solicitud se centra en el potencial diagnstico de las biopelculas en el cncer colorrectal.</span>WO2015038731 discusses a method for treating colon cancer by altering a colonic biofilm by administering an antimicrobial agent or a probiotic agent. The application lists a large number of bacteria that can be used in a probiotic, but provides no demonstration of the efficacy of any of the bacteria in treating colon cancer. Instead, this application focuses on the diagnostic potential of biofilms in colorectal cancer.</span>
  </p>
  <p id="p0009" num="0009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El nmero de registro de la base de datos EMBL XP002787383 proporciona una secuencia gnica de ARNr 16S de una <i class="style-scope patent-text">Megasphaera sp </i>propuesta, mientras que el nmero de registro de la base de datos EMBL XP002787384 proporciona un gen ARNr 16S de una cepa de <i class="style-scope patent-text">Megasphaera massiliensis. </i>Estos documentos detallan el anlisis genmico de cepas aisladas y no proporcionan orientacin sobre el beneficio teraputico de <i class="style-scope patent-text">Megasphaera</i>.</span>EMBL database accession number XP002787383 provides a 16S rRNA gene sequence from a proposed <i class="style-scope patent-text">Megasphaera sp</i> , while EMBL database accession number XP002787384 provides a 16S rRNA gene from a <i class="style-scope patent-text">Megasphaera massiliensis strain.</i> These documents detail the genomic analysis of isolates and do not provide guidance on the therapeutic benefit of <i class="style-scope patent-text">Megasphaera</i> .</span>
  </p>
  <p id="p0010" num="0010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ahmed et al (presentado en Frontiers Cellular Neuroscience) considera la caracterizacin <i class="style-scope patent-text">in vitro </i>de cepas bacterianas derivadas del microbiota intestinal. La US2004/120963 describe composiciones que contienen bacterias capaces de convertir el cido lctico en cido butrico y un mtodo para prevenir/tratar la acidemia hiperlctica en el tracto digestivo y el cncer de colon usando las mismas. La CN104415060A describe una composicin comestible que comprende inulina y cido butrico que produce bacterias. La JPS5557520 describe la preparacin de una sustancia carcinosttica tratando las paredes celulares de bacterias que pertenecen al gnero <i class="style-scope patent-text">Bacteroides, </i>etc. con una enzima y dializando con agua. La US2017/354697 describe el tratamiento de infeccin por <i class="style-scope patent-text">Clostridium difficile. </i>La US2016/223553 describe la formacin de biopelculas para definir el riesgo de cncer de colon. La WO2017122197A1 describe bacterias que utilizan cido lctico modificadas genticamente para secretas enzimas degradadoras de polisacridos. La US2016199424A1 describe composiciones probiticas y prebiticas y mtodos de uso de las mismas para la modulacin del microbioma. La WO2004085628 describe bacterias que utilizan cido 
lctico y su uso teraputico. Nallabelli et al. (Scientific Reports, 6(1), 2016) describe anlisis de secuencias de genoma y bioqumicos de la cepa de <i class="style-scope patent-text">Megasphaera </i>sp. DISK18 de la placa dental de un individuo sano. Padmanabhan et al. (Standards in Genomic Sciences, 8(3), 2013) divulga una secuencia de genoma finalizada no contigua y la descripcin de <i class="style-scope patent-text">Megasphaera massiliensis </i>sp. nov.</span>Ahmed et al (featured in Frontiers Cellular Neuroscience) consider the <i class="style-scope patent-text">in vitro</i> characterization of bacterial strains derived from the gut microbiota. US2004/120963 describes compositions containing bacteria capable of converting lactic acid to butyric acid and a method for preventing/treating hyperlactic acidemia in the digestive tract and colon cancer using the same. CN104415060A describes an edible composition comprising inulin and butyric acid producing bacteria. JPS5557520 describes the preparation of a carcinostatic substance by treating cell walls of bacteria belonging to the genus <i class="style-scope patent-text">Bacteroides,</i> etc. with an enzyme and dialyzing with water. US2017/354697 describes the treatment of <i class="style-scope patent-text">Clostridium difficile infection.</i> US2016/223553 describes the formation of biofilms to define the risk of colon cancer. WO2017122197A1 describes genetically modified lactic acid-using bacteria to secrete polysaccharide-degrading enzymes. US2016199424A1 describes probiotic and prebiotic compositions and methods of using them for the modulation of the microbiome. WO2004085628 describes bacteria that use acid  lactic acid and its therapeutic use. Nallabelli et al. (Scientific Reports, 6(1), 2016) describes biochemical and genome sequence analyzes of the <i class="style-scope patent-text">Megasphaera</i> sp. DISK18 from dental plaque of a healthy individual. Padmanabhan et al. (Standards in Genomic Sciences, 8(3), 2013) discloses a non-contiguous finalized genome sequence and description of <i class="style-scope patent-text">Megasphaera massiliensis</i> sp. nov.</span>
  </p>
  <p id="p0011" num="0011" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hay un requisito en la tcnica para nuevos mtodos de tratamiento de enfermedades. Tambin hay un requisito para caracterizar los efectos potenciales de las bacterias intestinales para que puedan desarrollarse nuevas terapias que usen bacterias intestinales.</span>There is a requirement in the art for new methods of treating diseases. There is also a requirement to characterize the potential effects of gut bacteria so that new therapies using gut bacteria can be developed.</span>
  </p>
  <p id="p0012" num="0012" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SUMARIO DE LA INVENCIN</span>SUMMARY OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0013" num="0013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16S que es por lo menos un 97% idntica a la SEQ ID NO: 1. La invencin proporciona adems una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1; (a) para su uso en el tratamiento o prevencin del cncer, (b) para su uso en el tratamiento, prevencin o retraso de la inmunosenescencia, (c) para su uso como adyuvante de vacunas, o (d) para su uso en terapia con clulas T con receptores de antgenos quimricos (CAR-T), terapia de clulas madre mesenquimales (MSC), o terapia de trasplante de clulas madre; en un sujeto humano.</span>The invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in the treatment of diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to the SEQ ID NO: 1. The invention further provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1; (a) for use in the treatment or prevention of cancer, (b) for use in the treatment, prevention, or delay of immunosenescence, (c) for use as an adjuvant to vaccines, or (d) for use in chimeric antigen receptor T cell (CAR-T) therapy, mesenchymal stem cell (MSC) therapy, or stem cell transplant therapy; in a human subject.</span>
  </p>
  <p id="p0014" num="0014" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencin tambin proporciona una composicin que comprende una clula de la cepa bacteriana como se define en las reivindicaciones, en donde la clula expresa uno o ms antgenos heterlogos; para su uso como una vacuna; opcionalmente en donde la clula presenta el uno o ms antgenos heterlogos. La invencin tambin proporciona una clula de la cepa bacteriana como se define en las reivindicaciones, en donde la clula expresa uno o ms antgenos heterlogos; para su uso como una vacuna; opcionalmente en donde la clula presenta el uno o ms antgenos heterlogos.</span>The invention also provides a composition comprising a cell of the bacterial strain as defined in the claims, wherein the cell expresses one or more heterologous antigens; for use as a vaccine; optionally wherein the cell presents the one or more heterologous antigens. The invention also provides a cell of the bacterial strain as defined in the claims, wherein the cell expresses one or more heterologous antigens; for use as a vaccine; optionally wherein the cell presents the one or more heterologous antigens.</span>
  </p>
  <p id="p0015" num="0015" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencin proporciona adems una cepa bacteriana para su uso en terapia, en donde la cepa bacteriana tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o un 99,9% idntica a cualquiera de las SEQ ID NO: 8, 11 o 12. La invencin tambin proporciona una cepa bacteriana que tiene la secuencia de ARNr 16S representada por cualquiera de las SEQ ID NO: 8, 10, 11 o 12 para su uso en terapia.</span>The invention further provides a bacterial strain for use in therapy, wherein the bacterial strain has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to any one of SEQ ID NO: 8 , 11 or 12. The invention also provides a bacterial strain having the 16S rRNA sequence represented by any of SEQ ID NO: 8, 10, 11 or 12 for use in therapy.</span>
  </p>
  <p id="p0016" num="0016" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han desarrollado nuevas composiciones que comprenden una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>que puede usarse para estimular el sistema inmunitario y tratar y prevenir enfermedades, en particular cncer.</span>The inventors have developed new compositions comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> that can be used to stimulate the immune system and treat and prevent diseases, in particular cancer.</span>
  </p>
  <p id="p0017" num="0017" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 97% idntica a la SEQ ID NO: 1. Preferiblemente, la cepa bacteriana es de la especie <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>Therefore, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16s rRNA gene sequence that is at least 97 % identical to SEQ ID NO: 1. Preferably, the bacterial strain is of the species <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0018" num="0018" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1; para su uso en el tratamiento o la prevencin del cncer, como el melanoma metastsico, el cncer de mama, el cncer de ovario, el cncer de cuello uterino, el neuroblastoma, el glioblastoma, el carcinoma, el cncer de pulmn, la leucemia linfoctica crnica, cncer de prstata, linfoma y/o cncer gstrico. En aspectos adicionales, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1, para su uso en el tratamiento o la prevencin del cncer, como el cncer colorrectal y/o enfermedades malignas hematolgicas.</span>In further aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1; for use in the treatment or prevention of cancer, such as metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, glioblastoma, carcinoma, lung cancer, lymphocytic leukemia chronic, prostate cancer, lymphoma and/or gastric cancer. In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use in the treatment or prevention of cancer, such as colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0019" num="0019" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1, para su uso en el tratamiento, prevencin o retraso de la inmunosenescencia.</span>In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use in the treatment, prevention or delay of immunosenescence.</span>
  </p>
  <p id="p0020" num="0020" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1, para su uso como adyuvante de vacunas.</span>In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use as a vaccine adjuvant.</span>
  </p>
  <p id="p0021" num="0021" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1, para su uso en la potenciacin de una terapia celular, tal como CAR-T. 
</span>In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use in enhancing a cell therapy, such as CAR-T. </span>
  </p>
  <p id="p0022" num="0022" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, la bacteria usada en la invencin es la cepa depositada con el nmero de registro 42787 en NCIMB.</span>Preferably, the bacterium used in the invention is the strain deposited under accession number 42787 at NCIMB.</span>
  </p>
  <p id="p0023" num="0023" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">BREVE DESCRIPCIN DE LOS DIBUJOS</span>BRIEF DESCRIPTION OF THE DRAWINGS</span>
    </b>
  </p>
  <p id="p0024" num="0024" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 1</b>: Niveles de expresin de tubulina p3: inmunotincin e imagenologa celular (Figura 1A); inmunotransferencia (Figura 1B)</span> <b class="style-scope patent-text">Figure 1</b> : p3 tubulin expression levels: immunostaining and cell imaging (Figure 1A); Western blot (Figure 1B)</span>
  </p>
  <p id="p0025" num="0025" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 2 </b>: Niveles de expresin de MAP2: inmunotincin e imagenologa celular (Figura 2A); inmunotransferencia (Figura 2B); veces el cambio en la expresin (Figura 2C)</span> <b class="style-scope patent-text">Figure 2</b> : MAP2 expression levels: immunostaining and cell imaging (Figure 2A); immunoblot (Figure 2B); fold change in expression (Figure 2C)</span>
  </p>
  <p id="p0026" num="0026" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 3 </b>: Cambio en la expresin de DRD2</span> <b class="style-scope patent-text">Figure 3</b> : Change in DRD2 expression</span>
  </p>
  <p id="p0027" num="0027" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 4 </b>: Cambio en la expresin de Casp3</span> <b class="style-scope patent-text">Figure 4</b> : Change in Casp3 expression</span>
  </p>
  <p id="p0028" num="0028" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 5 </b>: Cambio en la viabilidad celular</span> <b class="style-scope patent-text">Figure 5</b> : Change in cell viability</span>
  </p>
  <p id="p0029" num="0029" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 6 </b>: fenotipado celular de clulas auxiliares T CD4 (Figura 6A); clulas CD4+ activadas (Figura 6B); clulas Tregs (Figura 6C); clulas T citotxicas CD8 (Figura 6D); clulas activadas CD8+ (Figura 6E); clulas B (Figura 6F); Proporcin CD8/Tregs (Figura 6G); Proporcin CD8 activadas/Tregs (Figura 6H).</span> <b class="style-scope patent-text">Figure 6</b> : Cellular phenotyping of CD4 T helper cells (Figure 6A); activated CD4+ cells (FIG. 6B); Treg cells (FIG. 6C); CD8 cytotoxic T cells (FIG. 6D); activated CD8+ cells (FIG. 6E); B cells (FIG. 6F); CD8/Tregs ratio (FIG. 6G); Activated CD8/Tregs ratio (Figure 6H).</span>
  </p>
  <p id="p0030" num="0030" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 7 </b>: Anlisis de citoquinas de IL-1 p (Figura 7A); TNF-a (Figura 7B); IL-23 (Figura 7C); IL-6 (Figura 7D); MIP-3a (Figura 7E); CXCL9 (Figura 7F); M<sup class="style-scope patent-text">c </sup>P-1 (Figura 7G); IL-10 (Figura 7H); GM-CSF (Figura 7I).</span> <b class="style-scope patent-text">Figure 7</b> : Cytokine analysis of IL-1p (Figure 7A); TNF-a (FIG. 7B); IL-23 (FIG. 7C); IL-6 (FIG. 7D); MIP-3a (FIG. 7E); CXCL9 (FIG. 7F); M <sup class="style-scope patent-text">c</sup> P-1 (FIG. 7G); IL-10 (FIG. 7H); GM-CSF (FIG. 7I).</span>
  </p>
  <p id="p0031" num="0031" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 8 </b>: Estrategia de regulacin usada para analizar las diferentes poblaciones de clulas inmunitarias (clulas CD4, CD8 y CD 19+) mediante citometra de flujo para los datos presentados en la Figura 6.</span> <b class="style-scope patent-text">Figure 8</b> : Regulation strategy used to analyze the different populations of immune cells (CD4, CD8, and CD 19+ cells) using flow cytometry for the data presented in Figure 6.</span>
  </p>
  <p id="p0032" num="0032" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 9 </b>: Secrecin de Interleucina-8 (IL-8)).</span> <b class="style-scope patent-text">Figure 9</b> : Secretion of Interleukin-8 (IL-8)).</span>
  </p>
  <p id="p0033" num="0033" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 10</b>: Cambio en la actividad de la histona deacetilasa (HDAC)</span> <b class="style-scope patent-text">Figure 10</b> : Change in histone deacetylase (HDAC) activity</span>
  </p>
  <p id="p0034" num="0034" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 11A</b>: Cambios inducidos por cepas en la actividad de histona deacetilasa de clulas completas y lisado celular; <b class="style-scope patent-text">Figura 11B</b>: produccin de metabolitos por cepas; <b class="style-scope patent-text">Figura 11C</b>: cambios inducidos por cido en la actividad de histona deacetilasa.</span> <b class="style-scope patent-text">Figure 11A</b> : Strain-induced changes in histone deacetylase activity of whole cells and cell lysate; <b class="style-scope patent-text">Figure 11B</b> : Metabolite production by strains; <b class="style-scope patent-text">Figure 11C</b> : Acid-induced changes in histone deacetylase activity.</span>
  </p>
  <p id="p0035" num="0035" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 12A</b>: inhibicin de HDAC1; <b class="style-scope patent-text">Figura 12B</b>: inhibicin de HDAC2; <b class="style-scope patent-text">Figura 12C</b>: Inhibicin de HDAC3.</span> <b class="style-scope patent-text">Figure 12A</b> : HDAC1 inhibition; <b class="style-scope patent-text">Figure 12B</b> : HDAC2 inhibition; <b class="style-scope patent-text">Figure 12C</b> : HDAC3 inhibition.</span>
  </p>
  <p id="p0036" num="0036" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 13A</b>: Inhibicin de HDAC de Clase I; <b class="style-scope patent-text">Figura 13B</b>: inhibicin de HDAC1; <b class="style-scope patent-text">Figura 13C</b>: inhibicin de HDAC2; <b class="style-scope patent-text">Figura 13D</b>: inhibicin de HDAC3.</span> <b class="style-scope patent-text">Figure 13A</b> : Class I HDAC inhibition; <b class="style-scope patent-text">Figure 13B</b> : HDAC1 inhibition; <b class="style-scope patent-text">Figure 13C</b> : HDAC2 inhibition; <b class="style-scope patent-text">Figure 13D</b> : HDAC3 inhibition.</span>
  </p>
  <p id="p0037" num="0037" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 14</b>: Efectos sobre la funcin de barrera intestinal.</span> <b class="style-scope patent-text">Figure 14</b> : Effects on intestinal barrier function.</span>
  </p>
  <p id="p0038" num="0038" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 15</b>: Cambios en la expresin hipocampal del Receptor 4 tipo Toll (TLR-4).</span> <b class="style-scope patent-text">Figure 15</b> : Changes in hippocampal expression of Toll-like Receptor 4 (TLR-4).</span>
  </p>
  <p id="p0039" num="0039" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 16</b>: Cambios en la expresin hipocampal de TNF-a.</span> <b class="style-scope patent-text">Figure 16</b> : Changes in hippocampal expression of TNF-.</span>
  </p>
  <p id="p0040" num="0040" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 17</b>: Cambios en la expresin hipocampal de interleucina-1 p (IL-1 p).</span> <b class="style-scope patent-text">Figure 17</b> : Changes in hippocampal expression of interleukin-1p (IL-1p).</span>
  </p>
  <p id="p0041" num="0041" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 18</b>: Cambios en la expresin hipocampal de interleucina-6 (IL-6).</span> <b class="style-scope patent-text">Figure 18</b> : Changes in hippocampal expression of interleukin-6 (IL-6).</span>
  </p>
  <p id="p0042" num="0042" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 19</b>: Cambios en la expresin hipocampal de CD11b.</span> <b class="style-scope patent-text">Figure 19</b> : Changes in hippocampal expression of CD11b.</span>
  </p>
  <p id="p0043" num="0043" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 20</b>: Cambios en la expresin de la amgdala de TLR-4.</span> <b class="style-scope patent-text">Figure 20</b> : Changes in amygdala expression of TLR-4.</span>
  </p>
  <p id="p0044" num="0044" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 21</b>: Cambios en la expresin de la amgdala de CD11b.</span> <b class="style-scope patent-text">Figure 21</b> : Changes in CD11b amygdalin expression.</span>
  </p>
  <p id="p0045" num="0045" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 22</b>: Cambios en la expresin de la amgdala de IL-6.</span> <b class="style-scope patent-text">Figure 22</b> : Changes in amygdalin expression of IL-6.</span>
  </p>
  <p id="p0046" num="0046" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 23</b>: Cambios en la expresin de la corteza prefrontal de TLR-4.</span> <b class="style-scope patent-text">Figure 23</b> : Changes in prefrontal cortex expression of TLR-4.</span>
  </p>
  <p id="p0047" num="0047" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 24</b>: Cambios en la expresin de la corteza prefrontal de CD11b.</span> <b class="style-scope patent-text">Figure 24</b> : Changes in prefrontal cortex expression of CD11b.</span>
  </p>
  <p id="p0048" num="0048" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 25</b>: Cambios en la expresin de la corteza prefrontal de IL-6.</span> <b class="style-scope patent-text">Figure 25</b> : Changes in prefrontal cortex expression of IL-6.</span>
  </p>
  <p id="p0049" num="0049" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 26</b>: Efecto sobre la produccin de interfern-Y a partir de esplenocitos de ratn de ratones a los que se les 
administr MRx0029.</span> <b class="style-scope patent-text">Figure 26</b> : Effect on interferon-Y production from mouse splenocytes from mice given  administered MRx0029.</span>
  </p>
  <p id="p0050" num="0050" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 27</b>: Efecto sobre la produccin de IL-1 p a partir de esplenocitos de ratn de ratones a los que se les administr MRx0029.</span> <b class="style-scope patent-text">Figure 27</b> : Effect on IL-1p production from mouse splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0051" num="0051" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 28</b>: Efecto sobre la produccin de IL-6 a partir de esplenocitos de ratn de ratones a los que se les administr MRx0029.</span> <b class="style-scope patent-text">Figure 28</b> : Effect on IL-6 production from mouse splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0052" num="0052" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 29</b>: Efecto sobre la produccin de TNF-a a partir de esplenocitos de ratones a los que se les administr MRx0029.</span> <b class="style-scope patent-text">Figure 29</b> : Effect on TNF- production from splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0053" num="0053" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 30</b>: Efecto sobre la produccin de CXCL1 a partir de esplenocitos de ratones a los que se les administr MRx0029.</span> <b class="style-scope patent-text">Figure 30</b> : Effect on CXCL1 production from splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0054" num="0054" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 31</b>: Expresin gnica de MAP2 en la lnea celular SKMEL2 despus de varios tratamientos, con respecto a GAPDH. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 31</b> : MAP2 gene expression in the SKMEL2 cell line after various treatments, with respect to GAPDH. YCFA = YCFA+</span>
  </p>
  <p id="p0055" num="0055" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 32</b>: Supervivencia clonognica de la lnea celular SKMEL2 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 32</b> : Clonogenic survival of the SKMEL2 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0056" num="0056" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 33</b>: Crecimiento en agar blando de la lnea celular SKMEL2 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 33</b> : Growth in soft agar of the SKMEL2 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0057" num="0057" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 34</b>: Sealizacin de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la lnea celular SKMEL2 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 34</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the SKMEL2 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0058" num="0058" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 35</b>: Expresin gnica de MAP2 en la lnea celular SKMEL28 despus de varios tratamientos, con respecto a GAPDH. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 35</b> : MAP2 gene expression in the SKMEL28 cell line after various treatments, with respect to GAPDH. YCFA = YCFA+</span>
  </p>
  <p id="p0059" num="0059" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 36</b>: Supervivencia clonognica de la lnea celular SKMEL28 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 36</b> : Clonogenic survival of the SKMEL28 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0060" num="0060" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 37</b>: Crecimiento en agar blando de la lnea celular SKMEL28 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 37</b> : Growth in soft agar of the SKMEL28 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0061" num="0061" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 38</b>: Sealizacin de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la lnea celular SKMEL28 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 38</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the SKMEL28 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0062" num="0062" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 39</b>: Expresin gnica de MAP2 en la lnea celular SKMEL31 despus de varios tratamientos, con respecto a GAPDH. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 39</b> : MAP2 gene expression in the SKMEL31 cell line after various treatments, with respect to GAPDH. YCFA = YCFA+</span>
  </p>
  <p id="p0063" num="0063" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 40</b>: Supervivencia clonognica de la lnea celular SKMEL31 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 40</b> : Clonogenic survival of the SKMEL31 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0064" num="0064" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 41</b>: Crecimiento en agar blando de la lnea celular SKMEL31 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 41</b> : Growth in soft agar of the SKMEL31 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0065" num="0065" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 42</b>: Sealizacin de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la lnea celular SKMEL31 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 42</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the SKMEL31 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0066" num="0066" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 43</b>: Expresin gnica de MAP2 en la lnea celular 451Lu despus de varios tratamientos, con respecto a GAPDH. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 43</b> : MAP2 gene expression in the 451Lu cell line after various treatments, with respect to GAPDH. YCFA = YCFA+</span>
  </p>
  <p id="p0067" num="0067" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 44</b>: Supervivencia clonognica de la lnea celular 451Lu despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 44</b> : Clonogenic survival of the 451Lu cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0068" num="0068" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 45</b>: Crecimiento en agar blando de la lnea celular 451Lu despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 45</b> : Growth in soft agar of the 451Lu cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0069" num="0069" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 46</b>: Sealizacin de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la lnea celular 451 Lu despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 46</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the 451 Lu cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0070" num="0070" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 47</b>: Expresin gnica de MAP2 en la lnea celular F1T-29 despus de varios tratamientos, con respecto a GAPDH. YCFA = YCFA+ 
</span> <b class="style-scope patent-text">Figure 47</b> : MAP2 gene expression in the F1T-29 cell line after various treatments, with respect to GAPDH. YCFA = YCFA+ </span>
  </p>
  <p id="p0071" num="0071" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 48</b>: Supervivencia clonognica de la lnea celular HT-29 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 48</b> : Clonogenic survival of the HT-29 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0072" num="0072" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 49A</b>: Crecimiento en agar blando de la lnea celular HT-29 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 49A</b> : Growth in soft agar of the HT-29 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0073" num="0073" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 49B</b>: Crecimiento en agar blando de la lnea celular HT-29 despus de varios tratamientos (fotografa de placas de agar). YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 49B</b> : Growth in soft agar of the HT-29 cell line after various treatments (photograph of agar plates). YCFA = YCFA+</span>
  </p>
  <p id="p0074" num="0074" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 50</b>: Sealizacin de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la lnea celular HT29 despus de varios tratamientos. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 50</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the HT29 cell line after various treatments. YCFA = YCFA+</span>
  </p>
  <p id="p0075" num="0075" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 51</b>: Descripcin general de la va MAP-quinasa (de [72]).</span> <b class="style-scope patent-text">Figure 51</b> : Overview of the MAP-kinase pathway (from [72]).</span>
  </p>
  <p id="p0076" num="0076" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 52</b>: Expresin de ARN de GPR109a en clulas Caco-2 diferenciadas (A) sin y (B) con tratamiento con miristato de forbol adems de MRx0029. YCFA = YCFA+</span> <b class="style-scope patent-text">Figure 52</b> : GPR109a RNA expression in differentiated Caco-2 cells (A) without and (B) with phorbol myristate treatment in addition to MRx0029. YCFA = YCFA+</span>
  </p>
  <p id="p0077" num="0077" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 53</b>: Induccin de la secrecin de IL-8 a partir de clulas HT29 por (A) MRx0029 con medio acondicionado y (B) MRx0029 solo.</span> <b class="style-scope patent-text">Figure 53</b> : Induction of IL-8 secretion from HT29 cells by (A) MRx0029 with conditioned medium and (B) MRx0029 alone.</span>
  </p>
  <p id="p0078" num="0078" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 54</b>: Anlisis de metabolitos para la cepa NCIMB 42787 de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span> <b class="style-scope patent-text">Figure 54</b> : Metabolite analysis for <i class="style-scope patent-text">Megasphaera massiliensis strain NCIMB 42787.</i> </span>
  </p>
  <p id="p0079" num="0079" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 55</b>: Produccin de cido valrico en el sobrenadante de las cepas MRx0029 y <i class="style-scope patent-text">Megasphaera massiliensis </i>de referencia.</span> <b class="style-scope patent-text">Figure 55</b> : Production of valeric acid in the supernatant of the reference strains MRx0029 and <i class="style-scope patent-text">Megasphaera massiliensis</i> .</span>
  </p>
  <p id="p0080" num="0080" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 56</b>: Produccin y consumo de cidos orgnicos por las cepas MRx0029 y <i class="style-scope patent-text">Megasphaera massiliensis </i>de referencia.</span> <b class="style-scope patent-text">Figure 56</b> : Production and consumption of organic acids by the MRx0029 and <i class="style-scope patent-text">Megasphaera massiliensis</i> reference strains.</span>
  </p>
  <p id="p0081" num="0081" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 57</b>: Supresin de NSE/Enolasa 2 por MRX029. YCFA = YCFA+.</span> <b class="style-scope patent-text">Figure 57</b> : Suppression of NSE/Enolase 2 by MRX029. "YCFA" = YCFA+.</span>
  </p>
  <p id="p0082" num="0082" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 58</b>: Produccin y consumo de cidos orgnicos por NCIMB 42787, NCIMB 43385, NCIMB 43388 y NCIMB 43389.</span> <b class="style-scope patent-text">Figure 58</b> : Production and consumption of organic acids by NCIMB 42787, NCIMB 43385, NCIMB 43388, and NCIMB 43389.</span>
  </p>
  <p id="p0083" num="0083" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 59</b>: Regulacin por incremento de la secrecin de IL-6 en clulas U373 por NCIMB 42787 y otras cepas depositadas (n=3).</span> <b class="style-scope patent-text">Figure 59</b> : Upregulation of IL-6 secretion in U373 cells by NCIMB 42787 and other deposited strains (n=3).</span>
  </p>
  <p id="p0084" num="0084" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 60</b>: Supresin de enolasa 2 por NCIMB 42787, NCIMB 43385, NCIMB 43388, NCIMB 43389, NCIMB 43386 y NCIMB 43387.</span> <b class="style-scope patent-text">Figure 60</b> : Suppression of enolase 2 by NCIMB 42787, NCIMB 43385, NCIMB 43388, NCIMB 43389, NCIMB 43386, and NCIMB 43387.</span>
  </p>
  <p id="p0085" num="0085" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 61A</b>: NCIMB 42787 y otras depositadas aumentan la expresin de MAP2; <b class="style-scope patent-text">Figura 61B y C</b>: Modulacin de los niveles de citoquinas y promotor de NP<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>B-AP1 por NCIMB 42787.</span> <b class="style-scope patent-text">Figure 61A</b> : NCIMB 42787 and others deposited increase MAP2 expression; <b class="style-scope patent-text">Figure 61B and C</b> : Modulation of NP <b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b> B-AP1 promoter and cytokine levels by NCIMB 42787.</span>
  </p>
  <p id="p0086" num="0086" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 62</b>: NCIMB 42787 produce cido butrico, valrico y hexanoico</span> <b class="style-scope patent-text">Figure 62</b> : NCIMB 42787 produces butyric, valeric and hexanoic acid</span>
  </p>
  <p id="p0087" num="0087" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 63</b>: Actividad inmunoestimuladora de metabolitos producidos por NCIMB 42787.</span> <b class="style-scope patent-text">Figure 63</b> : Immunostimulatory activity of metabolites produced by NCIMB 42787.</span>
  </p>
  <p id="p0088" num="0088" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 64</b>: Anlisis del papel de los metabolitos en la actividad inmunoestimuladora de NCIMB 42787.</span> <b class="style-scope patent-text">Figure 64</b> : Analysis of the role of metabolites in the immunostimulatory activity of NCIMB 42787.</span>
  </p>
  <p id="p0089" num="0089" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 65</b>: La cepa NCIMB 43387 de <i class="style-scope patent-text">Megasphaera </i>afecta a la expresin del ARNm de IDO-1 del colon en ratones BALB/c.</span> <b class="style-scope patent-text">Figure 65</b> : Megasphaera strain NCIMB <i class="style-scope patent-text">43387</i> affects colonic IDO-1 mRNA expression in BALB/c mice.</span>
  </p>
  <p id="p0090" num="0090" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 66</b>: Las cepas NCIMB 43385 y NCIMB 43387 de <i class="style-scope patent-text">Megasphaera </i>afectan a la expresin del ARNm de Tph1 del colon en ratones BALB/c.</span> <b class="style-scope patent-text">Figure 66</b> : Megasphaera strains NCIMB 43385 and NCIMB <i class="style-scope patent-text">43387</i> affect colonic Tph1 mRNA expression in BALB/c mice.</span>
  </p>
  <p id="p0091" num="0091" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 67</b>: la cepa NCIMB 43385 de <i class="style-scope patent-text">Megasphaera </i>modula la produccin de IPNy e IL-6 tras la estimulacin con ConA de esplenocitos de ratones BALB/c.</span> <b class="style-scope patent-text">Figure 67</b> : Megasphaera strain NCIMB <i class="style-scope patent-text">43385</i> modulates IPNy and IL-6 production after ConA stimulation of splenocytes from BALB/c mice.</span>
  </p>
  <p id="p0092" num="0092" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 68</b>: La cepa NCIMB 43385 de <i class="style-scope patent-text">Megasphaera </i>modula la expresin de IL-6 y CD11b en el cerebro de ratones BALB/c.</span> <b class="style-scope patent-text">Figure 68</b> : Megasphaera strain NCIMB <i class="style-scope patent-text">43385</i> modulates the expression of IL-6 and CD11b in the brain of BALB/c mice.</span>
  </p>
  <p id="p0093" num="0093" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 69</b>: NCIMB 42787 modula la expresin de TLR4 en la amgdala de ratones BALB/c.</span> <b class="style-scope patent-text">Figure 69</b> : NCIMB 42787 modulates TLR4 expression in the amygdala of BALB/c mice.</span>
  </p>
  <p id="p0094" num="0094" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DIVULGACIN DE LA INVENCIN</span>DISCLOSURE OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0095" num="0095" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas </span>bacterial strains</span>
      </i>
    </b>
    
  </p>
  <p id="p0096" num="0096" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin, como se define en las reivindicaciones, comprenden una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera. </i>Los Ejemplos demuestran que las bacterias de este gnero son tiles para estimular el sistema inmunitario y para tratar enfermedades, en particular cncer. Las cepas bacterianas preferidas son las de la especie <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>The compositions of the invention, as defined in the claims, comprise a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> The Examples demonstrate that bacteria of this genus are useful for stimulating the immune system and for treating diseases, in particular cancer. Preferred bacterial strains are those of the species <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0097" num="0097" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos de especies de <i class="style-scope patent-text">Megasphaera </i>para su uso en la invencin incluyen <i class="style-scope patent-text">Megasphaera elsdenii, Megasphaera cerevisiae, Megasphaera massiliensis, Megasphaera indica, Megasphaera paucivorans, Megasphaera sueciensis </i>y <i class="style-scope patent-text">Megasphaera micronuciformis. </i>Un ejemplo adicional de una especie de <i class="style-scope patent-text">Megasphaera </i>para su uso en la invencin es <i class="style-scope patent-text">Megasphaera hexanoica. </i>Los <i class="style-scope patent-text">Megasphaera </i>son microbios gastrointestinales obligadamente anaerbicos, fermentadores de lactato, de mamferos rumiantes y no rumiantes, incluyendo los humanos.</span>Examples of <i class="style-scope patent-text">Megasphaera</i> species for use in the invention include <i class="style-scope patent-text">Megasphaera elsdenii, Megasphaera cerevisiae, Megasphaera massiliensis, Megasphaera indica, Megasphaera paucivorans, Megasphaera sueciensis,</i> and <i class="style-scope patent-text">Megasphaera micronuciformis.</i> A further example of a <i class="style-scope patent-text">Megasphaera</i> species for use in the invention is <i class="style-scope patent-text">Megasphaera hexanoica.</i> <i class="style-scope patent-text">Megasphaera</i> are obligately anaerobic, lactate-fermenting gastrointestinal microbes of ruminant and non-ruminant mammals, including humans.</span>
  </p>
  <p id="p0098" num="0098" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa tipo de <i class="style-scope patent-text">M massiliensis </i>es NP3 (=CSUR P245=DSM 26228) [16]. El nmero de registro del GenBank para las secuencias del gen ARNr 16S de la cepa NP3 de <i class="style-scope patent-text">M massiliensis </i>es JX424772.1.</span>The type strain of <i class="style-scope patent-text">M massiliensis</i> is NP3 (=CSUR P245=DSM 26228) [16]. The GenBank accession number for the 16S rRNA gene sequences of the <i class="style-scope patent-text">M massiliensis</i> strain NP3 is JX424772.1.</span>
  </p>
  <p id="p0099" num="0099" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A la bacteria <i class="style-scope patent-text">Megasphaera massiliensis </i>probada en los Ejemplos se hace referencia en la presente como cepa MRx0029. En la SEQ ID NO: 1 se proporciona una secuencia de ARNr 16S para la cepa MRx0029 que se prob.</span>The <i class="style-scope patent-text">Megasphaera massiliensis</i> bacterium tested in the Examples is referred to herein as strain MRx0029. A 16S rRNA sequence for strain MRx0029 that was tested is given in SEQ ID NO: 1.</span>
  </p>
  <p id="p0100" num="0100" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa MRx0029 fue depositada en la autoridad de depsito internacional NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Escocia) por 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB252ZS, Escocia) el 13 de julio de 2017 como <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029 y se le asign el nmero de registro nCiMB 42787.</span>Strain MRx0029 was deposited with the International Depository Authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) by 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB252ZS, Scotland) on 13 July 2017 as <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029 and assigned nCiMB registration number 42787.</span>
  </p>
  <p id="p0101" num="0101" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambin se espera que las cepas bacterianas estrechamente relacionadas con la cepa probada en los Ejemplos sean eficaces para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 97%, 98%, 99%, 99,5% o 99,9% idntica a la SEQ ID NO: 1. Preferiblemente, la cepa bacteriana para su uso en la invencin tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 1.</span>Bacterial strains closely related to the strain tested in the Examples are also expected to be effective in stimulating the immune system and in treating and preventing disease, particularly cancer. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 97%, 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO: 1. Preferably, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 1.</span>
  </p>
  <p id="p0102" num="0102" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambin se espera que las cepas bacterianas que son biotipos de las cepas MRx0029 sean eficaces para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer. Un biotipo es una cepa estrechamente relacionada que tiene caractersticas fisiolgicas y bioqumicas iguales o muy similares.</span>Bacterial strains that are biotypes of the MRx0029 strains are also expected to be effective in stimulating the immune system and in treating and preventing disease, particularly cancer. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.</span>
  </p>
  <p id="p0103" num="0103" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas que son biotipos de las cepas MRx0029 y que son adecuadas para su uso en la invencin pueden identificarse secuenciando otras secuencias de nucletidos para las cepas MRx0029. Por ejemplo, puede secuenciarse sustancialmente el genoma completo y una cepa de biotipo para su uso en la invencin puede tener por lo menos un 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia en por lo menos un 80% de su genoma completo (por ejemplo, en por lo menos el 85%, 90%, 95% o 99%, o en su genoma completo). Otras secuencias adecuadas para su uso en la identificacin de cepas de biotipo pueden incluir hsp60 o secuencias repetitivas como BOX, ERIC, (GTG)5o REP o [17]. Las cepas de biotipo pueden tener secuencias con por lo menos un 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia con la secuencia correspondiente de las cepas MRx0029.</span>Strains that are biotypes of the MRx0029 strains and that are suitable for use in the invention can be identified by sequencing other nucleotide sequences for the MRx0029 strains. For example, substantially the entire genome can be sequenced, and a biotype strain for use in the invention can be at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% of sequence identity to at least 80% of its entire genome (for example, to at least 85%, 90%, 95%, or 99%, or to its entire genome). Other sequences suitable for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)5 or REP or [17]. Biotype strains may have sequences with at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% sequence identity to the corresponding sequence of MRx0029 strains.</span>
  </p>
  <p id="p0104" num="0104" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente, las cepas que son biotipos de las cepas MRx0029 y que son adecuadas para su uso en la invencin pueden identificarse usando cepas MRx0029 y anlisis de fragmentos de restriccin y/o anlisis por PCR, por ejemplo usando polimorfismo de longitud de fragmento amplificado fluorescente (FAFLP) e identificacin de elemento de ADN repetitivo (rep)-PCR, o realizacin de perfiles de protenas, o secuenciacin parcial de ADNr 16S o 23S. En realizaciones preferidas, tales tcnicas pueden usarse para identificar otras cepas de <i class="style-scope patent-text">Megasphaera massiliensis</i>.</span>Alternatively, strains that are biotypes of the MRx0029 strains and that are suitable for use in the invention can be identified using MRx0029 strains and restriction fragment analysis and/or PCR analysis, for example using fluorescent amplified fragment length polymorphism ( FAFLP) and repetitive DNA element identification (rep)-PCR, or protein profiling, or partial 16S or 23S rDNA sequencing. In preferred embodiments, such techniques can be used to identify other <i class="style-scope patent-text">Megasphaera massiliensis</i> strains.</span>
  </p>
  <p id="p0105" num="0105" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las cepas que son biotipos de las cepas MRx0029 y que son adecuadas para su uso en la invencin son cepas que proporcionan el mismo patrn que la cepa MRx0029 cuando se analizan mediante anlisis de restriccin de ADN ribosmico amplificado (ARDRA), por ejemplo, cuando se usa la enzima de restriccin Sau3AI (para mtodos ejemplares y orientacin, consultar, por ejemplo, [18]). Alternativamente, las cepas de biotipo se identifican como cepas que tienen los mismos patrones de fermentacin de carbohidratos que las cepas MRx0029.</span>In certain embodiments, the strains that are biotypes of the MRx0029 strains and that are suitable for use in the invention are strains that provide the same pattern as the MRx0029 strain when analyzed by amplified ribosomal DNA restriction analysis (ARDRA), e.g. example, when using the restriction enzyme Sau3AI (for exemplary methods and guidance, see, eg, [18]). Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as the MRx0029 strains.</span>
  </p>
  <p id="p0106" num="0106" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otras cepas de <i class="style-scope patent-text">Megasphaera </i>que son tiles en las composiciones y mtodos de la invencin, como los biotipos de la cepa MRx0029, pueden identificarse usando cualquier mtodo o estrategia apropiados, incluyendo los ensayos descritos en los Ejemplos. Por ejemplo, las cepas para su uso en la invencin pueden identificarse aadindolas al lisado celular o a clulas completas y analizando la expresin de MAP2, la expresin de DRD2, los niveles de citoquinas o la supervivencia celular. En particular, las cepas bacterianas que tienen patrones de crecimiento, tipo metablico y/o antgenos de superficie similares a las cepas MRx0029 pueden ser tiles en la invencin. Una cepa til tendr una actividad inmunomoduladora comparable a las cepas MRx0029. En particular, una cepa de biotipo provocar efectos comparables sobre la expresin de MAP2, la expresin de DRD2, los niveles 
de citoquinas o la supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos. Una cepa de biotipo puede provocar efectos comparables sobre la actividad inhibidora de histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos.</span>Other <i class="style-scope patent-text">Megasphaera</i> strains that are useful in the compositions and methods of the invention, such as biotypes of strain MRx0029, can be identified using any appropriate method or strategy, including the assays described in the Examples. For example, strains for use in the invention can be identified by adding them to cell lysate or whole cells and analyzing for MAP2 expression, DRD2 expression, cytokine levels, or cell survival. In particular, bacterial strains that have similar growth patterns, metabolic type, and/or surface antigens to the MRx0029 strains may be useful in the invention. A useful strain will have immunomodulatory activity comparable to the MRx0029 strains. In particular, a biotype strain will elicit comparable effects on MAP2 expression, DRD2 expression, levels  of cytokines or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A biotype strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples.</span>
  </p>
  <p id="p0107" num="0107" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las cepas bacterianas tiles en la invencin pueden identificarse realizando perfiles rutinariamente de la produccin y el consumo de metabolitos por una cepa bacteriana. Los inventores han descubierto que la cepa bacteriana usada en los Ejemplos produce butirato, cido valrico y cido hexanoico y consume acetato y propionato (ver las Figuras 54-56). Tambin se descubri que las cepas Ref 1, Ref 2 y Ref 3 de <i class="style-scope patent-text">Megasphaera massiliensis </i>consumen y producen estos metabolitos (ver las Figuras 54-56). Por lo tanto, en algunas realizaciones, la cepa bacteriana de la invencin produce uno o ms de los metabolitos butirato, cido valrico y cido hexanoico. En algunas realizaciones, la cepa bacteriana de la invencin consume uno o ambos de acetato y propionato. En realizaciones preferidas, la cepa bacteriana de la invencin produce butirato, cido valrico y cido hexanoico y consume acetato y propionato.</span>In some embodiments, bacterial strains useful in the invention can be identified by routinely profiling the production and consumption of metabolites by a bacterial strain. The inventors have found that the bacterial strain used in the Examples produces butyrate, valeric acid and hexanoic acid and consumes acetate and propionate (see Figures 54-56). <i class="style-scope patent-text">Megasphaera massiliensis</i> strains Ref 1, Ref 2 and Ref 3 were also found to consume and produce these metabolites (see Figures 54-56). Therefore, in some embodiments, the bacterial strain of the invention produces one or more of the metabolites butyrate, valeric acid, and hexanoic acid. In some embodiments, the bacterial strain of the invention consumes one or both of acetate and propionate. In preferred embodiments, the bacterial strain of the invention produces butyrate, valeric acid, and hexanoic acid and consumes acetate and propionate.</span>
  </p>
  <p id="p0108" num="0108" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una cepa particularmente preferida de la invencin es la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis. </i>Esta es la cepa ejemplar probada en los Ejemplos y que ha demostrado ser eficaz para tratar enfermedades. Por lo tanto, la invencin proporciona una clula, como una clula aislada, de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis</i>, o un derivado de la misma. La invencin tambin proporciona una composicin que comprende una clula de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis, </i>o un derivado de la misma. La invencin tambin proporciona un cultivo biolgicamente puro de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis. </i>La invencin tambin proporciona una clula de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis, </i>o un derivado de la misma, para su uso en terapia, en particular para las enfermedades descritas en la presente.</span>A particularly preferred strain of the invention is <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029.</i> This is the exemplary strain tested in the Examples and has been shown to be effective in treating disease. Thus, the invention provides a cell, as an isolated cell, of <i class="style-scope patent-text">Megasphaera massiliensis</i> strain MRx0029, or a derivative thereof. The invention also provides a composition comprising a cell of <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029,</i> or a derivative thereof. The invention also provides a biologically pure culture of <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029.</i> The invention also provides a cell of <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029,</i> or a derivative thereof, for use in therapy, in particular for the diseases described herein.</span>
  </p>
  <p id="p0109" num="0109" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una cepa particularmente preferida de la invencin es la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 42787. Esta es la cepa MRx0029 ejemplar probada en los Ejemplos y que ha demostrado ser eficaz para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer. Por lo tanto, la invencin proporciona una clula, tal como una clula aislada, de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 42787, o un derivado de la misma. La invencin tambin proporciona una composicin que comprende una clula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 42787, o un derivado de la misma. La invencin tambin proporciona un cultivo biolgicamente puro de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 42787. La invencin tambin proporciona una clula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 42787, o un derivado de la misma, para su uso en terapia, en particular para las enfermedades descritas en la presente.</span>A particularly preferred strain of the invention is the <i class="style-scope patent-text">Megasphaera massiliensis</i> strain deposited under accession number NCIMB 42787. This is the exemplary MRx0029 strain tested in the Examples and has been shown to be effective in stimulating the immune system and in treating and preventing disease, in particularly cancer. Therefore, the invention provides a cell, such as an isolated cell, of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 42787, or a derivative thereof. The invention also provides a composition comprising a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 42787, or a derivative thereof. The invention also provides a biologically pure culture of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 42787. The invention also provides a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 42787, or a derivative thereof, for their use in therapy, in particular for the diseases described herein.</span>
  </p>
  <p id="p0111" num="0111" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un derivado de la cepa de la invencin puede ser una cepa hija (progenie) o una cepa cultivada (subclonada) a partir de la original. Un derivado de una cepa de la invencin puede modificarse, por ejemplo a nivel gentico, sin extirpar la actividad biolgica. En particular, una cepa derivada de la invencin es teraputicamente activa. Una cepa derivada tendr una actividad teraputica comparable a la cepa MRx0029. En particular, una cepa derivada provocar efectos comparables sobre la expresin de MAP2, la expresin de DRD2, los niveles de citoquinas o la supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos. Una cepa derivada puede provocar efectos comparables sobre la actividad inhibidora de la histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos. Un derivado de la cepa MRx0029 ser generalmente un biotipo de la cepa MRx0029.</span>A derivative of the strain of the invention may be a daughter strain (progeny) or a cultivated strain (subcloned) from the original. A derivative of a strain of the invention can be modified, for example at the genetic level, without removing biological activity. In particular, a strain derived from the invention is therapeutically active. A derived strain will have comparable therapeutic activity to the MRx0029 strain. In particular, a derived strain will elicit comparable effects on MAP2 expression, DRD2 expression, cytokine levels, or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative of strain MRx0029 will generally be a biotype of strain MRx0029.</span>
  </p>
  <p id="p0112" num="0112" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las referencias a clulas de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis </i>abarcan cualquier clula que tenga las mismas caractersticas de seguridad y eficacia teraputica que la cepa MRx0029, y tales clulas estn abarcadas por la invencin.</span>References to <i class="style-scope patent-text">Megasphaera massiliensis</i> strain MRx0029 cells encompass any cell that has the same safety and therapeutic efficacy characteristics as strain MRx0029, and such cells are encompassed by the invention.</span>
  </p>
  <p id="p0113" num="0113" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las cepas bacterianas en las composiciones de la invencin son viables y capaces de colonizar parcial o totalmente el intestino.</span>In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonizing the intestine.</span>
  </p>
  <p id="p0114" num="0114" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>aumentan la activacin de citoquinas inflamatorias como IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 y/o <sup class="style-scope patent-text">i</sup>L-6.</span>The inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains increase the activation of inflammatory cytokines such as IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 and/or <sup class="style-scope patent-text">i</sup> L-6.</span>
  </p>
  <p id="p0115" num="0115" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>aumentan la activacin de las clulas inmunitarias y mejoran la secrecin de citoquinas como IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 y/o IL-6.</span>The inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains increase the activation of immune cells and enhance the secretion of cytokines such as IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 and/or IL-6 .</span>
  </p>
  <p id="p0116" num="0116" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 42787, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulacin del sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer, ms preferiblemente cncer de cerebro, como el neuroblastoma. En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 42787, o un 
derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer gstrico, cncer colorrectal y/o enfermedades malignas hematolgicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 42787, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited with the NCIMB under accession number NCIMB 42787, or a  derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma , gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0117" num="0117" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las cepas bacterianas en las composiciones de la invencin son viables y capaces de colonizar parcial o totalmente el intestino.</span>In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonizing the intestine.</span>
  </p>
  <p id="p0118" num="0118" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin no comprende una clula de la cepa 42787 de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>In certain embodiments, the composition of the invention does not comprise a <i class="style-scope patent-text">Megasphaera massiliensis strain 42787 cell.</i> </span>
  </p>
  <p id="p0119" num="0119" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la cepa bacteriana en las composiciones de la invencin es una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 42787.</span>In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under NCIMB accession number 42787.</span>
  </p>
  <p id="p0120" num="0120" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la cepa bacteriana en las composiciones de la invencin es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 42787.</span>In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> wherein the bacterial strain is not the strain deposited under NCIMB accession number 42787.</span>
  </p>
  <p id="p0121" num="0121" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estas cepas bacterianas fueron depositadas ante la autoridad de depsito internacional NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Escocia) por 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB25 2ZS, Escocia) el 6 de mayo de 2019 como <i class="style-scope patent-text">Megasphaera massiliensis </i>(con los nmeros de registro NCIMB 43388 y NCIMB 43389) y <i class="style-scope patent-text">Megasphaera spp. </i>(nmeros de registro NCIMB 43385, NCIMB 43386 y NCIMB 43387). Por consiguiente, en una realizacin alternativa, las composiciones de la invencin comprenden una o ms de estas cepas bacterianas, o biotipos o derivados de las mismas. Para evitar dudas, la Ref 1 mencionada anteriormente es la cepa depositada con el nmero de registro NCIMB 43385, la Ref 2 mencionada anteriormente es la cepa depositada con el nmero de registro NCIMB 43388, y la Ref 3 mencionada anteriormente es la cepa depositada con el nmero de registro NCIMB 43389.</span>These bacterial strains were deposited with the International Depository Authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) by 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB25 2ZS, Scotland) on 6 May 2019 as <i class="style-scope patent-text">Megasphaera massiliensis</i> (with accession numbers NCIMB 43388 and NCIMB 43389) and <i class="style-scope patent-text">Megasphaera spp.</i> (NCIMB registry numbers 43385, NCIMB 43386, and NCIMB 43387). Therefore, in an alternative embodiment, the compositions of the invention comprise one or more of these bacterial strains, or biotypes or derivatives thereof. For the avoidance of doubt, the above-mentioned Ref 1 is the strain deposited under registration number NCIMB 43385, the above-mentioned Ref 2 is the strain deposited under registration number NCIMB 43388, and the above-mentioned Ref 3 is the strain deposited under registration number NCIMB 43388. NCIMB registration number 43389.</span>
  </p>
  <p id="p0122" num="0122" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambin se espera que las cepas bacterianas estrechamente relacionadas con las cepas probadas en los Ejemplos sean eficaces para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer.</span>Bacterial strains closely related to the strains tested in the Examples are also expected to be effective in stimulating the immune system and in treating and preventing disease, particularly cancer.</span>
  </p>
  <p id="p0123" num="0123" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin es la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 43388. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43388, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43388, o un derivado de la misma, para su uso en la estimulacin del sistema inmunitario y para el tratamiento y la prevencin de enfermedades, en particular cncer. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43388, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43388. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43388, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43388, or a derivative thereof, for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer. . In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43388, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0124" num="0124" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invencin proporciona el uso de una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43388, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulacin del sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer, ms preferiblemente cncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invencin proporciona el uso de una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43388, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer gstrico, cncer colorrectal y/o enfermedades malignas hematolgicas.</span>In preferred embodiments, the invention provides the use of a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43388, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and preventing diseases, in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides the use of a composition comprising the strain deposited in the NCIMB under registration number NCIMB 43388, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0125" num="0125" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin para el uso de acuerdo con la invencin no comprende una clula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 43388. En algunas realizaciones, la cepa bacteriana en las composiciones para el uso de acuerdo con la invencin es una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera</i>, en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43388. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invencin es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43388.</span>In certain embodiments, the composition for use according to the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43388. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the bacterial strain is not the strain deposited under NCIMB Accession Number 43388. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> where the bacterial strain is not the strain deposited under the registration number NCIMB 43388.</span>
  </p>
  <p id="p0126" num="0126" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, en ciertas realizaciones, la cepa bacteriana para su uso en la invencin es la <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 43389. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43389, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43389, o un derivado de la misma, para su uso en la estimulacin del sistema 
inmunitario y para tratar y prevenir enfermedades, en particular cncer. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43389, para su uso en cualquiera de las enfermedades descritas en la presente.</span>Accordingly, in certain embodiments, the bacterial strain for use in the invention is <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under NCIMB Accession Number 43389. In certain embodiments, the invention provides a cell of the strain deposited under NCIMB Accession Number 43389, or a derivative thereof, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43389, or a derivative thereof, for use in stimulating the immune system.  immune system and to treat and prevent disease, particularly cancer. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43389, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0127" num="0127" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43389, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulacin del sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer, ms preferiblemente cncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43389, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer gstrico, cncer colorrectal y/o enfermedades malignas hematolgicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43389, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at NCIMB under registration number NCIMB 43389, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer , ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0128" num="0128" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin para su uso de acuerdo con la invencin no comprende una clula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 43389. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invencin es una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43389. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invencin es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43389.</span>In certain embodiments, the composition for use according to the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43389. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under registry number NCIMB 43389. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> where the bacterial strain is not the strain deposited under the registration number NCIMB 43389.</span>
  </p>
  <p id="p0129" num="0129" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idntica a la SEQ ID NO:9. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene la secuencia de ARNr 16S representada por la SEQ ID NO:9. En ciertas realizaciones, la invencin proporciona una cepa bacteriana que tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idntica a la SEQ ID NO:9 para su uso en terapia.</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:9. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO:9. In certain embodiments, the invention provides a bacterial strain having a 16S rRNA sequence that is at least 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:9 for use in therapy.</span>
  </p>
  <p id="p0130" num="0130" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idntica a la SEQ ID NO:10. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 10. En ciertas realizaciones, la invencin proporciona una cepa bacteriana que tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idntica a la SEQ ID NO: 10 para su uso en terapia. En ciertas realizaciones, la invencin proporciona una cepa bacteriana que tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 10 para su uso en terapia.</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:10. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 10. In certain embodiments, the invention provides a bacterial strain that has a 16S rRNA sequence that is at least 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: 10 for use in therapy. In certain embodiments, the invention provides a bacterial strain having the 16S rRNA sequence represented by SEQ ID NO: 10 for use in therapy.</span>
  </p>
  <p id="p0131" num="0131" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% idntica a la secuencia de ARNr 16S de una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera</i>. La cepa bacteriana para su uso en la invencin es del gnero <i class="style-scope patent-text">Megasphaera</i>.</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical. to the 16S rRNA sequence of a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> . The bacterial strain for use in the invention is of the genus <i class="style-scope patent-text">Megasphaera</i> .</span>
  </p>
  <p id="p0132" num="0132" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin es la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el nmero de registro NCIMB 43385. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43385, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43385, o un derivado de la misma, para su uso en la estimulacin del sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43385, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB 43385. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43385, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43385, or a derivative thereof, for use in stimulating the immune system and treating and preventing disease, in particular cancer. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43385, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0133" num="0133" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43385, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulacin del sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer, ms preferiblemente cncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43385, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer gstrico, cncer colorrectal y/o enfermedades malignas hematolgicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43385, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at the NCIMB under registration number NCIMB 43385, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer , ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0134" num="0134" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin no comprende una clula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 43385. En algunas realizaciones, la cepa bacteriana en las composiciones de la invencin es una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43385. En algunas realizaciones, la cepa bacteriana en las composiciones de la invencin es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa 
bacteriana no es la cepa depositada con el nmero de registro NCIMB 43385.</span>In certain embodiments, the composition of the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 43385. In some embodiments, the bacterial strain in the compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under accession number NCIMB 43385. In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> wherein the strain  bacterial is not the strain deposited under accession number NCIMB 43385.</span>
  </p>
  <p id="p0136" num="0136" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin es la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el nmero de registro NCIMB 43386. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43386, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43386, o un derivado de la misma, para su uso en la estimulacin del sistema inmunitario y para el tratamiento y la prevencin de enfermedades, en particular cncer. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43386, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB 43386. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43386, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43386, or a derivative thereof, for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer. . In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43386, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0138" num="0138" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43386, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulacin del sistema inmunitario y para tratar y prevenir enfermedades, en particular cncer, ms preferiblemente cncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43386, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer gstrico, cncer colorrectal y/o enfermedades malignas hematolgicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43386, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at the NCIMB under registration number NCIMB 43386, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer , ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0140" num="0140" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin para su uso de acuerdo con la invencin no comprende una clula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 43386. En algunas realizaciones, la cepa bacteriana en las composiciones de la invencin es una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43386. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invencin es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43386.</span>In certain embodiments, the composition for use according to the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43386. In some embodiments, the bacterial strain in the compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under registry number NCIMB 43386. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> in where the bacterial strain is not the strain deposited under NCIMB accession number 43386.</span>
  </p>
  <p id="p0142" num="0142" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin es la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el nmero de registro NCIMB 43387. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43387, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43387, o un derivado de la misma, para su uso en la estimulacin del sistema inmunitario y para el tratamiento y la prevencin de enfermedades, en particular cncer. En ciertas realizaciones, la invencin proporciona una clula de la cepa depositada con el nmero de registro NCIMB 43387, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB 43387. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43387, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43387, or a derivative thereof, for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer. . In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43387, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0144" num="0144" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en el NCIMB con el nmero de registro NCIMB 43387, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulacin del sistema inmunitario y para el tratamiento y prevencin de enfermedades, en particular cncer, ms preferiblemente cncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invencin proporciona una composicin que comprende la cepa depositada en NCIMB con el nmero de registro NCIMB 43387, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer gstrico, cncer colorrectal y/o enfermedades malignas hematolgicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with registration number NCIMB 43387, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at NCIMB under accession number NCIMB 43387, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0146" num="0146" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin no comprende una clula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 43387. En algunas realizaciones, la cepa bacteriana en las composiciones de la invencin es una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43387. En algunas realizaciones, la cepa bacteriana en las composiciones de la invencin es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el nmero de registro NCIMB 43387.</span>In certain embodiments, the composition of the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 43387. In some embodiments, the bacterial strain in the compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under registry number NCIMB 43387. In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> wherein the bacterial strain is not the strain deposited under NCIMB registration number 43387.</span>
  </p>
  <p id="p0148" num="0148" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idntica a la SEQ ID NO:8. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idntica a la SEQ ID NO: 11. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idntica a la SEQ ID NO: 12. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idntica a las SEQ ID NO: 8, 11 o 12. En ciertas realizaciones, la invencin proporciona una cepa bacteriana que tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idntica a las SEQ ID NO: 8, 11 o 12 para su uso en terapia. 
</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO:8. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO: 11. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO: 12. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO: 8, 11 or 12. In certain embodiments, the invention provides a bacterial strain having a 16S rRNA sequence which is at least 99.5% or 99.9% identical to SEQ ID NO: 8, 11 or 12 for use in therapy. </span>
  </p>
  <p id="p0149" num="0149" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 8. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 11. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene la secuencia de ARNr 16S representada por la SEQ ID NO:12. En ciertas realizaciones, la cepa bacteriana para su uso en la invencin tiene la secuencia de ARNr 16S representada por las SEQ ID NO: 8, 11 o 12. En ciertas realizaciones, la invencin proporciona una cepa bacteriana que tiene la secuencia de ARNr 16S representada por las SEQ ID NO: 8, 11 o 12 para su uso en terapia.</span>In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 8. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 11. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO:12. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 8, 11 or 12. In certain embodiments, the invention provides a bacterial strain having the 16S rRNA sequence represented by SEQ ID NO: 8, 11 or 12 for use in therapy.</span>
  </p>
  <p id="p0151" num="0151" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tambin se espera que las cepas bacterianas que son biotipos de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 sean eficaces para estimular el sistema inmunitario y tratar y prevenir enfermedades. en particular cncer. Un biotipo es una cepa estrechamente relacionada que tiene caractersticas fisiolgicas y bioqumicas iguales o muy similares.</span>Bacterial strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 are also expected to be effective in stimulating the immune system and treating and preventing diseases. particularly cancer. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.</span>
  </p>
  <p id="p0153" num="0153" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona las cepas bacterianas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o biotipos de las mismas, para su uso en terapia.</span>In certain embodiments, the invention provides bacterial strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389, or biotypes thereof, for use in therapy.</span>
  </p>
  <p id="p0155" num="0155" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas que son biotipos de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y que son adecuadas para su uso en la invencin pueden identificarse secuenciando otras secuencias de nucletidos para una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. Por ejemplo, puede secuenciarse sustancialmente el genoma completo y una cepa de biotipo para su uso en la invencin puede tener por lo menos un 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia en por lo menos el 80% de su genoma completo (por ejemplo, en por lo menos el 85%, 90%, 95% o 99%, o en su genoma completo). Otras secuencias adecuadas para su uso en la identificacin de cepas de biotipo pueden incluir hsp60 o secuencias repetitivas como BOX, ERIC, (GTG)5 o REP. Las cepas de biotipo pueden tener secuencias con por lo menos un 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia con la secuencia correspondiente de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389.</span>Strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 and that are suitable for use in the invention may be identified by sequencing other sequences of nucleotides for one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389. For example, substantially the entire genome and a biotype strain can be sequenced for use in invention may have at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% sequence identity in at least 80% of its genome-wide (eg, at least 85%, 90%, 95%, or 99%, or genome-wide). Other sequences suitable for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)5 or REP. Biotype strains may have sequences with at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity with the corresponding sequence from one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389.</span>
  </p>
  <p id="p0157" num="0157" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente, las cepas que son biotipos de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, <sup class="style-scope patent-text">n</sup>C<sup class="style-scope patent-text">i</sup>MB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y que son adecuadas para su uso en la invencin pueden identificarse usando uno o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y anlisis de fragmentos de restriccin y/o anlisis de PCR, por ejemplo usando polimorfismo de longitud de fragmento amplificado fluorescente (FAFLP) e identificacin de elemento de ADN repetitivo (rep)-PCR, o realizacin de perfiles de protenas o secuenciacin parcial de ADNr 16S o 23S. En realizaciones preferidas, tales tcnicas pueden usarse para identificar otras cepas de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>Alternatively, strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, <sup class="style-scope patent-text">n</sup> C <sup class="style-scope patent-text">i</sup> MB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 and that are suitable for use in the invention may identified using one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389 and restriction fragment analysis and/or PCR analysis, for example using length polymorphism Fluorescent Amplified Fragment (FAFLP) and repetitive DNA element identification (rep)-PCR, or protein profiling or partial 16S or 23S rDNA sequencing. In preferred embodiments, such techniques can be used to identify other strains of <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0159" num="0159" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las cepas que son biotipos de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y que son adecuadas para su uso en la invencin son cepas que proporcionan el misma patrn que una o ms de las cepas depositadas con los nmeros de registro NCiMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 cuando se analiza mediante anlisis de restriccin de ADN ribosmico amplificado (ARDRA), por ejemplo, cuando se usa la enzima de restriccin Sau3AI. Alternativamente, las cepas de biotipo se identifican como cepas que tienen los mismos patrones de fermentacin de carbohidratos que una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389.</span>In certain embodiments, strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 and that are suitable for use in the invention are strains that give the same pattern as one or more of the strains deposited under accession numbers NCiMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 when analyzed by amplified ribosomal DNA restriction analysis (ARDRA), e.g. example, when the restriction enzyme Sau3AI is used. Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389.</span>
  </p>
  <p id="p0161" num="0161" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otras cepas que son tiles en las composiciones y mtodos de la invencin, como los biotipos de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, pueden identificarse usando cualquier mtodo o estrategia apropiados, incluyendo los ensayos descritos en los Ejemplos. Por ejemplo, las cepas para su uso en la invencin pueden identificarse aadindolas al lisado celular o a clulas completas y analizando la expresin de MAP2, la expresin de DRD2, los niveles de citoquinas o la supervivencia celular. En particular, las cepas bacterianas que tienen patrones de crecimiento, tipo metablico y/o antgenos de superficie similares a una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCiMB 43389 pueden ser tiles en la invencin. Una cepa til tendr una actividad inmunomoduladora comparable a una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. En particular, una cepa de biotipo provocar efectos comparables sobre la expresin de MAP2, expresin de DRD2, niveles de citoquinas o supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos. Una cepa de biotipo puede provocar efectos comparables sobre la actividad inhibidora de histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos.</span>Other strains that are useful in the compositions and methods of the invention, such as biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389, can be identified using any appropriate method or strategy, including the assays described in the Examples. For example, strains for use in the invention can be identified by adding them to cell lysate or whole cells and analyzing for MAP2 expression, DRD2 expression, cytokine levels, or cell survival. In particular, bacterial strains that have growth patterns, metabolic type, and/or surface antigens similar to one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCiMB 43389 may be useful in the invention. A useful strain will have comparable immunomodulatory activity to one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389. In particular, a biotype strain will elicit comparable effects on the MAP2 expression, DRD2 expression, cytokine levels, or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A biotype strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples.</span>
  </p>
  <p id="p0163" num="0163" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las cepas preferidas de la invencin son cepas depositadas con los nmeros de 
registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. Estas son cepas ejemplares analizadas en los Ejemplos y que han demostrado ser eficaces para tratar enfermedades. Por tanto, la invencin proporciona una clula, como una clula aislada, de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o un derivado de las mismas. La invencin tambin proporciona una composicin que comprende una clula de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o un derivado de las mismas. La invencin tambin proporciona un cultivo biolgicamente puro de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o un derivado de las mismas, para su uso en terapia, en particular para las enfermedades descritas en la presente.</span>In certain embodiments, preferred strains of the invention are strains deposited under accession numbers  registration NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389. These are exemplary strains discussed in the Examples and have been shown to be effective in treating disease. Thus, the invention provides a cell, such as an isolated cell, from one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389, or a derivative thereof. . The invention also provides a composition comprising a cell from one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389, or a derivative thereof. The invention also provides a biologically pure culture of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389, or a derivative thereof, for use in therapy. , in particular for the diseases described herein.</span>
  </p>
  <p id="p0165" num="0165" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un derivado de la cepa de la invencin puede ser una cepa hija (progenie) o una cepa cultivada (subclonada) a partir de la original. Un derivado de una cepa de la invencin puede modificarse, por ejemplo a nivel gentico, sin eliminar la actividad biolgica. En particular, una cepa derivada de la invencin es teraputicamente activa. Una cepa derivada tendr una actividad teraputica comparable a una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. En particular, una cepa derivada provocar efectos comparables sobre la expresin de MAP2, expresin de DRD2, niveles de citoquinas o supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos. Una cepa derivada puede provocar efectos comparables sobre la actividad inhibidora de la histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administracin descritos en los Ejemplos. Un derivado de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 ser generalmente un biotipo de una o ms de las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, respectivamente.</span>A derivative of the strain of the invention may be a daughter strain (progeny) or a cultivated strain (subcloned) from the original. A derivative of a strain of the invention can be modified, for example at the genetic level, without eliminating biological activity. In particular, a strain derived from the invention is therapeutically active. A derivative strain will have therapeutic activity comparable to one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389. In particular, a derivative strain will elicit comparable effects on expression of MAP2, DRD2 expression, cytokine levels, or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389 will generally be a biotype of one or more of the strains deposited under accession numbers NCIMB 43385. , NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389, respectively.</span>
  </p>
  <p id="p0167" num="0167" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han descubierto que la cepa bacteriana usada en los Ejemplos produce cido 2-metilpropanoico y cido 3-metil-butanoico y consume cido frmico (ver Figura 58). Tambin se descubri que las cepas depositadas con los nmeros de registro NCIMB 43385, NC<sup class="style-scope patent-text">i</sup>M<sup class="style-scope patent-text">b </sup>43388 y NCIMB 43389 producan cido 2-metilpropanoico y cido 3-metil-butanoico. Adems, tambin se descubri que las cepas depositadas con los nmeros de registro NCIMB 43385 y NCIMB 43388 consuman cido frmico.</span>The inventors have found that the bacterial strain used in the Examples produces 2-methyl-propanoic acid and 3-methyl-butanoic acid and consumes formic acid (see Figure 58). Strains deposited under accession numbers NCIMB 43385, NC <sup class="style-scope patent-text">i</sup> M <sup class="style-scope patent-text">b</sup> 43388 and NCIMB 43389 were also found to produce 2-methyl-propanoic acid and 3-methyl-butanoic acid. In addition, strains deposited under accession numbers NCIMB 43385 and NCIMB 43388 were also found to consume formic acid.</span>
  </p>
  <p id="p0169" num="0169" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, en algunas realizaciones, la cepa bacteriana de la invencin produce uno o ms de los metabolitos cido 2-metil-propanoico y cido 3-metil-butanoico. En algunas realizaciones, la cepa bacteriana de la invencin consume cido frmico. En algunas realizaciones, la cepa bacteriana de la invencin produce cido 2-metil-propanoico y cido 3-metil-butanoico y consume cido frmico. En realizaciones preferidas, la cepa bacteriana de la invencin produce butirato, cido valrico, cido hexanoico, cido 2-metil-propanoico y cido 3-metil-butanoico, y consume acetato, propionato y cido frmico.</span>Therefore, in some embodiments, the bacterial strain of the invention produces one or more of the metabolites 2-methyl-propanoic acid and 3-methyl-butanoic acid. In some embodiments, the bacterial strain of the invention consumes formic acid. In some embodiments, the bacterial strain of the invention produces 2-methyl-propanoic acid and 3-methyl-butanoic acid and consumes formic acid. In preferred embodiments, the bacterial strain of the invention produces butyrate, valeric acid, hexanoic acid, 2-methyl-propanoic acid, and 3-methyl-butanoic acid, and consumes acetate, propionate, and formic acid.</span>
  </p>
  <p id="p0171" num="0171" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la produccin de butirato y/o cido valrico genera secrecin de IL-8. Por consiguiente, en ciertas realizaciones, las composiciones de la invencin pueden estimular el sistema inmunitario a travs de la produccin de butirato y/o cido valrico.</span>In certain embodiments, the production of butyrate and/or valeric acid generates secretion of IL-8. Accordingly, in certain embodiments, the compositions of the invention can stimulate the immune system through the production of butyrate and/or valeric acid.</span>
  </p>
  <p id="p0173" num="0173" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin no comprenden <i class="style-scope patent-text">Megasphaera elsdenii. </i>En ciertas realizaciones, la cepa bacteriana til en las composiciones y mtodos de la invencin no es <i class="style-scope patent-text">Megasphaera elsdenii.</i> </span>In certain embodiments, the compositions of the invention do not comprise <i class="style-scope patent-text">Megasphaera elsdenii.</i> In certain embodiments, the bacterial strain useful in the compositions and methods of the invention is not <i class="style-scope patent-text">Megasphaera elsdenii.</i> </span>
  </p>
  <p id="p0175" num="0175" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Usos teraputicos</span>therapeutic uses</span>
    </i>
  </p>
  <p id="p0177" num="0177" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estimulacin del sistema inmunitario</span>Stimulation of the immune system</span>
    </i>
  </p>
  <p id="p0179" num="0179" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos muestran que la administracin de las composiciones para su uso de acuerdo con la invencin puede llevar a una estimulacin inmunitaria en clulas mononucleares de sangre perifrica humanas (PBMC). Como se ha demostrado que la administracin de las composiciones de la invencin tiene un efecto inmunoestimulador sobre las PBMC, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades, en particular enfermedades caracterizadas por activacin inmunitaria reducida y enfermedades que pueden tratarse por una respuesta inmunitaria aumentada. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de enfermedades mediante la estimulacin del sistema inmunitario. En ciertas realizaciones, las composiciones de la invencin son para su uso en la promocin de promover una respuesta inmunitaria.</span>The examples show that administration of the compositions for use according to the invention can lead to immune stimulation in human peripheral blood mononuclear cells (PBMC). As administration of the compositions of the invention has been shown to have an immunostimulatory effect on PBMCs, the compositions of the invention may be useful in the treatment of diseases, in particular diseases characterized by reduced immune activation and diseases that can be treated by increased immune response. In certain embodiments, the compositions of the invention are for use in treating disease by stimulating the immune system. In certain embodiments, the compositions of the invention are for use in promoting an immune response.</span>
  </p>
  <p id="p0181" num="0181" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administracin de las composiciones para su uso de acuerdo con la invencin puede llevar a una disminucin del porcentaje de Tregs en las PBMC (Figura 6C). Las Tregs, tambin conocidas como clulas T supresoras, son una poblacin de clulas T que funcionan para suprimir la respuesta inmunitaria. Las Tregs se caracterizan por la alta expresin del marcador de superficie celular CD25 y la baja expresin de CD127 [19]. Como se ha demostrado que la administracin de las composiciones de la invencin 
reduce selectivamente la poblacin de Tregs (Figura 6C), las composiciones para su uso de acuerdo con la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por un aumento en el porcentaje de Tregs en una poblacin celular. En una realizacin, las composiciones para su uso de acuerdo con la invencin pueden ser tiles para tratar o prevenir enfermedades caracterizadas por un aumento en el porcentaje de Tregs en una poblacin celular. En una realizacin, las composiciones de la invencin pueden ser tiles para el tratamiento o prevencin de enfermedades caracterizadas por un aumento en el porcentaje de clulas CD4+CD25+CD127- en una poblacin celular. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades disminuyendo el porcentaje de Tregs en las poblaciones celulares. En una realizacin, las composiciones de la invencin son para su uso en la reduccin de la supresin de la respuesta inmunitaria por Tregs. En una realizacin, las composiciones de la invencin son para su uso en la estimulacin de la respuesta inmunitaria mediante la reduccin selectiva de Tregs. En una realizacin, las composiciones de la invencin son para su uso en la inmunoestimulacin, en donde las composiciones de la invencin reducen el nmero o porcentaje de Tregs.</span>The Examples show that the administration of the compositions for use according to the invention can lead to a decrease in the percentage of Tregs in PBMC (Figure 6C). Tregs, also known as suppressor T cells, are a population of T cells that function to suppress the immune response. Tregs are characterized by high expression of the cell surface marker CD25 and low expression of CD127 [19]. As it has been shown that the administration of the compositions of the invention  selectively reduces the population of Tregs (Figure 6C), the compositions for use according to the invention may be useful in the treatment of diseases characterized by an increase in the percentage of Tregs in a cell population. In one embodiment, compositions for use according to the invention may be useful for treating or preventing diseases characterized by an increase in the percentage of Tregs in a cell population. In one embodiment, the compositions of the invention may be useful for the treatment or prevention of diseases characterized by an increase in the percentage of CD4+CD25+CD127- cells in a cell population. In one embodiment, the compositions of the invention are for use in treating or preventing disease by lowering the percentage of Tregs in cell populations. In one embodiment, the compositions of the invention are for use in reducing suppression of the immune response by Tregs. In one embodiment, the compositions of the invention are for use in stimulating the immune response through the selective reduction of Tregs. In one embodiment, the compositions of the invention are for use in immunostimulation, wherein the compositions of the invention reduce the number or percentage of Tregs.</span>
  </p>
  <p id="p0183" num="0183" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invencin pueden ser capaces de dirigirse selectivamente a las Tregs, sin afectar significativamente a clulas como clulas B, clulas T CD4 o clulas T CD8. Por lo tanto, las composiciones de la invencin pueden reducir selectivamente las Tregs en las PBMC, sin afectar significativamente al porcentaje de los otros tipos de clulas analizadas. En una realizacin, las composiciones de la invencin son para su uso en la reduccin selectiva del nmero o porcentaje de Tregs, en donde el nmero o porcentaje de clulas T CD4 no cambia significativamente. En una realizacin, las composiciones de la invencin son para su uso en la reduccin selectiva del nmero o porcentaje de Tregs, en donde el nmero o porcentaje de clulas T CD8 no cambia significativamente. En una realizacin, las composiciones de la invencin son para su uso en la reduccin selectiva del nmero o porcentaje de Tregs, en donde el nmero o porcentaje de clulas B no cambia significativamente. En una realizacin adicional, las composiciones de la invencin son para su uso en la reduccin selectiva del nmero o porcentaje de Tregs, en donde el nmero o porcentaje de clulas B, clulas T CD4 y/o clulas T CD8 no cambia significativamente.</span>The examples demonstrate that the compositions of the invention may be able to selectively target Tregs, without significantly affecting cells such as B cells, CD4 T cells or CD8 T cells. Therefore, the compositions of the invention can selectively reduce Tregs in PBMC, without significantly affecting the percentage of the other cell types tested. In one embodiment, the compositions of the invention are for use in selectively reducing the number or percentage of Tregs, wherein the number or percentage of CD4 T cells does not change significantly. In one embodiment, the compositions of the invention are for use in selectively reducing the number or percentage of Tregs, wherein the number or percentage of CD8 T cells does not change significantly. In one embodiment, the compositions of the invention are for use in the selective reduction of the number or percentage of Tregs, wherein the number or percentage of B cells does not change significantly. In a further embodiment, the compositions of the invention are for use in selectively reducing the number or percentage of Tregs, wherein the number or percentage of B cells, CD4 T cells, and/or CD8 T cells does not change significantly.</span>
  </p>
  <p id="p0185" num="0185" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La disminucin en el porcentaje de Tregs fue particularmente sorprendente porque la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis </i>produce butirato, y el butirato se ha asociado con niveles de clulas Tregs aumentados en sangre y una actividad de Tregs aumentada [20]. Por lo tanto, era inesperado que las composiciones de la invencin llevaran a una disminucin en el porcentaje de Tregs en las PBMC.</span>The decrease in the percentage of Tregs was particularly surprising because the <i class="style-scope patent-text">Megasphaera massiliensis</i> strain MRx0029 produces butyrate, and butyrate has been associated with increased blood Treg cell levels and increased Treg activity [20]. Therefore, it was unexpected that the compositions of the invention lead to a decrease in the percentage of Tregs in PBMC.</span>
  </p>
  <p id="p0187" num="0187" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la proporcin de clulas CD8 a clulas Tregs. Las clulas T CD8+ (clulas CD8) son clulas T citotxicas y desempean un papel clave en la defensa inmunitaria contra los patgenos intracelulares. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la proporcin tanto de las clulas CD8/Tregs como de las clulas CD8/Tregs activadas (Figura 6G y Figura 6H), las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin en la proporcin de clulas CD8/Tregs y/o CD8/Tregs activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por la disminucin de la proporcin de clulas CD8/Tregs. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por la disminucin de la proporcin de clulas CD8/Tregs activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o la prevencin de enfermedades disminuyendo el porcentaje de clulas Tregs en las poblaciones celulares, aumentando de este modo la proporcin de clulas CD8/Tregs. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o la prevencin de enfermedades disminuyendo el porcentaje de clulas Tregs en las poblaciones celulares, aumentando de este modo la proporcin de clulas CD8/Tregs, en donde el aumento en la proporcin de clulas CD8/Tregs da como resultado la inmunoestimulacin. En otra realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades disminuyendo el porcentaje de Tregs en las poblaciones celulares, aumentando de este modo la proporcin de clulas CD8/Tregs activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o la prevencin de enfermedades disminuyendo el porcentaje de clulas Tregs en las poblaciones celulares, aumentando de este modo la proporcin de clulas CD8/Tregs, en donde el aumento en la proporcin de clulas CD8/Tregs activadas da como resultado la estimulacin inmunitaria. En una realizacin, las composiciones de la invencin son para su uso en la estimulacin de la respuesta inmunitaria aumentando la proporcin de clulas CD8/Tregs. En una realizacin, las composiciones de la invencin son para su uso en la estimulacin de la respuesta inmunitaria aumentando la proporcin de clulas CD8/Tregs activadas.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the ratio of CD8 cells to Treg cells. CD8+ T cells (CD8 cells) are cytotoxic T cells and play a key role in immune defense against intracellular pathogens. As administration of the compositions of the invention has been shown to increase the proportion of both CD8/Tregs cells and activated CD8/Tregs cells (Figure 6G and Figure 6H), the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the proportion of activated CD8/Tregs and/or CD8/Tregs cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by decreased CD8/Treg cell ratios. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decreased ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Treg cells in cell populations, thereby increasing the CD8/Treg cell ratio. In one embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Treg cells in cell populations, thereby increasing the CD8/Treg cell ratio, wherein the increase in CD8/Treg cell ratio results in immunostimulation. In another embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Tregs in cell populations, thereby increasing the ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Treg cells in cell populations, thereby increasing the CD8/Treg cell ratio, wherein the increase in ratio of activated CD8/Treg cells results in immune stimulation. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the ratio of CD8/Treg cells. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the ratio of activated CD8/Treg cells.</span>
  </p>
  <p id="p0189" num="0189" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en el porcentaje de clulas CD19+CD3- en las PBMC (Figura 6F). Por lo tanto, la administracin de las composiciones de la invencin puede llevar a un aumento del porcentaje de clulas B en una poblacin celular. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta el porcentaje de clulas B, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin en el nmero o porcentaje de clulas B. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en el nmero o porcentaje de clulas B. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o 
prevencin de enfermedades caracterizadas por una disminucin del nmero o porcentaje de clulas CD19+CD3-. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando el nmero o porcentaje de clulas B en poblaciones celulares, en donde el aumento en el nmero o porcentaje de clulas B da como resultado una estimulacin inmunitaria. En una realizacin, las composiciones de la invencin son para su uso en la estimulacin de la respuesta inmunitaria aumentando el nmero o porcentaje de clulas B.</span>The Examples also show that the administration of the compositions of the invention can lead to an increase in the percentage of CD19+CD3- cells in PBMC (Figure 6F). Therefore, administration of the compositions of the invention can lead to an increase in the percentage of B cells in a cell population. Since administration of the compositions of the invention has been shown to increase the percentage of B cells, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the number or percentage of B cells. In one embodiment, The compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the number or percentage of B cells. In one embodiment, the compositions of the invention are for use in the treatment or  prevention of diseases characterized by a decrease in the number or percentage of CD19+CD3- cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the number or percentage of B cells in cell populations, wherein the increase in the number or percentage of B cells results in immune stimulation. . In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the number or percentage of B cells.</span>
  </p>
  <p id="p0191" num="0191" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en el porcentaje de clulas T-citotxicas CD8 (Figura 6D) en las PBMC. Por lo tanto, la administracin de las composiciones de la invencin puede llevar a un aumento del porcentaje de clulas T CD8 en una poblacin celular. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta el porcentaje de clulas T citotxicas CD8, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin en el nmero o porcentaje de clulas T citotxicas CD8. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en el nmero o porcentaje de clulas T citotxicas CD8. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando el nmero o porcentaje de clulas T citotxicas CD8 en poblaciones celulares, en donde el aumento en el nmero o porcentaje de clulas T citotxicas CD8 da como resultado una estimulacin inmunitaria. En una realizacin, las composiciones de la invencin son para su uso en la estimulacin de la respuesta inmunitaria aumentando el nmero o porcentaje de clulas T-citotxicas CD8.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the percentage of CD8 cytotoxic T-cells (FIG. 6D) in PBMC. Therefore, administration of the compositions of the invention can lead to an increase in the percentage of CD8 T cells in a cell population. Since administration of the compositions of the invention has been shown to increase the percentage of CD8 cytotoxic T cells, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the number or percentage of CD8 cytotoxic T cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the number or percentage of CD8 cytotoxic T cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the number or percentage of CD8 cytotoxic T cells in cell populations, wherein increasing the number or percentage of CD8 cytotoxic T cells results in result in immune stimulation. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the number or percentage of CD8 cytotoxic T-cells.</span>
  </p>
  <p id="p0193" num="0193" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en el porcentaje de clulas CD8+ activadas (Figura 6E) en las PBMC. Por lo tanto, la administracin de las composiciones de la invencin puede llevar a un aumento del porcentaje de clulas CD8+ activadas en una poblacin celular. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta el porcentaje de clulas CD8+ activadas, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin en el nmero o porcentaje de clulas CD8+ activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en el nmero o porcentaje de clulas CD8+ activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o la prevencin de enfermedades aumentando el nmero o porcentaje de clulas CD8+ activadas en poblaciones celulares, en donde el aumento en el nmero o porcentaje de clulas CD8+ activadas da como resultado una estimulacin inmunitaria. En una realizacin, las composiciones de la invencin son para su uso en la estimulacin de la respuesta inmunitaria aumentado el nmero o porcentaje de clulas CD8+ activadas.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the percentage of activated CD8+ cells (FIG. 6E) in PBMC. Therefore, the administration of the compositions of the invention can lead to an increase in the percentage of activated CD8+ cells in a cell population. Since administration of the compositions of the invention has been shown to increase the percentage of activated CD8+ cells, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the number or percentage of activated CD8+ cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the number or percentage of activated CD8+ cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the number or percentage of activated CD8+ cells in cell populations, wherein the increase in the number or percentage of activated CD8+ cells results in an immune stimulation. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the number or percentage of activated CD8+ cells.</span>
  </p>
  <p id="p0195" num="0195" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administracin de las composiciones para su uso de acuerdo con la invencin puede llevar a un aumento en la expresin de molculas proinflamatorias en las PBMC, como citoquinas proinflamatorias (Figura 7 y Figura 9). Los ejemplos de molculas inmunoestimuladoras (por ejemplo, proinflamatorias) que mostraron un aumento en los niveles de expresin tras la administracin de las composiciones de la invencin incluyen IL-23, TNF-a, IL-1 p, MIP-3a, IL-8 e IL -6. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de molculas inmunoestimuladoras (por ejemplo, proinflamatorias), las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin de molculas proinflamatorias, como las citoquinas proinflamatorias. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de molculas proinflamatorias, en particular enfermedades caracterizadas por una disminucin en la expresin y/o actividad de citoquinas proinflamatorias. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-23, TNF-a, IL-1 p, MIP-3a y/o IL-6. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-8. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de CD11b. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y /o actividad de IL-23, TNF-a, IL-1 p, MIP-3a y/o IL-6. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-8. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o la actividad de CD11b. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y /o actividad de IL-23, TNF-a, IL-1 p, MIP-3a y/o IL-6. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de IL-8. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de CD11b.</span>The Examples show that administration of the compositions for use according to the invention can lead to an increase in the expression of proinflammatory molecules in PBMC, such as proinflammatory cytokines (Figure 7 and Figure 9). Examples of immunostimulatory (eg, proinflammatory) molecules that showed increased expression levels following administration of the compositions of the invention include IL-23, TNF-a, IL-1p, MIP-3a, IL-8 and IL-6. As administration of the compositions of the invention has been shown to increase the expression of immunostimulatory (eg, proinflammatory) molecules, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of proinflammatory molecules, such as proinflammatory cytokines. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of proinflammatory molecules, in particular diseases characterized by a decrease in the expression and/or activity of proinflammatory cytokines. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-23, TNF-a, IL-1 p, MIP-3a and /or IL-6. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-8. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases by increasing the expression and/or activity of IL-23, TNF-a, IL-1 p, MIP-3a and/or IL-6. . In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-23, TNF-a, IL-1 p, MIP-3a and/or IL-6. . In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of CD11b.</span>
  </p>
  <p id="p0197" num="0197" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-1 p en las PBMC. IL-1 p es una citoquina proinflamatoria [21]. La produccin y 
secrecin de IL-1 p est regulada por el inflamasoma, un complejo proteico que est asociado con la activacin de la respuesta inflamatoria [22]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-1 p, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin de IL-1 p. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-1 p. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-1 p. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de IL-1 p. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es til en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-1 p. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es til en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-1 p. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es til en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de IL-1 p.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-1 p in PBMC. IL-1p is a proinflammatory cytokine [21]. the production and  IL-1 p secretion is regulated by the inflammasome, a protein complex that is associated with the activation of the inflammatory response [22]. Since administration of the compositions of the invention has been shown to increase the expression of IL-1p, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-1p. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-1 p. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-1 p. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-1 p. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is useful in the treatment of diseases characterized by decreased expression and/or activity of IL-1 p. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is useful in treating or preventing disease by increasing the expression and/or activity of IL-1 p. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is useful in promoting the immune response by increasing the expression and/or activity of IL-1 p.</span>
  </p>
  <p id="p0199" num="0199" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-23. La IL-23 se ha relacionado con la inflamacin [23,24] Las funciones propuestas de la IL-23 en la respuesta inmunitaria incluyen promover la proliferacin de clulas T de memoria CD4+ y promover la secrecin de IFN-<b class="style-scope patent-text"> <sup class="style-scope patent-text">y </sup> </b>por las clulas dendrticas (DC) [25]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-23, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin de la expresin de IL-23. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-23. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-23. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de IL-23. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-23. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-23. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de IL-23.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-23. IL-23 has been linked to inflammation [23,24] Proposed roles of IL-23 in the immune response include promoting proliferation of CD4+ memory T cells and promoting IFN <b class="style-scope patent-text"> <sup class="style-scope patent-text">-</sup> </b>  secretion by dendritic cells ( DC) [25]. Since administration of the compositions of the invention has been shown to increase the expression of IL-23, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-23. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-23. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-23. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-23. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of IL-23. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing the expression and/or activity of IL-23. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of IL-23.</span>
  </p>
  <p id="p0201" num="0201" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de Protena Inflamatoria de Macrfagos-3 (MIP3-a) o CCL20 en las PBMC. La MIP3-a es una quimiocina inflamatoria que se une al receptor CCR6 y funciona como quimioatrayente para las DC y las clulas T de memoria. La MIP3-a se asocia con el desencadenamiento de la respuesta inmunitaria adaptativa mediante el reclutamiento de DC inmaduras en el sitio de la inflamacin [26]. La expresin desregulada de MIP3-a se ha asociado con enfermedades como la enfermedad inflamatoria intestinal [27]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de MIP3-a, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizado por una disminucin en la expresin de MIP3-a. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de MIP3-a. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de MIP3-a. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de MIP3-a. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de MIP3-a. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de MIP3-a. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de MIP3-a</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of Macrophage Inflammatory Protein-3 (MIP3-a) or CCL20 in PBMC. MIP3-a is an inflammatory chemokine that binds to the CCR6 receptor and functions as a chemoattractant for DC and memory T cells. MIP3-a is associated with the triggering of the adaptive immune response by recruiting immature DC to the site of inflammation [26]. Deregulated expression of MIP3-a has been associated with diseases such as inflammatory bowel disease [27]. As administration of the compositions of the invention has been shown to increase the expression of MIP3-a, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the expression of MIP3-a. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of MIP3-a. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of MIP3-a. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of MIP3-a. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of MIP3-a. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing the expression and/or activity of MIP3-a. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of MIP3-a</span>
  </p>
  <p id="p0203" num="0203" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin del Factor de Necrosis Tumoral alfa (TNF-a). El TNF-a es una citoquina proinflamatoria que se sabe que est implicada en varias vas de sealizacin para promover la muerte celular. TNF-a inicia la apoptosis al unirse a su receptor afn, TNFR-1, lo que lleva a una cascada de eventos de escisin en la va apopttica [28]. El TNF-a tambin puede desencadenar necrosis a travs de un mecanismo dependiente de la quinasa RIP [29]. Como la administracin de las composiciones de la invencin muestra un aumento en la expresin de TNF-a, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades, en particular para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin de TNF-a. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin de TNF-a. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de TNF-a. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar o prevenir enfermedades aumentando la expresin y/o actividad de TNF-a. En una realizacin, las composiciones de la 
invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de TNF-a. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de TNF-a. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de TNF-a. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de TNF-a.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of Tumor Necrosis Factor alpha (TNF-a). TNF- is a proinflammatory cytokine that is known to be involved in various signaling pathways to promote cell death. TNF- initiates apoptosis by binding to its cognate receptor, TNFR-1, leading to a cascade of cleavage events in the apoptotic pathway [28]. TNF-a can also trigger necrosis through a RIP kinase-dependent mechanism [29]. As the administration of the compositions of the invention shows an increase in the expression of TNF-a, the compositions of the invention may be useful in the treatment of diseases, in particular for use in the treatment or prevention of diseases characterized by a decrease in the expression of TNF-a. In one embodiment, the compositions of the invention are for use in the treatment of diseases characterized by decreased expression of TNF-. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of TNF-a. In one embodiment, the compositions of the invention may be useful for treating or preventing disease by increasing the expression and/or activity of TNF-. In one embodiment, the compositions of the  invention are for use in promoting the immune response by increasing the expression and/or activity of TNF-. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of TNF-. In one embodiment, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating or preventing disease by increasing the expression and/or activity of TNF-. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of TNF-.</span>
  </p>
  <p id="p0205" num="0205" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-6 en PBMC. La IL-6 es una citoquina proinflamatoria que se produce durante la inflamacin y promueve la diferenciacin de clulas T CD4+ inmaduras y la diferenciacin de clulas T CD8+ en clulas T citotxicas [30]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-6, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin de la expresin de IL-6. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-6. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-6. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de IL-6. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-6. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-6. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de IL-6.</span>The Examples also show that administration of the compositions of the invention can lead to increased expression of IL-6 in PBMC. IL-6 is a proinflammatory cytokine that is produced during inflammation and promotes the differentiation of immature CD4+ T cells and the differentiation of CD8+ T cells into cytotoxic T cells [30]. Since administration of the compositions of the invention has been shown to increase the expression of IL-6, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-6. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-6. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-6. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-6. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of IL-6. In one embodiment, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating or preventing disease by increasing IL-6 expression and/or activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of IL-6.</span>
  </p>
  <p id="p0207" num="0207" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bettelli et al. [31] informaron que la IL-6 inhibe la produccin de Tregs. Como los Ejemplos muestran que las composiciones de la invencin aumentan la expresin de IL-6, las composiciones de la invencin pueden disminuir selectivamente el nmero o porcentaje de Tregs aumentando la expresin de IL-6. En una realizacin, las composiciones de la invencin son para su uso en inmunoestimulacin aumentando la expresin de IL-6. En otra realizacin, las composiciones de la invencin son para su uso en inmunoestimulacin disminuyendo el nmero o porcentaje de Tregs. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en inmunoestimulacin aumentando la expresin de IL-6. En otra realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en inmunoestimulacin disminuyendo el nmero o porcentaje de Tregs.</span>Bettelli et al. [31] reported that IL-6 inhibits the production of Tregs. As the Examples show that the compositions of the invention increase the expression of IL-6, the compositions of the invention can selectively decrease the number or percentage of Tregs by increasing the expression of IL-6. In one embodiment, the compositions of the invention are for use in immunostimulation by increasing the expression of IL-6. In another embodiment, the compositions of the invention are for use in immunostimulation by decreasing the number or percentage of Tregs. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in immunostimulation by increasing the expression of IL-6. In another embodiment, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in immunostimulation by decreasing the number or percentage of Tregs.</span>
  </p>
  <p id="p0209" num="0209" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-8 (ver Ejemplo 8). La IL-8 es una citoquina proinflamatoria secretada predominantemente por macrfagos con efectos inmunoestimuladores. Induce la quimiotaxis en las clulas objetivo, principalmente los neutrfilos pero tambin otros granulocitos, lo que hace que migren hacia el sitio de la infeccin. IL-8 tambin estimula la fagocitosis. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-8, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin de la expresin de IL-8. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de IL-8. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-8. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de IL-8. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin de IL-8 y/o la actividad de IL-8. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de IL-8. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de IL-8.</span>The Examples also show that the administration of the compositions of the invention can lead to an increase in the expression of IL-8 (see Example 8). IL-8 is a proinflammatory cytokine secreted predominantly by macrophages with immunostimulatory effects. It induces chemotaxis in target cells, mainly neutrophils but also other granulocytes, causing them to migrate towards the site of infection. IL-8 also stimulates phagocytosis. Since administration of the compositions of the invention has been shown to increase the expression of IL-8, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-8. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-8. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating diseases characterized by decreased IL-8 expression and/or IL-8 activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing the expression and/or activity of IL-8. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of IL-8.</span>
  </p>
  <p id="p0211" num="0211" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de CD11b (ver Ejemplo 12). La CD11b es una citoquina proinflamatoria con efectos inmunoestimuladores. La CD11b se expresa en la superficie de muchos leucocitos implicados en el sistema inmunitario innato y media la inflamacin regulando la adhesin y migracin de leucocitos. CD11b se ha implicado en varios procesos inmunitarios, por ejemplo, fagocitosis, citotoxicidad mediada por clulas, quimiotaxis y activacin celular. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de CD11b, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin de CD11 b. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por una disminucin en la expresin y/o actividad de CD11b. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de CD11b. En una realizacin, las composiciones de la invencin son para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o actividad de CD11b. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera </i>
<i class="style-scope patent-text">massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminucin en la expresin de CD11b y/o la actividad de CD11b. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades aumentando la expresin y/o actividad de CD11b. En una realizacin, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promocin de la respuesta inmunitaria aumentando la expresin y/o la actividad de CD11b.</span>The Examples also show that the administration of the compositions of the invention can lead to an increase in the expression of CD11b (see Example 12). CD11b is a proinflammatory cytokine with immunostimulatory effects. CD11b is expressed on the surface of many leukocytes involved in the innate immune system and mediates inflammation by regulating leukocyte adhesion and migration. CD11b has been implicated in various immune processes, eg, phagocytosis, cell-mediated cytotoxicity, chemotaxis, and cell activation. Since administration of the compositions of the invention has been shown to increase CD11b expression, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of CD11b. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of CD11b. In certain embodiments, a bacterial strain of <i class="style-scope patent-text">Megasphaera</i> species  <i class="style-scope patent-text">massiliensis</i> is for use in the treatment of diseases characterized by a decrease in CD11b expression and/or CD11b activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing CD11b expression and/or activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing CD11b expression and/or activity.</span>
  </p>
  <p id="p0213" num="0213" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que las composiciones de la invencin pueden inducir la activacin del promotor NF-<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>BAp1 (ver Figura 61). El NF-<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>B est implicado en la activacin de la respuesta inmunitaria, en particular estimulando la expresin de mediadores de la inflamacin y de citoquinas implicadas en la respuesta inmunitaria, por ejemplo, la IL-6. Como se ha descrito anteriormente, un aumento en la expresin de IL-6 ayuda a estimular el sistema inmunitario y, por lo tanto, la activacin de la va NF-<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>B tiene actividad inmunoestimuladora. Por consiguiente, en ciertas realizaciones, las composiciones de la invencin activan la sealizacin de NF-kB y estimulan por tanto el sistema inmunitario. En ciertas realizaciones, las composiciones de la invencin estimulan la expresin de mediadores de inflamacin y citoquinas inmunoestimuladoras aumentando la activacin del promotor NF-kB.</span>The Examples show that the compositions of the invention can induce activation of the NF- <b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b> B-Ap1 promoter (see Figure 61). NF- <b class="style-scope patent-text"> <sup class="style-scope patent-text">kB</sup> </b> is involved in the activation of the immune response, in particular by stimulating the expression of inflammatory mediators and cytokines involved in the immune response, for example, IL-6. As described above, an increase in IL-6 expression helps to stimulate the immune system, and therefore activation of the NF- <b class="style-scope patent-text"> <sup class="style-scope patent-text">kB</sup> </b> pathway has immunostimulatory activity. Accordingly, in certain embodiments, the compositions of the invention activate NF-kB signaling and thereby stimulate the immune system. In certain embodiments, the compositions of the invention stimulate the expression of inflammatory mediators and immunostimulatory cytokines by increasing activation of the NF-kB promoter.</span>
  </p>
  <p id="p0215" num="0215" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cncer</span>Cancer</span>
    </i>
  </p>
  <p id="p0217" num="0217" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de cerebro, en particular el neuroblastoma. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin del melanoma, en particular el melanoma metastsico. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de cerebro. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del neuroblastoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del melanoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del melanoma metastsico. En una realizacin ms preferida, la composicin de la invencin comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>y es para su uso en el tratamiento o prevencin del cncer de cerebro, en particular el neuroblastoma. En otra realizacin ms preferida, la composicin de la invencin comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>y es para su uso en el tratamiento o prevencin del melanoma, en particular el melanoma metastsico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of cancer. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of brain cancer, in particular neuroblastoma. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of melanoma, in particular metastatic melanoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of brain cancer. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of neuroblastoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of melanoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of metastatic melanoma. In a more preferred embodiment, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> and is for use in the treatment or prevention of brain cancer, in particular neuroblastoma. In another more preferred embodiment, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> and is for use in the treatment or prevention of melanoma, in particular metastatic melanoma.</span>
  </p>
  <p id="p0219" num="0219" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos (Ejemplo 1) demuestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de tubulina beta de Clase III (Tubulina p3) en clulas de neuroblastoma no diferenciadas. La tubulina p3 es ampliamente conocida como marcador neuronal [32]. Los ejemplos tambin demuestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de la protena 2 asociada a microtbulos (MAP2) en clulas de neuroblastoma no diferenciadas. MAP2 se expresa predominantemente en las neuronas y funciona para estabilizar los microtbulos, para promover el desarrollo de las dendritas y para el crecimiento de las neuritas [33]. MAP2 es conocido como un marcador de neuronas diferenciadas.</span>The Examples (Example 1) demonstrate that administration of the compositions of the invention can lead to an increase in the expression of Class III beta tubulin (Tubulin p3) in undifferentiated neuroblastoma cells. Tubulin p3 is widely known as a neuronal marker [32]. The examples also demonstrate that administration of the compositions of the invention can lead to increased expression of microtubule-associated protein 2 (MAP2) in undifferentiated neuroblastoma cells. MAP2 is predominantly expressed in neurons and functions to stabilize microtubules, to promote dendrite development and neurite outgrowth [33]. MAP2 is known as a marker of differentiated neurons.</span>
  </p>
  <p id="p0221" num="0221" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los agentes que provocan la diferenciacin celular se han asociado con agentes teraputicos contra el cncer, ya que la administracin de agentes de diferenciacin celular se ha correlacionado con la inhibicin del crecimiento tumoral [34]. Por lo tanto, las composiciones de la invencin pueden ser tiles en el tratamiento del cncer. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento de cnceres induciendo la diferenciacin celular, en particular la diferenciacin neuronal. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer de cerebro induciendo la diferenciacin neuronal, en particular el tratamiento del neuroblastoma.</span>Agents that cause cell differentiation have been associated with anticancer therapeutics, as administration of cell differentiation agents has been correlated with inhibition of tumor growth [34]. Therefore, the compositions of the invention may be useful in the treatment of cancer. In a particular embodiment, the compositions of the invention are for use in the treatment of cancers by inducing cell differentiation, in particular neuronal differentiation. In one embodiment, the compositions of the invention are for use in the treatment of brain cancer by inducing neuronal differentiation, in particular the treatment of neuroblastoma.</span>
  </p>
  <p id="p0223" num="0223" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, se ha descubierto que MAP2 se expresa en gran medida en los melanomas cutneos primarios, pero tiene una expresin reducida en los melanomas metastsicos [35]. Se ha propuesto que la expresin aumentada de protenas estabilizadoras de microtbulos o el tratamiento con protenas estabilizadoras de microtbulos como MAP2 pueden interferir en la inestabilidad dinmica de los microtbulos que se requiere durante la divisin celular. Por lo tanto, se cree que la regulacin por incremento de MAP2 dificulta la divisin celular y retrasa el crecimiento tumoral en el cncer [35]. Por lo tanto, las composiciones de la invencin pueden ser tiles para tratar el cncer, en particular los cnceres metastsicos. En una realizacin, las composiciones de la invencin son para su uso en un mtodo para tratar el cncer. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres mediados por expresin disminuida de MAP2. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres caracterizados por una expresin de MAP2 disminuida o ausente. En ciertas realizaciones, las composiciones de la invencin son para su uso en el aumento de la expresin de MAP2 en el tratamiento del cncer. En una realizacin preferida, las composiciones de la invencin son para su uso en el tratamiento o prevencin del melanoma. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin del melanoma metastsico. 
</span>Furthermore, MAP2 has been found to be highly expressed in primary cutaneous melanomas, but has reduced expression in metastatic melanomas [35]. It has been proposed that increased expression of microtubule-stabilizing proteins or treatment with microtubule-stabilizing proteins such as MAP2 may interfere with the dynamic instability of microtubules that is required during cell division. Therefore, upregulation of MAP2 is thought to hinder cell division and delay tumor growth in cancer [35]. Therefore, the compositions of the invention may be useful for treating cancer, particularly metastatic cancers. In one embodiment, the compositions of the invention are for use in a method of treating cancer. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancers mediated by decreased expression of MAP2. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancers characterized by decreased or absent MAP2 expression. In certain embodiments, the compositions of the invention are for use in increasing MAP2 expression in the treatment of cancer. In a preferred embodiment, the compositions of the invention are for use in the treatment or prevention of melanoma. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of metastatic melanoma. </span>
  </p>
  <p id="p0224" num="0224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las combinaciones teraputicas de la invencin son para su uso en el tratamiento o prevencin del melanoma. De acuerdo con algunas realizaciones, las combinaciones teraputicas de la invencin tienen un efecto sobre los melanocitos y pueden ser eficaces para tratar el melanoma. En ciertas realizaciones, las combinaciones teraputicas de la invencin son para su uso en la reduccin del tamao del tumor, reducir el crecimiento del tumor o reducir la angiognesis en el tratamiento del melanoma.</span>In certain embodiments, the therapeutic combinations of the invention are for use in the treatment or prevention of melanoma. According to some embodiments, the therapeutic combinations of the invention have an effect on melanocytes and may be effective in treating melanoma. In certain embodiments, the therapeutic combinations of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of melanoma.</span>
  </p>
  <p id="p0226" num="0226" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En particular, los Ejemplos muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de MAP2 en clulas de neuroblastoma no diferenciadas. Como MAP2 es ampliamente conocido como un marcador de neuronas diferenciadas y se ha demostrado que su expresin tiene implicaciones en el cncer, las composiciones de la invencin pueden ser particularmente tiles para tratar el cncer de cerebro, como el neuroblastoma. En una realizacin, las composiciones de la invencin son para su uso en un mtodo para tratar el cncer de cerebro. En una realizacin preferida, las composiciones de la invencin son para su uso en un mtodo para tratar el neuroblastoma.</span>In particular, the Examples show that administration of the compositions of the invention can lead to increased expression of MAP2 in undifferentiated neuroblastoma cells. As MAP2 is widely known as a marker of differentiated neurons and its expression has been shown to have implications in cancer, the compositions of the invention may be particularly useful for treating brain cancer, such as neuroblastoma. In one embodiment, the compositions of the invention are for use in a method of treating brain cancer. In a preferred embodiment, the compositions of the invention are for use in a method of treating neuroblastoma.</span>
  </p>
  <p id="p0228" num="0228" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a una disminucin significativa en la expresin del Receptor de Dopamina D2 (DRD2) (ver el Ejemplo 2 y la Figura 3). El DRD2 es un receptor acoplado a protena G (GPCR) y es parte de la familia de los receptores de dopamina. DRD2 est implicado en las vas de sealizacin que promueven la supervivencia celular y, por lo tanto, est asociado con el cncer. La sobreexpresin o regulacin por incremento de DRD2 se ha implicado en varios tipos de cncer, ya que las clulas malignas muestran una expresin de DRD2 aumentada en comparacin con las clulas normales [36]. Se ha demostrado que la inhibicin de DRD2 a travs de antagonistas especficos de DRD2 tiene efectos antitumorales. Se ha demostrado que los antagonistas de DRD2 tienen eficacia antitumoral en muchos tipos de cncer, incluyendo el cncer de mama [37][38], el glioblastoma [39][40][4l], el neuroblastoma [42], carcinoma hepatocelular [43], cncer de pulmn, cncer de prstata [44], cncer de cuello uterino [45], cncer de ovario [46], linfoma [47] y cncer gstrico [48]. Por lo tanto, las composiciones que disminuyen el nivel de expresin de DRD2 pueden ser tiles para el tratamiento del cncer. Como se ha demostrado que la administracin de las composiciones de la invencin disminuye la expresin de DRD2, las composiciones de la invencin pueden ser tiles en el tratamiento del cncer, en particular para su uso en el tratamiento o prevencin de cnceres caracterizados por una expresin de DRD2 aumentada. En una realizacin, las composiciones de la invencin pueden ser tiles en el tratamiento o prevencin de cnceres caracterizados por una expresin y/o actividad de DRD2 aumentadas. En ciertas realizaciones, las composiciones de la invencin son para su uso en la disminucin de la expresin y/o actividad de DRD2 en el tratamiento del cncer. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar el cncer, en particular cncer de mama, el cncer de ovario, el cncer de cuello uterino, el cncer de cerebro, en particular el glioblastoma y el neuroblastoma, el carcinoma, en particular el carcinoma hepatocelular, el cncer de pulmn, el cncer de prstata, el linfoma y/o el cncer gstrico. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar o prevenir el cncer disminuyendo el nivel y/o la actividad de DRD2.</span>Furthermore, the Examples also show that administration of the compositions of the invention can lead to a significant decrease in Dopamine Receptor D2 (DRD2) expression (see Example 2 and Figure 3). DRD2 is a G protein-coupled receptor (GPCR) and is part of the dopamine receptor family. DRD2 is involved in signaling pathways that promote cell survival and is therefore associated with cancer. Overexpression or upregulation of DRD2 has been implicated in several types of cancer, as malignant cells show increased expression of DRD2 compared to normal cells [36]. Inhibition of DRD2 through specific DRD2 antagonists has been shown to have antitumor effects. DRD2 antagonists have been shown to have antitumor efficacy in many types of cancer, including breast cancer [37][38], glioblastoma [39][40][4l], neuroblastoma [42], hepatocellular carcinoma [ 43], lung cancer, prostate cancer [44], cervical cancer [45], ovarian cancer [46], lymphoma [47], and gastric cancer [48]. Therefore, compositions that decrease the expression level of DRD2 may be useful for the treatment of cancer. As administration of the compositions of the invention has been shown to decrease the expression of DRD2, the compositions of the invention may be useful in the treatment of cancer, in particular for use in the treatment or prevention of cancers characterized by an expression of increased DRD2. In one embodiment, the compositions of the invention may be useful in the treatment or prevention of cancers characterized by increased DRD2 expression and/or activity. In certain embodiments, the compositions of the invention are for use in decreasing the expression and/or activity of DRD2 in the treatment of cancer. In one embodiment, the compositions of the invention may be useful for treating cancer, particularly breast cancer, ovarian cancer, cervical cancer, brain cancer, particularly glioblastoma and neuroblastoma, carcinoma, in particular hepatocellular carcinoma, lung cancer, prostate cancer, lymphoma and/or gastric cancer. In one embodiment, the compositions of the invention may be useful for treating or preventing cancer by lowering the level and/or activity of DRD2.</span>
  </p>
  <p id="p0230" num="0230" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Prabhu et al. informaron que ONC201, un antagonista de DRD2, ha demostrado eficacia en la reduccin de tumores en modelos de glioblastoma. La expresin de DRD2 est regulada por incremento en los tumores de glioblastoma y, por lo tanto, DRD2 es un objetivo atractivo para agentes teraputicos contra el cncer [49]. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del glioblastoma.</span>Prabhu et al. reported that ONC201, a DRD2 antagonist, has shown efficacy in shrinking tumors in glioblastoma models. DRD2 expression is upregulated in glioblastoma tumors and therefore DRD2 is an attractive target for anticancer therapeutics [49]. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of glioblastoma.</span>
  </p>
  <p id="p0232" num="0232" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de Caspasa 3 (Casp3) en clulas SH-SY5Y. Las caspasas son parte de la familia de las cistenas proteasas y se sabe que promueven la apoptosis. Casp3 se conoce como una caspasa ejecutora, que desempea un papel importante en la cascada de escisin de protenas celulares en la va apopttica. La regulacin por disminucin de la expresin de Casp3 se ha demostrado previamente en cnceres de tejidos tumorales de mama, ovario y cuello uterino, y se cree que la disminucin de la expresin de Casp3 promueve la supervivencia celular en el tejido canceroso [50]. Por lo tanto, las composiciones que aumentan el nivel de expresin de las caspasas ejecutoras, en particular Casp3, pueden ser tiles para el tratamiento del cncer. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de Casp3, las composiciones de la invencin pueden ser tiles en el tratamiento del cncer, en particular para su uso en el tratamiento o prevencin de cnceres mediados por la expresin de Casp3. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres caracterizados por una expresin disminuida o ausente de Casp3. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar cnceres caracterizados por una expresin disminuida o ausente de la caspasa ejecutora. En una realizacin particular, las composiciones de la invencin pueden ser tiles para tratar o prevenir cnceres caracterizados por una expresin disminuida o ausente de Casp3. En ciertas realizaciones, las composiciones de la invencin son para su uso en el aumento de la expresin de Casp3 en el tratamiento del cncer. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar el cncer, en particular cncer de mama, cncer de ovario y/o cncer de cuello uterino. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar el cncer aumentando el nivel y/o la actividad de Casp3.</span>The Examples also show that administration of the compositions of the invention can lead to increased expression of Caspase 3 (Casp3) in SH-SY5Y cells. Caspases are part of the cysteine protease family and are known to promote apoptosis. Casp3 is known as an executor caspase, which plays an important role in the cellular protein cleavage cascade in the apoptotic pathway. Down-regulation of Casp3 expression has been previously shown in breast, ovarian, and cervical tumor tissue cancers, and downregulation of Casp3 expression is thought to promote cell survival in cancer tissue [50]. Therefore, compositions that increase the expression level of executor caspases, in particular Casp3, may be useful for the treatment of cancer. As administration of the compositions of the invention has been shown to increase the expression of Casp3, the compositions of the invention may be useful in the treatment of cancer, in particular for use in the treatment or prevention of cancers mediated by the expression of Casp3. Casp3. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancers characterized by decreased or absent expression of Casp3. In one embodiment, the compositions of the invention may be useful for treating cancers characterized by decreased or absent expression of the executioner caspase. In a particular embodiment, the compositions of the invention may be useful for treating or preventing cancers characterized by decreased or absent expression of Casp3. In certain embodiments, the compositions of the invention are for use in increasing Casp3 expression in the treatment of cancer. In one embodiment, the compositions of the invention may be useful for treating cancer, particularly breast cancer, ovarian cancer, and/or cervical cancer. In one embodiment, the compositions of the invention may be useful for treating cancer by increasing the level and/or activity of Casp3.</span>
  </p>
  <p id="p0234" num="0234" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, se ha informado que las caspasas estn implicadas en procesos distintos a la apoptosis, como la 
diferenciacin celular [51]. Los Ejemplos (Ejemplo 1 y Ejemplo 3) demuestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de los marcadores neuronales Tubulina p3 y MAP2, y tambin aumentar la expresin de Casp3 en clulas de neuroblastoma indiferenciado. Como las composiciones de la invencin pueden llevar a un aumento en la expresin de marcadores neuronales y protenas que se sabe que desempean un papel en la diferenciacin celular, las composiciones de la invencin pueden ser tiles en la diferenciacin de neuronas de clulas indiferenciadas.</span>Furthermore, caspases have been reported to be involved in processes other than apoptosis, such as  cell differentiation [51]. The Examples (Example 1 and Example 3) demonstrate that the administration of the compositions of the invention can lead to an increase in the expression of the neuronal markers Tubulin p3 and MAP2, and also increase the expression of Casp3 in undifferentiated neuroblastoma cells. As the compositions of the invention may lead to an increase in the expression of neuronal markers and proteins known to play a role in cell differentiation, the compositions of the invention may be useful in the differentiation of neurons from undifferentiated cells.</span>
  </p>
  <p id="p0236" num="0236" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a una disminucin de la viabilidad celular en clulas de neuroblastoma no diferenciadas (Figura 5). En particular, los Ejemplos muestran que la administracin de MRx0029 a una concentracin del 5% o del 10% provoca una disminucin significativa, dependiente de la dosis, en la viabilidad celular (Figura 5).</span>The Examples also show that administration of the compositions of the invention can lead to decreased cell viability in undifferentiated neuroblastoma cells (Figure 5). In particular, the Examples show that administration of MRx0029 at a concentration of 5% or 10% causes a significant, dose-dependent decrease in cell viability (Figure 5).</span>
  </p>
  <p id="p0238" num="0238" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sabe que una disminucin de la viabilidad celular o un aumento de la muerte celular de las clulas cancerosas es un objetivo para el tratamiento del cncer [52] Por lo tanto, las composiciones que disminuyen la viabilidad celular en lneas celulares de cncer, como las lneas celulares de neuroblastoma, pueden ser tiles para el tratamiento del cncer. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer disminuyendo la viabilidad celular. En otra realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer aumentando la muerte celular.</span>A decrease in cell viability or an increase in cell death of cancer cells is known to be a target for cancer treatment [52]. Therefore, compositions that decrease cell viability in cancer cell lines, such as neuroblastoma cell lines, may be useful for cancer treatment. In one embodiment, the compositions of the invention are for use in treating cancer by decreasing cell viability. In another embodiment, the compositions of the invention are for use in treating cancer by increasing cell death.</span>
  </p>
  <p id="p0240" num="0240" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, como los Ejemplos muestran que las composiciones de la invencin aumentan tanto la expresin de Casp3 como disminuyen la viabilidad celular (Figura 4 y Figura 5), se propone que las composiciones de la invencin disminuyan la viabilidad celular regulando por incremento la apoptosis. En una realizacin, las composiciones de la invencin son para su uso en la regulacin por incremento de la apoptosis. En otra realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer aumentando la muerte celular, en particular aumentando la apoptosis. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de cnceres disminuyendo la viabilidad celular. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de cnceres disminuyendo la viabilidad celular. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de cnceres mediante la regulacin por incremento de la apoptosis. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento de cnceres mediante la regulacin por incremento de la apoptosis. En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento de cnceres caracterizados por una expresin reducida o ausente de Casp3 mediante la regulacin por incremento de la apoptosis. En ciertas realizaciones, las composiciones de la invencin son para su uso en el aumento de la apoptosis en el tratamiento del cncer. En ciertas realizaciones, las composiciones de la invencin son para su uso en la disminucin de la viabilidad celular en el tratamiento del cncer.</span>Furthermore, as the Examples show that the compositions of the invention both increase Casp3 expression and decrease cell viability (Figure 4 and Figure 5), it is proposed that the compositions of the invention decrease cell viability by upregulating apoptosis. In one embodiment, the compositions of the invention are for use in upregulating apoptosis. In another embodiment, the compositions of the invention are for use in the treatment of cancer by increasing cell death, in particular by increasing apoptosis. In one embodiment, the compositions of the invention are for use in treating cancers by decreasing cell viability. In one embodiment, the compositions of the invention are for use in treating cancers by decreasing cell viability. In one embodiment, the compositions of the invention are for use in treating cancers by upregulating apoptosis. In a particular embodiment, the compositions of the invention are for use in the treatment of cancers by upregulating apoptosis. In a particular embodiment, the compositions of the invention are for use in the treatment of cancers characterized by reduced or absent expression of Casp3 through upregulation of apoptosis. In certain embodiments, the compositions of the invention are for use in increasing apoptosis in the treatment of cancer. In certain embodiments, the compositions of the invention are for use in decreasing cell viability in the treatment of cancer.</span>
  </p>
  <p id="p0242" num="0242" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que las composiciones de la invencin aumentan tanto la expresin de Casp3 como la de MAP2. Por lo tanto, la regulacin por incremento de Casp3 y la regulacin por incremento de MAP2 pueden estar relacionadas.</span>The Examples show that the compositions of the invention increase both Casp3 and MAP2 expression. Therefore, the upregulation of Casp3 and the upregulation of MAP2 may be related.</span>
  </p>
  <p id="p0244" num="0244" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La acetilacin y desacetilacin de histonas son importantes reguladores epigenticos de la expresin gnica. La regulacin epigentica es una poderosa herramienta para regular todos los aspectos de la funcin celular. Las histonas deacetilasas (HDAC) reprimen la expresin gnica eliminando los grupos acetilo de un aminocido s-N-acetil lisina en una histona, permitiendo que las histonas envuelvan el ADN con ms fuerza y dando como resultado la supresin transcripcional a travs de la inaccesibilidad del nucleosoma. HDAC tiene 18 isoformas que se organizan en cuatro clases: Clase I, II, III y IV. Se han observado alteraciones en los niveles de HDAC en muchos tipos de enfermedades incluyendo, por ejemplo, cnceres, enfermedades infecciosas, enfermedades inflamatorias y enfermedades neurodegenerativas [53,54,55].</span>Histone acetylation and deacetylation are important epigenetic regulators of gene expression. Epigenetic regulation is a powerful tool for regulating all aspects of cell function. Histone deacetylases (HDACs) repress gene expression by removing the acetyl groups from an amino acid s-N-acetyl lysine on a histone, allowing histones to wrap DNA more tightly and resulting in transcriptional suppression through nucleosome inaccessibility. HDAC has 18 isoforms that are organized into four classes: Class I, II, III, and IV. Alterations in HDAC levels have been observed in many types of diseases including, for example, cancers, infectious diseases, inflammatory diseases, and neurodegenerative diseases [53,54,55].</span>
  </p>
  <p id="p0246" num="0246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inhibidores de HDAC (HDACi) son una clase emergente de frmacos anticancergenos prometedores que han demostrado que provocan la detencin del crecimiento, la diferenciacin, la apoptosis, la reduccin de la angiognesis y la modulacin de la respuesta inmunitaria en una variedad de lneas celulares de cncer [56,57,58,59]. Aunque el mecanismo preciso por el cual est mediada la actividad clnica de estos agentes sigue sin estar claro, actualmente se estn investigando una amplia variedad de HDACi como posibles agentes anticancergenos. Adems, debido a la actividad anticancergena demostrable en estudios tanto in vitro como in vivo, muchos HDACi han progresado rpidamente a travs del desarrollo clnico, ya sea como monoterapias o en combinacin con otros agentes anticancergenos [60]. Entre ellos, el vorinostat (Zolinza), la romidepsina (Istodax) y el belinostat (Beleodaq) han recibido la aprobacin de la FDA de los Estados Unidos para el tratamiento del linfoma. El linfoma y otros tipos de cncer de la sangre (tambin llamados cnceres hematolgicos o enfermedades malignas hematolgicas) son particularmente sensibles a los HDACi. El microbiota intestinal, con su inmensa diversidad y capacidad metablica, representa un enorme depsito metablico para la produccin de una amplia variedad de molculas con efectos potenciales sobre la actividad de HDAC. Pocos estudios han evaluado la actividad inhibidora de HDAC de metabolitos derivados de microbios distintos del butirato, que se ha demostrado que inhibe HDAC y se asocia con una mejora de la funcin motora en la enfermedad de Huntington [61].</span>HDAC inhibitors (HDACi) are an emerging class of promising anticancer drugs that have been shown to cause growth arrest, differentiation, apoptosis, reduced angiogenesis, and modulation of the immune response in a variety of cell lines from cancer [56,57,58,59]. Although the precise mechanism by which the clinical activity of these agents is mediated remains unclear, a wide variety of HDACi are currently being investigated as potential anticancer agents. Furthermore, due to demonstrable anticancer activity in both in vitro and in vivo studies, many HDACi have rapidly progressed through clinical development, either as monotherapies or in combination with other anticancer agents [60]. Among them, vorinostat (Zolinza), romidepsin (Istodax), and belinostat (Beleodaq) have received US FDA approval for the treatment of lymphoma. Lymphoma and other blood cancers (also called hematologic cancers or hematologic malignancies) are particularly sensitive to HDACi. The gut microbiota, with its immense diversity and metabolic capacity, represents a huge metabolic reservoir for the production of a wide variety of molecules with potential effects on HDAC activity. Few studies have evaluated the HDAC inhibitory activity of microbially derived metabolites other than butyrate, which has been shown to inhibit HDAC and is associated with improved motor function in Huntington's disease [61].</span>
  </p>
  <p id="p0248" num="0248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que las composiciones de la invencin inhiben la actividad HDAC, en particular 
HDAC de Clase I, por ejemplo HDAC2 (Ejemplos 9 y 10). Por consiguiente, en ciertas realizaciones, las composiciones de la invencin modulan la actividad de HDAC. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC. En ciertas realizaciones, las composiciones de la invencin inhiben HDAC. En ciertas realizaciones, las composiciones de la invencin son HDACi. En realizaciones preferidas, las composiciones de la invencin reducen la actividad de HDAC Clase I. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC de Clase II. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC de Clase III. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC de Clase IV. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC1. En realizaciones preferidas, las composiciones de la invencin reducen la actividad de HDAC2. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC3. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC a travs de la produccin de cido valrico. En ciertas realizaciones, las composiciones de la invencin reducen la actividad de HDAC a travs de la produccin de butirato de sodio. En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer reduciendo la actividad de HDAC. En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres asociados con HDAC. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, neuroblastoma, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer colorrectal, enfermedades malignas hematolgicas y/o cncer gstrico reduciendo la actividad de HDAC. En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades malignas hematolgicas reduciendo la actividad de HDAC.</span>The Examples show that the compositions of the invention inhibit HDAC activity, in particular  Class I HDAC, for example HDAC2 (Examples 9 and 10). Accordingly, in certain embodiments, the compositions of the invention modulate HDAC activity. In certain embodiments, the compositions of the invention reduce HDAC activity. In certain embodiments, the compositions of the invention inhibit HDAC. In certain embodiments, the compositions of the invention are HDACi. In preferred embodiments, compositions of the invention reduce HDAC Class I activity. In certain embodiments, compositions of the invention reduce HDAC Class II activity. In certain embodiments, the compositions of the invention reduce Class III HDAC activity. In certain embodiments, the compositions of the invention reduce Class IV HDAC activity. In certain embodiments, the compositions of the invention reduce the activity of HDAC1. In preferred embodiments, the compositions of the invention reduce the activity of HDAC2. In certain embodiments, the compositions of the invention reduce the activity of HDAC3. In certain embodiments, the compositions of the invention reduce HDAC activity through the production of valeric acid. In certain embodiments, the compositions of the invention reduce HDAC activity through the production of sodium butyrate. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of cancer by reducing HDAC activity. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of HDAC-associated cancers. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, cancer prostate, lymphoma, colorectal cancer, hematological malignancies and/or gastric cancer by reducing HDAC activity. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of hematologic malignancies by reducing HDAC activity.</span>
  </p>
  <p id="p0250" num="0250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invencin da como resultado la detencin del crecimiento. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invencin da como resultado la detencin del ciclo celular. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invencin da como resultado la diferenciacin celular. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invencin da como resultado la apoptosis. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invencin da como resultado la reduccin de la angiognesis. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invencin da como resultado la modulacin de la respuesta inmunitaria. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin de la actividad de HDAC como monoterapia. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin de la actividad de HDAC como terapia de combinacin. En ciertas realizaciones, las composiciones de la invencin se utilizan en combinacin con otro agente anticancergeno. En ciertas realizaciones, las composiciones de la invencin son para su uso en combinacin con ms de otro agente anticancergeno. En ciertas realizaciones, las composiciones de la invencin son para su uso en combinacin con un agente quimioteraputico. En ciertas realizaciones, las composiciones de la invencin son para su uso en combinacin con un inhibidor de proteasomas. En aspectos adicionales, las composiciones de la invencin son reguladores epigenticos. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades caracterizadas por aberraciones epigenticas.</span>In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in growth arrest. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in cell cycle arrest. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in cell differentiation. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in apoptosis. In certain embodiments, the HDAC inhibitory activity of the compositions of the invention results in the reduction of angiogenesis. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in modulation of the immune response. In certain embodiments, the compositions of the invention are for use in reducing HDAC activity as monotherapy. In certain embodiments, the compositions of the invention are for use in reducing HDAC activity as combination therapy. In certain embodiments, the compositions of the invention are used in combination with another anticancer agent. In certain embodiments, the compositions of the invention are for use in combination with more than one other anticancer agent. In certain embodiments, the compositions of the invention are for use in combination with a chemotherapeutic agent. In certain embodiments, the compositions of the invention are for use in combination with a proteasome inhibitor. In additional aspects, the compositions of the invention are epigenetic regulators. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of diseases characterized by epigenetic aberrations.</span>
  </p>
  <p id="p0252" num="0252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>modula la actividad de HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>inhibe HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es una HDACi. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase I. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase II. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase III. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase IV. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC1. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC2. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC3. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC a travs de la produccin de cido valrico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC a travs de la produccin de butirato de sodio. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer mediante la reduccin de la actividad de HDAC. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de cnceres asociados con HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, neuroblastoma, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer colorrectal, enfermedades malignas hematolgicas y/o cncer gstrico reduciendo la actividad de HDAC. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades malignas hematolgicas mediante la reduccin de la actividad de HDAC. 
</span>In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> modulates HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> inhibits HDAC. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is an HDACi. In preferred embodiments, a bacterial strain of <i class="style-scope patent-text">Megasphaera massiliensis</i> species reduces Class I HDAC activity. In certain embodiments, a bacterial strain of <i class="style-scope patent-text">Megasphaera massiliensis</i> species reduces Class II HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces Class III HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces Class IV HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces the activity of HDAC1. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces the activity of HDAC2. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces the activity of HDAC3. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces HDAC activity through the production of valeric acid. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces HDAC activity through the production of sodium butyrate. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing cancer by reducing HDAC activity. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of HDAC-associated cancers. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, glioblastoma, carcinoma, lung cancer, lymphocytic leukemia. chronic, prostate cancer, lymphoma, colorectal cancer, hematological malignancies and/or gastric cancer by reducing HDAC activity. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing hematological malignancies by reducing HDAC activity. </span>
  </p>
  <p id="p0253" num="0253" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la detencin del crecimiento. En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la detencin del ciclo celular. En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la diferenciacin celular. En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la apoptosis. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado una reduccin de la angiognesis. En ciertas realizaciones, la actividad inhibidora de HDAC de una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la modulacin de la respuesta inmunitaria. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin de la actividad de HDAC como monoterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin de la actividad de HDAC como terapia de combinacin. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinacin con otro agente anticancergeno. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinacin con ms de otro agente anticancergeno. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinacin con un agente quimioteraputico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinacin con un inhibidor de proteasomas. En aspectos adicionales, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es un regulador epigentico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades caracterizadas por aberraciones epigenticas.</span>In certain embodiments, the HDAC inhibitory activity of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species bacterial strain results in growth arrest. In certain embodiments, the HDAC inhibitory activity of the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> results in cell cycle arrest. In certain embodiments, the HDAC inhibitory activity of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species bacterial strain results in cell differentiation. In certain embodiments, the HDAC inhibitory activity of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species bacterial strain results in apoptosis. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> results in reduced angiogenesis. In certain embodiments, HDAC inhibitory activity of a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> results in modulation of the immune response. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing HDAC activity as monotherapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing HDAC activity as a combination therapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in combination with another anticancer agent. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in combination with more than one other anticancer agent. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in combination with a chemotherapeutic agent. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in combination with a proteasome inhibitor. In additional aspects, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is an epigenetic regulator. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating or preventing diseases characterized by epigenetic aberrations.</span>
  </p>
  <p id="p0255" num="0255" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden regular la permeabilidad epitelial modificando la transduccin de seales intracelulares implicadas en la expresin y localizacin de protenas implicadas en la funcin de barrera intestinal. En particular, las composiciones de la invencin mejoran la expresin de ARNm de ocludina, villina, protena de unin estrecha 1 (TJP1) y protena de unin estrecha 2 (TJP2). Por lo tanto, las composiciones de la invencin funcionan para aumentar la funcin de barrera intestinal y reducir la permeabilidad intestinal (Ejemplo 11). En ciertas realizaciones, las composiciones de la invencin son para su uso en el aumento de la funcin de barrera intestinal. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin de la permeabilidad intestinal. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de la reduccin de la funcin de barrera intestinal. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del aumento de la permeabilidad intestinal. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades o condiciones que se caracterizan por la reduccin de la funcin de barrera intestinal. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades o afecciones que se caracterizan por una permeabilidad intestinal aumentada. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o la prevencin de la reduccin de la funcin de barrera intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o la prevencin del aumento de la permeabilidad intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de la caquexia aumentando la funcin de barrera intestinal. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin de la caquexia reduciendo la permeabilidad intestinal. En ciertas realizaciones, la caquexia es caquexia por cncer.</span>The compositions of the invention can regulate epithelial permeability by modifying intracellular signal transduction involved in the expression and localization of proteins involved in intestinal barrier function. In particular, the compositions of the invention enhance the expression of occludin, villin, tight junction protein 1 (TJP1), and tight junction protein 2 (TJP2) mRNA. Therefore, the compositions of the invention function to increase intestinal barrier function and reduce intestinal permeability (Example 11). In certain embodiments, the compositions of the invention are for use in enhancing intestinal barrier function. In certain embodiments, the compositions of the invention are for use in reducing intestinal permeability. In certain embodiments, the compositions of the invention are for use in treating or preventing reduced intestinal barrier function. In certain embodiments, the compositions of the invention are for use in treating or preventing increased intestinal permeability. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of diseases or conditions characterized by reduced intestinal barrier function. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of diseases or conditions that are characterized by increased intestinal permeability. In certain embodiments, the compositions of the invention are for use in treating or preventing reduced intestinal barrier function resulting from radiation therapy or chemotherapy. In certain embodiments, the compositions of the invention are for use in treating or preventing increased intestinal permeability resulting from radiation therapy or chemotherapy. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cachexia by increasing intestinal barrier function. In certain embodiments, the compositions of the invention are for use in treating or preventing cachexia by reducing intestinal permeability. In certain embodiments, the cachexia is cancer cachexia.</span>
  </p>
  <p id="p0257" num="0257" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>espara su uso en el aumento de la funcin de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin de la permeabilidad intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de la reduccin de la funcin de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del aumento de la permeabilidad intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades o afecciones que se caracterizan por la reduccin de la funcin de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades o afecciones que se caracterizan por una permeabilidad intestinal aumentada. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de la reduccin de la funcin de barrera intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del aumento de la permeabilidad intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de la caquexia aumentando la funcin de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de la caquexia reduciendo la permeabilidad intestinal. En ciertas realizaciones, la caquexia es caquexia por cncer.</span>In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in augmenting intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing intestinal permeability. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing reduced intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing increased intestinal permeability. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of diseases or conditions characterized by reduced intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of diseases or conditions that are characterized by increased intestinal permeability. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing reduced intestinal barrier function resulting from radiation therapy or chemotherapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing increased intestinal permeability resulting from radiation therapy or chemotherapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing cachexia by increasing intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing cachexia by reducing intestinal permeability. In certain embodiments, the cachexia is cancer cachexia.</span>
  </p>
  <p id="p0259" num="0259" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones son para tratar el cncer en un paciente que se est sometiendo a radioterapia o quimioterapia. En tales realizaciones, la composicin puede administrarse antes, 
durante o despus de la radioterapia o la quimioterapia. A los pacientes sometidos a radioterapia o quimioterapia no se les debe administrar ningn agente que induzca un intestino permeable, pero la <i class="style-scope patent-text">Megasphaera massiliensis </i>promueve la funcin de barrera intestinal [62], por lo que las composiciones de la invencin son particularmente adecuadas para tratar pacientes sometidos a radioterapia o quimioterapia. Se ha demostrado que la activacin de TLR-5 mejora el dao epitelial inducido por la radiacin in vivo [63]. Las composiciones de la invencin tambin activan el sistema inmunitario. En algunas realizaciones, las composiciones de la invencin son para su uso en el tratamiento del dao inducido por radioterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento del dao inducido por radioterapia.</span>In preferred embodiments, the compositions are for treating cancer in a patient undergoing radiation therapy or chemotherapy. In such embodiments, the composition may be administered before,  during or after radiation therapy or chemotherapy. Patients undergoing radiotherapy or chemotherapy should not be given any agent that induces leaky gut, but <i class="style-scope patent-text">Megasphaera massiliensis</i> promotes intestinal barrier function [62], so the compositions of the invention are particularly suitable for treating patients undergoing to radiotherapy or chemotherapy. Activation of TLR-5 has been shown to ameliorate radiation-induced epithelial damage in vivo [63]. The compositions of the invention also activate the immune system. In some embodiments, the compositions of the invention are for use in the treatment of radiation therapy-induced damage. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating radiation-induced damage.</span>
  </p>
  <p id="p0261" num="0261" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invencin pueden llevar a una reduccin del crecimiento tumoral.</span>In some embodiments, the compositions of the invention may lead to a reduction in tumor growth.</span>
  </p>
  <p id="p0263" num="0263" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, el tratamiento con las composiciones de la invencin da como resultado una reduccin del tamao del tumor o una reduccin del crecimiento del tumor. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor o reduccin del crecimiento del tumor. Las composiciones de la invencin pueden ser eficaces para reducir el tamao o el crecimiento del tumor. En ciertas realizaciones, las composiciones de la invencin son para su uso en pacientes con tumores slidos. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin o prevencin de la angiognesis en el tratamiento del cncer. Las composiciones de la invencin pueden tener un efecto sobre los sistemas inmunitario o inflamatorio, que tienen funciones centrales en la angiognesis. Las composiciones de la invencin pueden tener actividad antimetastsica. Una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>puede tener actividad antimetastsica. En ciertas realizaciones, las composiciones de la invencin son para su uso en la prevencin de la metstasis. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la prevencin de la metstasis.</span>In certain embodiments, treatment with the compositions of the invention results in a reduction in tumor size or a reduction in tumor growth. In certain embodiments, the compositions of the invention are for use in reducing tumor size or reducing tumor growth. The compositions of the invention may be effective in reducing tumor size or growth. In certain embodiments, the compositions of the invention are for use in patients with solid tumors. In certain embodiments, the compositions of the invention are for use in reducing or preventing angiogenesis in the treatment of cancer. The compositions of the invention may have an effect on the immune or inflammatory systems, which have central roles in angiogenesis. The compositions of the invention may have antimetastatic activity. A bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> may have antimetastatic activity. In certain embodiments, the compositions of the invention are for use in the prevention of metastasis. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in preventing metastasis.</span>
  </p>
  <p id="p0265" num="0265" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administracin de las composiciones de la invencin puede llevar a una disminucin del porcentaje de Tregs en las PBMC (Figura 6C). Las Tregs se han relacionado con el cncer, y la infiltracin de Tregs en el tejido tumoral se ha relacionado con un mal pronstico [64]. Como se ha demostrado que la administracin de las composiciones de la invencin reduce selectivamente la poblacin de Tregs (Figura 6C), las composiciones de la invencin pueden ser tiles en el tratamiento del cncer. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres caracterizados por un aumento en el porcentaje de Tregs en una poblacin celular. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar o prevenir cnceres caracterizados por un aumento en el porcentaje de clulas CD4+CD25+CD127-en una poblacin celular. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres disminuyendo el nmero o porcentaje de Tregs, en particular en tejido canceroso. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer mediante la reduccin selectiva de Tregs.</span>The Examples show that the administration of the compositions of the invention can lead to a decrease in the percentage of Tregs in PBMC (Figure 6C). Tregs have been linked to cancer, and infiltration of Tregs into tumor tissue has been linked to poor prognosis [64]. As administration of the compositions of the invention has been shown to selectively reduce the population of Tregs (FIG. 6C), the compositions of the invention may be useful in the treatment of cancer. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by an increase in the percentage of Tregs in a cell population. In one embodiment, the compositions of the invention may be useful for treating or preventing cancers characterized by an increase in the percentage of CD4+CD25+CD127- cells in a cell population. In one embodiment, the compositions of the invention are for use in treating or preventing cancers by decreasing the number or percentage of Tregs, in particular in cancerous tissue. In one embodiment, the compositions of the invention are for use in the treatment of cancer by the selective reduction of Tregs.</span>
  </p>
  <p id="p0267" num="0267" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha propuesto que reducir selectivamente el nmero de Tregs y activar las clulas T efectoras, como las clulas T CD8+, ser una terapia eficaz contra el cncer [64]. Los ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la proporcin de clulas CD8 a clulas Tregs. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la proporcin de tanto las clulas CD8/Tregs como las clulas CD8/Tregs activadas (Figura 6G y Figura 6H), las composiciones de la invencin pueden ser tiles en el tratamiento del cncer. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres caracterizados por una disminucin en la proporcin de clulas CD8/Tregs y/o CD8/Tregs activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres caracterizados por una disminucin en la proporcin de clulas CD8/Tregs. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres caracterizados por una disminucin en la proporcin de clulas CD8/Tregs activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer disminuyendo el porcentaje de Tregs en las poblaciones celulares, aumentando de este modo la proporcin de clulas CD8/Tregs. En otra realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer disminuyendo el porcentaje de Tregs en las poblaciones celulares, aumentando de este modo la proporcin de clulas CD8/Tregs activadas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer aumentando la proporcin de clulas CD8/Tregs. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer aumentando la proporcin de clulas CD8/Tregs activadas.</span>It has been proposed that selectively reducing the number of Tregs and activating effector T cells, such as CD8+ T cells, will be an effective cancer therapy [64]. The examples also show that administration of the compositions of the invention can lead to an increase in the ratio of CD8 cells to Treg cells. As administration of the compositions of the invention has been shown to increase the proportion of both CD8/Tregs cells and activated CD8/Tregs cells (Figure 6G and Figure 6H), the compositions of the invention may be useful in the treatment of cancer. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by a decrease in the proportion of activated CD8/Tregs and/or CD8/Tregs cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by a decrease in the CD8/Tregs cell ratio. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by a decrease in the ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating or preventing cancer by decreasing the percentage of Tregs in cell populations, thereby increasing the ratio of CD8 cells/Tregs. In another embodiment, the compositions of the invention are for use in the treatment or prevention of cancer by decreasing the percentage of Tregs in cell populations, thereby increasing the ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating cancer by increasing the ratio of CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating cancer by increasing the ratio of activated CD8/Treg cells.</span>
  </p>
  <p id="p0269" num="0269" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-1 p. En el cncer asociado a la colitis, la disminucin de la expresin de IL-1 p en los sitios tumorales se ha relacionado con sntomas como un resultado de la enfermedad y morbilidad aumentados [65]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-1 p, las composiciones de la invencin pueden ser tiles en el tratamiento del cncer. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin de cnceres caracterizados por una expresin disminuida o ausente de IL-1 p. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer aumentando la expresin de IL-1 p. 
</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-1 p. In colitis-associated cancer, decreased IL-1p expression at tumor sites has been associated with symptoms as a result of increased disease and morbidity [65]. Since administration of the compositions of the invention has been shown to increase the expression of IL-1 p, the compositions of the invention may be useful in the treatment of cancer. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by decreased or absent expression of IL-1 p. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancer by increasing the expression of IL-1 p. </span>
  </p>
  <p id="p0270" num="0270" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin del Factor de Necrosis Tumoral alfa (TNF-a). El TNF-a es una citoquina proinflamatoria que se sabe que est implicada en varias vas de sealizacin para promover la muerte celular. TNF-a inicia la apoptosis unindose a su receptor afn, TNFR-1, lo que lleva a una cascada de eventos de escisin en la va apopttica. TNF-a tambin desencadena la necrosis a travs de un mecanismo dependiente de quinasa RIP. Como muchos tipos de cncer tienen vas apoptticas y necrticas defectuosas, y se sabe que el TNF-a media en estas vas de muerte celular, el TNF-a es un objetivo potencial para la terapia contra el cncer. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de TNF-a, las composiciones de la invencin pueden ser tiles en el tratamiento del cncer, en particular para su uso en el tratamiento o prevencin de cnceres mediados por la expresin de TNF-a. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar cnceres mediados por la expresin de TNF-a, en particular cnceres con expresin y/o actividad disminuida de TNF-a. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar el cncer. En una realizacin, las composiciones de la invencin pueden ser tiles para tratar el cncer aumentando el nivel y/o la actividad de TNF-a.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of Tumor Necrosis Factor alpha (TNF-a). TNF- is a proinflammatory cytokine that is known to be involved in various signaling pathways to promote cell death. TNF- initiates apoptosis by binding to its cognate receptor, TNFR-1, leading to a cascade of cleavage events in the apoptotic pathway. TNF-a also triggers necrosis through a RIP kinase-dependent mechanism. As many types of cancer have defective apoptotic and necrotic pathways, and TNF- is known to mediate these cell death pathways, TNF- is a potential target for anticancer therapy. As administration of the compositions of the invention has been shown to increase the expression of TNF-, the compositions of the invention may be useful in the treatment of cancer, particularly for use in the treatment or prevention of TNF- mediated cancers. expression of TNF-a. In one embodiment, the compositions of the invention may be useful for treating cancers mediated by expression of TNF-, in particular cancers with decreased expression and/or activity of TNF-. In one embodiment, the compositions of the invention may be useful for treating cancer. In one embodiment, the compositions of the invention may be useful for treating cancer by increasing the level and/or activity of TNF-.</span>
  </p>
  <p id="p0272" num="0272" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de mama. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de mama. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de mama. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de mama. En realizaciones preferidas, el cncer es carcinoma mamario. En realizaciones preferidas, el cncer es cncer de mama en estadio IV.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of breast cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of breast cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of breast cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of breast cancer. In preferred embodiments, the cancer is mammary carcinoma. In preferred embodiments, the cancer is stage IV breast cancer.</span>
  </p>
  <p id="p0274" num="0274" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de pulmn. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de pulmn. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de pulmn. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de pulmn. En realizaciones preferidas, el cncer es carcinoma de pulmn.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of lung cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lung cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of lung cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lung cancer. In preferred embodiments, the cancer is lung carcinoma.</span>
  </p>
  <p id="p0276" num="0276" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de hgado. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, la reduccin del crecimiento del tumor o la reduccin de la angiognesis en el tratamiento del cncer de hgado. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de hgado. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de hgado. En realizaciones preferidas, el cncer es un hepatoma (carcinoma hepatocelular).</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of liver cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of liver cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of liver cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of liver cancer. In preferred embodiments, the cancer is a hepatoma (hepatocellular carcinoma).</span>
  </p>
  <p id="p0278" num="0278" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del melanoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del melanoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del melanoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del melanoma. En realizaciones preferidas, el melanoma es un melanoma metastsico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of melanoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of melanoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of melanoma. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of melanoma. In preferred embodiments, the melanoma is a metastatic melanoma.</span>
  </p>
  <p id="p0280" num="0280" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de ovario. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de ovario. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de ovario. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de ovario.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of ovarian cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of ovarian cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of ovarian cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of ovarian cancer.</span>
  </p>
  <p id="p0282" num="0282" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de cuello uterino. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de cuello uterino. En realizaciones preferidas, una cepa bacteriana de la especie 
<i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de cuello uterino. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de cuello uterino.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of cervical cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of cervical cancer. In preferred embodiments, a bacterial strain of the species  <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of cervical cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of cervical cancer.</span>
  </p>
  <p id="p0284" num="0284" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del neuroblastoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del neuroblastoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del neuroblastoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del neuroblastoma.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of neuroblastoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of neuroblastoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of neuroblastoma. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of neuroblastoma.</span>
  </p>
  <p id="p0286" num="0286" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del glioblastoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento tumoral, o reduccin de la angiognesis en el tratamiento del glioblastoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del glioblastoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del glioblastoma.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of glioblastoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of glioblastoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of glioblastoma. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of glioblastoma.</span>
  </p>
  <p id="p0288" num="0288" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de prstata. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de prstata. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de prstata. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de prstata.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of prostate cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of prostate cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of prostate cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of prostate cancer.</span>
  </p>
  <p id="p0290" num="0290" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades malignas hematolgicas. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento de enfermedades malignas hematolgicas. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de enfermedades malignas hematolgicas. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento de enfermedades malignas hematolgicas. En ciertas realizaciones, la enfermedad maligna hematolgica es leucemia aguda. En ciertas realizaciones, la enfermedad maligna hematolgica es leucemia crnica. En ciertas realizaciones, la enfermedad maligna hematolgica es leucemia mielgena aguda. En ciertas realizaciones, la enfermedad maligna hematolgica es leucemia mielgena crnica. En ciertas realizaciones, la enfermedad maligna hematolgica es leucemia linfoctica aguda. En ciertas realizaciones, la enfermedad maligna hematolgica es leucemia linfoctica crnica. En ciertas realizaciones, la enfermedad maligna hematolgica es linfoma. En ciertas realizaciones, la enfermedad maligna hematolgica es mieloma mltiple. En ciertas realizaciones, la enfermedad maligna hematolgica es un sndrome mielodisplsico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of hematological malignancies. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of hematologic malignancies. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of hematological malignancies. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of hematologic malignancies. In certain embodiments, the hematologic malignancy is acute leukemia. In certain embodiments, the hematologic malignancy is chronic leukemia. In certain embodiments, the hematologic malignancy is acute myelogenous leukemia. In certain embodiments, the hematologic malignancy is chronic myelogenous leukemia. In certain embodiments, the hematologic malignancy is acute lymphocytic leukemia. In certain embodiments, the hematologic malignancy is chronic lymphocytic leukemia. In certain embodiments, the hematologic malignancy is lymphoma. In certain embodiments, the hematologic malignancy is multiple myeloma. In certain embodiments, the hematologic malignancy is a myelodysplastic syndrome.</span>
  </p>
  <p id="p0292" num="0292" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin de la leucemia linfoctica crnica. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento de la leucemia linfoctica crnica. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin de la leucemia linfoctica crnica. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento de la leucemia linfoctica crnica.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of chronic lymphocytic leukemia. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of chronic lymphocytic leukemia. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of chronic lymphocytic leukemia. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of chronic lymphocytic leukemia.</span>
  </p>
  <p id="p0294" num="0294" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del linfoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del linfoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del linfoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del linfoma. En ciertas realizaciones, el linfoma es linfoma de Hodgkin. En ciertas realizaciones, el linfoma es un linfoma no Hodgkin.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of lymphoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lymphoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of lymphoma. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lymphoma. In certain embodiments, the lymphoma is Hodgkin's lymphoma. In certain embodiments, the lymphoma is non-Hodgkin's lymphoma.</span>
  </p>
  <p id="p0296" num="0296" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer gstrico. En ciertas realizaciones, las composiciones de la invencin son para su uso en la 
reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer gstrico. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer gstrico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer gstrico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of gastric cancer. In certain embodiments, the compositions of the invention are for use in the  reduction of tumor size, reduction of tumor growth or reduction of angiogenesis in the treatment of gastric cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of gastric cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of gastric cancer.</span>
  </p>
  <p id="p0298" num="0298" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer de colon. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer colorrectal. Las composiciones de la invencin pueden tener un efecto sobre las clulas de cncer de colon y pueden ser eficaces para tratar el cncer de colon. Las composiciones de la invencin pueden tener un efecto sobre las clulas de cncer de colon y pueden ser eficaces para tratar el cncer colorrectal. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de colon. En ciertas realizaciones, las composiciones de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer colorrectal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de colon. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer colorrectal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer de colon. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer colorrectal. En realizaciones preferidas, el cncer es adenocarcinoma colorrectal.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of colon cancer. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of colorectal cancer. The compositions of the invention may have an effect on colon cancer cells and may be effective in treating colon cancer. The compositions of the invention may have an effect on colon cancer cells and may be effective in treating colorectal cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colon cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colorectal cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of colon cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of colorectal cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colon cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colorectal cancer. In preferred embodiments, the cancer is colorectal adenocarcinoma.</span>
  </p>
  <p id="p0300" num="0300" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las combinaciones teraputicas de la invencin son para su uso en el tratamiento o prevencin del cncer de rin (tambin denominado en la presente cncer renal). En ciertas realizaciones, las combinaciones teraputicas de la invencin son para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer renal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer de rin (tambin denominado en la presente cncer renal). En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reduccin del tamao del tumor, reduccin del crecimiento del tumor o reduccin de la angiognesis en el tratamiento del cncer renal. Los Ejemplos demuestran que las combinaciones teraputicas de la invencin tienen un efecto sobre las clulas de cncer renal y pueden ser eficaces para tratar el cncer renal. En realizaciones preferidas, el cncer es carcinoma de clulas renales o carcinoma de clulas de transicin. En algunas realizaciones, el cncer es del intestino. En algunas realizaciones, el cncer es de una parte del cuerpo que no es el intestino. En algunas realizaciones, el cncer no es cncer del intestino. En algunas realizaciones, el cncer no es cncer colorrectal. En algunas realizaciones, el cncer no es cncer del intestino delgado. En algunas realizaciones, el tratamiento o la prevencin se produce en un sitio distinto del intestino. En algunas realizaciones, el tratamiento o la prevencin se produce en el intestino y tambin en un sitio distinto del intestino.</span>In certain embodiments, the therapeutic combinations of the invention are for use in the treatment or prevention of kidney cancer (also referred to herein as renal cancer). In certain embodiments, the therapeutic combinations of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of kidney cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of kidney cancer (also referred to herein as kidney cancer). In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of kidney cancer. The Examples demonstrate that the therapeutic combinations of the invention have an effect on kidney cancer cells and can be effective in treating kidney cancer. In preferred embodiments, the cancer is renal cell carcinoma or transitional cell carcinoma. In some embodiments, the cancer is of the intestine. In some embodiments, the cancer is from a part of the body other than the intestine. In some embodiments, the cancer is not cancer of the intestine. In some embodiments, the cancer is not colorectal cancer. In some embodiments, the cancer is not cancer of the small intestine. In some embodiments, the treatment or prevention occurs at a site other than the intestine. In some embodiments, the treatment or prevention occurs in the intestine and also at a site other than the intestine.</span>
  </p>
  <p id="p0302" num="0302" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del carcinoma. Las composiciones de la invencin pueden ser eficaces para tratar numerosos tipos de carcinoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer no inmunognico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del carcinoma. Una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>puede ser eficaz para tratar numerosos tipos de carcinoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevencin del cncer no inmunognico. Los Ejemplos demuestran que las composiciones de la invencin pueden ser eficaces para tratar cnceres no inmunognicos.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of carcinoma. The compositions of the invention can be effective in treating numerous types of carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of non-immunogenic cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of carcinoma. A bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> may be effective in treating numerous types of carcinoma. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of non-immunogenic cancer. The Examples demonstrate that the compositions of the invention can be effective in treating non-immunogenic cancers.</span>
  </p>
  <p id="p0304" num="0304" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los efectos teraputicos de las composiciones de la invencin sobre el cncer pueden estar mediados por un mecanismo proinflamatorio. La expresin de una serie de citoquinas proinflamatorias puede aumentar despus de la administracin de MRx0029. La inflamacin puede tener un efecto supresor del cncer [66] y las citoquinas proinflamatorias como la TNF-a se estn investigando como terapias contra el cncer [67]. La regulacin por incremento de genes como el TNF-a que se muestra en los Ejemplos puede indicar que las composiciones de la invencin pueden ser tiles para tratar el cncer a travs de un mecanismo similar. La regulacin por incremento de un ligando de CXCR3 como CXCL9) puede indicar que las composiciones de la invencin provocan una respuesta de tipo IPN<sup class="style-scope patent-text">y</sup>. IPN<sup class="style-scope patent-text">y </sup>es un potente factor activador de macrfagos que puede estimular la actividad tumoricida [68], y CXCL9, por ejemplo, tambin tiene efectos anticancergenos [69-71] Los ejemplos demuestran que la expresin de una serie de citoquinas proinflamatorias puede aumentar despus de la administracin de MRx0029. Por lo tanto, en ciertas realizaciones, las composiciones de la invencin son para su uso en la promocin de la inflamacin en el tratamiento del cncer. En realizaciones preferidas, las composiciones de la invencin son para su uso en la promocin de la inflamacin de Th1 en el tratamiento del cncer. Las clulas Th1 producen IPNy y tienen potentes efectos anticancergenos [66]. En ciertas realizaciones, las composiciones de la invencin son para su uso en el 
tratamiento de un cncer en estadio temprano, como un cncer que no ha hecho metstasis, o un cncer en estadio 0 o estadio 1. Promover la inflamacin puede ser ms eficaz contra los cnceres en estadio temprano [66]. En ciertas realizaciones, las composiciones de la invencin son para potenciar el efecto de un segundo agente anticancergeno. En ciertas realizaciones, las composiciones de la invencin son para su uso en la promocin de la inflamacin para mejorar el efecto de un segundo agente anticancergeno. En ciertas realizaciones, el tratamiento o prevencin del cncer comprende aumentar el nivel de expresin de una o ms citoquinas. En ciertas realizaciones, el tratamiento o la prevencin del cncer comprende aumentar el nivel de expresin de una o ms citoquinas proinflamatorias. Por ejemplo, en ciertas realizaciones, el tratamiento o la prevencin del cncer comprende aumentar el nivel de expresin de uno o ms de IL-1 p, IL-6, MIP-3a, CXCL9, IL-23, MCP-1, GMCSF y TNF-a. En ciertas realizaciones, el tratamiento o prevencin del cncer comprende aumentar el nivel de expresin de uno o ms de IL-1 p y MIP-3a. Se sabe que los aumentos en los niveles de expresin de cualquiera de IL-1 p, IL-6 y TNF-a son indicativos de eficacia en el tratamiento contra el cncer.</span>The therapeutic effects of the compositions of the invention on cancer may be mediated through a pro-inflammatory mechanism. The expression of a number of proinflammatory cytokines can be increased after administration of MRx0029. Inflammation may have a suppressive effect on cancer [66] and proinflammatory cytokines such as TNF-a are being investigated as anticancer therapies [67]. The upregulation of genes such as TNF- shown in the Examples may indicate that the compositions of the invention may be useful in treating cancer through a similar mechanism. Upregulation of a CXCR3 ligand such as CXCL9) may indicate that the compositions of the invention elicit an IPN <sup class="style-scope patent-text">y</sup> -type response. IPN <sup class="style-scope patent-text">y</sup> is a potent macrophage activating factor that can stimulate tumoricidal activity [68], and CXCL9, for example, also has anticancer effects [69-71]. Examples demonstrate that the expression of a number of proinflammatory cytokines can be increased after the administration of MRx0029. Therefore, in certain embodiments, the compositions of the invention are for use in promoting inflammation in the treatment of cancer. In preferred embodiments, the compositions of the invention are for use in promoting Th1 inflammation in the treatment of cancer. Th1 cells produce IPNy and have potent anticancer effects [66]. In certain embodiments, the compositions of the invention are for use in the  treatment of early-stage cancer, such as cancer that has not metastasized, or stage 0 or stage 1 cancer. Promoting inflammation may be more effective against early-stage cancers [66]. In certain embodiments, the compositions of the invention are for enhancing the effect of a second anticancer agent. In certain embodiments, the compositions of the invention are for use in promoting inflammation to enhance the effect of a second anticancer agent. In certain embodiments, the treatment or prevention of cancer comprises increasing the expression level of one or more cytokines. In certain embodiments, treating or preventing cancer comprises increasing the expression level of one or more proinflammatory cytokines. For example, in certain embodiments, treating or preventing cancer comprises increasing the expression level of one or more of IL-1 p, IL-6, MIP-3a, CXCL9, IL-23, MCP-1, GMCSF, and TNF-a. In certain embodiments, the treatment or prevention of cancer comprises increasing the expression level of one or more of IL-1 p and MIP-3a. Increases in the expression levels of any of IL-1 p, IL-6 and TNF-a are known to be indicative of efficacy in treating cancer.</span>
  </p>
  <p id="p0305" num="0305" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando se usa una cepa bacteriana como se describe en la presente en combinacin con lipopolisacrido (LPS), puede haber un aumento sinrgico en IL-1 p. Se sabe que el LPS provoca un efecto proinflamatorio. Por tanto, en ciertas realizaciones, el tratamiento o la prevencin comprende el uso de una cepa bacteriana como se describe en la presente en combinacin con un agente que regula por incremento IL-1 p. En ciertas realizaciones, el tratamiento o la prevencin comprende el uso de una cepa bacteriana como se describe en la presente en combinacin con LPS. Por consiguiente, una composicin de la invencin puede comprender adicionalmente un agente que regula por incremento Il-1p. Por consiguiente, una composicin de la invencin puede comprender adicionalmente LPS.</span>When a bacterial strain as described herein is used in combination with lipopolysaccharide (LPS), there may be a synergistic increase in IL-1 p. LPS is known to cause a pro-inflammatory effect. Thus, in certain embodiments, the treatment or prevention comprises the use of a bacterial strain as described herein in combination with an agent that upregulates IL-1 p. In certain embodiments, the treatment or prevention comprises the use of a bacterial strain as described herein in combination with LPS. Accordingly, a composition of the invention may further comprise an Il-1p upregulating agent. Accordingly, a composition of the invention may additionally comprise LPS.</span>
  </p>
  <p id="p0306" num="0306" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de un paciente que ha recibido quimioterapia con anterioridad. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de un paciente que no ha tolerado un tratamiento de quimioterapia. Las composiciones de la invencin pueden ser particularmente adecuadas para tales pacientes.</span>In certain embodiments, the compositions of the invention are for use in treating a patient who has previously received chemotherapy. In certain embodiments, the compositions of the invention are for use in treating a patient who has not tolerated chemotherapy treatment. The compositions of the invention may be particularly suitable for such patients.</span>
  </p>
  <p id="p0307" num="0307" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para prevenir la recada. Las composiciones de la invencin pueden ser adecuadas para la administracin a largo plazo. En ciertas realizaciones, las composiciones de la invencin son para su uso en la prevencin de la progresin del cncer.</span>In certain embodiments, the compositions of the invention are for preventing relapse. The compositions of the invention may be suitable for long-term administration. In certain embodiments, the compositions of the invention are for use in preventing the progression of cancer.</span>
  </p>
  <p id="p0308" num="0308" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de carcinoma de pulmn de clulas no pequeas. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento del carcinoma de pulmn de clulas pequeas. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento del carcinoma de clulas escamosas. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de adenocarcinoma. En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de tumores glandulares, tumores carcinoides o carcinomas indiferenciados.</span>In certain embodiments, the compositions of the invention are for use in the treatment of non-small cell lung carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of small cell lung carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of squamous cell carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of adenocarcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of glandular tumors, carcinoid tumors, or undifferentiated carcinomas.</span>
  </p>
  <p id="p0309" num="0309" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de hepatoblastoma, colangiocarcinoma, cistoadenocarcinoma colangiocelular o cncer de hgado resultante de una infeccin viral.</span>In certain embodiments, the compositions of the invention are for use in the treatment of hepatoblastoma, cholangiocarcinoma, cholangiocellular cystadenocarcinoma, or liver cancer resulting from viral infection.</span>
  </p>
  <p id="p0310" num="0310" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin son para su uso en el tratamiento de carcinoma ductal invasivo, carcinoma ductal in situ o carcinoma lobular invasivo.</span>In certain embodiments, the compositions of the invention are for use in the treatment of invasive ductal carcinoma, ductal carcinoma in situ, or invasive lobular carcinoma.</span>
  </p>
  <p id="p0311" num="0311" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones adicionales, las composiciones de la invencin son para su uso en el tratamiento o prevencin de la leucemia linfoblstica aguda (ALL), leucemia mieloide aguda, carcinoma adrenocortical, carcinoma de clulas basales, cncer de conducto biliar, cncer de vejiga, tumor seo, osteosarcoma/histiocitoma fibroso maligno, glioma del tronco enceflico, tumor cerebral, astrocitoma cerebeloso, astrocitoma cerebral/glioma maligno, ependimoma, meduloblastoma, tumores neuroectodrmicos primitivos supratentoriales, cncer de mama, adenomas bronquiales/carcinoides, linfoma de Burkitt, tumor carcinoide, cncer de cuello uterino, leucemia linfoctica crnica, leucemia mielgena crnica, trastornos mieloproliferativos crnicos, cncer de colon, linfoma cutneo de clulas T, cncer de endometrio, ependimoma, cncer de esfago, sarcoma de Ewing, melanoma intraocular, retinoblastoma, cncer de vescula biliar, cncer gstrico, tumor carcinoide gastrointestinal, tumor del estroma gastrointestinal (GIST), tumor de clulas germinales, glioma, va visual infantil e hipotalmico, linfoma de Hodgkin, melanoma, carcinoma de clulas de los islotes, sarcoma de Kaposi, cncer de clulas renales, cncer de laringe, leucemias, linfomas, mesotelioma, neuroblastoma, linfoma no Hodgkin, cncer de orofaringe, osteosarcoma, cncer de ovario, cncer de pncreas, cncer de paratiroides, cncer de faringe, adenoma pituitario, neoplasia de clulas plasmticas, cncer de prstata, carcinoma de clulas renales, retinoblastoma, sarcoma, cncer testicular, cncer de tiroides o cncer uterino. En realizaciones adicionales, las composiciones de la invencin son para su uso en el tratamiento o prevencin de enfermedades malignas hematolgicas, mieloma mltiple, o sndromes mielodisplsicos.</span>In additional embodiments, the compositions of the invention are for use in the treatment or prevention of acute lymphoblastic leukemia (ALL), acute myeloid leukemia, adrenocortical carcinoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone tumor , osteosarcoma/malignant fibrous histiocytoma, brain stem glioma, brain tumor, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor, cancer cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor stinal (GIST), germ cell tumor, glioma, childhood and hypothalamic visual pathway, Hodgkin lymphoma, melanoma, islet cell carcinoma, Kaposi's sarcoma, renal cell cancer, laryngeal cancer, leukemias, lymphomas, mesothelioma, neuroblastoma, non-Hodgkin's lymphoma, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasm, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, cancer testicular, thyroid cancer, or uterine cancer. In additional embodiments, the compositions of the invention are for use in the treatment or prevention of hematologic malignancies, multiple myeloma, or myelodysplastic syndromes.</span>
  </p>
  <p id="p0312" num="0312" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden ser particularmente eficaces cuando se usan en combinacin con agentes teraputicos adicionales. Los efectos inmunomoduladores de las composiciones de la invencin pueden 
ser eficaces cuando se combinan con agentes anticancergenos ms directos. Por lo tanto, en ciertas realizaciones, la invencin proporciona una composicin que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>y un agente anticancergeno. En ciertas realizaciones, la composicin de la invencin que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la estimulacin de un cncer para mejorar su susceptibilidad al tratamiento con un segundo agente anticancergeno. En ciertas realizaciones, la composicin de la invencin que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de un cncer, como un cncer de cerebro, aumentando su susceptibilidad al tratamiento con un segundo agente anticancergeno. El segundo agente anticancergeno puede administrarse concurrentemente, o puede administrarse despus de la composicin que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>como por lo menos un da, una semana o un mes despus.</span>The compositions of the invention can be particularly effective when used in combination with additional therapeutic agents. The immunomodulatory effects of the compositions of the invention can  be effective when combined with more direct anticancer agents. Therefore, in certain embodiments, the invention provides a composition comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> and an anticancer agent. In certain embodiments, the composition of the invention comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in stimulating a cancer to improve its susceptibility to treatment with a second anticancer agent. In certain embodiments, the composition of the invention comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating a cancer, such as brain cancer, by increasing its susceptibility to treatment with a second anticancer agent. The second anticancer agent may be administered concurrently, or may be administered after the composition comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> such as at least one day, one week or one month later.</span>
  </p>
  <p id="p0314" num="0314" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, el agente anticancergeno es un inhibidor del punto de control inmunitario, una inmunoterapia con anticuerpos dirigidos, una terapia con clulas CAR-T, un virus oncoltico o un frmaco citosttico. En realizaciones preferidas, la composicin comprende un agente anticancergeno seleccionado del grupo que consiste de: Yervoy (ipilimumab, b Ms ); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/MedImmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/MedImmune); CT-011 (pidilizumab, CureTech); BMS-986015 (lirilumab, BMS); MEDI0680 (AZ/MedImmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/MedImmune); B<sup class="style-scope patent-text">m </sup>S-986016 (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prima Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX-2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetics); INCB024360 (Incyte); IPH2201 (Innate Immotherapeutics/AZ); NLG-919 (NewLink Genetics); anti-VISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (University of Pennsylvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); CC 90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO-2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Ewha Womens University, Korea); Vemurafenib (Plexxikon); Dabrafenib (Genentech/GSK); BMS-777607 (BMS); BLZ945 (Memorial Sloan-Kettering Cancer Centre); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (ado-trastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, Takeda/Millennium); Arzerra (ofatumumab, GSK); Vectibix (panitumumab, Amgen); Avastina (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-I131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptina (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); AbT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab estafenatox (Active Biotech); AFM13 (Affimed); AFM11 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT-836 (Altor Bioscience); A<sup class="style-scope patent-text">l</sup>T-801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); AMG 228 (Amgen); AMG820 (Amgen); AMG172 (Amgen); AMG595 (Amgen); AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/MedImmune); BAY20-10112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/Med-Immune); MEDI3617 (AZ/MedImmune); MEDI6383 (AZ/MedImmune); MEDI551 (AZ/MedImmune); Moxetumomab pasudotox (AZ/MedImmune); MEDI565 (AZ/MedImmune); MEDI0639 (AZ/MedImmune); MEDI0680 (AZ/MedImmune); MEDI562 (AZ/MedImmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansina (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingleheim); BI-836845 (Boehringer Ingleheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-010t (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U3-1565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217(Eli Lilly); LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY3012211 (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TR1 (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); FG-3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); IMAB027 (Ganymed); HuMax-CD74 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK); mapatumumab (GSK); IMGN289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); IMMU-130 (Immunomedics); milatuzumab-dox (Immunomedics); IMMU-115 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab (Immunomedics); IPH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirrin); KW-2871 (ecromeximab, Life Science); Sonepcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck Serono); DI17E6 (Merck Serono); MOR208 (Morphosys); MOR202 (Morphosys); Xmab5574 (Morphosys); BPC-1C (ensituximab, Precision Biologics); TAS266 (Novartis); LFA102 (Novartis); BHQ880 
(Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716 (Novartis); AT355 (Novartis); OMP-21M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantictumab (Oncomed/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIV1A (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); SGN-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganitumab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); Xmab2512 (Xencor); Xmab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); Ma GE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JCAR015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellectis); BPX-401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTCK20 (Unum Therapeutics); cAr-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunwaybio); DnX-2401 (DNAtrix); Vc N-01 (VCN Biosciences); Colo-Adl (PsiOxus Therapeutics); ProstAtak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONC1 (Genelux); T-VEC (Amgen); G207 (Medigene); <sup class="style-scope patent-text">h </sup>F10 (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienX010 (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SVV-001 (Neotropix); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, folinic acid, methotrexate, cyclophosphamide, 5-fluorouracilo, Zykadia (Novartis), Tafinlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eisai Pharma), Veliparib (Abbvie), AZD9291 (AZ), Alectinib (Chugai), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GV1001 (Kael-GemVax), Tivantinib (ArQule); Cytoxan (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexavar (Bayer); IMMU-132 (Immunomedics); E7449 (Eisai); Thermodox (Celsion); Cometriq (Exellxis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); y TS-1 (Taiho Pharmaceuticals).</span>In preferred embodiments, the anticancer agent is an immune checkpoint inhibitor, a targeted antibody immunotherapy, a CAR-T cell therapy, an oncolytic virus, or a cytostatic drug. In preferred embodiments, the composition comprises an anticancer agent selected from the group consisting of: Yervoy (ipilimumab, b Ms ); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/MedImmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/MedImmune); CT-011 (pidilizumab, CureTech); BMS-986015 (lirilumab, BMS); MEDI0680 (AZ/MedImmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/MedImmune); BmS- <sup class="style-scope patent-text">986016</sup> (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prime Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX-2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetics); INCB024360 (Incyte); IPH2201 (Innate Immotherapeutics/AZ); NLG-919 (New Link Genetics); anti-VISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (University of Pennsylvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); CC 90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO-2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Ewha Women's University, Korea); Vemurafenib (Plexxikon); Dabrafenib (Genentech/GSK); BMS-777607 (BMS); BLZ945 (Memorial Sloan-Kettering Cancer Centre); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (ado-trastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, Takeda/Millennium); Arzerra (ofatumumab, GSK); Vectibix (panitumumab, Amgen); Avastin (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-I131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptin (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); AbT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab stafenatox (Active Biotech); AFM13 (Affimed); AFM11 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT-836 (Altor Bioscience); <sup class="style-scope patent-text">AI T</sup> -801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); AMG 228 (Amgen); AMG820 (Amgen); AMG172 (Amgen); AMG595 (Amgen); AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/MedImmune); BAY20-10112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/Med-Immune); MEDI3617 (AZ/MedImmune); MEDI6383 (AZ/MedImmune); MEDI551 (AZ/MedImmune); Moxetumomab pasudotox (AZ/MedImmune); MEDI565 (AZ/MedImmune); MEDI0639 (AZ/MedImmune); MEDI0680 (AZ/MedImmune); MEDI562 (AZ/MedImmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansine (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingleheim); BI-836845 (Boehringer Ingleheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-010t (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U3-1565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217(Eli Lilly); LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY3012211 (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TR1 (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); FG-3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); IMAB027 (Ganymed); HuMax-CD74 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK); mapatumumab (GSK); IMGN289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); IMMU-130 (Immunomedics); milatuzumab-dox (Immunomedics); IMMU-115 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab (Immunomedics); IPH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirrin); KW-2871 (ecromeximab, Life Science); Sonepcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck Serono); DI17E6 (Merck Serono); MOR208 (Morphosys); MOR202 (Morphosys); Xmab5574 (Morphosys); PCB-1C (ensituximab, Precision Biologics); TAS266 (Novartis); LFA102 (Novartis); BHQ880  (Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716 (Novartis); AT355 (Novartis); OMP-21M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantictumab (Oncomed/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIV1A (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); SGN-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganitumab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); Xmab2512 (Xencor); Xmab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); Ma GE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JCAR015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellectis); BPX-401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTCK20 (Unum Therapeutics); cAr-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunway bio); DnX-2401 (DNAtrix); VcN-01 (VCN Biosciences); Colo-Adl (PsiOxus Therapeutics); Prostak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONC1 (Genelux); T-VEC (Amgen); G207 (Medigene); <sup class="style-scope patent-text">hF10</sup> (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienX010 (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SVV-001 (Neotropyx); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, folinic acid, methotrexate, cyclophosphamide, 5-fluorouracil, Zykadia (Novartis), Tafinlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eisai Pharma), Veliparib (Abbvie), AZD9291 (AZ), Alectinib (Chugai), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GV1001 (Kael-GemVax ), Tivantinib (ArQule); Cytoxane (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexvar (Bayer); IMMU-132 (Immunomedics); E7449 (Eisai); Thermodox (Celsion); Cometriq (Exellxis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); and TS-1 (Taiho Pharmaceuticals).</span>
  </p>
  <p id="p0316" num="0316" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la cepa bacteriana de <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el nmero de registro NCIMB 42761 es el nico agente teraputicamente activo en una composicin de la invencin.</span>In some embodiments, the <i class="style-scope patent-text">Megasphaera massiliensis</i> bacterial strain deposited under accession number NCIMB 42761 is the sole therapeutically active agent in a composition of the invention.</span>
  </p>
  <p id="p0318" num="0318" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han identificado que las cepas bacterianas del gnero <i class="style-scope patent-text">Megasphaera </i>pueden ser particularmente eficaces para tratar o prevenir el cncer que comprende la sealizacin de la quinasa relacionada con la seal extracelular (ERK) oncognica. La quinasa relacionada con la seal extracelular (ERK) es un efector en sentido descendente en la va de la quinasa de la protena activada por mitgenos (MAP), una va de transduccin de seales altamente conservada que se encuentra en todos los eucariotas [72]. La va de la MAP-quinasa regula procesos como la proliferacin celular, la diferenciacin, la supervivencia y la apoptosis, y la activacin aberrante de la va est estrechamente relacionada con la patognesis del cncer. Como se describe en los ejemplos, la administracin de composiciones que comprenden cepas de <i class="style-scope patent-text">Megasphaera </i>puede inhibir la sealizacin de ERK en lneas celulares de cncer; es decir, reduce los niveles celulares de ERK fosforilada con respecto a la protena ERK total. Los inventores tambin han identificado que el tratamiento con cepas de <i class="style-scope patent-text">Megasphaera </i>puede reducir la supervivencia clonognica de lneas celulares de cncer que comprenden sealizacin de ERK oncognica, en particular en lneas celulares de melanoma y cncer colorrectal. Los inventores tambin han identificado que el tratamiento con cepas de <i class="style-scope patent-text">Megasphaera </i>puede inducir la expresin gnica de la protena 2 asociada a microtbulos (MAP2), lo que indica una utilidad particular en el tratamiento de cnceres metastsicos.</span>The inventors have identified that bacterial strains of the genus <i class="style-scope patent-text">Megasphaera</i> may be particularly effective in treating or preventing cancer involving oncogenic extracellular signal-related kinase (ERK) signaling. Extracellular signal-related kinase (ERK) is a downstream effector in the mitogen-activated protein (MAP) kinase pathway, a highly conserved signal transduction pathway found in all eukaryotes [72] . The MAP-kinase pathway regulates processes such as cell proliferation, differentiation, survival, and apoptosis, and aberrant activation of the pathway is closely related to cancer pathogenesis. As described in the examples, administration of compositions comprising <i class="style-scope patent-text">Megasphaera</i> strains can inhibit ERK signaling in cancer cell lines; that is, it reduces cellular levels of phosphorylated ERK relative to total ERK protein. The inventors have also identified that treatment with <i class="style-scope patent-text">Megasphaera</i> strains can reduce the clonogenic survival of cancer cell lines comprising oncogenic ERK signaling, particularly in melanoma and colorectal cancer cell lines. The inventors have also identified that treatment with <i class="style-scope patent-text">Megasphaera</i> strains can induce microtubule-associated protein 2 (MAP2) gene expression, indicating particular utility in the treatment of metastatic cancers.</span>
  </p>
  <p id="p0320" num="0320" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, en ciertas realizaciones, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>para su uso en un mtodo para tratar o prevenir el cncer, en donde el cncer comprende la sealizacin de ERK oncognica.</span>Therefore, in certain embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in a method of treating or preventing cancer, wherein the cancer comprises oncogenic ERK signaling.</span>
  </p>
  <p id="p0322" num="0322" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se usa en la presente, "sealizacin de ERK oncognica" se refiere al cncer que comprende sealizacin celular desregulada, como la sealizacin independiente del estmulo, a travs de la va de la MAP quinasa, cuyo resultado es una sealizacin hiperactiva por parte de ERK (ya sea la isoforma ERK1 o ERK2, o ambas), que impulsa una proliferacin y/o supervivencia aumentada de las clulas cancerosas. ERK1 est activo (es decir, sealizacin) cuando se fosforila en las posiciones Thr202 y Tyr204. ERK2 est activo (es decir, sealizacin) cuando se fosforila en las posiciones Thr173 y Tyr185. Por consiguiente, la "sealizacin de ERK oncognica" puede ser el resultado de la presencia de mutaciones oncognicas en (mutaciones de ganancia de funcin) o sobreexpresin de reguladores positivos de la va de la MAP quinasa, o mutaciones oncognicas en (mutaciones de prdida de funcin) o expresin regulada por disminucin de reguladores negativos de la va de la MAP quinasa.</span>As used herein, "oncogenic ERK signaling" refers to cancer involving dysregulated cell signaling, such as stimulus-independent signaling, via the MAP kinase pathway, resulting in hyperactive ERK signaling. (either the ERK1 or ERK2 isoform, or both), which drives increased proliferation and/or survival of cancer cells. ERK1 is active (ie signaling) when it is phosphorylated at positions Thr202 and Tyr204. ERK2 is active (ie signaling) when phosphorylated at positions Thr173 and Tyr185. Therefore, "oncogenic ERK signaling" may be the result of the presence of oncogenic mutations in (gain-of-function mutations) or overexpression of positive regulators of the MAP kinase pathway, or oncogenic mutations in (loss-of-function mutations). function) or down-regulated expression of negative regulators of the MAP kinase pathway.</span>
  </p>
  <p id="p0324" num="0324" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El cncer que comprende la sealizacin de ERK oncognica puede definirse alternativamente como cncer que muestra o caracterizado por la sealizacin de ERK oncognica. El cncer que comprende la sealizacin de ERK oncognica puede definirse alternativamente como un cncer en el que se "estimulan", "inducen" o "regulan por incremento" la proliferacin y/o la supervivencia de las clulas malignas mediante la sealizacin de ERK. El cncer que comprende ERK oncognico puede definirse alternativamente como cncer que 
comprende, muestra o se caracteriza por la sealizacin de ERK "independiente del estmulo".</span>Cancer that comprises oncogenic ERK signaling may alternatively be defined as cancer that "displays" or "characterized by" oncogenic ERK signaling. Cancer comprising oncogenic ERK signaling may alternatively be defined as a cancer in which the proliferation and/or survival of malignant cells are "stimulated", "induced" or "up-regulated" by ERK signaling. Cancer comprising oncogenic ERK can alternatively be defined as cancer that  comprises, displays, or is characterized by "stimulus-independent" ERK signaling.</span>
  </p>
  <p id="p0325" num="0325" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La "mutacin oncognica" abarca cualquier variacin de aminocidos en una protena, con respecto a la protena de tipo salvaje, que promueve la proliferacin y/o supervivencia de clulas cancerosas incluyendo, pero no limitado a, sustituciones (incluyendo sustituciones de un solo aminocido), inserciones y/o deleciones. Como se ha indicado anteriormente, las mutaciones oncognicas pueden ser mutaciones de prdida de funcin o de ganancia de funcin, dependiendo de la protena y su funcin dentro de la va de la MAP-quinasa. "Sobreexpresin" o "expresin regulada por disminucin" se refieren respectivamente al aumento o disminucin de la expresin de una protena en una clula cancerosa con respecto a una clula no cancerosa.</span>"Oncogenic mutation" encompasses any amino acid variation in a protein, relative to the wild-type protein, that promotes cancer cell proliferation and/or survival including, but not limited to, substitutions (including single amino acid substitutions) , insertions and/or deletions. As noted above, oncogenic mutations can be loss-of-function or gain-of-function mutations, depending on the protein and its function within the MAP kinase pathway. "Over-expression" or "down-regulated expression" refer respectively to the increased or decreased expression of a protein in a cancer cell relative to a non-cancer cell.</span>
  </p>
  <p id="p0326" num="0326" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, los cnceres que comprenden la sealizacin de ERK oncognica incluyen aquellos que comprenden una mutacin oncognica en, o sobreexpresin de, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, s Os , HRAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 o ERK2; como BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2. Estas protenas son reguladores positivos de la va de MAP quinasa (es decir, oncoprotenas) [72] Por ejemplo, el cncer puede comprender una mutacin oncognica en BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2.</span>Accordingly, cancers that comprise oncogenic ERK signaling include those that comprise an oncogenic mutation in, or overexpression of, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, sOs, HRAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 or ERK2; such as BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1, or ERK2. These proteins are positive regulators of the MAP kinase pathway (i.e., oncoproteins) [72] For example, cancer may comprise an oncogenic mutation in BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2 , ERK1 or ERK2.</span>
  </p>
  <p id="p0327" num="0327" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los cnceres que comprenden la sealizacin de ERK oncognica tambin incluyen aquellos que comprenden (ya sea alternativamente o adems de las mutaciones/sobreexpresiones oncognicas anteriores) una mutacin oncognica o una expresin regulada por disminucin de RSK, DUSP1, DUSP5, DUSP6 o SPRY. Estas protenas son reguladores negativos de la va MAP quinasa (es decir, protenas supresoras de tumores) [72].</span>Cancers that comprise oncogenic ERK signaling also include those that comprise (either alternatively or in addition to the above oncogenic mutations/overexpressions) an oncogenic mutation or down-regulated expression of RSK, DUSP1, DUSP5, DUSP6, or SPRY. These proteins are negative regulators of the MAP kinase pathway (ie, tumor suppressor proteins) [72].</span>
  </p>
  <p id="p0328" num="0328" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cualquier cncer que comprenda la sealizacin de ERK oncognica puede tratarse o prevenirse usando composiciones de la invencin, como tumores slidos o enfermedades malignas hematolgicas. Tales cnceres incluyen, pero no se limitan a, cncer colorrectal, melanoma, leucemia linfoblstica aguda (ALL), leucemia mieloide aguda, carcinoma adrenocortical, carcinoma de clulas basales, cncer de las vas biliares, cncer de vejiga, tumor seo, osteosarcoma/histiocitoma fibroso maligno, glioma del tronco enceflico, tumor cerebral, astrocitoma cerebeloso, astrocitoma cerebral/glioma maligno, ependimoma, meduloblastoma, tumores neuroectodrmicos primitivos supratentoriales, cncer de mama, adenomas/carcinoides bronquiales, linfoma de Burkitt, tumor carcinoide, cncer de cuello uterino, leucemia linfoctica crnica, leucemia mielgena crnica, trastornos mieloproliferativos crnicos, linfoma cutneo de clulas T, cncer de endometrio, ependimoma, cncer de esfago, sarcoma de Ewing, melanoma intraocular, retinoblastoma, cncer de vescula biliar, cncer gstrico, tumor carcinoide gastrointestinal, tumor del estroma gastrointestinal (GIST), tumor de clulas germinales, glioma, va visual infantil e hipotalmico, linfoma de Hodgkin, carcinoma de clulas de los islotes, sarcoma de Kaposi, cncer de clulas renales, cncer de laringe, leucemias, linfomas, mesotelioma, neuroblastoma, linfoma no Hodgkin, cncer de orofaringe, osteosarcoma, cncer de ovario, cncer de pncreas, cncer de paratiroides, cncer de faringe, adenoma hipofisario, neoplasia de clulas plasmticas, cncer de prstata, carcinoma de clulas renales, retinoblastoma, sarcoma, cncer testicular, cncer de tiroides o cncer uterino.</span>Any cancer that comprises oncogenic ERK signaling can be treated or prevented using compositions of the invention, such as solid tumors or hematological malignancies. Such cancers include, but are not limited to, colorectal cancer, melanoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia, adrenocortical carcinoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone tumor, osteosarcoma/histiocytoma malignant fibrous tumor, brainstem glioma, brain tumor, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, tumor gastrointestinal stromal tumor (GIST), germ cell tumor, glioma, childhood visual and hypothalamic, Hodgkin's lymphoma, islet cell carcinoma, Kaposi's sarcoma, renal cell cancer, laryngeal cancer, leukemias, lymphomas, mesothelioma, neuroblastoma, non-Hodgkin's lymphoma, oropharyngeal cancer, osteosarcoma, ovarian cancer , pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasm, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, testicular cancer, thyroid cancer, or uterine cancer.</span>
  </p>
  <p id="p0329" num="0329" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cualquier cncer que comprenda la sealizacin de ERK oncognica puede tratarse o prevenirse mediante una composicin que comprenda una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>y preferiblemente cncer colorrectal, melanoma, cncer de prstata, adenocarcinoma de pulmn como adenocarcinoma de pulmn de clulas no pequeas, cncer de pncreas, cncer de vejiga, leucemia como leucemia de clulas pilosas o leucemia mieloide aguda, glioma, astrocitoma piloctico, cncer de ovario, cncer de tiroides papilar o folicular, seminoma, cncer de hgado, sndrome mielodisplsico, cncer de rin o enfermedad de Hodgkin.</span>Any cancer comprising oncogenic ERK signaling can be treated or prevented by a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> and preferably colorectal cancer, melanoma, prostate cancer, lung adenocarcinoma such as non-small cell lung adenocarcinoma, pancreas, bladder cancer, leukemia such as hairy cell leukemia or acute myeloid leukemia, glioma, pilocytic astrocytoma, ovarian cancer, papillary or follicular thyroid cancer, seminoma, liver cancer, myelodysplastic syndrome, kidney cancer, or Hodgkin's disease.</span>
  </p>
  <p id="p0330" num="0330" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>para su uso en un mtodo para tratar o prevenir el cncer que comprende una mutacin oncognica en BRAF, opcionalmente en donde el cncer comprende adems la sobreexpresin de BRAF. Los inventores han identificado que el tratamiento con cepas de <i class="style-scope patent-text">Megasphaera </i>puede inhibir la supervivencia clonognica, inhibir la sealizacin de ERK y regular por incremento la expresin del gen MAP2 en lneas celulares de cncer que comprenden mutaciones de BRAF oncognicas, en particular la mutacin oncognica BRAF V600E en lneas celulares de cncer colorrectal y melanoma. Por lo tanto, en realizaciones preferidas, la invencin tambin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>para su uso en un mtodo de tratamiento o prevencin del cncer que comprende una mutacin oncognica en la posicin 600 de BRAF, preferiblemente BRAF V600E. En realizaciones especialmente preferidas, el cncer es cncer colorrectal o melanoma.</span>In preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in a method of treating or preventing cancer comprising an oncogenic mutation in BRAF, optionally wherein the cancer further comprises overexpression of BRAF. The inventors have identified that treatment with <i class="style-scope patent-text">Megasphaera</i> strains can inhibit clonogenic survival, inhibit ERK signaling, and upregulate MAP2 gene expression in cancer cell lines comprising oncogenic BRAF mutations, in particular the BRAF V600E oncogenic mutation. in colorectal cancer and melanoma cell lines. Therefore, in preferred embodiments, the invention also provides a composition comprising a bacterial strain of the <i class="style-scope patent-text">Megasphaera genus,</i> for use in a method of treating or preventing cancer comprising an oncogenic mutation at position 600 of BRAF, preferably BRAF V600E . In especially preferred embodiments, the cancer is colorectal cancer or melanoma.</span>
  </p>
  <p id="p0331" num="0331" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems de, o en lugar de, una mutacin oncognica en la posicin 600 de BRAF (como V600E), el cncer puede comprender una mutacin oncognica seleccionada de BRAF K601E, G469A, G469V, L597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A o G469E; opcionalmente en donde el cncer es cncer colorrectal. En otra realizacin, adems de, o en lugar de, la mutacin V600E, el cncer puede comprender una mutacin oncognica seleccionada de BRAF V600K, V600R o V600D; opcionalmente en donde el cncer es melanoma.</span>In addition to, or instead of, an oncogenic mutation at position 600 of BRAF (such as V600E), the cancer may comprise a selected oncogenic mutation of BRAF K601E, G469A, G469V, L597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A or G469E; optionally wherein the cancer is colorectal cancer. In another embodiment, in addition to, or instead of, the V600E mutation, the cancer may comprise a selected oncogenic mutation of BRAF V600K, V600R, or V600D; optionally wherein the cancer is melanoma.</span>
  </p>
  <p id="p0332" num="0332" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invencin tambin proporciona una composicin que comprende una cepa 
bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>para su uso en un mtodo para tratar el cncer colorrectal, como el cncer colorrectal metastsico. Como se muestra en los ejemplos, los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>pueden inhibir la supervivencia clonognica y la sealizacin de ERK en lneas celulares de cncer colorrectal.</span>In a further aspect, the invention also provides a composition comprising a strain  bacteria of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> for use in a method of treating colorectal cancer, such as metastatic colorectal cancer. As shown in the examples, the inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains can inhibit clonogenic survival and ERK signaling in colorectal cancer cell lines.</span>
  </p>
  <p id="p0333" num="0333" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invencin tambin proporciona una composicin que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis</i>, para su uso en un mtodo para tratar el melanoma, como el melanoma metastsico. Como se muestra en los ejemplos, los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>pueden inhibir la supervivencia clonognica y la sealizacin de ERK en lneas celulares de melanoma. Adems, la capacidad de las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>para inducir la expresin del gen MAP2 en lneas celulares de melanoma indica una eficacia particular contra el melanoma metastsico.</span>In a further aspect, the invention also provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> , for use in a method of treating melanoma, such as metastatic melanoma. As shown in the examples, the inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains can inhibit clonogenic survival and ERK signaling in melanoma cell lines. Furthermore, the ability of <i class="style-scope patent-text">Megasphaera massiliensis</i> strains to induce MAP2 gene expression in melanoma cell lines indicates particular efficacy against metastatic melanoma.</span>
  </p>
  <p id="p0334" num="0334" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, un inhibidor de BRAF se administra simultneamente, por separado o secuencialmente, con respecto a la administracin de la composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera. </i>Preferiblemente, el inhibidor de BRAF es un inhibidor selectivo de BRAFV600E, preferiblemente seleccionado de Vemurafenib, Dabrafinib o Encorafenib. Ms preferiblemente, el inhibidor de BRAF es Vemurafenib.</span>In preferred embodiments, a BRAF inhibitor is administered simultaneously, separately or sequentially, with respect to the administration of the composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> Preferably, the BRAF inhibitor is a selective BRAFV600E inhibitor, preferably selected from Vemurafenib, Dabrafinib or Encorafenib. More preferably, the BRAF inhibitor is Vemurafenib.</span>
  </p>
  <p id="p0335" num="0335" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional de la invencin, la invencin tambin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>y un inhibidor de BRAF, preferiblemente los definidos anteriormente, para su uso simultneo, separado o secuencial en el tratamiento o prevencin del cncer.</span>In a further aspect of the invention, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> and a BRAF inhibitor, preferably those defined above, for simultaneous, separate or sequential use in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0336" num="0336" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otras realizaciones preferidas, un anlogo de citidina se administra simultneamente, por separado o secuencialmente, con respecto a la administracin de la composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera. </i>Preferiblemente, el anlogo de citidina se selecciona de Azacitidina-c, Decitabina o Zebularina. Ms preferiblemente, el anlogo de citidina es Azacitidina-c.</span>In other preferred embodiments, a cytidine analog is administered simultaneously, separately or sequentially, with respect to the administration of the composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> Preferably, the cytidine analog is selected from Azacitidine-c, Decitabine or Zebularin. More preferably, the cytidine analog is Azacitidine-c.</span>
  </p>
  <p id="p0337" num="0337" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invencin tambin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>y un anlogo de citidina, preferiblemente los definidos anteriormente, para su uso simultneo, separado o secuencial en el tratamiento o prevencin del cncer.</span>In an additional aspect, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> and a cytidine analog, preferably those defined above, for simultaneous, separate or sequential use in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0338" num="0338" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otras realizaciones preferidas, un inhibidor de la polimerizacin de tubulina o un inhibidor de la despolimerizacin de tubulina se administran simultneamente, por separado o secuencialmente, con respecto a la administracin de la composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera. </i>Preferiblemente, el inhibidor de la polimerizacin de tubulina o el inhibidor de la despolimerizacin de tubulina se selecciona de Paclitaxel, Abraxane, Docetaxel, Epotilona, (+-)-Discodermolida, Colchicina, Combretastatina, 2-Metoxiestradiol, E7010, Vincristina, Vinblastina, Vinorelbina o Vinflunina; ms preferiblemente Paclitaxel.</span>In other preferred embodiments, a tubulin polymerization inhibitor or a tubulin depolymerization inhibitor is administered simultaneously, separately, or sequentially, with respect to the administration of the composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> Preferably, the tubulin polymerization inhibitor or tubulin depolymerization inhibitor is selected from Paclitaxel, Abraxane, Docetaxel, Epothilone, (+-)-Discodermolide, Colchicine, Combretastatin, 2-Methoxyestradiol, E7010, Vincristine, Vinblastine, Vinorelbine or Vinflunine; more preferably Paclitaxel.</span>
  </p>
  <p id="p0339" num="0339" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invencin tambin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>y un inhibidor de la polimerizacin de tubulina o inhibidor de la despolimerizacin de tubulina, preferiblemente los definidos anteriormente, para su uso simultneo, separado o secuencial en el tratamiento o prevencin del cncer. En un aspecto adicional, la invencin tambin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera</i>, para su uso en la terapia contra el cncer aumentando la susceptibilidad del cncer a un inhibidor de la polimerizacin o despolimerizacin de la tubulina, preferiblemente los definidos anteriormente.</span>In a further aspect, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> and a tubulin polymerization inhibitor or tubulin depolymerization inhibitor, preferably those defined above, for simultaneous, separate or sequential use in the cancer treatment or prevention. In an additional aspect, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , for use in cancer therapy by increasing the susceptibility of cancer to a tubulin polymerization or depolymerization inhibitor, preferably those defined above. .</span>
  </p>
  <p id="p0340" num="0340" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En tales realizaciones adicionales, la invencin proporciona:</span>In such additional embodiments, the invention provides:</span>
  </p>
  <p id="p0341" num="0341" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera</i>, en donde la cepa bacteriana tiene una secuencia del gel de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1, para su uso en un mtodo de tratamiento o prevencin del cncer, en particular, en donde el cncer comprende la sealizacin oncognica de ERK.</span>1. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the bacterial strain has a 16s rRNA gel sequence that is at least 95% identical to SEQ ID NO: 1, for use in a method of treating or preventing cancer, in particular, wherein the cancer comprises ERK oncogenic signaling.</span>
  </p>
  <p id="p0342" num="0342" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Una composicin para su uso de acuerdo con la realizacin 1, en donde el cncer comprende una mutacin oncognica en, o sobreexpresin de, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, F1RAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 o ERK2.</span>2. A composition for use according to embodiment 1, wherein the cancer comprises an oncogenic mutation in, or overexpression of, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, F1RAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 or ERK2.</span>
  </p>
  <p id="p0343" num="0343" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. Una composicin para su uso de acuerdo con cualquier realizacin anterior, en donde el cncer comprende una mutacin oncognica o una expresin regulada a la baja de RSK, DUSP1, DUSP5, DUSP6 o SPRY.</span>3. A composition for use according to any preceding embodiment, wherein the cancer comprises an oncogenic mutation or down-regulated expression of RSK, DUSP1, DUSP5, DUSP6, or SPRY.</span>
  </p>
  <p id="p0344" num="0344" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. Una composicin para su uso de acuerdo con la realizacin 2, en donde el cncer comprende una mutacin oncognica o sobreexpresin de BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2.</span>4. A composition for use according to embodiment 2, wherein the cancer comprises an oncogenic mutation or overexpression of BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1, or ERK2.</span>
  </p>
  <p id="p0345" num="0345" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. Una composicin para su uso de acuerdo con la realizacin 2, en donde el cncer comprende una mutacin oncognica en BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2.</span>5. A composition for use according to embodiment 2, wherein the cancer comprises an oncogenic mutation in BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1, or ERK2.</span>
  </p>
  <p id="p0346" num="0346" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. La composicin para su uso de acuerdo con cualquier realizacin anterior, en donde el cncer comprende una mutacin oncognica en BRAF o NRAS, opcionalmente en donde el cncer comprende adems la sobreexpresin de BRAF o NRAS.</span>6. The composition for use according to any preceding embodiment, wherein the cancer comprises an oncogenic mutation in BRAF or NRAS, optionally wherein the cancer further comprises overexpression of BRAF or NRAS.</span>
  </p>
  <p id="p0347" num="0347" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. La composicin para su uso de acuerdo con la realizacin 6, en donde el cncer comprende una mutacin oncognica en BRAF, opcionalmente en donde el cncer comprende adems la sobreexpresin de BRAF. 
</span>7. The composition for use according to embodiment 6, wherein the cancer comprises an oncogenic mutation in BRAF, optionally wherein the cancer further comprises BRAF overexpression. </span>
  </p>
  <p id="p0348" num="0348" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. La composicin para su uso de acuerdo con la realizacin 7, en donde el cncer comprende una mutacin oncognica en la posicin 600 de BRAF.</span>8. The composition for use according to embodiment 7, wherein the cancer comprises an oncogenic mutation at position 600 of BRAF.</span>
  </p>
  <p id="p0349" num="0349" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. La composicin para su uso de acuerdo con cualquiera de las realizaciones 6-8, en donde el cncer comprende una mutacin oncognica seleccionada de BRAF V600E, K601E, G469A, G469V, L597R, K601N, G464V, N581S, L597Q, A598V, G464R, G466A o G469E; opcionalmente en donde el cncer es cncer colorrectal.</span>9. The composition for use according to any of embodiments 6-8, wherein the cancer comprises a selected oncogenic mutation of BRAF V600E, K601E, G469A, G469V, L597R, K601N, G464V, N581S, L597Q, A598V, G464R , G466A or G469E; optionally wherein the cancer is colorectal cancer.</span>
  </p>
  <p id="p0350" num="0350" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. La composicin para su uso de acuerdo con cualquiera de las realizaciones 6-8, en donde el cncer comprende una mutacin oncognica seleccionada de BRAF V600E, V600K, V600R o V600D; opcionalmente en donde el cncer es melanoma.</span>10. The composition for use according to any of embodiments 6-8, wherein the cancer comprises a selected oncogenic mutation of BRAF V600E, V600K, V600R or V600D; optionally wherein the cancer is melanoma.</span>
  </p>
  <p id="p0351" num="0351" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. La composicin para su uso de acuerdo con cualquiera de las realizaciones 6-10, en donde el cncer comprende la mutacin oncognica BRAF V600E.</span>11. The composition for use according to any of embodiments 6-10, wherein the cancer comprises the BRAF V600E oncogenic mutation.</span>
  </p>
  <p id="p0352" num="0352" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. La composicin para su uso de acuerdo con cualquiera de las realizaciones 6-11, en donde el cncer comprende la mutacin oncognica NRAS Q61R, opcionalmente en donde el cncer es melanoma.</span>12. The composition for use according to any of embodiments 6-11, wherein the cancer comprises the NRAS Q61R oncogenic mutation, optionally wherein the cancer is melanoma.</span>
  </p>
  <p id="p0353" num="0353" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. La composicin para su uso de acuerdo con cualquier realizacin anterior, en donde el cncer se selecciona de cncer colorrectal, melanoma, cncer de prstata, adenocarcinoma de pulmn como adenocarcinoma de pulmn de clulas no pequeas, cncer de pncreas, cncer de vejiga, leucemia como leucemia de clulas pilosas o leucemia mieloide aguda, glioma, astrocitoma piloctico, cncer de ovario, cncer de tiroides papilar o folicular, seminoma, cncer de hgado, sndrome mielodisplsico, cncer de rin o enfermedad de Hodgkin. 14. La composicin para su uso de acuerdo con cualquier realizacin anterior, en donde el cncer es cncer colorrectal.</span>13. The composition for use according to any previous embodiment, wherein the cancer is selected from colorectal cancer, melanoma, prostate cancer, lung adenocarcinoma such as non-small cell lung adenocarcinoma, pancreatic cancer, bladder cancer, leukemia such as hairy cell leukemia or acute myeloid leukemia, glioma, pilocytic astrocytoma, ovarian cancer, papillary or follicular thyroid cancer, seminoma, liver cancer, myelodysplastic syndrome, kidney cancer, or Hodgkin's disease. 14. The composition for use according to any preceding embodiment, wherein the cancer is colorectal cancer.</span>
  </p>
  <p id="p0354" num="0354" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. La composicin para su uso de acuerdo con cualquiera de las realizaciones 1-13, en donde el cncer es melanoma.</span>15. The composition for use according to any of embodiments 1-13, wherein the cancer is melanoma.</span>
  </p>
  <p id="p0355" num="0355" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. La composicin para su uso de acuerdo con cualquier realizacin anterior, en donde la cepa bacteriana es de la especie <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>16. The composition for use according to any previous embodiment, wherein the bacterial strain is of the species <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0356" num="0356" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17. La composicin para su uso de acuerdo con cualquier realizacin anterior, en un mtodo para inhibir la sealizacin de ERK1 y/o ERK2 en el tratamiento o prevencin del cncer.</span>17. The composition for use according to any preceding embodiment, in a method of inhibiting ERK1 and/or ERK2 signaling in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0357" num="0357" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18. La composicin para su uso de acuerdo con cualquier realizacin anterior, en un mtodo para inhibir la fosforilacin de ERK1 y/o ERK2 en el tratamiento o prevencin del cncer.</span>18. The composition for use according to any previous embodiment, in a method of inhibiting the phosphorylation of ERK1 and/or ERK2 in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0358" num="0358" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19. La composicin para su uso de acuerdo con cualquier realizacin anterior, en un mtodo para inducir la expresin del gen MAP2 en el tratamiento o prevencin del cncer.</span>19. The composition for use according to any previous embodiment, in a method of inducing the expression of the MAP2 gene in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0359" num="0359" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20. La composicin para su uso de acuerdo con cualquier realizacin anterior, en un mtodo para reducir el tamao del tumor, el crecimiento del tumor, prevenir o inhibir la metstasis o prevenir la angiognesis en el tratamiento o la prevencin del cncer.</span>20. The composition for use according to any preceding embodiment, in a method of reducing tumor size, tumor growth, preventing or inhibiting metastasis, or preventing angiogenesis in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0360" num="0360" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21. La composicin para su uso de acuerdo con cualquier realizacin anterior, en un mtodo para inhibir la metstasis en el tratamiento del cncer.</span>21. The composition for use according to any preceding embodiment, in a method of inhibiting metastasis in the treatment of cancer.</span>
  </p>
  <p id="p0361" num="0361" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">22. La composicin para su uso de acuerdo con cualquier realizacin anterior, en donde el mtodo comprende la administracin simultnea, separada o secuencial de un inhibidor de BRAF, con respecto a la administracin de la composicin.</span>22. The composition for use according to any preceding embodiment, wherein the method comprises the simultaneous, separate or sequential administration of a BRAF inhibitor, with respect to the administration of the composition.</span>
  </p>
  <p id="p0362" num="0362" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">23. La composicin para su uso de acuerdo con la realizacin 22, en donde BRAF inhibe selectivamente BRAFv600E, preferiblemente en donde el inhibidor de BRAF se selecciona de Vemurafenib, Dabrafinib o Encorafenib.</span>23. The composition for use according to embodiment 22, wherein BRAF selectively inhibits BRAFv600E, preferably wherein the BRAF inhibitor is selected from Vemurafenib, Dabrafinib or Encorafenib.</span>
  </p>
  <p id="p0363" num="0363" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">24. La composicin para su uso de acuerdo con la realizacin 23, en donde el inhibidor de BRAF es Vemurafenib.</span>24. The composition for use according to embodiment 23, wherein the BRAF inhibitor is Vemurafenib.</span>
  </p>
  <p id="p0364" num="0364" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25. La composicin para su uso de acuerdo con cualquier realizacin anterior, en donde el mtodo comprende la administracin simultnea, separada o secuencial de un anlogo de citidina, con respecto a la administracin de la composicin.</span>25. The composition for use according to any preceding embodiment, wherein the method comprises the simultaneous, separate or sequential administration of a cytidine analog, relative to the administration of the composition.</span>
  </p>
  <p id="p0365" num="0365" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">26. La composicin para su uso de acuerdo con la realizacin 25, en donde el anlogo de citidina se selecciona de Azacitidina-c, Decitabina o Zebularina.</span>26. The composition for use according to embodiment 25, wherein the cytidine analog is selected from Azacitidine-c, Decitabine or Zebularin.</span>
  </p>
  <p id="p0366" num="0366" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">27. La composicin para su uso de acuerdo con la realizacin 26, en donde el anlogo de citidina es Aazacitidina-c.</span>27. The composition for use according to embodiment 26, wherein the cytidine analog is Aazacytidine-c.</span>
  </p>
  <p id="p0367" num="0367" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">28. La composicin para su uso de acuerdo con cualquier realizacin anterior, en donde el mtodo comprende la administracin simultnea, separada o secuencial de un inhibidor de la polimerizacin de tubulina o un inhibidor de la despolimerizacin de tubulina, con respecto a la administracin de la composicin.</span>28. The composition for use according to any previous embodiment, wherein the method comprises the simultaneous, separate or sequential administration of a tubulin polymerization inhibitor or a tubulin depolymerization inhibitor, with respect to the administration of the composition.</span>
  </p>
  <p id="p0368" num="0368" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">29. La composicin para su uso de acuerdo con la realizacin 28, en donde el inhibidor de la polimerizacin de tubulina o el inhibidor de la despolimerizacin de tubulina se selecciona de Paclitaxel, Abraxane, Docetaxel, Epotilona, (+)-Discodermolida, Colchicina, Combretastatina, 2-Metoxiestradiol, E7010, Vincristina, Vinblastina, Vinorelbina o Vinflunina.</span>29. The composition for use according to embodiment 28, wherein the tubulin polymerization inhibitor or tubulin depolymerization inhibitor is selected from Paclitaxel, Abraxane, Docetaxel, Epothilone, (+)-Discodermolide, Colchicine, Combretastatin, 2-Methoxyestradiol, E7010, Vincristine, Vinblastine, Vinorelbine or Vinflunine.</span>
  </p>
  <p id="p0370" num="0370" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, los cnceres que comprenden sealizacin de ERK oncognica que pueden tratarse o prevenirse usando composiciones de la invencin (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>incluyen, pero no se limitan a, cncer colorrectal, melanoma, cncer de prstata, adenocarcinoma de pulmn como adenocarcinoma de pulmn de clulas no pequeas, cncer de pncreas, cncer de vejiga, leucemia como leucemia de clulas pilosas o leucemia mieloide aguda, glioma, astrocitoma piloctico, cncer de ovario, cncer de tiroides papilar o folicular, seminoma, cncer de hgado, sndrome mielodisplsico, cncer de rin y enfermedad de Hodgkin. Se ha informado que tales cnceres comprenden una va 
de MAP-quinasa hiperactiva (es decir, sealizacin ERK oncognica) [72].</span>Preferably, cancers comprising oncogenic ERK signaling that can be treated or prevented using compositions of the invention (in particular, those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> include, but are not limited to, colorectal cancer, melanoma, cancer prostate, lung adenocarcinoma such as non-small cell lung adenocarcinoma, pancreatic cancer, bladder cancer, leukemia such as hairy cell leukemia or acute myeloid leukemia, glioma, pilocytic astrocytoma, ovarian cancer, papillary or follicular thyroid cancer, seminoma, liver cancer, myelodysplastic syndrome, kidney cancer, and Hodgkin's disease. Such cancers have been reported to comprise a pathway  of overactive MAP-kinase (ie, oncogenic ERK signaling) [72].</span>
  </p>
  <p id="p0371" num="0371" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una realizacin particular, las composiciones de la invencin son para su uso en el tratamiento o prevencin del cncer que comprende una mutacin oncognica en BRAF o NRAS, opcionalmente en donde el cncer comprende adems la sobreexpresin de BRAF o NRAS. Preferiblemente, las composiciones de la invencin (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>son para su uso en el tratamiento o prevencin del cncer que comprende una mutacin oncognica en BRAF y la sobreexpresin opcional de BRAF.</span>In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of cancer comprising an oncogenic mutation in BRAF or NRAS, optionally where the cancer further comprises overexpression of BRAF or NRAS. Preferably, the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are for use in the treatment or prevention of cancer comprising an oncogenic mutation in BRAF and optional overexpression of BRAF.</span>
  </p>
  <p id="p0372" num="0372" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las mutaciones oncognicas en BRAF incluyen V600E, K601E, G469A, G469V, F597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A o G469E, que se han identificado en cnceres colorrectales [73], y las composiciones de las composiciones de la invencin (en particular, las que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>pueden usarse para tratar o prevenir tales cnceres. Otras mutaciones oncognicas en BRAF incluyen V600E, V600K, V600R o V600D, que se han identificado en melanomas [74], y las composiciones de las composiciones de la invencin (en particular, las que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>pueden usarse para tratar o prevenir tales cnceres. Los aminocidos en BRAF se numeran de acuerdo con la entrada P15056 de UniProt [75] (BRAF de tipo salvaje).</span>Oncogenic mutations in BRAF include V600E, K601E, G469A, G469V, F597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A, or G469E, which have been identified in colorectal cancers [73], and the compositions of the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> can be used to treat or prevent such cancers. Other oncogenic mutations in BRAF include V600E, V600K, V600R or V600D, which have been identified in melanomas [74], and the compositions of the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> can used to treat or prevent such cancers. The amino acids in BRAF are numbered according to UniProt entry P15056 [75] (wild-type BRAF).</span>
  </p>
  <p id="p0373" num="0373" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una realizacin especialmente preferida, las composiciones de la invencin (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>son para su uso en el tratamiento o prevencin del cncer que comprende la mutacin BRAF V600E. Las lneas celulares de cncer SKMEF28, 451Lu y HT29 comprenden esta mutacin en BRAF, y se descubri que una cepa de <i class="style-scope patent-text">Megasphaera </i>de los Ejemplos inhiba la supervivencia clonognica, inhiba la sealizacin de ERK e induca la expresin del gen MAP2 en dichas lneas celulares. El cncer puede comprender adems la mutacin oncognica NRAS Q61R. La lnea celular de cncer SKMEL2 comprende esta mutacin en NRAS, y se descubri que una cepa de <i class="style-scope patent-text">Megasphaera </i>de los Ejemplos induca la expresin del gen MAP2 en esta lnea celular.</span>In an especially preferred embodiment, the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are for use in the treatment or prevention of cancer comprising the BRAF V600E mutation. Cancer cell lines SKMEF28, 451Lu, and HT29 comprise this mutation in BRAF, and a <i class="style-scope patent-text">Megasphaera</i> strain of Examples was found to inhibit clonogenic survival, inhibit ERK signaling, and induce MAP2 gene expression in these cell lines. The cancer may further comprise the NRAS Q61R oncogenic mutation. The cancer cell line SKMEL2 comprises this mutation in NRAS, and a <i class="style-scope patent-text">Megasphaera</i> strain of the Examples was found to induce expression of the MAP2 gene in this cell line.</span>
  </p>
  <p id="p0374" num="0374" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La lnea celular HT29 usada en los Ejemplos es una lnea celular de cncer colorrectal, y se descubri que una cepa de <i class="style-scope patent-text">Megasphaera </i>inhiba la supervivencia clonognica e inhiba la sealizacin de ERK en esta lnea celular. Por lo tanto, en realizaciones especialmente preferidas, las composiciones de la invencin (en particular, las que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>son para su uso en el tratamiento o prevencin del cncer colorrectal, como el cncer colorrectal que comprende la mutacin BRAF V600E.</span>The HT29 cell line used in the Examples is a colorectal cancer cell line, and a Megasphaera strain was found to inhibit <i class="style-scope patent-text">clonogenic</i> survival and inhibit ERK signaling in this cell line. Therefore, in especially preferred embodiments, the compositions of the invention (in particular, those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are for use in the treatment or prevention of colorectal cancer, such as colorectal cancer comprising the BRAF V600E mutation.</span>
  </p>
  <p id="p0375" num="0375" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las lneas celulares SKMEL2 y SKMEL28 y 451Lu usadas en los Ejemplos son lneas celulares de melanoma, y se descubri que una cepa de <i class="style-scope patent-text">Megasphaera </i>inhiba la supervivencia clonognica, inhiba la sealizacin de ERK e induca la expresin del gen MAP2 en dichas lneas celulares. Por lo tanto, en realizaciones especialmente preferidas, las composiciones de la invencin (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>se usan para tratar o prevenir el melanoma, como el melanoma que comprende la mutacin BRAF V600E.</span>The SKMEL2 and SKMEL28 and 451Lu cell lines used in the Examples are melanoma cell lines, and a Megasphaera strain was found to inhibit <i class="style-scope patent-text">clonogenic</i> survival, inhibit ERK signaling and induce MAP2 gene expression in these cell lines. Therefore, in especially preferred embodiments, the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are used to treat or prevent melanoma, such as melanoma comprising the BRAF V600E mutation.</span>
  </p>
  <p id="p0376" num="0376" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otro aspecto, la composicin de la invencin comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>para su uso en un mtodo de tratamiento del cncer colorrectal. En otro aspecto, la composicin de la invencin comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>para su uso en un mtodo de tratamiento del melanoma.</span>In another aspect, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> for use in a method of treating colorectal cancer. In another aspect, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> for use in a method of treating melanoma.</span>
  </p>
  <p id="p0377" num="0377" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En cualquiera de los aspectos y realizaciones detallados anteriormente, la composicin de la invencin (en particular, una composicin que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>es preferiblemente para su uso en el tratamiento de un cncer metastsico. Como se informa en los Ejemplos, se descubri que una cepa de <i class="style-scope patent-text">Megasphaera </i>regulaba por incremento la expresin del gen MAP2. Se ha descubierto que MAP2 se expresa en gran medida en los melanomas cutneos primarios, pero tiene una expresin reducida en los melanomas metastsicos [76]. Se ha propuesto que la expresin aumentada de protenas estabilizadoras de microtbulos o el tratamiento con protenas estabilizadoras de microtbulos como MAP2 pueden interferir con la inestabilidad dinmica de los microtbulos que se requiere durante la divisin celular. Por lo tanto, se cree que la regulacin por incremento de MAP2 dificulta la divisin celular y retrasa el crecimiento tumoral en el cncer [76], lo que indica que las composiciones de la invencin pueden tener un uso particular en el tratamiento de cnceres metastsicos.</span>In any of the aspects and embodiments detailed above, the composition of the invention (in particular, a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> is preferably for use in the treatment of metastatic cancer. As reported in the Examples, one strain of <i class="style-scope patent-text">Megasphaera</i> was found to up-regulate the expression of the MAP2 gene. MAP2 has been found to be highly expressed in primary cutaneous melanomas, but has reduced expression in metastatic melanomas [76]. It has been proposed that increased expression of microtubule-stabilizing proteins or treatment with microtubule-stabilizing proteins such as MAP2 may interfere with the dynamic instability of microtubules that is required during cell division. Thus, upregulation of MAP2 is believed to impair cell division and retard tumor growth in cancer [76], indicating that the compositions of the invention may have particular use in the treatment of metastatic cancers.</span>
  </p>
  <p id="p0378" num="0378" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se demuestra en los Ejemplos, las composiciones de la invencin que comprenden una cepa de <i class="style-scope patent-text">Megasphaera </i>tienen los efectos de inducir la expresin del gen MAP2 e inhibir la sealizacin de ERK en lneas celulares de melanoma y cncer colorrectal. Por lo tanto, las composiciones de la invencin son tiles en mtodos para inhibir la sealizacin de ERK, como la sealizacin de ERK1 y/o ERK2, en el tratamiento o prevencin de cnceres que comprenden la sealizacin de ERK oncognica, como se ha definido anteriormente. Las composiciones de la invencin tambin son tiles en mtodos para inhibir la fosforilacin de ERK, como la fosforilacin de ERK1 y/o ERK2, en el tratamiento o prevencin de tales cnceres. Las composiciones de la invencin tambin son tiles en mtodos para inducir la expresin del gen MAP2 en el tratamiento o prevencin de 
tales cnceres. La expresin del gen MAP2 se ha asociado con una sensibilidad aumentada del cncer a compuestos dirigidos a microtbulos como Paclitaxel [77]. Por lo tanto, las composiciones de la invencin pueden usarse para aumentar la susceptibilidad de tales cnceres a un inhibidor de la polimerizacin o despolimerizacin de tubulina, en particular Paclitaxel. Las composiciones de la invencin tambin son tiles en mtodos para reducir el tamao del tumor, reducir el crecimiento del tumor, prevenir o inhibir la metstasis o prevenir la angiognesis en el tratamiento o la prevencin de cnceres que comprenden la sealizacin de ERK oncognica. Debido a los efectos sobre la expresin del gen MAP2 demostrados en los Ejemplos, las composiciones de la invencin son preferiblemente para su uso en mtodos de inhibicin de metstasis en el tratamiento de tales cnceres.</span>As demonstrated in the Examples, compositions of the invention comprising a <i class="style-scope patent-text">Megasphaera</i> strain have the effects of inducing MAP2 gene expression and inhibiting ERK signaling in melanoma and colorectal cancer cell lines. Therefore, the compositions of the invention are useful in methods of inhibiting ERK signaling, such as ERK1 and/or ERK2 signaling, in the treatment or prevention of cancers that comprise oncogenic ERK signaling, as defined above. . The compositions of the invention are also useful in methods of inhibiting ERK phosphorylation, such as ERK1 and/or ERK2 phosphorylation, in the treatment or prevention of such cancers. The compositions of the invention are also useful in methods of inducing MAP2 gene expression in the treatment or prevention of  such cancers. MAP2 gene expression has been associated with increased sensitivity of cancer to microtubule-targeted compounds such as Paclitaxel [77]. Therefore, the compositions of the invention can be used to increase the susceptibility of such cancers to an inhibitor of tubulin polymerization or depolymerization, in particular Paclitaxel. The compositions of the invention are also useful in methods of reducing tumor size, reducing tumor growth, preventing or inhibiting metastasis, or preventing angiogenesis in the treatment or prevention of cancers that comprise oncogenic ERK signaling. Due to the effects on MAP2 gene expression demonstrated in the Examples, the compositions of the invention are preferably for use in methods of inhibiting metastasis in the treatment of such cancers.</span>
  </p>
  <p id="p0379" num="0379" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>es para su uso en un mtodo para inhibir la sealizacin de ERK1 y/o ERK2 en el tratamiento o la prevencin del cncer. En un aspecto adicional, una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>es para su uso en un mtodo para inhibir la fosforilacin de ERK1 y/o ERK2 en el tratamiento o prevencin del cncer. En un aspecto adicional, una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>es para su uso en un mtodo para inducir la expresin del gen MAP2 en el tratamiento o prevencin del cncer. En dichos aspectos adicionales, preferiblemente los cnceres se caracterizan como se ha detallado anteriormente ("Cnceres y caractersticas de los mismos").</span>In a further aspect, a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is for use in a method of inhibiting ERK1 and/or ERK2 signaling in the treatment or prevention of cancer. In a further aspect, a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is for use in a method of inhibiting ERK1 and/or ERK2 phosphorylation in the treatment or prevention of cancer. In a further aspect, a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is for use in a method of inducing MAP2 gene expression in the treatment or prevention of cancer. In such additional aspects, cancers are preferably characterized as detailed above ("Cancers and characteristics thereof").</span>
  </p>
  <p id="p0380" num="0380" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin es para su uso en el tratamiento del cncer de intestino delgado, como el adenocarcinoma de intestino delgado. La lnea celular HT29 tratada con metotrexato usada en los ejemplos tiene un fenotipo que se asemeja a las clulas epiteliales del intestino delgado y se demostr que las composiciones de la invencin tienen un efecto til sobre tales clulas. En ciertas realizaciones, las composiciones de la invencin se usan para promover la apoptosis en el tratamiento o prevencin del cncer, en particular del cncer de intestino delgado.</span>In certain embodiments, the composition of the invention is for use in the treatment of cancer of the small intestine, such as adenocarcinoma of the small intestine. The methotrexate-treated cell line HT29 used in the examples has a phenotype resembling epithelial cells of the small intestine and the compositions of the invention were shown to have a useful effect on such cells. In certain embodiments, the compositions of the invention are used to promote apoptosis in the treatment or prevention of cancer, particularly cancer of the small intestine.</span>
  </p>
  <p id="p0381" num="0381" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin es para su uso en un mtodo para inducir la expresin del gen GPR109a en el tratamiento o la prevencin del cncer.</span>In certain embodiments, the composition of the invention is for use in a method of inducing GPR109a gene expression in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0382" num="0382" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin es para su uso en un mtodo para aumentar los niveles de IL-8 en el tratamiento o la prevencin del cncer.</span>In certain embodiments, the composition of the invention is for use in a method of increasing IL-8 levels in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0383" num="0383" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin es para su uso en el tratamiento del cncer colorrectal, como el adenocarcinoma colorrectal. La lnea celular Caco-2 utilizada en los ejemplos es una lnea celular de adenocarcinoma colorrectal y se demostr que las composiciones de la invencin tienen un efecto til sobre tales clulas.</span>In certain embodiments, the composition of the invention is for use in the treatment of colorectal cancer, such as colorectal adenocarcinoma. The Caco-2 cell line used in the examples is a colorectal adenocarcinoma cell line and the compositions of the invention were shown to have a useful effect on such cells.</span>
  </p>
  <p id="p0384" num="0384" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones son para su uso en el tratamiento o prevencin del melanoma metastsico, el cncer de pulmn de clulas pequeas o el carcinoma de pulmn adenoescamoso. El efecto sobre NSE que se muestra en los ejemplos sugiere que las composiciones de la invencin pueden ser especialmente eficaces contra estos cnceres.</span>In certain embodiments, the compositions are for use in the treatment or prevention of metastatic melanoma, small cell lung cancer, or adenosquamous lung carcinoma. The effect on NSE shown in the examples suggests that the compositions of the invention may be especially effective against these cancers.</span>
  </p>
  <p id="p0385" num="0385" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin no es para su uso en el tratamiento del cncer. En ciertas realizaciones, la composicin de la invencin es para su uso en el tratamiento de una enfermedad o trastorno que no es cncer.</span>In certain embodiments, the composition of the invention is not for use in the treatment of cancer. In certain embodiments, the composition of the invention is for use in the treatment of a disease or disorder that is not cancer.</span>
  </p>
  <p id="p0386" num="0386" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uso como adyuvante de vacunas</span>Use as a vaccine adjuvant</span>
    </i>
  </p>
  <p id="p0387" num="0387" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin del Factor de Necrosis Tumoral alfa (TNF-a). Se sabe que el TNF-a es importante para las respuestas a las vacunas. Por ejemplo, se ha demostrado que se requiere el TNF-a para una respuesta vacunal eficaz en la vacunacin contra la gripe de la poblacin de edad avanzada [78]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de TNF-a, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvantes de vacunas aumentando el nivel y/o la actividad de TNF-a. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas en la terapia contra la gripe. En ciertas realizaciones, las composiciones de la invencin son para su uso en la potenciacin de una respuesta inmunitaria contra un antgeno. En ciertas realizaciones, la invencin proporciona una composicin para administrar en combinacin con un antgeno. En ciertas realizaciones, las composiciones de la invencin son para su administracin a un paciente poco antes o despus de la vacunacin.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of Tumor Necrosis Factor alpha (TNF-a). TNF- is known to be important for responses to vaccines. For example, TNF- has been shown to be required for an effective vaccine response in influenza vaccination of the elderly population [78]. Since administration of the compositions of the invention has been shown to increase the expression of TNF-, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention are for use as vaccine adjuvants by increasing the level and/or activity of TNF-. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in influenza therapy. In certain embodiments, the compositions of the invention are for use in enhancing an immune response against an antigen. In certain embodiments, the invention provides a composition for administration in combination with an antigen. In certain embodiments, the compositions of the invention are for administration to a patient shortly before or after vaccination.</span>
  </p>
  <p id="p0388" num="0388" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-6. La expresin de IL-6 aumentada se ha asociado con respuestas a vacunas para muchas enfermedades. Por ejemplo, los monocitos inflamatorios CD14+CD16- produjeron IL-6 despus de que se administrase una vacuna contra la gripe a adultos [79], y los niveles ms altos de IL-6 se asociaron con el logro de 
una respuesta vacunal a una vacuna contra la gripe [80]. Adems, se produjo IL-6 despus de la inyeccin del sistema adyuvante AS03 [81] y se demostr que la regulacin por disminucin de IL-6 en ratones reduce la respuesta de las clulas T auxiliares despus de la administracin de una vacuna contra la tuberculosis [82]. Como se demostr que la administracin de las composiciones de la invencin aumenta la expresin de IL-6, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas aumentando el nivel y/o la actividad de IL-6. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas en la terapia contra la tuberculosis.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in IL-6 expression. Increased IL-6 expression has been associated with responses to vaccines for many diseases. For example, inflammatory monocytes CD14+CD16- produced IL-6 after an influenza vaccine was administered to adults [79], and higher levels of IL-6 were associated with achievement of  a vaccinal response to an influenza vaccine [80]. In addition, IL-6 was produced after injection of the AS03 adjuvant system [81] and down-regulation of IL-6 in mice was shown to reduce the T helper cell response after administration of a tuberculosis vaccine. [82]. Since administration of the compositions of the invention was shown to increase IL-6 expression, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant by increasing the level and/or activity of IL-6. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in tuberculosis therapy.</span>
  </p>
  <p id="p0390" num="0390" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, se ha demostrado que la expresin de IL-6 y TNF-a se correlaciona con la eficacia de una vacuna teraputica contra el VIH [Huang et al], una vacuna contra la tuberculosis y una vacuna contra la clamidia [83]. Su et al. [84] demostraron que la coinoculacin de IL-6 o TNF-a con la vacuna de ADN contra el FMDV dio como resultado un aumento de la expresin de IFN-<sup class="style-scope patent-text">y </sup>por las clulas T CD4+ y CD8+, una mayor expresin de IL-4 en las clulas T CD4+ y una mayor expresin de la respuesta citotxica especfica del antgeno. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-6 y TNF-a, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas. En una realizacin, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas aumentando el nivel y/o la actividad de TNF-a. En una realizacin, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas aumentando el nivel y/o la actividad de IL-6. En una realizacin particular, las composiciones de la invencin pueden ser tiles como adyuvante de vacunas aumentando el nivel y/o actividad de TNF-a e IL-6. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas en la terapia del VIH. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas en la terapia de clamidia.</span>Furthermore, the expression of IL-6 and TNF- has been shown to correlate with the efficacy of a therapeutic HIV vaccine [Huang et al], a tuberculosis vaccine, and a chlamydia vaccine [83]. His et al. [84] showed that co-inoculation of IL-6 or TNF- with FMDV DNA vaccine resulted in increased expression of IFN- <sup class="style-scope patent-text">and</sup> , by CD4+ and CD8+ T cells, increased expression of IL-4 on CD4+ T cells and increased expression of the antigen-specific cytotoxic response. Since administration of the compositions of the invention has been shown to increase the expression of IL-6 and TNF-, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention may be useful as vaccine adjuvants by increasing the level and/or activity of TNF-. In one embodiment, the compositions of the invention may be useful as vaccine adjuvants by increasing the level and/or activity of IL-6. In a particular embodiment, the compositions of the invention may be useful as a vaccine adjuvant by increasing the level and/or activity of TNF-a and IL-6. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in HIV therapy. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in the therapy of chlamydia.</span>
  </p>
  <p id="p0392" num="0392" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de MIP-3a. Se ha demostrado que MIP-3a aumenta la respuesta a una vacuna contra el VIH [85]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de MIP-3a, las composiciones de la invencin pueden ser tiles como adyuvante de vacunas.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of MIP-3a. MIP-3a has been shown to increase the response to an HIV vaccine [85]. Since administration of the compositions of the invention has been shown to increase the expression of MIP-3a, the compositions of the invention may be useful as a vaccine adjuvant.</span>
  </p>
  <p id="p0394" num="0394" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-1 p. Li et al. [86] demostraron que el adyuvante hidrxido de aluminio activaba la secrecin de IL-1 p y sugirieron que la propia IL-1 p puede actuar como adyuvante. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-1 p, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas. Los ejemplos muestran que la administracin de las composiciones de la invencin puede aumentar la proporcin de clulas T CD8+ a Tregs. Se ha demostrado que los adyuvantes estimulan las clulas T CD8+ [87] y como se ha demostrado que la administracin de las composiciones de la invencin aumenta la proporcin de clulas T CD8+ a Tregs, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvantes de vacunas aumentando la proporcin de clulas T CD8+ a Tregs.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-1 p. Li et al. [86] showed that aluminum hydroxide adjuvant activated IL-1p secretion and suggested that IL-1p itself may act as an adjuvant. Since administration of the compositions of the invention has been shown to increase IL-1 p expression, the compositions of the invention may be useful as vaccine adjuvants. The examples show that administration of the compositions of the invention can increase the ratio of CD8+ T cells to Tregs. Adjuvants have been shown to stimulate CD8+ T cells [87] and since administration of the compositions of the invention has been shown to increase the ratio of CD8+ T cells to Tregs, the compositions of the invention may be useful as vaccine adjuvants. . In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as vaccine adjuvants by increasing the ratio of CD8+ T cells to Tregs.</span>
  </p>
  <p id="p0396" num="0396" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-8. El aumento de la expresin de 11-8 se ha asociado con respuestas a vacunas para muchas enfermedades. Por ejemplo, los niveles ms altos de IL-8 se asociaron con el logro de una respuesta vacunal a una vacuna contra la gripe aviar [88]. Adems, la IL-8 sirve como adyuvante molecular en un modelo de vacunacin con ADN [89]. Por lo tanto, la IL-8 puede usarse como inmunoestimulante para potenciar la eficacia inmunitaria de, por ejemplo, una vacuna contra la gripe aviar. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-8, las composiciones de la invencin pueden ser tiles como adyuvantes de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvantes de vacunas aumentando el nivel y/o la actividad de IL-8. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas. En una realizacin, las composiciones de la invencin son para su uso como adyuvante de vacunas en la terapia contra la gripe. En algunas realizaciones, cuando se usan como adyuvantes de vacunas, las composiciones de la invencin se administrarn por s solas para proporcionar un efecto adyuvante para un antgeno que se ha administrado por separado al paciente. En ciertas realizaciones, la composicin de la invencin se administra por va oral, mientras que el antgeno se inyecta por va parenteral.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-8. Increased expression of 11-8 has been associated with responses to vaccines for many diseases. For example, higher levels of IL-8 were associated with achieving a vaccine response to an avian influenza vaccine [88]. In addition, IL-8 serves as a molecular adjuvant in a DNA vaccination model [89]. Therefore, IL-8 can be used as an immunostimulant to enhance the immune efficacy of, for example, an avian influenza vaccine. Since administration of the compositions of the invention has been shown to increase IL-8 expression, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention are for use as vaccine adjuvants by increasing the level and/or activity of IL-8. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in influenza therapy. In some embodiments, when used as vaccine adjuvants, the compositions of the invention will be administered alone to provide an adjuvant effect for an antigen that has been separately administered to the patient. In certain embodiments, the composition of the invention is administered orally, while the antigen is injected parenterally.</span>
  </p>
  <p id="p0398" num="0398" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden usarse para potenciar una respuesta inmunitaria a cualquier antgeno til. Ejemplos de antgenos para su uso con la invencin incluyen: antgenos virales, como protenas de superficie virales; antgenos bacterianos, como antgenos proteicos y/o sacridos; antgenos fngicos; antgenos de parsitos; y antgenos tumorales. La invencin es particularmente til para vacunas contra el virus de la gripe, VIH, anquilostomiasis, virus de la hepatitis B, virus del herpes simple, rabia, virus respiratorio sincitial, citomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus, </i>clamidia, coronavirus del SARS, virus de la varicela zoster, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis, </i>virus de Epstein Barr, virus del papiloma humano, etc. Antgenos adicionales para su uso con la invencin incluyen antgenos de glicoprotena y lipoglicano, antgenos de arqueas, antgeno de melanoma E (MAGE), antgeno carcinoembrionario (CEA), MUC-1, HER2, sialilTn (STn), transcriptasa inversa de telomerasa humana (hTERT), gen del tumor de Wilms (WT1), CA-125, antgeno prosttico especfico (PSA), antgenos del virus de Epstein-Barr, neoantgenos, oncoprotenas, amiloide-beta, Tau, PCSK9 y sustancias que crean hbito, por ejemplo, nicotina, alcohol u opiceos.</span>The compositions of the invention can be used to enhance an immune response to any useful antigen. Examples of antigens for use with the invention include: viral antigens, such as viral surface proteins; bacterial antigens, such as protein and/or saccharide antigens; fungal antigens; parasite antigens; and tumor antigens. The invention is particularly useful for vaccines against influenza virus, HIV, hookworm, hepatitis B virus, herpes simplex virus, rabies, respiratory syncytial virus, cytomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus,</i> chlamydia, SARS coronavirus, varicella virus zoster, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis,</i> Epstein Barr virus, human papilloma virus, etc. Additional antigens for use with the invention include glycoprotein and lipoglycan antigens, archaeal antigens, melanoma antigen E (MAGE), carcinoembryonic antigen (CEA), MUC-1, HER2,  sialylTn (STn), human telomerase reverse transcriptase (hTERT), Wilms tumor gene (WT1), CA-125, prostate-specific antigen (PSA), Epstein-Barr virus antigens, neoantigens, oncoproteins, amyloid-beta, Tau, PCSK9, and habit-forming substances, for example, nicotine, alcohol, or opiates.</span>
  </p>
  <p id="p0399" num="0399" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los antgenos preferidos para su uso con la invencin incluyen antgenos patgenos y antgenos tumorales. Un antgeno provocar una respuesta inmunitaria especfica para el antgeno que ser eficaz para proteger contra la infeccin por el patgeno o atacar el tumor. Los antgenos pueden ser, por ejemplo, pptidos o polisacridos.</span>Preferred antigens for use with the invention include pathogen antigens and tumor antigens. An antigen will elicit an antigen-specific immune response that will be effective in protecting against infection by the pathogen or attacking the tumor. The antigens can be, for example, peptides or polysaccharides.</span>
  </p>
  <p id="p0400" num="0400" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencin tambin proporciona el uso de: (i) una preparacin acuosa de un antgeno; y (ii) una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>preferiblemente la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en la fabricacin de un medicamento para obtener una respuesta inmunitaria en un paciente.</span>The invention also provides the use of: (i) an aqueous preparation of an antigen; and (ii) a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> preferably the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> in the manufacture of a medicament for eliciting an immune response in a patient.</span>
  </p>
  <p id="p0401" num="0401" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La respuesta inmunitaria provocada por estos mtodos y usos incluir generalmente una respuesta de anticuerpos, preferiblemente una respuesta de anticuerpos protectores.</span>The immune response elicited by these methods and uses will generally include an antibody response, preferably a protective antibody response.</span>
  </p>
  <p id="p0402" num="0402" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, se manipula una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>para que presente un antgeno. La presentacin de un antgeno en la cepa bacteriana de la invencin puede maximizar las actividades inmunoestimuladoras y potenciar adicionalmente la respuesta inmunitaria protectora generada contra el antgeno. Adems, la fabricacin y el suministro de productos teraputicos que comprenden un antgeno y una bacteria de la invencin pueden ser ms eficientes y eficaces de esta manera que cuando cada antgeno y la composicin que comprende la cepa bacteriana se fabrican y suministran por separado. Por tanto, en algunas realizaciones, la invencin proporciona una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>que presenta un antgeno, por ejemplo, en su superficie celular. En algunas realizaciones, la composicin que comprende la cepa bacteriana que presenta un antgeno es para su uso como antgeno vacunal. En algunas realizaciones, el antgeno se deriva de VIH, anquilostomiasis, virus de la hepatitis B, virus del herpes simple, rabia, virus respiratorio sincitial, citomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus, </i>clamidia, coronavirus del SARS, virus de la varicela zoster, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis, </i>virus de Epstein Barr o virus del papiloma humano. En algunas realizaciones, el antgeno es un antgeno de glicoprotena, antgeno de lipoglicano, antgeno de arqueas, antgeno de melanoma E (MAGE), antgeno carcinoembrionario (CEA), MUC-1, HER2, sialil-T n (STn), transcriptasa inversa de telomerasa humana (hTERT), gen del tumor de Wilms (WT1), CA-125, antgeno prosttico especfico (PSA), antgenos del virus de Epstein-Barr, neoantgenos, oncoprotenas, amiloide-beta, Tau, PCSK9 y sustancias que crean hbito, por ejemplo, nicotina, alcohol u opiceos y similares.</span>In some embodiments, a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is manipulated to present an antigen. Presentation of an antigen in the bacterial strain of the invention can maximize immunostimulatory activities and further enhance the protective immune response generated against the antigen. Furthermore, the manufacture and supply of therapeutics comprising an antigen and a bacteria of the invention can be more efficient and effective in this manner than when each antigen and the composition comprising the bacterial strain are manufactured and supplied separately. Thus, in some embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> that presents an antigen, for example, on its cell surface. In some embodiments, the composition comprising the antigen presenting bacterial strain is for use as a vaccine antigen. In some embodiments, the antigen is derived from HIV, hookworm, hepatitis B virus, herpes simplex virus, rabies, respiratory syncytial virus, cytomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus,</i> chlamydia, SARS coronavirus, varicella zoster virus, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis,</i> Epstein Barr virus, or human papillomavirus. In some embodiments, the antigen is a glycoprotein antigen, lipoglycan antigen, archaeal antigen, melanoma antigen E (MAGE), carcinoembryonic antigen (CEA), MUC-1, HER2, sialyl-T n (STn), reverse transcriptase human telomerase (hTERT), Wilms tumor gene (WT1), CA-125, prostate-specific antigen (PSA), Epstein-Barr virus antigens, neoantigens, oncoproteins, amyloid-beta, Tau, PCSK9, and substances that create habit, for example, nicotine, alcohol or opiates and the like.</span>
  </p>
  <p id="p0403" num="0403" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las bacterias de la invencin expresan uno o ms antgenos. Generalmente, el antgeno se expresar de manera recombinante y ser heterlogo para las bacterias de la invencin. Por lo tanto, la invencin proporciona una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>que expresa un antgeno heterlogo. El antgeno puede ser parte de un polipptido de fusin expresado con uno o ms polipptidos homlogos a las bacterias. En algunas realizaciones, las bacterias expresan el antgeno como un polipptido no de fusin. En algunas realizaciones, la invencin proporciona una composicin que comprende una clula de una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera, </i>en donde la clula expresa un antgeno heterlogo. En algunas realizaciones, la composicin es para su uso como vacuna. En algunas realizaciones, la invencin proporciona una clula de una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera</i>, en donde la clula expresa un antgeno heterlogo. En algunas realizaciones, la clula se usa como una vacuna.</span>In some embodiments, the bacteria of the invention express one or more antigens. Generally, the antigen will be expressed recombinantly and will be heterologous to the bacteria of the invention. Therefore, the invention provides a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> that expresses a heterologous antigen. The antigen may be part of an expressed fusion polypeptide with one or more bacterially homologous polypeptides. In some embodiments, the bacteria express the antigen as a non-fusion polypeptide. In some embodiments, the invention provides a composition comprising a cell of a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the cell expresses a heterologous antigen. In some embodiments, the composition is for use as a vaccine. In some embodiments, the invention provides a cell of a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the cell expresses a heterologous antigen. In some embodiments, the cell is used as a vaccine.</span>
  </p>
  <p id="p0404" num="0404" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los antgenos ejemplares para su uso con la invencin incluyen: antgenos virales, como protenas de superficie viral; antgenos bacterianos, como antgenos proteicos y/o sacridos; antgenos fngicos; antgenos de parsitos; y antgenos tumorales. Antgenos adicionales para expresar en una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera </i>incluyen antgenos de glicoprotena y lipoglicano, antgenos de arqueas, antgeno de melanoma E (MAGE), antgeno carcinoembrionario (CEA), MUC-1, HER2, sialil-Tn (STn), transcriptasa inversa de telomerasa humana (hTERT), gen del tumor de Wilms (WT1), CA-125, antgeno prosttico especfico (PSA), antgenos del virus de Epstein-Barr, neoantgenos, oncoprotenas, amiloide-beta, Tau, PCSK9 y sustancias que crean hbito, por ejemplo, nicotina, alcohol, opiceos o similares.</span>Exemplary antigens for use with the invention include: viral antigens, such as viral surface proteins; bacterial antigens, such as protein and/or saccharide antigens; fungal antigens; parasite antigens; and tumor antigens. Additional antigens to express on a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> include glycoprotein and lipoglycan antigens, archaeal antigens, melanoma antigen E (MAGE), carcinoembryonic antigen (CEA), MUC-1, HER2, sialyl-Tn (STn), transcriptase telomerase inverse enzyme (hTERT), Wilms tumor gene (WT1), CA-125, prostate-specific antigen (PSA), Epstein-Barr virus antigens, neoantigens, oncoproteins, amyloid-beta, Tau, PCSK9, and substances that are habit forming, for example, nicotine, alcohol, opiates or the like.</span>
  </p>
  <p id="p0405" num="0405" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencin tambin puede ser til para potenciar la respuesta a las vacunas contra enfermedades no transmisibles como la enfermedad de Alzheimer y otros trastornos neurodegenerativos, en cuyo caso el antgeno para su uso con la invencin puede ser amiloide-beta o Tau. Otros antgenos de este tipo para enfermedades no transmisibles incluyen PCSK9 (para el tratamiento del colesterol elevado).</span>The invention may also be useful for enhancing the response to vaccines against non-communicable diseases such as Alzheimer's disease and other neurodegenerative disorders, in which case the antigen for use with the invention may be amyloid-beta or Tau. Other such antigens for non-communicable diseases include PCSK9 (for the treatment of high cholesterol).</span>
  </p>
  <p id="p0406" num="0406" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencin tambin puede ser til para potenciar la respuesta a las vacunas contra las sustancias que crean hbito, por ejemplo, nicotina, alcohol u opiceos.</span>The invention may also be useful for enhancing the response to vaccinations against habit-forming substances, eg, nicotine, alcohol, or opiates.</span>
  </p>
  <p id="p0407" num="0407" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Terapias celulares</span>cell therapies</span>
    </i>
  </p>
  <p id="p0408" num="0408" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Terapia de clulas T con receptores de antgenos quimricos </i>(<i class="style-scope patent-text">CAR-T) </i> </span> <i class="style-scope patent-text">Chimeric Antigen Receptor T-Cell Therapy</i> ( <i class="style-scope patent-text">CAR-T)</i> </span>
  </p>
  <p id="p0409" num="0409" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede llevar a un aumento en la expresin de IL-6. El aumento de la expresin de IL-6 se ha correlacionado con la respuesta a la terapia con CD19 CAR-T de la leucemia linfoctica crnica. Un aumento en la IL-6 en suero se ha asociado con la expansin de las clulas CAR-T, mientras que la inhibicin de la IL-6 se ha asociado con la inhibicin de la proliferacin de las clulas CAR-T [90]. Como se ha demostrado que la administracin de las composiciones de la invencin aumenta la expresin de IL-6, las composiciones de la invencin pueden ser tiles en terapia celular, en particular en terapia celular CAR-T. En una realizacin, las composiciones de la invencin son para su uso en terapia celular. En una realizacin, las composiciones de la invencin son para su uso en terapia celular CAR-T. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de leucemia linfoctica crnica.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in IL-6 expression. Increased IL-6 expression has been correlated with response to CD19 CAR-T therapy of chronic lymphocytic leukemia. An increase in serum IL-6 has been associated with expansion of CAR-T cells, while inhibition of IL-6 has been associated with inhibition of CAR-T cell proliferation [90]. As administration of the compositions of the invention has been shown to increase IL-6 expression, the compositions of the invention may be useful in cell therapy, in particular CAR-T cell therapy. In one embodiment, the compositions of the invention are for use in cell therapy. In one embodiment, the compositions of the invention are for use in CAR-T cell therapy. In one embodiment, the compositions of the invention are for use in the treatment of chronic lymphocytic leukemia.</span>
  </p>
  <p id="p0411" num="0411" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sorprendentemente, los Ejemplos tambin muestran que la administracin de las composiciones de la invencin redujo selectivamente el porcentaje de Tregs en una poblacin de PBMC (Figura 6C). Se ha demostrado que el agotamiento selectivo de Tregs mejora la eficacia de los linfocitos citotxicos [91]. Las clulas CAR-T son un subconjunto de linfocitos citotxicos y, por lo tanto, se cree que el agotamiento selectivo de Tregs es eficaz en la terapia con clulas CAR-T. Como se ha demostrado que la administracin de las composiciones de la invencin agota las Tregs, las composiciones de la invencin pueden ser tiles en terapia celular, en particular en terapia con clulas CAR-T.</span>Surprisingly, the Examples also show that administration of the compositions of the invention selectively reduced the percentage of Tregs in a population of PBMC (Figure 6C). Selective depletion of Tregs has been shown to enhance the efficacy of cytotoxic lymphocytes [91]. CAR-T cells are a subset of cytotoxic lymphocytes and therefore selective depletion of Tregs is believed to be effective in CAR-T cell therapy. As administration of the compositions of the invention have been shown to deplete Tregs, the compositions of the invention may be useful in cell therapy, particularly CAR-T cell therapy.</span>
  </p>
  <p id="p0413" num="0413" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, las composiciones de la invencin pueden ser tiles en la terapia celular, en particular para potenciar la respuesta a una terapia celular.</span>Therefore, the compositions of the invention may be useful in cell therapy, in particular for enhancing response to cell therapy.</span>
  </p>
  <p id="p0415" num="0415" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Terapia con clulas madre mesenquimales </i>(<i class="style-scope patent-text">MSC)</i> </span> <i class="style-scope patent-text">Mesenchymal stem cell</i> ( <i class="style-scope patent-text">MSC)</i> therapy</span>
  </p>
  <p id="p0417" num="0417" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha informado que la terapia con clulas madre mesenquimales (MSC) tiene propiedades inmunoestimuladoras. Cuando las MSC se tratan con LPS, regulan por incremento las citoquinas proinflamatorias IL-6 e IL-8, lo que provoca una mayor proliferacin de clulas B [92]. Por lo tanto, como se ha demostrado que las composiciones de la invencin aumentan la expresin de IL-6, pueden ser tiles en combinacin con la terapia celular con MSC.</span>Mesenchymal stem cell (MSC) therapy has been reported to have immunostimulatory properties. When MSCs are treated with LPS, they upregulate the proinflammatory cytokines IL-6 and IL-8, leading to increased B-cell proliferation [92]. Therefore, as the compositions of the invention have been shown to increase IL-6 expression, they may be useful in combination with MSC cell therapy.</span>
  </p>
  <p id="p0419" num="0419" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Terapia de trasplante de clulas madre</span>stem cell transplant therapy</span>
    </i>
  </p>
  <p id="p0421" num="0421" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha informado que, en lugar de usar clulas madre no diferenciadas en la terapia de trasplante de clulas madre, puede ser beneficioso diferenciar las clulas madre hasta cierto punto antes del trasplante. Por ejemplo, Heng et al. [93] informaron que la diferenciacin cardiomiognica de las clulas madre puede ser beneficiosa ya que tiene una mayor eficiencia de injerto, una regeneracin de los miocitos mejorada y una restauracin aumentada de la funcin cardaca. Como la administracin de las composiciones de la invencin inici la diferenciacin neuronal en clulas de neuroblastoma no diferenciadas, las composiciones de la invencin pueden ser tiles para la diferenciacin de clulas madre en la terapia de trasplante de clulas madre.</span>It has been reported that instead of using undifferentiated stem cells in stem cell transplant therapy, it may be beneficial to differentiate the stem cells to some extent before transplantation. For example, Heng et al. [93] reported that cardiomyogenic stem cell differentiation may be beneficial as it has higher graft efficiency, enhanced myocyte regeneration, and increased restoration of cardiac function. Since administration of the compositions of the invention initiated neuronal differentiation into undifferentiated neuroblastoma cells, the compositions of the invention may be useful for stem cell differentiation in stem cell transplantation therapy.</span>
  </p>
  <p id="p0423" num="0423" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunosenescencia</span>immunosenescence</span>
    </i>
  </p>
  <p id="p0425" num="0425" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos tambin muestran que la administracin de las composiciones de la invencin puede agotar selectivamente las Tregs y aumentar el nmero de clulas B (Figura 6C y Figura 6F). Fulop et al. [94] identificaron que un aumento en el nmero de clulas Tregs y una disminucin en el nmero de clulas B estn asociados con el envejecimiento en el sistema inmunitario adaptativo. Por lo tanto, las composiciones de la invencin pueden usarse para prevenir o retrasar la inmunosenescencia. En una realizacin, las composiciones de la invencin son para su uso en la prevencin de la inmunosenescencia. En otra realizacin, las composiciones de la invencin son para su uso en el retraso de la inmunosenescencia caracterizada por un aumento en el nmero de clulas Tregs. En otra realizacin, las composiciones de la invencin son para su uso en el retraso de la inmunosenescencia caracterizada por una disminucin en el nmero de clulas B. En otra realizacin, las composiciones de la invencin son para su uso en el retraso de la inmunosenescencia caracterizada por un aumento en el nmero de clulas Tregs y una disminucin en el nmero de clulas B. En una realizacin, las composiciones de la invencin son para su uso en el retraso de la inmunosenescencia disminuyendo el nmero de clulas Tregs. En una realizacin, las composiciones de la invencin son para su uso en el retraso de la inmunosenescencia aumentando el nmero de clulas B. En otra realizacin, las composiciones de la invencin son para su uso en el retraso de la inmunosenescencia disminuyendo el nmero de clulas Tregs y aumentando el nmero de clulas B. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de enfermedades provocadas por inmunosenescencia. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de enfermedades relacionadas con el envejecimiento retrasando y/o previniendo la inmunosenescencia.</span>The Examples also show that administration of the compositions of the invention can selectively deplete Tregs and increase the number of B cells (Figure 6C and Figure 6F). Fulop et al. [94] identified that an increase in the number of Treg cells and a decrease in the number of B cells are associated with aging in the adaptive immune system. Therefore, the compositions of the invention can be used to prevent or delay immunosenescence. In one embodiment, the compositions of the invention are for use in the prevention of immunosenescence. In another embodiment, the compositions of the invention are for use in delaying immunosenescence characterized by an increase in the number of Treg cells. In another embodiment, the compositions of the invention are for use in delaying immunosenescence characterized by a decrease in the number of B cells. In another embodiment, the compositions of the invention are for use in delaying immunosenescence characterized by a decrease in the number of B cells. by an increase in the number of Treg cells and a decrease in the number of B cells. In one embodiment, the compositions of the invention are for use in delaying immunosenescence by decreasing the number of Treg cells. In one embodiment, the compositions of the invention are for use in delaying immunosenescence by increasing the number of B cells. In another embodiment, the compositions of the invention are for use in delaying immunosenescence by decreasing the number of B cells. Tregs and increasing the number of B cells. In one embodiment, the compositions of the invention are for use in the treatment of diseases caused by immunosenescence. In one embodiment, the compositions of the invention are for use in treating age-related diseases by delaying and/or preventing immunosenescence.</span>
  </p>
  <p id="p0427" num="0427" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, se ha propuesto que los adyuvantes de las vacunas pueden superar la inmunosenescencia [95]. Como las composiciones de la invencin son adecuadas para su uso como adyuvante de vacunas, las composiciones de la invencin pueden ser tiles para prevenir o retrasar la inmunosenescencia. En otra realizacin, las composiciones de la invencin son para su uso en el retraso y/o prevencin de la inmunosenescencia como 
adyuvante de vacunas. En otra realizacin, las composiciones de la invencin son para su uso como adyuvantes de vacunas, en donde las composiciones retrasan y/o previenen la inmunosenescencia.</span>In addition, it has been proposed that vaccine adjuvants can overcome immunosenescence [95]. As the compositions of the invention are suitable for use as a vaccine adjuvant, the compositions of the invention may be useful in preventing or delaying immunosenescence. In another embodiment, the compositions of the invention are for use in delaying and/or preventing immunosenescence as  vaccine adjuvant. In another embodiment, the compositions of the invention are for use as vaccine adjuvants, wherein the compositions delay and/or prevent immunosenescence.</span>
  </p>
  <p id="p0428" num="0428" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las enfermedades que estn asociadas con la inmunosenescencia incluyen enfermedades cardiovasculares, enfermedades neurodegenerativas, como la enfermedad de Alzheimer y la enfermedad de Parkinson, cncer, diabetes mellitus tipo 2 [96] y trastornos autoinmunes [97] En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de enfermedades cardiovasculares. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de enfermedades cardiovasculares al retrasar y/o prevenir la inmunosenescencia. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de enfermedades neurodegenerativas. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de enfermedades neurodegenerativas, en particular la enfermedad de Alzheimer y la enfermedad de Parkinson, al retrasar y/o prevenir la inmunosenescencia. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento del cncer al retrasar y/o prevenir la inmunosenescencia. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de la diabetes mellitus tipo 2. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de la diabetes mellitus tipo 2 al retrasar y/o prevenir la inmunosenescencia. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de trastornos autoinmunes. En una realizacin, las composiciones de la invencin son para su uso en el tratamiento de trastornos autoinmunes al retrasar y/o prevenir la inmunosenescencia.</span>Diseases that are associated with immunosenescence include cardiovascular diseases, neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, cancer, type 2 diabetes mellitus [96], and autoimmune disorders [97]. In one embodiment, the compositions of the invention are for use in the treatment of cardiovascular diseases. In one embodiment, the compositions of the invention are for use in the treatment of cardiovascular diseases by delaying and/or preventing immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of neurodegenerative diseases. In one embodiment, the compositions of the invention are for use in the treatment of neurodegenerative diseases, in particular Alzheimer's disease and Parkinson's disease, by delaying and/or preventing immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of cancer by delaying and/or preventing immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of type 2 diabetes mellitus. In one embodiment, the compositions of the invention are for use in the treatment of type 2 diabetes mellitus by delaying and/or prevent immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of autoimmune disorders. In one embodiment, the compositions of the invention are for use in the treatment of autoimmune disorders by delaying and/or preventing immunosenescence.</span>
  </p>
  <p id="p0429" num="0429" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Modos de administracin</span>Administration modes</span>
      </i>
    </b>
  </p>
  <p id="p0430" num="0430" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, las composiciones de la invencin son para su administracin en el tracto gastrointestinal para permitir el suministro y/o la colonizacin parcial o total del intestino con la cepa bacteriana de la invencin. Generalmente, las composiciones de la invencin se administran por va oral, pero pueden administrarse por va rectal, intranasal o por va bucal o sublingual.</span>Preferably, the compositions of the invention are for administration to the gastrointestinal tract to allow partial or total delivery and/or colonization of the intestine with the bacterial strain of the invention. Generally, the compositions of the invention are administered orally, but may be administered rectally, intranasally, or buccally or sublingually.</span>
  </p>
  <p id="p0431" num="0431" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin pueden administrarse como una espuma, un aerosol o un gel.</span>In certain embodiments, the compositions of the invention can be administered as a foam, an aerosol, or a gel.</span>
  </p>
  <p id="p0432" num="0432" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin pueden administrarse como un supositorio, como un supositorio rectal, por ejemplo en forma de aceite de teobroma (manteca de cacao), grasa dura sinttica (por ejemplo, suppocire, witepsol), glicerogelatina, composicin de polietilenglicol o glicerina de jabn.</span>In certain embodiments, the compositions of the invention may be administered as a suppository, such as a rectal suppository, for example in the form of theobroma oil (cocoa butter), synthetic hard fat (eg suppocire, witepsol), glycerogelatin, composition of polyethylene glycol or soap glycerin.</span>
  </p>
  <p id="p0433" num="0433" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin se administra al tracto gastrointestinal a travs de un tubo, como un tubo nasogstrico, un tubo orogstrico, un tubo gstrico, un tubo de yeyunostoma (tubo en J), una gastrostoma endoscpica percutnea (PEG) o un puerto, como como puerto de pared torcica que proporciona acceso al estmago, yeyuno y otros puertos de acceso adecuados.</span>In certain embodiments, the composition of the invention is administered to the gastrointestinal tract through a tube, such as a nasogastric tube, an orogastric tube, a gastric tube, a jejunostomy tube (J-tube), a percutaneous endoscopic gastrostomy (PEG) or a port, such as a chest wall port that provides access to the stomach, jejunum, and other suitable access ports.</span>
  </p>
  <p id="p0434" num="0434" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden administrarse una vez o pueden administrarse secuencialmente como parte de un rgimen de tratamiento. En ciertas realizaciones, las composiciones de la invencin son para su administracin diaria.</span>The compositions of the invention may be administered once or may be administered sequentially as part of a treatment regimen. In certain embodiments, the compositions of the invention are for daily administration.</span>
  </p>
  <p id="p0435" num="0435" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones de la invencin, el tratamiento de acuerdo con la invencin va acompaado de una evaluacin del microbiota intestinal del paciente. El tratamiento puede repetirse si no se logra el suministro y/o la colonizacin parcial o total con la cepa de la invencin de tal manera que no se observa eficacia, o puede suspenderse el tratamiento si el suministro y/o la colonizacin parcial o total tiene xito y se observa eficacia.</span>In certain embodiments of the invention, treatment according to the invention is accompanied by an assessment of the patient's gut microbiota. Treatment may be repeated if delivery and/or partial or total colonization with the strain of the invention is not achieved such that no efficacy is observed, or treatment may be discontinued if delivery and/or partial or total colonization has success and efficacy is observed.</span>
  </p>
  <p id="p0436" num="0436" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin de la invencin puede administrarse a un animal preado, por ejemplo, un mamfero como un humano, para reducir la probabilidad de que se desarrolle cncer en su hijo <i class="style-scope patent-text">in utero </i>y/o despus de su nacimiento.</span>In certain embodiments, the composition of the invention may be administered to a pregnant animal, eg, a mammal such as a human, to reduce the likelihood of cancer developing in her child <i class="style-scope patent-text">in utero</i> and/or after birth.</span>
  </p>
  <p id="p0437" num="0437" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden administrarse a un paciente al que se le ha diagnosticado una enfermedad o afeccin mediada por una actividad inmunitaria reducida, o que se ha identificado como en riesgo de una enfermedad o afeccin mediada por una actividad inmunitaria reducida. Las composiciones tambin pueden administrarse como medida profilctica para prevenir el desarrollo de enfermedades o afecciones mediadas por una actividad inmunitaria reducida en un paciente sano.</span>The compositions of the invention may be administered to a patient who has been diagnosed as having a disease or condition mediated by reduced immune activity, or who has been identified as being at risk for a disease or condition mediated by reduced immune activity. The compositions may also be administered as a prophylactic measure to prevent the development of diseases or conditions mediated by reduced immune activity in a healthy patient.</span>
  </p>
  <p id="p0438" num="0438" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden administrarse a un paciente al que se le ha diagnosticado cncer, o que se ha identificado que tiene riesgo de cncer. Por ejemplo, el paciente puede tener una colonizacin reducida o ausente por <i class="style-scope patent-text">Megasphaera, </i>y en particular <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>The compositions of the invention may be administered to a patient who has been diagnosed with cancer, or who has been identified as being at risk for cancer. For example, the patient may have reduced or absent colonization by <i class="style-scope patent-text">Megasphaera,</i> and in particular <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0439" num="0439" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden administrarse como un producto alimenticio, como un suplemento nutricional.</span>The compositions of the invention can be administered as a food product, as a nutritional supplement.</span>
  </p>
  <p id="p0440" num="0440" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generalmente, las composiciones de la invencin son para el tratamiento de humanos, aunque pueden 
usarse para tratar animales que incluyen mamferos monogstricos como aves, cerdos, gatos, perros, caballos o conejos. Las composiciones de la invencin pueden ser tiles para mejorar el crecimiento y el rendimiento de los animales. Si se administra a animales, puede usarse alimentacin forzada oral.</span>Generally, the compositions of the invention are for the treatment of humans, although they may  be used to treat animals including monogastric mammals such as birds, pigs, cats, dogs, horses or rabbits. The compositions of the invention may be useful for improving the growth and performance of animals. If administered to animals, oral gavage can be used.</span>
  </p>
  <p id="p0441" num="0441" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones</span>compositions</span>
      </i>
    </b>
  </p>
  <p id="p0442" num="0442" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generalmente, la composicin de la invencin comprende bacterias. En realizaciones preferidas de la invencin, la composicin se formula en forma secada por congelacin. Por ejemplo, la composicin de la invencin puede comprender grnulos o cpsulas de gelatina, por ejemplo cpsulas de gelatina dura, que comprenden una cepa bacteriana de la invencin.</span>Generally, the composition of the invention comprises bacteria. In preferred embodiments of the invention, the composition is formulated in freeze-dried form. For example, the composition of the invention may comprise gelatin capsules or granules, eg hard gelatin capsules, comprising a bacterial strain of the invention.</span>
  </p>
  <p id="p0443" num="0443" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, la composicin de la invencin comprende bacterias liofilizadas. La liofilizacin de bacterias es un procedimiento bien establecido y la orientacin relevante est disponible, por ejemplo, en las referencias [98, 100].</span>Preferably, the composition of the invention comprises freeze-dried bacteria. Lyophilization of bacteria is a well-established procedure and relevant guidance is available, for example, in references [98, 100].</span>
  </p>
  <p id="p0444" num="0444" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente, la composicin de la invencin puede comprender un cultivo bacteriano vivo activo.</span>Alternatively, the composition of the invention may comprise a live active bacterial culture.</span>
  </p>
  <p id="p0445" num="0445" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la composicin de la invencin se encapsula para permitir la administracin de la cepa bacteriana al intestino. La encapsulacin protege la composicin de la degradacin hasta la administracin en la localizacin objetivo mediante, por ejemplo, la ruptura con estmulos qumicos o fsicos como presin, actividad enzimtica o disgregacin fsica, que pueden desencadenarse por cambios en el pH. Puede usarse cualquier mtodo de encapsulacin apropiado. Las tcnicas de encapsulacin ejemplares incluyen atrapamiento dentro de una matriz porosa, unin o adsorcin sobre superficies portadoras slidas, autoagregacin por floculacin o con agentes de reticulacin y contencin mecnica detrs de una membrana microporosa o una microcpsula. La orientacin sobre la encapsulacin que puede ser til para preparar composiciones de la invencin est disponible en, por ejemplo, las referencias [101] y [102].</span>In preferred embodiments, the composition of the invention is encapsulated to allow administration of the bacterial strain to the intestine. Encapsulation protects the composition from degradation until delivery to the target location by, for example, breaking down with chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which can be triggered by changes in pH. Any suitable encapsulation method can be used. Exemplary encapsulation techniques include entrapment within a porous matrix, binding or adsorption onto solid carrier surfaces, self-aggregation by flocculation or with cross-linking agents, and mechanical containment behind a microporous membrane or microcapsule. Guidance on encapsulation that may be useful in preparing compositions of the invention is available in, for example, references [101] and [102].</span>
  </p>
  <p id="p0446" num="0446" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composicin puede administrarse por va oral y puede estar en forma de comprimido, cpsula o polvo. Se prefieren los productos encapsulados porque las <i class="style-scope patent-text">Megasphaera </i>son anaerobias. Pueden incluirse otros ingredientes (como la vitamina C, por ejemplo), como captadores de oxgeno y sustratos prebiticos para mejorar la administracin y/o la colonizacin parcial o total y la supervivencia in vivo. Alternativamente, la composicin probitica de la invencin puede administrarse por va oral como un producto alimenticio o nutricional, como leche o producto lcteo fermentado a base de suero, o como un producto farmacutico.</span>The composition can be administered orally and can be in the form of a tablet, capsule or powder. Encapsulated products are preferred because <i class="style-scope patent-text">Megasphaera</i> are anaerobes. Other ingredients (such as vitamin C, for example), such as oxygen scavengers and prebiotic substrates, may be included to improve delivery and/or partial or total colonization and survival in vivo. Alternatively, the probiotic composition of the invention may be administered orally as a food or nutritional product, such as milk or whey-based fermented milk product, or as a pharmaceutical.</span>
  </p>
  <p id="p0447" num="0447" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composicin puede formularse como un probitico.</span>The composition can be formulated as a probiotic.</span>
  </p>
  <p id="p0448" num="0448" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composicin de la invencin incluye una cantidad teraputicamente eficaz de una cepa bacteriana de la invencin. Una cantidad teraputicamente eficaz de una cepa bacteriana es suficiente para ejercer un efecto beneficioso sobre un paciente. Una cantidad teraputicamente eficaz de una cepa bacteriana puede ser suficiente para dar como resultado la administracin y/o colonizacin parcial o total del intestino del paciente.</span>A composition of the invention includes a therapeutically effective amount of a bacterial strain of the invention. A therapeutically effective amount of a bacterial strain is sufficient to exert a beneficial effect on a patient. A therapeutically effective amount of a bacterial strain may be sufficient to result in administration and/or partial or total colonization of the patient's intestine.</span>
  </p>
  <p id="p0449" num="0449" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una dosis diaria adecuada de las bacterias, por ejemplo para un humano adulto, puede ser de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias (UFC); por ejemplo, de aproximadamente 1 x 107 a aproximadamente 1 x 1010 UFC; en otro ejemplo de aproximadamente 1 x 106 a aproximadamente 1 x 1010 UFC; en otro ejemplo de aproximadamente 1 x 107 a aproximadamente 1 x 1011 UFC; en otro ejemplo de aproximadamente 1 x 108 a aproximadamente 1 x 1010 UFC; en otro ejemplo de aproximadamente 1 x 108 a aproximadamente 1 x 1011 UFC.</span>A suitable daily dose of the bacteria, for example for an adult human, may be from about 1 x 103 to about 1 x 1011 colony-forming units (CFUs); for example, from about 1 x 107 to about 1 x 1010 CFU; in another example from about 1 x 106 to about 1 x 1010 CFU; in another example from about 1 x 107 to about 1 x 1011 CFU; in another example from about 1 x 108 to about 1 x 1010 CFU; in another example from about 1 x 108 to about 1 x 1011 CFU.</span>
  </p>
  <p id="p0450" num="0450" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la dosis de la bacteria es de por lo menos 109 clulas al da, como por lo menos 1010, por lo menos 1011 o por lo menos 1012 clulas al da.</span>In certain embodiments, the dose of the bacteria is at least 109 cells per day, such as at least 1010, at least 1011, or at least 1012 cells per day.</span>
  </p>
  <p id="p0451" num="0451" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin contiene la cepa bacteriana en una cantidad de aproximadamente 1 x 106 a aproximadamente 1 x 1011 UFC/g, con respecto al peso de la composicin; por ejemplo, de aproximadamente 1 x 108 a aproximadamente 1 x 1010 UFC/g. La dosis puede ser de, por ejemplo, 1 g, 3 g, 5 g y 10 g.</span>In certain embodiments, the composition contains the bacterial strain in an amount of from about 1 x 106 to about 1 x 1011 CFU/g, based on the weight of the composition; for example, from about 1 x 108 to about 1 x 1010 CFU/g. The dose can be, for example, 1 g, 3 g, 5 g and 10 g.</span>
  </p>
  <p id="p0452" num="0452" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde la cantidad de la cepa bacteriana es de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias por gramo con respecto al peso de la composicin.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about 1 x 103 to about 1 x 1011 colony-forming units per gram based on the weight of the composition.</span>
  </p>
  <p id="p0453" num="0453" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde la composicin se administra a una dosis de entre 500 mg y 1000 mg, entre 600 mg y 900 mg, entre 700 mg y 800 mg, entre 500 mg y 750 mg o entre 750 mg y 1000 mg. En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde las bacterias liofilizadas de la composicin farmacutica se administran a una dosis de entre 500 mg y 1000 mg, entre 600 mg y 900 mg, entre 700 mg y 800 mg, entre 500 mg y 750 mg o entre 750 mg 
y 1000 mg.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg or between 750mg and 1000mg. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the lyophilized bacteria of the pharmaceutical composition are administered at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg or between 750 mg  and 1000mg.</span>
  </p>
  <p id="p0454" num="0454" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tpicamente, un probitico, como la composicin de la invencin, se combina opcionalmente con por lo menos un compuesto prebitico adecuado. Un compuesto prebitico es habitualmente un carbohidrato no digerible, como un oligo- o polisacrido, o un alcohol de azcar, que no se degrada ni se absorbe en el tracto digestivo superior. Los prebiticos conocidos incluyen productos comerciales como inulina y transgalacto-oligosacridos.</span>Typically, a probiotic, such as the composition of the invention, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually an indigestible carbohydrate, such as an oligo- or polysaccharide, or a sugar alcohol, that is not broken down or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalacto-oligosaccharides.</span>
  </p>
  <p id="p0455" num="0455" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composicin probitica de la presente invencin incluye un compuesto prebitico en una cantidad de aproximadamente el 1 a aproximadamente el 30% en peso, con respecto a la composicin en peso total (por ejemplo, del 5 al 20% en peso). Los carbohidratos pueden seleccionarse del grupo que consiste de: fructo-oligosacridos (o FOS), fructo-oligosacridos de cadena corta, inulina, isomaltoligosacridos, pectinas, xilo-oligosacridos (o XOS), quitosano-oligosacridos (o COS), beta-glucanos, goma de almendra modificada y almidones resistentes, polidextrosa, D-tagatosa, fibras de acacia, algarroba, avena y fibras de ctricos. En un aspecto, los prebiticos son los fructo-oligosacridos de cadena corta (por simplicidad mostrados a continuacin como FOSs-c.c.); dichos FOSs-c.c. son carbohidratos no digeribles, obtenidos generalmente por la conversin de azcar de remolacha y que incluyen una molcula de sacarosa a la que se unen tres molculas de glucosa.</span>In certain embodiments, the probiotic composition of the present invention includes a prebiotic compound in an amount of from about 1 to about 30% by weight, based on the total weight of the composition (for example, from 5 to 20% by weight). . Carbohydrates may be selected from the group consisting of: fructo-oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomaltoligosaccharides, pectins, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS), beta-glucans , modified almond gum and resistant starches, polydextrose, D-tagatose, acacia fibers, carob, oats and citrus fibers. In one aspect, the prebiotics are short-chain fructo-oligosaccharides (for simplicity shown below as FOSs-c.c.); said FOSs-c.c. they are non-digestible carbohydrates, generally obtained by the conversion of beet sugar and that include a sucrose molecule to which three glucose molecules are attached.</span>
  </p>
  <p id="p0456" num="0456" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden comprender excipientes o portadores farmacuticamente aceptables. Ejemplos de tales excipientes adecuados pueden encontrarse en la referencia [103]. Los portadores o diluyentes aceptables para uso teraputico son bien conocidos en la tcnica farmacutica y se describen, por ejemplo, en la referencia [104]. Los ejemplos de portadores adecuados incluyen lactosa, almidn, glucosa, metilcelulosa, estearato de magnesio, manitol, sorbitol y similares. Ejemplos de diluyentes adecuados incluyen etanol, glicerol y agua. La eleccin del portador, excipiente o diluyente farmacutico puede seleccionarse con respecto a la va de administracin pretendida y la prctica farmacutica estndar. Las composiciones farmacuticas pueden comprender como, o adems del portador, excipiente o diluyente, cualquier aglutinante, lubricante, agente de suspensin, agente de recubrimiento, agente de solubilizacin adecuado. Los ejemplos de aglutinantes adecuados incluyen almidn, gelatina, azcares naturales como glucosa, lactosa anhidra, lactosa de flujo libre, betalactosa, edulcorantes de maz, gomas naturales y sintticas como acacia, tragacanto o alginato de sodio, carboximetilcelulosa y polietilenglicol. Los ejemplos de lubricantes adecuados incluyen oleato de sodio, estearato de sodio, estearato de magnesio, benzoato de sodio, acetato de sodio, cloruro de sodio y similares. En la composicin farmacutica pueden proporcionarse conservantes, estabilizadores, colorantes e incluso agentes aromatizantes. Los ejemplos de conservantes incluyen benzoato de sodio, cido srbico y steres de cido p-hidroxibenzoico. Tambin pueden usarse antioxidantes y agentes de suspensin.</span>The compositions of the invention may comprise pharmaceutically acceptable excipients or carriers. Examples of such suitable excipients can be found in reference [103]. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in reference [104]. Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, and the like. Examples of suitable diluents include ethanol, glycerol, and water. The choice of pharmaceutical carrier, excipient or diluent can be selected with respect to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions may comprise as or in addition to the carrier, excipient or diluent, any suitable binder, lubricant, suspending agent, coating agent, solubilizing agent. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flowing lactose, beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Preservatives, stabilizers, colorants and even flavoring agents can be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents can also be used.</span>
  </p>
  <p id="p0457" num="0457" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden formularse como un producto alimenticio. Por ejemplo, un producto alimenticio puede proporcionar un beneficio nutricional adems del efecto teraputico de la invencin, como en un suplemento nutricional. De manera similar, un producto alimenticio puede formularse para mejorar el sabor de la composicin de la invencin o para hacer que la composicin sea ms atractiva para el consumo al ser ms similar a un producto alimenticio comn, que a una composicin farmacutica. En ciertas realizaciones, la composicin de la invencin se formula como un producto a base de leche. El trmino "producto a base de leche" significa cualquier producto a base de leche o suero lquido o semislido que tenga un contenido variable de grasa. El producto a base de leche puede ser, por ejemplo, leche de vaca, leche de cabra, leche de oveja, leche desnatada, leche entera, leche recombinada a partir de leche en polvo y suero sin ningn procesamiento, o un producto procesado, como yogur, leche cuajada, cuajada, leche agria, leche entera agria, leche de mantequilla y otros productos de leche agria. Otro grupo importante incluye las bebidas lcteas, como las bebidas de suero, las leches fermentadas, las leches condensadas, las leches infantiles o para bebs; leches aromatizadas, helados; alimentos que contienen leche, como dulces.</span>The compositions of the invention can be formulated as a food product. For example, a food product may provide a nutritional benefit in addition to the therapeutic effect of the invention, as in a nutritional supplement. Similarly, a food product may be formulated to enhance the taste of the composition of the invention or to make the composition more attractive for consumption by being more similar to a common food product, rather than a pharmaceutical composition. In certain embodiments, the composition of the invention is formulated as a milk-based product. The term "milk-based product" means any liquid or semi-solid milk or whey-based product having variable fat content. The milk-based product can be, for example, cow's milk, goat's milk, sheep's milk, skim milk, whole milk, milk recombined from milk powder and whey without any processing, or a processed product, such as yogurt, curdled milk, curd, sour milk, sour whole milk, butter milk and other sour milk products. Another important group includes milk drinks, such as whey drinks, fermented milks, condensed milks, infant or baby milks; flavored milks, ice creams; foods that contain milk, such as sweets.</span>
  </p>
  <p id="p0458" num="0458" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invencin contienen una nica cepa o especie bacteriana y no contienen ninguna otra cepa o especie bacteriana. Tales composiciones pueden comprender solo cantidades mnimas o biolgicamente irrelevantes de otras cepas o especies bacterianas. Tales composiciones pueden ser un cultivo que est sustancialmente libre de otras especies de organismos.</span>In certain embodiments, the compositions of the invention contain a single bacterial strain or species and do not contain any other bacterial strain or species. Such compositions may comprise only minute or biologically irrelevant amounts of other bacterial strains or species. Such compositions can be a culture that is substantially free of other species of organisms.</span>
  </p>
  <p id="p0459" num="0459" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones para su uso de acuerdo con la invencin pueden requerir o no aprobacin de comercializacin.</span>Compositions for use in accordance with the invention may or may not require marketing approval.</span>
  </p>
  <p id="p0460" num="0460" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunos casos, la cepa bacteriana liofilizada se reconstituye antes de la administracin. En algunos casos, la reconstitucin se realiza mediante el uso de un diluyente descrito en la presente.</span>In some cases, the lyophilized bacterial strain is reconstituted prior to administration. In some cases, reconstitution is accomplished by use of a diluent described herein.</span>
  </p>
  <p id="p0461" num="0461" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invencin pueden comprender excipientes, diluyentes o portadores farmacuticamente aceptables.</span>The compositions of the invention may comprise pharmaceutically acceptable excipients, diluents or carriers.</span>
  </p>
  <p id="p0462" num="0462" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa 
bacteriana est en una cantidad suficiente para tratar un trastorno cuando se administra a un sujeto con necesidad de ello; y en donde el trastorno es cncer, como neuroblastoma, cncer de cerebro, melanoma, cncer de prstata, cncer colorrectal, cncer de mama, cncer de pulmn, cncer de hgado o cncer gstrico. En una realizacin adicional, el cncer es cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, leucemia linfoctica crnica, linfoma o enfermedades malignas hematolgicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; where the strain  bacterial is in an amount sufficient to treat a disorder when administered to a subject in need thereof; and wherein the disorder is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0463" num="0463" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por MAP2. En realizaciones preferidas, dicha enfermedad o afeccin es cncer, como neuroblastoma, cncer de cerebro, melanoma, cncer de prstata, cncer colorrectal, cncer de mama, cncer de pulmn, cncer de hgado o cncer gstrico. En una realizacin adicional, el cncer es cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, leucemia linfoctica crnica, linfoma o enfermedades malignas hematolgicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a MAP2-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0464" num="0464" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por tubulina p3. En realizaciones preferidas, dicha enfermedad o afeccin es cncer, como neuroblastoma, cncer de cerebro, melanoma, cncer de prstata, cncer colorrectal, cncer de mama, cncer de pulmn, cncer de hgado o cncer gstrico. En una realizacin adicional, el cncer es cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, leucemia linfoctica crnica, linfoma o enfermedades malignas hematolgicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a p3 tubulin-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0465" num="0465" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por DRD2. En realizaciones preferidas, dicha enfermedad o afeccin es cncer como neuroblastoma, cncer de cerebro, melanoma, cncer de prstata, cncer colorrectal, cncer de mama, cncer de pulmn, cncer de hgado o cncer gstrico. En una realizacin adicional, el cncer es cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, leucemia linfoctica crnica, linfoma o enfermedades malignas hematolgicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a DRD2-mediated disease or condition. In preferred embodiments, said disease or condition is cancer such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0466" num="0466" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por HDAC. En realizaciones preferidas, dicha enfermedad o afeccin es cncer, como neuroblastoma, cncer de cerebro, melanoma, cncer de prstata, cncer colorrectal, cncer de mama, cncer de pulmn, cncer de hgado o cncer gstrico, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, linfocito crnico leucemia, linfoma o enfermedades malignas hematolgicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent an HDAC-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer or gastric cancer, ovarian cancer, cervical cancer , glioblastoma, carcinoma, chronic lymphocyte leukemia, lymphoma or hematological malignancies.</span>
  </p>
  <p id="p0467" num="0467" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por citoquinas proinflamatorias, como IL-1 p, TNF-a, MIP-3a, IL-23 o IL-6. En una realizacin preferida, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por TNF-a. En una realizacin preferida, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por IL-8. En una realizacin preferida, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por CD11b. En realizaciones preferidas, dicha enfermedad o afeccin es cncer, como neuroblastoma, cncer de cerebro, melanoma, cncer de prstata, cncer colorrectal, cncer de mama, cncer de pulmn, cncer de hgado o cncer gstrico. En una realizacin adicional, dicho cncer es cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, leucemia linfoctica crnica, linfoma o enfermedades malignas hematolgicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a disease or condition mediated by proinflammatory cytokines, such as IL-1 p, TNF-a, MIP-3a, IL-23, or IL-6. In a preferred embodiment, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a TNF- mediated disease or condition. In a preferred embodiment, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent an IL-8 mediated disease or condition. In a preferred embodiment, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a CD11b-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, said cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma or hematological malignancies.</span>
  </p>
  <p id="p0468" num="0468" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona una composicin farmacutica que comprende: una cepa bacteriana de la invencin; y un excipiente, portador o diluyente farmacuticamente aceptable; en donde la cepa bacteriana est en una cantidad suficiente para tratar o prevenir una enfermedad o afeccin mediada por Casp3. En realizaciones preferidas, dicha enfermedad o afeccin es cncer, como neuroblastoma, cncer de cerebro, melanoma, cncer de prstata, cncer colorrectal, cncer de mama, cncer de pulmn, cncer de hgado o cncer gstrico.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a Casp3-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer.</span>
  </p>
  <p id="p0469" num="0469" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una realizacin adicional, dicho cncer es cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, leucemia linfoctica crnica, linfoma o enfermedades malignas hematolgicas. 
</span>In a further embodiment, said cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma or hematological malignancies. </span>
  </p>
  <p id="p0470" num="0470" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde la cantidad de la cepa bacteriana es de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias por gramo con respecto al peso de la composicin.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about 1 x 103 to about 1 x 1011 colony-forming units per gram based on the weight of the composition.</span>
  </p>
  <p id="p0471" num="0471" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde la composicin se administra a una dosis de 1 g, 3 g, 5 g o 10 g.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of 1 g, 3 g, 5 g, or 10 g.</span>
  </p>
  <p id="p0472" num="0472" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde la composicin se administra mediante un mtodo seleccionado del grupo que consiste de oral, rectal, subcutneo, nasal, bucal y sublingual.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal, and sublingual.</span>
  </p>
  <p id="p0473" num="0473" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, que comprende un portador seleccionado del grupo que consiste de lactosa, almidn, glucosa, metilcelulosa, estearato de magnesio, manitol y sorbitol.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a carrier selected from the group consisting of lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, and sorbitol.</span>
  </p>
  <p id="p0474" num="0474" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, que comprende un diluyente seleccionado del grupo que consiste de etanol, glicerol y agua.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a diluent selected from the group consisting of ethanol, glycerol, and water.</span>
  </p>
  <p id="p0475" num="0475" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, que comprende un excipiente seleccionado del grupo que consiste de almidn, gelatina, glucosa, lactosa anhidra, lactosa de flujo libre, beta-lactosa, edulcorante de maz, acacia, tragacanto, alginato de sodio, carboximetilcelulosa, polietilenglicol, oleato de sodio, estearato de sodio, estearato de magnesio, benzoato de sodio, acetato de sodio y cloruro de sodio.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweetener, acacia, tragacanth, alginate sodium, carboxymethylcellulose, polyethylene glycol, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, and sodium chloride.</span>
  </p>
  <p id="p0476" num="0476" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, que comprende adems por lo menos uno de un conservante, un antioxidante y un estabilizador.</span>In certain embodiments, the invention provides the above pharmaceutical composition, further comprising at least one of a preservative, an antioxidant, and a stabilizer.</span>
  </p>
  <p id="p0477" num="0477" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, que comprende un conservante seleccionado del grupo que consiste de benzoato de sodio, cido srbico y steres de cido phidroxibenzoico.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.</span>
  </p>
  <p id="p0478" num="0478" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde dicha cepa bacteriana est liofilizada.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilized.</span>
  </p>
  <p id="p0479" num="0479" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invencin proporciona la composicin farmacutica anterior, en donde cuando la composicin se almacena en un recipiente sellado a aproximadamente 4 C o aproximadamente 25 C y el recipiente se coloca en una atmsfera que tiene una humedad relativa del 50%, permanece por lo menos un 80% de la cepa bacteriana medida en unidades formadoras de colonias, despus de un perodo de por lo menos aproximadamente: 1 mes, 3 meses, 6 meses, 1 ao, 1,5 aos, 2 aos, 2,5 aos o 3 aos.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4C or about 25C and the container is placed in an atmosphere having a relative humidity of 50%, At least 80% of the bacterial strain measured in colony-forming units remains after a period of at least approximately: 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2, 5 years or 3 years.</span>
  </p>
  <p id="p0480" num="0480" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodos de cultivo</span>cultivation methods</span>
      </i>
    </b>
  </p>
  <p id="p0481" num="0481" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas bacterianas para su uso en la presente invencin pueden cultivarse usando tcnicas estndar de microbiologa como se detalla, por ejemplo, en las referencias [105,107].</span>Bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed, for example, in references [105,107].</span>
  </p>
  <p id="p0482" num="0482" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El medio slido o lquido usado para el cultivo puede ser agar YCFA o medio YCFA. El medio YCFA puede incluir (por 100 ml, valores aproximados): casitona (1,0 g), extracto de levadura (0,25 g), NaHC3 (0,4 g), cistena (0,1 g), K2HPO4 (0,045 g), KH2PO4 (0,045 g), NaCl (0,09 g), (NH4)2S4 (0,09 g), MgS4  7H2O (0,009 g), CaCl2 (0,009 g), resazurina (0,1 mg), hemina (1 mg), biotina (1 pg), cobalamina (1 pg), cido p-aminobenzoico (3 pg), cido flico (5 pg) y piridoxamina (15 pg).</span>The solid or liquid medium used for the culture may be YCFA agar or YCFA medium. YCFA medium may include (per 100 mL, approximate values): casitone (1.0 g), yeast extract (0.25 g), NaHC3 (0.4 g), cysteine (0.1 g), K2HPO4 ( 0.045 g), KH2PO4 (0.045 g), NaCl (0.09 g), (NH4)2S4 (0.09 g), MgS4  7H2O (0.009 g), CaCl2 (0.009 g), Resazurin (0.1 mg) , hemin (1 mg), biotin (1 pg), cobalamin (1 pg), p-aminobenzoic acid (3 pg), folic acid (5 pg) and pyridoxamine (15 pg).</span>
  </p>
  <p id="p0483" num="0483" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas para su uso en composiciones de vacunas.</span>Bacterial strains for use in vaccine compositions.</span>
      </i>
    </b>
  </p>
  <p id="p0484" num="0484" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han identificado que las cepas bacterianas de la invencin son tiles para tratar o prevenir enfermedades o afecciones asociadas con una actividad inmunitaria reducida. Es probable que esto sea el resultado del efecto que las cepas bacterianas de la invencin tienen sobre el sistema inmunitario del husped. Por lo tanto, las composiciones de la invencin tambin pueden ser tiles para prevenir enfermedades o afecciones como el cncer, cuando se administran como composiciones de vacunas. En ciertas realizaciones de este tipo, las cepas bacterianas de la invencin pueden estar muertas, inactivadas o atenuadas. En ciertas realizaciones de este tipo, las composiciones pueden comprender un adyuvante de vacuna. En ciertas realizaciones, las composiciones son para administracin mediante inyeccin, como mediante inyeccin subcutnea.</span>The inventors have identified that the bacterial strains of the invention are useful for treating or preventing diseases or conditions associated with reduced immune activity. This is likely to be the result of the effect that the bacterial strains of the invention have on the host's immune system. Therefore, the compositions of the invention may also be useful in preventing diseases or conditions such as cancer, when administered as vaccine compositions. In certain such embodiments, the bacterial strains of the invention may be killed, inactivated, or attenuated. In certain such embodiments, the compositions may comprise a vaccine adjuvant. In certain embodiments, the compositions are for administration by injection, such as by subcutaneous injection.</span>
  </p>
  <p id="p0485" num="0485" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, una cepa bacteriana de la especie Megasphaera massiliensis reduce los niveles de cido frmico. El cido frmico es la base conjugada del formiato que se ha implicado en la alteracin del transporte de electrones mitocondrial y la produccin de energa inhibiendo la actividad de la citocromo oxidasa, el 
aceptor de electrones terminal de la cadena de transporte de electrones. Por consiguiente, la reduccin del cido frmico y, por tanto, del formiato, reducira la incidencia de muerte celular o mediante la inhibicin de la citocromo oxidasa o la acumulacin de especies reactivas de oxgeno. Por consiguiente, en ciertas realizaciones, una cepa bacteriana de la especie Megasphaera massiliensis estimula el sistema inmunitario en el tratamiento de enfermedades reduciendo los niveles de cido frmico.</span>In certain embodiments, a bacterial strain of the species Megasphaera massiliensis reduces formic acid levels. Formic acid is the conjugate base of formate that has been implicated in the alteration of mitochondrial electron transport and energy production by inhibiting the activity of cytochrome oxidase, the  terminal electron acceptor of the electron transport chain. Therefore, reduction of formic acid, and thus formate, would reduce the incidence of cell death either by inhibiting cytochrome oxidase or the accumulation of reactive oxygen species. Accordingly, in certain embodiments, a bacterial strain of the species Megasphaera massiliensis stimulates the immune system in treating disease by reducing formic acid levels.</span>
  </p>
  <p id="p0486" num="0486" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">General</span>General</span>
      </i>
    </b>
  </p>
  <p id="p0487" num="0487" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La puesta en prctica de la presente invencin emplear, a menos que se indique lo contrario, mtodos convencionales de qumica, bioqumica, biologa molecular, inmunologa y farmacologa, dentro de la experiencia de la tcnica. Tales tcnicas se explican completamente en la bibliografa. Ver, por ejemplo, las referencias [108] y [109,115], etc.</span>The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are fully explained in the literature. See, for example, references [108] and [109,115], etc.</span>
  </p>
  <p id="p0488" num="0488" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trmino "que comprende" abarca "que incluye" as como "que consiste", por ejemplo, una composicin "que comprende" X puede consistir exclusivamente de X o puede incluir algo adicional, por ejemplo, X  Y.</span>The term "comprising" encompasses "including" as well as "consisting", for example, a composition "comprising" X may consist exclusively of X or may include something additional, for example, X and Y.</span>
  </p>
  <p id="p0489" num="0489" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trmino "aproximadamente" en relacin a un valor numrico x es opcional y significa, por ejemplo, x  10%.</span>The term "approximately" in relation to a numerical value x is optional and means, for example, x  10%.</span>
  </p>
  <p id="p0490" num="0490" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La palabra "sustancialmente" no excluye "completamente", por ejemplo, una composicin que est "sustancialmente libre" de Y puede estar completamente libre de Y. Cuando sea necesario, la palabra "sustancialmente" puede omitirse de la definicin de la invencin.</span>The word "substantially" does not exclude "completely", eg, a composition that is "substantially free" of Y may be completely free of Y. When necessary, the word "substantially" may be omitted from the definition of the invention.</span>
  </p>
  <p id="p0491" num="0491" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las referencias a un porcentaje de identidad de secuencia entre dos secuencias de nucletidos significan que, cuando se alinean, ese porcentaje de nucletidos es el mismo al comparar las dos secuencias. Esta alineacin y el porcentaje de homologa o identidad de secuencia pueden determinarse usando programas de software conocidos en la tcnica, por ejemplo, los descritos en la seccin 7.7.18 de la ref. [116]. El algoritmo de bsqueda de homologa Smith-Waterman determina una alineacin preferida usando una bsqueda de espacio afn con una penalizacin de espacio abierto de 12 y una penalizacin de extensin de espacio de 2, matriz BLOSUM de 62. El algoritmo de bsqueda de homologa Smith-Waterman se describe en la ref. [117]</span>References to a percentage of sequence identity between two nucleotide sequences mean that, when aligned, that percentage of nucleotides is the same when comparing the two sequences. This alignment and percent sequence homology or identity can be determined using software programs known in the art, eg, those described in section 7.7.18 of ref. [116]. The Smith-Waterman homology search algorithm determines a preferred alignment using an affine space search with an open space penalty of 12 and a space extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm Waterman is described in ref. [117]</span>
  </p>
  <p id="p0492" num="0492" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A menos que se indique especficamente, un proceso o mtodo que comprende numerosos pasos puede comprender pasos adicionales al principio o al final del mtodo, o puede comprender pasos intermedios adicionales. Adems, los pasos pueden combinarse, omitirse o realizarse en un orden alternativo, si es apropiado.</span>Unless specifically stated, a process or method comprising numerous steps may comprise additional steps at the beginning or end of the method, or may comprise additional intermediate steps. Additionally, the steps may be combined, omitted, or performed in an alternate order, if appropriate.</span>
  </p>
  <p id="p0493" num="0493" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En la presente se describen varias realizaciones de la invencin. Se apreciar que las caractersticas especificadas en cada realizacin pueden combinarse con otras caractersticas especificadas, para proporcionar realizaciones adicionales. En particular, las realizaciones resaltadas en la presente como adecuadas, tpicas o preferidas pueden combinarse entre s (excepto cuando sean mutuamente excluyentes).</span>Various embodiments of the invention are described herein. It will be appreciated that features specified in each embodiment may be combined with other features specified, to provide additional embodiments. In particular, embodiments highlighted herein as suitable, typical, or preferred may be combined with one another (except where mutually exclusive).</span>
  </p>
  <p id="p0494" num="0494" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MODOS DE LLEVAR A CABO LA INVENCIN</span>MODES OF CARRYING OUT THE INVENTION</span>
    </b>
  </p>
  <p id="p0495" num="0495" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 1 - MRx0029 induce un fenotipo maduro en clulas SH-SY5Y</span>Example 1 - MRx0029 induces a mature phenotype in SH-SY5Y cells</span>
      </i>
    </b>
  </p>
  <p id="p0496" num="0496" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0497" num="0497" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la expresin de marcadores de neurodiferenciacin, tubulina p3 y MAP2 en clulas de neuroblastoma. La tubulina p3 es un marcador de prediferenciacin en neuronas y MAP2 es un marcador de neuronas maduras (diferenciadas).</span>The inventors sought to identify the effect of MRx0029 on the expression of neurodifferentiation markers, tubulin p3 and MAP2 in neuroblastoma cells. Tubulin p3 is a marker of predidifferentiation in neurons and MAP2 is a marker of mature (differentiated) neurons.</span>
  </p>
  <p id="p0498" num="0498" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0499" num="0499" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0500" num="0500" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lnea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0501" num="0501" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Clulas SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0502" num="0502" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0503" num="0503" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">qPCR</span>qPCR</span>
    </i>
  </p>
  <p id="p0504" num="0504" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las SH-SY5Y se colocaron en placas petri de 10 cm con una densidad de 2 x 106 clulas. Despus de 24 h, las clulas se trataron en medio de diferenciacin (medio de crecimiento que contena FBS al 1% sin RA) con sobrenadantes de bacterias al 10% o YCFA+, RA 10 uM, cido hexanoico 200 uM o cido valproico 200 uM, durante 
17 horas. Posteriormente, se tomaron imgenes representativas usando un microscopio central EVOS XL de contraste de fase con un aumento de 40X/0,65. Se recogieron las clulas y se aisl el ARN total de acuerdo con el protocolo del mini kit RNeasy (Qiagen). Los ADNc se elaboraron usando el kit de transcripcin inversa de ADNc de alta capacidad (Applied Biosystems). La expresin gnica se midi usando qPCR. Se us GAPDH como control interno. El cambio de veces se calcul de acuerdo con el mtodo 2(-ct).</span>SH-SY5Y were plated in 10 cm petri dishes at a density of 2 x 10 6 cells. After 24 h, cells were treated in differentiation medium (growth medium containing 1% FBS without RA) with 10% bacteria supernatants or YCFA+, 10 uM RA, 200 uM hexanoic acid or 200 uM valproic acid, during  17 hours. Subsequently, representative images were taken using an EVOS XL phase contrast core microscope at 40X/0.65 magnification. Cells were harvested and total RNA isolated according to the RNeasy mini kit protocol (Qiagen). cDNAs were made using the High Throughput cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured using qPCR. GAPDH was used as an internal control. The fold change was calculated according to the 2(-ct) method.</span>
  </p>
  <p id="p0505" num="0505" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunomarcado e imagenologa celular</span>Immunostaining and cell imaging</span>
    </i>
  </p>
  <p id="p0506" num="0506" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas se sembraron en portaobjetos de cmara de 8 pocillos (Marienfeld Laboratory Glassware) a 5 x 104 clulas/pocillo durante la noche y se trataron con sobrenadante bacteriano al 10% durante 24 h. Para la diferenciacin, las clulas se trataron con RA 10 nM durante 5 das antes de tratarlas con sobrenadante bacteriano libre de clulas durante 24 h.</span>Cells were seeded on 8-well chamber slides (Marienfeld Laboratory Glassware) at 5 x 10 4 cells/well overnight and treated with 10% bacterial supernatant for 24 h. For differentiation, cells were treated with 10 nM RA for 5 days before being treated with cell-free bacterial supernatant for 24 h.</span>
  </p>
  <p id="p0507" num="0507" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Posteriormente, las clulas se fijaron con paraformaldehdo al 4% en PBS durante 20 minutos a temperatura ambiente (TA). Las clulas fijadas se lavaron con PBS y se permeabilizaron con Triton X-100 al 1% en PBS durante 10 minutos. Despus de lavarlos con PBS, los portaobjetos se incubaron con tampn de bloqueo (BSA/PBS al 4%) durante 1 h a TA antes de aadir el anticuerpo anti-MAP2 o tubulina p3 (sc-74421 y sc-80005 respectivamente, Santa Cruz Biotechnology Inc) diluidos en BSA/PBS al 1% durante 12 horas a 4 C. Luego se lavaron dos veces con PBS, seguido de incubacin con anti-ratn conjugado con Alexa Flour 488 (Molecular Probes Inc) y faloidina conjugada con Alexa Flour 594 (ab176757, Abeam) durante 1 h a TA. Despus de lavar 3X con PBS, los portaobjetos se tieron con DAPI y se montaron con Vectashield (Vector Laboratories). Los portaobjetos se observaron usando un microscopio Axioskop 50 (Zeiss) equipado con un conjunto de objetivo 63x/1.2 W Korr y filtros adecuados para la deteccin de los fluorocromos usados. Los tiempos de exposicin manual para la adquisicin digital de imgenes inmunomarcadas con MAP-2 se mantuvieron constantes, lo que permiti la comparacin entre diferentes pocillos y tratamientos. Los tiempos de exposicin de faloidina (actina F) y DAPI variaron para adaptarse al campo de visin. Los campos de visin aleatorizados se adquirieron usando una cmara Qlmaging controlada por el software Image Pro Plus. Las imgenes se guardaron como archivos TIFF y se abrieron en Adobe Photoshop CC 2015.1.2. Las imgenes de MAP-2, DAPI y Faloidina se superpusieron y fusionaron. Se seleccionaron imgenes representativas para ilustrar las diferencias en abundancia y localizacin de las protenas examinadas.</span>Subsequently, the cells were fixed with 4% paraformaldehyde in PBS for 20 minutes at room temperature (RT). Fixed cells were washed with PBS and permeabilized with 1% Triton X-100 in PBS for 10 minutes. After washing with PBS, slides were incubated with blocking buffer (4% BSA/PBS) for 1 h at RT before adding anti-MAP2 antibody or p3 tubulin (sc-74421 and sc-80005 respectively, Santa Cruz Biotechnology Inc) diluted in 1% BSA/PBS for 12 hours at 4C. They were then washed twice with PBS, followed by incubation with Alexa Flour 488-conjugated anti-mouse (Molecular Probes Inc) and Alexa Flour 594-conjugated phalloidin. (ab176757, Abeam) for 1 h at RT. After washing 3X with PBS, slides were stained with DAPI and mounted with Vectashield (Vector Laboratories). Slides were viewed using an Axioskop 50 microscope (Zeiss) equipped with a 63x/1.2 W Korr objective set and filters suitable for detection of the fluorochromes used. Manual exposure times for digital acquisition of MAP-2 immunolabeled images were kept constant, allowing comparison between different wells and treatments. Phalloidin (F-actin) and DAPI exposure times varied to suit the field of view. Randomized fields of view were acquired using a Qlmaging camera controlled by Image Pro Plus software. Images were saved as TIFF files and opened in Adobe Photoshop CC 2015.1.2. MAP-2, DAPI and Phalloidin images were superimposed and merged. Representative images were selected to illustrate the differences in abundance and localization of the proteins examined.</span>
  </p>
  <p id="p0508" num="0508" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunotransferencia</span>immunoblot</span>
    </i>
  </p>
  <p id="p0509" num="0509" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se trataron clulas SH-SY5Y cultivadas en las condiciones indicadas descritas anteriormente con MRx0029 durante 24 h y luego se lisaron en tampn RIPA que contena un cctel de inhibidores de proteasa (Roche Diagnostics, Reino Unido). La concentracin de protenas se estim usando el kit de ensayo de protenas BCA (Pierce Biotechnology, Rockford, IL), se separ mediante SDS-PAGE y se transfiri a una membrana de PVDF. Luego, las membranas se bloquearon con leche descremada en polvo al 5% o BSA al 5% y se incubaron durante la noche a 4 C con los anticuerpos primarios (respectivamente MAP2 y tubulina p3). Luego, las transferencias se incubaron con el anticuerpo secundario conjugado con peroxidasa de rbano picante (HRP) apropiado y las protenas se detectaron mediante un kit de deteccin de quimioluminiscencia (Pierce Biotechnology, Rockford, IL). Tanto para MAP2 como para tubulina p3, la p-actina sirvi como control para monitorizar la variabilidad de la carga de protenas entre las muestras.</span>SH-SY5Y cells grown under the conditions described above were treated with MRx0029 for 24 h and then lysed in RIPA buffer containing a cocktail of protease inhibitors (Roche Diagnostics, UK). Protein concentration was estimated using the BCA protein assay kit (Pierce Biotechnology, Rockford, IL), separated by SDS-PAGE, and blotted onto a PVDF membrane. Membranes were then blocked with 5% nonfat dry milk or 5% BSA and incubated overnight at 4C with the primary antibodies (respectively MAP2 and tubulin p3). The blots were then incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody and proteins detected using a chemiluminescence detection kit (Pierce Biotechnology, Rockford, IL). For both MAP2 and p3 tubulin, p-actin served as a control to monitor protein loading variability between samples.</span>
  </p>
  <p id="p0510" num="0510" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0511" num="0511" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 induce la expresin de tubulina p3 en clulas de neuroblastoma SH-SY5Y indiferenciadas. La Figura 1 muestra que el tratamiento con MRx0029 aumenta la expresin de tubulina p3 en comparacin con las clulas SH-SY5Y no tratadas.</span>MRx0029 induces p3 tubulin expression in undifferentiated SH-SY5Y neuroblastoma cells. Figure 1 shows that MRx0029 treatment increases p3 tubulin expression compared to untreated SH-SY5Y cells.</span>
  </p>
  <p id="p0512" num="0512" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 induce la expresin de MAP2 en clulas SH-SY5Y de neuroblastoma indiferenciadas. La Figura 2 muestra que el tratamiento con MRx0029 aument significativamente la expresin de MAP2 en comparacin con las clulas SH-SY5Y no tratadas.</span>MRx0029 induces MAP2 expression in undifferentiated SH-SY5Y neuroblastoma cells. Figure 2 shows that MRx0029 treatment significantly increased MAP2 expression compared to untreated SH-SY5Y cells.</span>
  </p>
  <p id="p0513" num="0513" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0514" num="0514" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 puede ser una composicin eficaz para promover la diferenciacin, en particular la diferenciacin neuronal. Adems, los resultados muestran que MRx0029 puede ser una composicin eficaz en el tratamiento de cncer de cerebro, en particular neuroblastoma y melanoma, en particular, melanoma metastsico.</span>The results show that MRx0029 may be an effective composition for promoting differentiation, particularly neuronal differentiation. Furthermore, the results show that MRx0029 may be an effective composition in the treatment of brain cancer, in particular neuroblastoma and melanoma, in particular metastatic melanoma.</span>
  </p>
  <p id="p0515" num="0515" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 2: MRx0029 disminuye la expresin de DRD2 en clulas SH-SY5Y</span>Example 2: MRx0029 Downregulates DRD2 Expression in SH-SY5Y Cells</span>
      </i>
    </b>
  </p>
  <p id="p0516" num="0516" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0517" num="0517" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la expresin de DRD2 en clulas de 
neuroblastoma.</span>The inventors sought to identify the effect of MRx0029 on the expression of DRD2 in cells of  neuroblastoma.</span>
  </p>
  <p id="p0518" num="0518" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0519" num="0519" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0520" num="0520" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lnea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0521" num="0521" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Clulas SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0522" num="0522" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0523" num="0523" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores midieron el cambio en la expresin de DRD2 en clulas de neuroblastoma usando el mismo mtodo que se describe en el Ejemplo 1.</span>The inventors measured the change in DRD2 expression in neuroblastoma cells using the same method as described in Example 1.</span>
  </p>
  <p id="p0524" num="0524" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0525" num="0525" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 disminuye la expresin de DRD2 en clulas de neuroblastoma SH-SY5Y. La Figura 3 muestra que el tratamiento con MRx0029 disminuy significativamente la expresin de DRD2 en comparacin con las clulas SH-SY5Y no tratadas.</span>MRx0029 downregulates DRD2 expression in SH-SY5Y neuroblastoma cells. Figure 3 shows that MRx0029 treatment significantly decreased DRD2 expression compared to untreated SH-SY5Y cells.</span>
  </p>
  <p id="p0526" num="0526" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0527" num="0527" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 puede ser una composicin eficaz en el tratamiento del cncer.</span>This shows that MRx0029 can be an effective composition in the treatment of cancer.</span>
  </p>
  <p id="p0528" num="0528" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 3 - MRx0029 induce la regulacin por incremento de Caspasa 3 en clulas SH-SY5Y</span>Example 3 - MRx0029 Induces Caspase 3 Upregulation in SH-SY5Y Cells</span>
      </i>
    </b>
  </p>
  <p id="p0529" num="0529" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0530" num="0530" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la expresin de Caspasa 3 (Casp3) en clulas de neuroblastoma.</span>The inventors sought to identify the effect of MRx0029 on Caspase 3 (Casp3) expression in neuroblastoma cells.</span>
  </p>
  <p id="p0531" num="0531" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0532" num="0532" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0533" num="0533" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lnea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0534" num="0534" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Clulas SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0535" num="0535" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0536" num="0536" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores midieron el cambio en la expresin de Casp3 en clulas de neuroblastoma.</span>The inventors measured the change in Casp3 expression in neuroblastoma cells.</span>
  </p>
  <p id="p0537" num="0537" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0538" num="0538" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 induce la regulacin por incremento de Casp3 en clulas SH-SY5Y de neuroblastoma indiferenciadas. La Figura 4 muestra que el tratamiento con MRx0029 aumenta la expresin de Casp3 en comparacin con las clulas SH-SY5Y no tratadas. En particular, la Figura 4 muestra que la administracin de MRx0029 aument tres veces la expresin de Casp3 en comparacin con el control.</span>MRx0029 induces upregulation of Casp3 in SH-SY5Y undifferentiated neuroblastoma cells. Figure 4 shows that MRx0029 treatment increases Casp3 expression compared to untreated SH-SY5Y cells. In particular, Figure 4 shows that administration of MRx0029 increased Casp3 expression threefold compared to control.</span>
  </p>
  <p id="p0539" num="0539" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0540" num="0540" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En clulas SH-SY5Y no diferenciadas, el aumento de la expresin del gen Casp3 por parte de MRx0029 podra estar relacionado tanto con la diferenciacin celular como con la induccin de muerte celular programada, como la apoptosis.</span>In undifferentiated SH-SY5Y cells, the increased expression of the Casp3 gene by MRx0029 could be related to both cell differentiation and the induction of programmed cell death, such as apoptosis.</span>
  </p>
  <p id="p0541" num="0541" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La caspasa 3 es una caspasa ejecutora y, por lo tanto, est asociada con la apoptosis. La apoptosis desregulada se ha implicado en los cnceres y, por lo tanto, los resultados muestran que MRx0029 puede ser una composicin eficaz en el tratamiento del cncer.</span>Caspase 3 is an executive caspase and is therefore associated with apoptosis. Dysregulated apoptosis has been implicated in cancers and therefore the results show that MRx0029 may be an effective composition in cancer treatment.</span>
  </p>
  <p id="p0542" num="0542" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha mostrado que las caspasas tienen funciones en la diferenciacin celular. Por lo tanto, el aumento de la expresin de Casp3 despus del tratamiento con MRx0029 muestra que MRx0029 puede ser una composicin eficaz para aumentar la diferenciacin celular. 
</span>Caspases have been shown to have roles in cell differentiation. Therefore, the increased expression of Casp3 after MRx0029 treatment shows that MRx0029 may be an effective composition for increasing cell differentiation. </span>
  </p>
  <p id="p0543" num="0543" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 4 - Ensayo MTT en clulas SH-SY5Y:</span>Example 4 - MTT assay in SH-SY5Y cells:</span>
      </i>
    </b>
  </p>
  <p id="p0544" num="0544" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0545" num="0545" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la viabilidad de las clulas de neuroblastoma, usando el ensayo MTT, que es un mtodo ampliamente usado para evaluar la actividad metablica celular que se refleja en el nmero de clulas viables.</span>The inventors sought to identify the effect of MRx0029 on the viability of neuroblastoma cells, using the MTT assay, which is a widely used method to assess cellular metabolic activity that is reflected in the number of viable cells.</span>
  </p>
  <p id="p0546" num="0546" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas</span>bacterial strains</span>
    </i>
  </p>
  <p id="p0547" num="0547" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0548" num="0548" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lnea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0549" num="0549" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Clulas SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0550" num="0550" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0551" num="0551" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo MTT</span>MTT test</span>
    </i>
  </p>
  <p id="p0552" num="0552" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas SH-SY5Y se sembraron en placas a una densidad de siembra de 10.000 clulas/pocillo, 24 horas despus, las clulas se trataron en 100 ul de medio de crecimiento FBS al 1% con diferentes concentraciones (expresadas como porcentaje v/v) de sobrenadantes bacterianos libres de clulas de los cultivos de la fase estacionaria durante 22 h. Luego, se aadieron 10 |jl de solucin de MTT y las clulas se incubaron en una incubadora de CO2 durante 4 h, al final de este tiempo se aadieron 100 j l de isopropanol con 0,04 HCl a cada pocillo. La absorbancia se midi a una longitud de onda de 560 nm y una longitud de onda de referencia de 655 nm. El kit de ensayo MTT se adquiri de Merck Millipore (N de Cat. CT01).</span>SH-SY5Y cells were plated at a seeding density of 10,000 cells/well, 24 hours later, the cells were treated in 100 ul of 1% FBS growth medium with different concentrations (expressed as percentage v/v). of cell-free bacterial supernatants from stationary phase cultures for 22 h. Then, 10 l of MTT solution was added and the cells were incubated in a CO2 incubator for 4 h, at the end of this time 100 l of isopropanol with 0.04 HCl was added to each well. The absorbance was measured at a wavelength of 560 nm and a reference wavelength of 655 nm. The MTT assay kit was purchased from Merck Millipore (Cat. No. CT01).</span>
  </p>
  <p id="p0553" num="0553" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0554" num="0554" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 mostr efectos dependientes de la dosis sobre la viabilidad de las clulas de neuroblastoma, en donde MRx0029 al 10% redujo la viabilidad en aproximadamente un 70% en comparacin con el control. El tratamiento con un 10% de sobrenadante bacteriano libre de clulas de MRx0029 mostr una disminucin de la viabilidad celular. Los resultados de los experimentos se muestran en la Figura 5.</span>MRx0029 showed dose-dependent effects on neuroblastoma cell viability, with 10% MRx0029 reducing viability by approximately 70% compared to control. Treatment with 10% cell-free bacterial supernatant of MRx0029 showed decreased cell viability. The results of the experiments are shown in Figure 5.</span>
  </p>
  <p id="p0555" num="0555" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0556" num="0556" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 puede ser una composicin eficaz para aumentar la muerte celular y, por lo tanto, MRx0029 puede ser una composicin eficaz para su uso en el tratamiento del cncer.</span>This shows that MRx0029 may be an effective composition for increasing cell death, and therefore MRx0029 may be an effective composition for use in treating cancer.</span>
  </p>
  <p id="p0557" num="0557" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 5: -fenotipado celular bsico en PBMC de donantes sanos</span>Example 5: Basic cell-phenotyping in PBMC from healthy donors</span>
      </i>
    </b>
  </p>
  <p id="p0558" num="0558" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0559" num="0559" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0560" num="0560" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0561" num="0561" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de PBMC</span>PBMC Treatment</span>
    </i>
  </p>
  <p id="p0562" num="0562" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se adquirieron PBMC humanas sanas congeladas de Stem Cells Technologies (Cambridge, Reino Unido). Brevemente, las clulas se descongelaron y se dejaron reposar durante la noche en medio de crecimiento completo (RPMI 1640 con FBS al 10%, glutamina 2 mM l, 2-mercapoetanol 55 jM y 100 U/ml de penicilina, 100 jg/ml estreptomicina) en una incubadora de CO2 a 37 C. Para el experimento, las clulas se sembraron en placas a una densidad de 750.000 clulas/pocillo en placas de 48 pocillos y se trataron en medio de crecimiento completo con sobrenadantes de bacterias al 10% en presencia o ausencia de 1 ng/ml de LPS. Se aadi medio de cultivo celular a los pocillos no tratados. Las clulas se dejaron reposar durante 72 h, posteriormente se recogieron los sobrenadantes libres de clulas y se centrifugaron durante 3 minutos a 10.000 g a 4 C. Las muestras se almacenaron a -80 C para el anlisis de citoquinas.</span>Frozen healthy human PBMC were purchased from Stem Cells Technologies (Cambridge, UK). Briefly, cells were thawed and allowed to stand overnight in complete growth medium (RPMI 1640 with 10% FBS, 2 mM l glutamine, 55 jM 2-mercapoethanol, and 100 U/ml penicillin, 100 jg/ml streptomycin). ) in a 37C CO2 incubator. For the experiment, cells were plated at a density of 750,000 cells/well in 48-well plates and treated in complete growth medium with 10% bacterial supernatants in presence or absence of 1 ng/ml of LPS. Cell culture medium was added to untreated wells. Cells were allowed to settle for 72 h, then cell-free supernatants were collected and centrifuged for 3 min at 10,000 g at 4C. Samples were stored at -80C for cytokine analysis.</span>
  </p>
  <p id="p0563" num="0563" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunofenotipado</span>Immunophenotyping</span>
    </i>
  </p>
  <p id="p0564" num="0564" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se tieron 1,5 x 106 clulas por muestra con colorante de viabilidad fijable (Miltenyi) para discriminar entre clulas vivas y muertas durante 10 min a TA. Posteriormente, las clulas se tieron con el cctel de anticuerpos enumerados a continuacin (Miltenyi) para inmunofenotipado bsico (CD3/CD4/CD8/CD25/CD127 y CD 19) y se 
incubaron durante 10 min a TA.</span>1.5 x 10 6 cells per sample were stained with fixable viability dye (Miltenyi) to discriminate between live and dead cells for 10 min at RT. Cells were subsequently stained with the antibody cocktail listed below (Miltenyi) for basic immunophenotyping (CD3/CD4/CD8/CD25/CD127 and CD19) and  incubated for 10 min at RT.</span>
  </p>
  <p id="p0565" num="0565" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se llevaron a cabo experimentos para medir el porcentaje de las siguientes poblaciones celulares:</span>Experiments were carried out to measure the percentage of the following cell populations:</span>
  </p>
  <p id="p0566" num="0566" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clulas CD4+ CD3+ (marcadores de clulas T auxiliares CD4)</span> CD4+ CD3+ cells (CD4 helper T cell markers)</span>
  </p>
  <p id="p0567" num="0567" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clulas CD4+ CD25+ (marcadores de clulas CD4+ activadas)</span> CD4+ CD25+ cells (markers of activated CD4+ cells)</span>
  </p>
  <p id="p0568" num="0568" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clulas CD25++ CD17- de la poblacin de clulas CD4+ (marcadores de clulas T regs)</span> CD25++ CD17- cells of the CD4+ cell population (T regs cell markers)</span>
  </p>
  <p id="p0569" num="0569" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clulas CD8+ CD3+ (marcadores de clulas T citotxicas)</span> CD8+ CD3+ cells (markers of cytotoxic T cells)</span>
  </p>
  <p id="p0570" num="0570" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clulas CD25+ CD8+ (marcadores de clulas CD8+ activadas)</span> CD25+ CD8+ cells (markers of activated CD8+ cells)</span>
  </p>
  <p id="p0571" num="0571" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Clulas CD19+ CD3-(marcadores de clulas B).</span> CD19+ CD3- cells (B cell markers).</span>
  </p>
  <p id="p0572" num="0572" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se determin la proporcin de clulas CD8+/Tregs y la proporcin de CD8/Tregs activadas.</span>The ratio of CD8+ cells/Tregs and the ratio of activated CD8/Tregs were determined.</span>
  </p>
  <p id="p0573" num="0573" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos</span>Antibodies</span>
    </i>
  </p>
  <p id="p0575" num="0575" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000047_0001" he="182" wi="606" file="imgf000047_0001.tif" img-format="tif" width="2424" height="728" alt="Figure imgf000047_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000047_0001" he="182" wi="606" file="imgf000047_0001.tif" img-format="tif" width="2424" height="728" alt="Figure imgf000047_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0578" num="0578" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0579" num="0579" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de los experimentos se muestran en la Figura 6.</span>The results of the experiments are shown in Figure 6.</span>
  </p>
  <p id="p0580" num="0580" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El resultado ms sorprendente es el efecto del tratamiento con MRx0029 sobre el porcentaje de clulas CD25++ CD17-, que representan clulas Tregs (ver Figura 6C). MRx0029 redujo selectivamente el porcentaje de Tregs en la poblacin de PBMC. El tratamiento con MRx0029 no cambi significativamente el porcentaje de clulas T auxiliares CD4, clulas CD4+ activadas, clulas T citotxicas, clulas CD8+ activadas o clulas B.</span>The most surprising result is the effect of MRx0029 treatment on the percentage of CD25++ CD17- cells, which represent Tregs cells (see Figure 6C). MRx0029 selectively reduced the percentage of Tregs in the PBMC population. MRx0029 treatment did not significantly change the percentage of CD4 helper T cells, activated CD4+ cells, cytotoxic T cells, activated CD8+ cells, or B cells.</span>
  </p>
  <p id="p0581" num="0581" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 aument la proporcin de CD8+/Tregs y la proporcin de clulas CD8/Tregs activadas en comparacin con las clulas no tratadas (ver la Figura 6G y la Figura 6H).</span>MRx0029 treatment increased the ratio of CD8+/Tregs and the ratio of activated CD8/Tregs cells compared to untreated cells (see Figure 6G and Figure 6H).</span>
  </p>
  <p id="p0582" num="0582" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0583" num="0583" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La observacin de que el tratamiento con MRx0029 disminuy selectivamente el porcentaje de Tregs, aumentando de este modo las proporciones de CD8/Tregs y CD8/Tregs activadas es sorprendente porque MRx0029 produce butirato, y la produccin de butirato se ha asociado con aumentos en la poblacin de Tregs.</span>The observation that treatment with MRx0029 selectively decreased the percentage of Tregs, thereby increasing the ratios of CD8/Tregs and activated CD8/Tregs is surprising because MRx0029 produces butyrate, and butyrate production has been associated with increases in population. of Tregs.</span>
  </p>
  <p id="p0584" num="0584" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El perfil de inmunofenotipado bsico de MRx0029 en PBMC de donantes sanos sugiere que el tratamiento con MRx0029 disminuye el porcentaje relativo de Tregs en la poblacin de linfocitos, lo que se refleja en una proporcin creciente entre clulas CD8/Tregs.</span>The basic immunophenotyping profile of MRx0029 in PBMC from healthy donors suggests that treatment with MRx0029 decreases the relative percentage of Tregs in the lymphocyte population, which is reflected in an increasing CD8/Tregs cell ratio.</span>
  </p>
  <p id="p0585" num="0585" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 puede ser una composicin eficaz para estimular la respuesta inmunitaria y disminuir la supresin inmunitaria por las Tregs. Los resultados tambin muestran que MRx0029 puede ser una composicin eficaz para su uso en el tratamiento del cncer.</span>This shows that MRx0029 can be an effective composition for stimulating the immune response and decreasing immune suppression by Tregs. The results also show that MRx0029 may be an effective composition for use in treating cancer.</span>
  </p>
  <p id="p0586" num="0586" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 6 - Anlisis de citoquinas de PBMC de donantes sanos</span>Example 6 - Cytokine analysis of PBMC from healthy donors</span>
      </i>
    </b>
  </p>
  <p id="p0587" num="0587" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0588" num="0588" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban analizar adicionalmente las PBMC despus de la incubacin con MRx0029. Los inventores analizaron la expresin de citoquinas particulares de PBMC tras el tratamiento con MRx0029, incluyendo las citoquinas proinflamatorias TNF-a, IL-1 p e IL-23.</span>The inventors sought to further analyze PBMCs after incubation with MRx0029. The inventors analyzed the expression of particular cytokines from PBMC after treatment with MRx0029, including the pro-inflammatory cytokines TNF-, IL-1p and IL-23.</span>
  </p>
  <p id="p0589" num="0589" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana </span>bacterial strain</span>
    </i>
    
  </p>
  <p id="p0590" num="0590" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0591" num="0591" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0592" num="0592" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de las PBMC</span>Treatment of PBMCs</span>
    </i>
  </p>
  <p id="p0593" num="0593" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las PBMC se trataron como se describe en el Ejemplo 5.</span>PBMCs were treated as described in Example 5.</span>
  </p>
  <p id="p0594" num="0594" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuantificacin de citoquinas</span>Cytokine quantification</span>
    </i>
  </p>
  <p id="p0595" num="0595" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cuantificacin de citoquinas se realiz usando un inmunoensayo multiplex ProcartaPlex siguiendo las recomendaciones del fabricante (Thermo Fischer Scientific). En resumen, se usaron 50 pl de sobrenadantes de cocultivo libres de clulas para la cuantificacin de citoquinas usando un sistema MAGPIX MILLIPLEX (Merck) con el software xPONENT (Luminex, Austin, TX, USA). Los datos se analizaron usando el software analista MILLIPLEX (Merck) usando una curva logstica de 5 parmetros y sustraccin de fondo para convertir la intensidad de fluorescencia media en valores de pg/ml.</span>Cytokine quantification was performed using a ProcartaPlex multiplex immunoassay following the manufacturer's recommendations (Thermo Fischer Scientific). Briefly, 50 l of cell-free co-culture supernatants were used for cytokine quantitation using a MAGPIX MILLIPLEX system (Merck) with xPONENT software (Luminex, Austin, TX, USA). Data was analyzed using MILLIPLEX Analyst Software (Merck) using a 5-parameter logistic curve and background subtraction to convert mean fluorescence intensity to pg/mL values.</span>
  </p>
  <p id="p0596" num="0596" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0597" num="0597" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados del anlisis de citoquinas de MRx0029 en cultivo de PBMC de donantes sanos mostraron una firma inmunoestimuladora para MRx0029. En particular, el tratamiento con MRx0029 aument la expresin de TNF-a, IL-1 p e IL-23.</span>Results of cytokine analysis of MRx0029 in cultured PBMC from healthy donors showed an immunostimulatory signature for MRx0029. In particular, MRx0029 treatment increased the expression of TNF-, IL-1p and IL-23.</span>
  </p>
  <p id="p0598" num="0598" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados tambin muestran que el tratamiento con MRx0029 aument la expresin de MIP-3a, IL-6 e IL-10. Los niveles de expresin de MCP-1, CXCL9 y GMCSF fueron similares a los de los controles.</span>The results also show that MRx0029 treatment increased the expression of MIP-3a, IL-6 and IL-10. Expression levels of MCP-1, CXCL9 and GMCSF were similar to controls.</span>
  </p>
  <p id="p0599" num="0599" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0600" num="0600" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 tiene propiedades inmunoestimuladoras y puede ser una composicin eficaz para la inmunoestimulacin. Los resultados tambin muestran que MRx0029 puede ser una composicin eficaz en el tratamiento del cncer.</span>This shows that MRx0029 has immunostimulatory properties and can be an effective composition for immunostimulation. The results also show that MRx0029 can be an effective composition in the treatment of cancer.</span>
  </p>
  <p id="p0601" num="0601" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 7 - Anlisis de citometra de flujo de diferentes poblaciones celulares</span>Example 7 - Flow cytometry analysis of different cell populations</span>
      </i>
    </b>
  </p>
  <p id="p0602" num="0602" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0603" num="0603" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban analizar adicionalmente las PBMC despus de la incubacin con MRx0029. Se us anlisis de citometra de flujo para determinar los porcentajes de clulas CD4 (CD4+ CD3+), Tregs (CD25++ CD127-), clulas CD8 (CD8+ CD3+) y clulas B (CD19+ CD3-).</span>The inventors sought to further analyze PBMCs after incubation with MRx0029. Flow cytometry analysis was used to determine the percentages of CD4 cells (CD4+ CD3+), Tregs (CD25++ CD127-), CD8 cells (CD8+ CD3+), and B cells (CD19+ CD3-).</span>
  </p>
  <p id="p0604" num="0604" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0605" num="0605" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de PBMC</span>PBMC Treatment</span>
    </i>
  </p>
  <p id="p0606" num="0606" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las PBMC se trataron como se describe en el Ejemplo 5.</span>PBMCs were treated as described in Example 5.</span>
  </p>
  <p id="p0607" num="0607" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis de citometra de flujo de diferentes poblaciones celulares</span>Flow cytometry analysis of different cell populations</span>
    </i>
  </p>
  <p id="p0608" num="0608" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se tieron 1,5 x 106 clulas por muestra con colorante de viabilidad fijable (Miltenyi) para discriminar entre clulas vivas y muertas durante 10 min a TA. Posteriormente, las clulas se tieron con el cctel de anticuerpos enumerados a continuacin (Miltenyi) para inmunofenotipado bsico (CD3/CD4/CD8/CD25/CD127 y CD19) y se incubaron durante 10 min a TA. Luego, las clulas se lavaron y resuspendieron en PBS y se analizaron inmediatamente usando un FACS Aria II equipado con lseres azul (488 nm), rojo (633 nm) y violeta (405 nm). Se incluyeron FMO en todos los experimentos. Para el anlisis se us el software Flowjo versin 10.4.2 (FlowJo, LLC). <i class="style-scope patent-text">Resultados</i> </span>1.5 x 10 6 cells per sample were stained with fixable viability dye (Miltenyi) to discriminate between live and dead cells for 10 min at RT. Cells were subsequently stained with the antibody cocktail listed below (Miltenyi) for basic immunophenotyping (CD3/CD4/CD8/CD25/CD127 and CD19) and incubated for 10 min at RT. Cells were then washed and resuspended in PBS and immediately analyzed using a FACS Aria II equipped with blue (488nm), red (633nm), and violet (405nm) lasers. FMOs were included in all experiments. For the analysis, Flowjo software version 10.4.2 (FlowJo, LLC) was used. <i class="style-scope patent-text">Results</i> </span>
  </p>
  <p id="p0609" num="0609" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de los experimentos de citometra de flujo se muestran en la Figura 8.</span>The results of the flow cytometry experiments are shown in Figure 8.</span>
  </p>
  <p id="p0610" num="0610" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 8A muestra que el 0,73% de las PBMC eran Tregs (CD25++ CD127-).</span>Figure 8A shows that 0.73% of the PBMCs were Tregs (CD25++ CD127-).</span>
  </p>
  <p id="p0611" num="0611" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0612" num="0612" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 puede ser til para regular por diminucin las Tregs. Adems, los resultados muestran que MRx0029 puede ser una composicin eficaz para estimular la respuesta inmunitaria y 
disminuir la supresin inmunitaria por las Tregs. Los resultados tambin muestran que MRx0029 puede ser una composicin eficaz para su uso en el tratamiento del cncer.</span>The results show that MRx0029 may be useful for down-regulating Tregs. Furthermore, the results show that MRx0029 can be an effective composition to stimulate the immune response and  decrease immune suppression by Tregs. The results also show that MRx0029 may be an effective composition for use in treating cancer.</span>
  </p>
  <p id="p0614" num="0614" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 8 - M R x0029 aum enta la secrecin de IL -8 en clulas M G U373</span>Example 8 - MR x0029 increases IL-8 secretion in M G U373 cells</span>
      </i>
    </b>
  </p>
  <p id="p0615" num="0615" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0616" num="0616" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la secrecin de IL-8 en clulas de neuroblastoma. Se trataron clulas de astrocitoma de glioblastoma de Fluman con composiciones que comprendan MRx0029 en combinacin con LPS para observar su capacidad para modular los niveles de IL-8. La IL-8 es una citoquina proinflamatoria secretada predominantemente por macrfagos con efectos inmunoestimuladores.</span>The inventors sought to identify the effect of MRx0029 on IL-8 secretion in neuroblastoma cells. Fluman glioblastoma astrocytoma cells were treated with compositions comprising MRx0029 in combination with LPS to observe their ability to modulate IL-8 levels. IL-8 is a proinflammatory cytokine secreted predominantly by macrophages with immunostimulatory effects.</span>
  </p>
  <p id="p0617" num="0617" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0618" num="0618" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0619" num="0619" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lnea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0620" num="0620" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MG U373 es un astrocitoma de glioblastoma humano derivado de un tumor maligno y se adquiri de Sigma-Aldrich (N de cat. 08061901 -1VL). Se cultivaron clulas de astrocitoma de glioblastoma humano MG U373 en MEM (Sigma Aldrich, N de cat. M-2279) suplementado con FBS al 10%, Pen Strep al 1%, L-Glut 4 mM, solucin de aminocidos no esenciales MEM 1X y piruvato sdico 1X.</span>MG U373 is a human glioblastoma astrocytoma derived from a malignant tumor and was purchased from Sigma-Aldrich (Cat# 08061901-1VL). MG U373 human glioblastoma astrocytoma cells were cultured in MEM (Sigma Aldrich, Cat. No. M-2279) supplemented with 10% FBS, 1% Pen Strep, 4 mM L-Glut, MEM non-essential amino acid solution. 1X and 1X sodium pyruvate.</span>
  </p>
  <p id="p0621" num="0621" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0622" num="0622" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una vez cultivadas, las clulas MG U373 se sembraron en una placa de 24 pocillos a 100.000 clulas/pocillo. Las clulas se trataron con LPS (1ug/ml) solo o con un 10% de bacterias sobrenadantes de MRx0029 durante 24 h. El LPS es un estimulador conocido de citoquinas proinflamatorias como la IL-8. Posteriormente se recogieron los sobrenadantes libres de clulas, se centrifugaron a 10.000 g durante 3 min a 4 C. La IL-8 se midi usando el kit IL-8 ELISA humano de Peprotech (N de cat. 900-K18) de acuerdo con las instrucciones del fabricante. <i class="style-scope patent-text">Resultados</i> </span>Once cultured, the MG U373 cells were seeded in a 24-well plate at 100,000 cells/well. Cells were treated with LPS (1ug/ml) alone or with 10% bacterial supernatants from MRx0029 for 24h. LPS is a known stimulator of proinflammatory cytokines such as IL-8. Cell-free supernatants were subsequently collected, centrifuged at 10,000 g for 3 min at 4C. IL-8 was measured using the Peprotech human IL-8 ELISA kit (Cat. No. 900-K18) according to with the manufacturer's instructions. <i class="style-scope patent-text">Results</i> </span>
  </p>
  <p id="p0623" num="0623" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de estos experimentos se muestran en la Figura 9. El tratamiento de las clulas con las cepas bacterianas llev a un aumento de la secrecin de IL-8 independientemente de la presencia de LPS.</span>The results of these experiments are shown in Figure 9. Treatment of the cells with the bacterial strains led to an increase in IL-8 secretion regardless of the presence of LPS.</span>
  </p>
  <p id="p0624" num="0624" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0625" num="0625" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 puede ser til para aumentar la secrecin de IL-8. Por lo tanto, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades, en particular enfermedades caracterizadas por una activacin inmunitaria reducida y enfermedades que pueden tratarse por una respuesta inmunitaria aumentada.</span>The results show that MRx0029 may be useful in increasing IL-8 secretion. Therefore, the compositions of the invention may be useful in the treatment of diseases, in particular diseases characterized by reduced immune activation and diseases that can be treated by an increased immune response.</span>
  </p>
  <p id="p0626" num="0626" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 9 - MRx0029 reduce los niveles de <i class="style-scope patent-text">activ idad </i>de histona deacetilasa en clulas HT-29 </span>Example 9 - MRx0029 Reduces Histone <i class="style-scope patent-text">Deacetylase</i> Activity Levels in HT-29 Cells</span>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0627" num="0627" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investig la capacidad de las composiciones que comprenden MRx0029 para alterar la actividad de histona deacetilasa. Se ha demostrado que HDACi provoca la detencin del crecimiento, la diferenciacin, la apoptosis, la reduccin de la angiognesis y la modulacin de la respuesta inmunitaria en una variedad de lneas de clulas cancerosas.</span>The ability of compositions comprising MRx0029 to alter histone deacetylase activity was investigated. HDACi has been shown to cause growth arrest, differentiation, apoptosis, reduced angiogenesis, and modulation of the immune response in a variety of cancer cell lines.</span>
  </p>
  <p id="p0628" num="0628" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0629" num="0629" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0630" num="0630" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lnea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0631" num="0631" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se us la lnea celular HT-29 porque est presente la histona deacetilasa.</span>The HT-29 cell line was used because histone deacetylase is present.</span>
  </p>
  <p id="p0632" num="0632" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0633" num="0633" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sobrenadantes libres de clulas de cultivos bacterianos en fase estacionaria se aislaron mediante centrifugacin y filtracin en un filtro de 0,22 uM. Las clulas HT-29 se usaron 3 das despus de la confluencia y se redujeron en 1 ml de DTS 24 horas antes del comienzo del experimento. Las clulas HT-29 se desafiaron con 
sobrenadante libre de clulas al 10% diluido en DTS y se dej incubar durante 48 horas. Luego, se extrajeron las protenas de nucleasa usando el kit de extraccin Sigma Aldrich Nuclease y las muestras se congelaron al instante antes de la medicin de la actividad de HDAC. La actividad de HDAC se evalu fluoromtricamente usando el kit Sigma Aldrich (Reino Unido).</span>Cell-free supernatants from stationary phase bacterial cultures were isolated by centrifugation and filtration on a 0.22 uM filter. HT-29 cells were used 3 days after confluency and reduced in 1 ml DTS 24 hours before the start of the experiment. HT-29 cells were challenged with  10% cell-free supernatant diluted in DTS and allowed to incubate for 48 hours. Nuclease proteins were then extracted using the Sigma Aldrich Nuclease Extraction Kit and samples snap frozen prior to measurement of HDAC activity. HDAC activity was assessed fluorometrically using the Sigma Aldrich kit (UK).</span>
  </p>
  <p id="p0634" num="0634" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0635" num="0635" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de los experimentos se muestran en la Figura 10. La Figura 109 muestra que MRx0029 es capaz de reducir los niveles de actividad de histona deacetilasa.</span>The results of the experiments are shown in Figure 10. Figure 109 shows that MRx0029 is capable of reducing histone deacetylase activity levels.</span>
  </p>
  <p id="p0636" num="0636" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
  </p>
  <p id="p0637" num="0637" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 es un candidato prometedor para su uso en el tratamiento o la prevencin de enfermedades caracterizadas por aberraciones epigenticas, mediante la inhibicin de la actividad HDAC. El cncer es una enfermedad caracterizada por aberraciones epigenticas. Adems, los inhibidores de HDAC (HDACi) son una clase emergente de frmacos anticancergenos prometedores que han demostrado que provocan la detencin del crecimiento, la diferenciacin, la apoptosis, la reduccin de la angiognesis y la modulacin de la respuesta inmunitaria en una variedad de lneas de clulas cancerosas. Por lo tanto, los resultados muestran que las composiciones de la invencin pueden ser eficaces para su uso en el tratamiento o prevencin del cncer.</span>The results show that MRx0029 is a promising candidate for use in the treatment or prevention of diseases characterized by epigenetic aberrations, by inhibiting HDAC activity. Cancer is a disease characterized by epigenetic aberrations. In addition, HDAC inhibitors (HDACi) are an emerging class of promising anticancer drugs that have been shown to cause growth arrest, differentiation, apoptosis, reduced angiogenesis, and modulation of the immune response in a variety of lines. of cancer cells. Therefore, the results show that the compositions of the invention may be effective for use in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0638" num="0638" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 10 - Anlisis adicional del mecanismo de inhibicin de la desacetilacin de histonas </span>Example 10 - Further analysis of the mechanism of inhibition of histone deacetylation</span>
      </i>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0639" num="0639" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El microbiota intestinal, con su inmensa diversidad y capacidad metablica, representa un enorme depsito metablico para la produccin de una gran variedad de molculas con potencial para influir en la actividad de HDAC. Por lo tanto, los inventores buscaban determinar qu metabolitos son responsables de la inhibicin de HDAC y dilucidar adicionalmente los mecanismos mediante los cuales se logra la inhibicin.</span>The gut microbiota, with its immense diversity and metabolic capacity, represents a huge metabolic reservoir for the production of a wide variety of molecules with the potential to influence HDAC activity. Therefore, the inventors sought to determine which metabolites are responsible for HDAC inhibition and to further elucidate the mechanisms by which inhibition is achieved.</span>
  </p>
  <p id="p0640" num="0640" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0641" num="0641" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0642" num="0642" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodo</span>Method</span>
    </i>
  </p>
  <p id="p0643" num="0643" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cultivo bacteriano y recogida de sobrenadante libre de clulas</span>Bacterial culture and collection of cell-free supernatant</span>
    </i>
  </p>
  <p id="p0644" num="0644" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los cultivos puros de bacterias se cultivaron anaerbicamente en caldo YCFA+ hasta que alcanzaron su fase de crecimiento estacionario. Los cultivos se centrifugaron a 5.000 x g durante 5 minutos y el sobrenadante libre de clulas (CFS) se filtr usando un filtro de 0,2 pM (Millipore, Reino Unido). Se almacenaron alcuotas de 1 ml de CFS a -80 C hasta su uso. El butirato de sodio, el cido hexanoico y el valrico se obtuvieron de Sigma Aldrich (Reino Unido) y se prepararon suspensiones en caldo YCFA+.</span>Pure cultures of bacteria were grown anaerobically in YCFA+ broth until they reached their stationary growth phase. Cultures were centrifuged at 5,000 x g for 5 minutes and cell free supernatant (CFS) was filtered using a 0.2 pM filter (Millipore, UK). Aliquots of 1 ml of CFS were stored at -80C until use. Sodium butyrate, hexanoic acid and valeric acid were obtained from Sigma Aldrich (UK) and suspensions were prepared in YCFA+ broth.</span>
  </p>
  <p id="p0645" num="0645" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuantificacin de SCFA y MCFA de sobrenadantes bacterianos</span>SCFA and MCFA quantification of bacterial supernatants</span>
    </i>
  </p>
  <p id="p0646" num="0646" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizaron y cuantificaron los cidos grasos de cadena corta (SCFA) y los cidos grasos de cadena media (MCFA) de sobrenadantes bacterianos por MS Omics APS de la siguiente manera. Las muestras se acidificaron usando cido clorhdrico y se aadieron estndares internos marcados con deuterio. Todas las muestras se analizaron en un orden aleatorio. El anlisis se realiz usando una columna de alta polaridad (Zebron ZB-FFAP, GC Cap. de 30 m x 0,25 mm x 0,25 pm) instalada en un GC (7890B, Agilent) acoplada a un detector de cuadropolo (59977B, Agilent). El sistema fue controlado por ChemStation (Agilent). Los datos sin procesar se convirtieron al formato netCDF usando Chemstation (Agilent), antes de que los datos fueran importados y procesados en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito en [118].</span>Short chain fatty acids (SCFA) and medium chain fatty acids (MCFA) of bacterial supernatants were analyzed and quantified by MS Omics APS as follows. Samples were acidified using hydrochloric acid and deuterium-labelled internal standards were added. All samples were analyzed in a random order. Analysis was performed using a high polarity column (Zebron ZB-FFAP, GC Cap. 30 m x 0.25 mm x 0.25 pm) installed on a GC (7890B, Agilent) coupled to a quadrupole detector (59977B , Agilent). The system was controlled by ChemStation (Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described in [118].</span>
  </p>
  <p id="p0647" num="0647" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis de actividad de HDAC especfica</span>Specific HDAC activity analysis</span>
    </i>
  </p>
  <p id="p0648" num="0648" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analiz la actividad de inhibicin especfica de HDAC para HDAC1,2, 3, 4, 5, 6, 9 usando kits de ensayo fluorognico para cada tipo de HDAC (BPS Bioscience, CA). Los ensayos se realizaron de acuerdo con las instrucciones del fabricante y cada muestra se realiz por duplicado. Los sobrenadantes libres de clulas se diluyeron 1 en 10 y se expusieron a protenas de HDAC especficas proporcionadas en el kit para mantener la consistencia entre los mtodos.</span>Specific HDAC inhibition activity was assayed for HDAC1,2,3,4,5,6,9 using fluorogenic assay kits for each type of HDAC (BPS Bioscience, CA). Assays were performed according to the manufacturer's instructions and each sample was run in duplicate. Cell-free supernatants were diluted 1 in 10 and challenged with specific HDAC proteins provided in the kit to maintain consistency between methods.</span>
  </p>
  <p id="p0649" num="0649" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados </span>Results</span>
    </i>
    
  </p>
  <p id="p0650" num="0650" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Los metabolitos microbianos comensales intestinales que inhiben la histona deacetilasa son butirato y cido valrico </i>MRx0029, cuyo sobrenadante mostr una fuerte inhibicin de HDAC tanto en clulas enteras HT29 como en lisados de clulas HT29 (ver Figura 11 A), produjo cido valrico y cido hexanoico a concentraciones medias de 5,08 mM y 1,60 mM, respectivamente (ver Figura 11B).</span> <i class="style-scope patent-text">Intestinal commensal microbial metabolites that inhibit histone deacetylase are butyrate and valeric acid</i> MRx0029, whose supernatant showed strong HDAC inhibition in both whole HT29 cells and HT29 cell lysates (see Figure 11A), produced valeric acid and hexanoic acid at mean concentrations of 5.08 mM and 1.60 mM, respectively (see Figure 11B).</span>
  </p>
  <p id="p0651" num="0651" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para investigar qu metabolitos eran responsables de la inhibicin de HDAC inducida por la cepa, se midieron diferentes concentraciones de cido hexanoico, cido valrico y butirato de sodio para determinar su inhibicin de HDAC en clulas HT-29 completas y en lisado de clulas HT-29. Los resultados en la Figura 11C muestran una inhibicin significativa (P&lt;0,05) de la actividad de HDAC por el butirato de sodio en clulas completas as como en el lisado celular, mientras que el cido hexanoico no mostr una actividad inhibidora significativa. El cido valrico tambin inhibi la actividad de HDAC en clulas enteras as como en el lisado celular (*(p&lt;0,05), **(p&lt;0,005), ***(P&lt;0,001), ****(p&lt;0,0001)).</span>To investigate which metabolites were responsible for strain-induced HDAC inhibition, different concentrations of hexanoic acid, valeric acid, and sodium butyrate were measured for their HDAC inhibition in whole HT-29 cells and in HT-29 cell lysate. . The results in Figure 11C show significant (P&lt;0.05) inhibition of HDAC activity by sodium butyrate in whole cells as well as in cell lysate, while hexanoic acid did not show significant inhibitory activity. Valeric acid also inhibited HDAC activity in whole cells as well as in cell lysate (*(p&lt;0.05), **(p&lt;0.005), ***(P&lt;0.001), ****( p&lt;0.0001)).</span>
  </p>
  <p id="p0652" num="0652" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los potentes inhibidores totales de HDAC investigados se dirigen a las HDAC de clase I.</span>The potent total HDAC inhibitors investigated target class I HDACs.</span>
    </i>
  </p>
  <p id="p0653" num="0653" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investig el perfil de inhibicin especfico de HDAC de la cepa de bacterias de prueba. Se llevaron a cabo ensayos de inhibicin especficos de HDAC (BPS Bioscience, CA) para HDAC de Clase I y Clase II. La capacidad de la cepa bacteriana para inhibir las enzimas de HDAC se compar con butirato, cido hexanoico y valrico. Nuestros resultados demuestran que MRx0029 es un inhibidor muy potente de las enzimas de HDAC de Clase 1 (HDAC1,2 y 3). La inhibicin de las HDAC de clase II no fue tan significativa (datos no mostrados).</span>The HDAC-specific inhibition profile of the test bacteria strain was investigated. Specific HDAC inhibition assays (BPS Bioscience, CA) were performed for Class I and Class II HDACs. The ability of the bacterial strain to inhibit HDAC enzymes was compared with butyrate, hexanoic and valeric acid. Our results demonstrate that MRx0029 is a very potent inhibitor of HDAC Class 1 enzymes (HDAC1,2 and 3). Inhibition of class II HDACs was not as significant (data not shown).</span>
  </p>
  <p id="p0654" num="0654" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0655" num="0655" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa con actividad inhibidora de HDAC produjo cantidades significativas de cido valrico y cido hexanoico, as como cantidades significativas de butirato de sodio (Figura 11B). Cuando se probaron como sustancias puras, el cido valrico y el butirato de sodio dieron como resultado una inhibicin significativa de HDAC (p&lt;0,0001).</span>The strain with HDAC inhibitory activity produced significant amounts of valeric acid and hexanoic acid, as well as significant amounts of sodium butyrate (FIG. 11B). When tested as pure substances, valeric acid and sodium butyrate resulted in significant HDAC inhibition (p&lt;0.0001).</span>
  </p>
  <p id="p0656" num="0656" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Curiosamente, los resultados de la actividad especfica de HDAC muestran que la cepa analizada es un potente inhibidor de las HDAC de clase I y, en particular, de HDAC2 (Figura 12 y Figura 13). Las HDAC de clase I (HDAC1,2, 3 y 8) residen en el ncleo y se expresan ubicuamente en varios tipos de clulas humanas. Las HDAC 1 -3 comparten ms del 50% de homologa, pero tienen estructuras y funciones celulares distintas [119]. Participan principalmente en la supervivencia, proliferacin y diferenciacin celular y, por lo tanto, su inhibicin puede ser til en una amplia variedad de enfermedades [120]; [121]; [122]; [123]; [124]. Por lo tanto, las composiciones de la invencin pueden ser particularmente tiles para el tratamiento de enfermedades en las que la actividad de las HDAC de Clase I est regulada por incremento. En particular, las composiciones de la invencin pueden ser particularmente tiles para el tratamiento de cnceres en los que la actividad de las HDAC de Clase I est regulada por incremento. Por ejemplo, las composiciones de la invencin pueden ser particularmente tiles para el tratamiento de cnceres en los que la actividad de HDAC2 est regulada por incremento.</span>Interestingly, the results of the specific activity of HDAC show that the tested strain is a potent inhibitor of HDAC class I and, in particular, of HDAC2 (Figure 12 and Figure 13). Class I HDACs (HDAC1,2, 3, and 8) reside in the nucleus and are ubiquitously expressed in various human cell types. HDACs 1-3 share more than 50% homology, but have distinct cellular structures and functions [119]. They are mainly involved in cell survival, proliferation, and differentiation, and therefore their inhibition may be useful in a wide variety of diseases [120]; [121]; [122]; [123]; [124]. Therefore, the compositions of the invention may be particularly useful for the treatment of diseases in which the activity of Class I HDACs is upregulated. In particular, the compositions of the invention may be particularly useful for the treatment of cancers in which Class I HDAC activity is upregulated. For example, the compositions of the invention may be particularly useful for the treatment of cancers in which HDAC2 activity is upregulated.</span>
  </p>
  <p id="p0657" num="0657" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 11 - Modulacin de la funcin de barrera intestinal y permeabilidad intestinal por MRx0029 </span>Example 11 - Modulation of intestinal barrier function and intestinal permeability by MRx0029</span>
      </i>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0658" num="0658" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investig la capacidad de MRx0029 para provocar cualquier disfuncin de la barrera intestinal. Se usaron monocapas de clulas epiteliales productoras de mucina HT29-mtx [125] como modelo in vitro para evaluar la alteracin de la barrera intestinal y la estimulacin inmunitaria despus del tratamiento con MRx0029.</span>The ability of MRx0029 to cause any intestinal barrier dysfunction was investigated. Monolayers of HT29-mtx mucin-producing epithelial cells [125] were used as an in vitro model to assess intestinal barrier disruption and immune stimulation after MRx0029 treatment.</span>
  </p>
  <p id="p0659" num="0659" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0660" num="0660" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0661" num="0661" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodos</span>Methods</span>
    </i>
  </p>
  <p id="p0662" num="0662" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Extraccin de ARN y anlisis qPCR</span>RNA extraction and qPCR analysis</span>
    </i>
  </p>
  <p id="p0663" num="0663" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El ARN total se extrajo usando el mini kit RNeasy (Qiagen, Manchester, JUK) de acuerdo con las instrucciones del fabricante, y la concentracin de ARN se determin por absorbancia a 260/280nm usando un espectrofotmetro (nano-Drop ND-1000; Thermo Scientific, Wilmington, DE). Para el anlisis de expresin de ARNm, se prepar ADNc a partir de ARN total usando el kit de transcripcin inversa de ADNc de alta capacidad (Applied Biosystems, Reino Unido) de acuerdo con las instrucciones del fabricante. Las reacciones de transcripcin inversa se realizaron en un termociclador (Biometra, Alemania) a 25 C durante 10 min, 37 C durante 120 min y 85 C durante 5 min, manteniendo a 4 C. El ADNc resultante se amplific por duplicado mediante el ensayo de PCR SYBR-Green y los productos se detectaron en la mquina de PCR en tiempo real QuantStudio 6 flex (Applied 
Biosystems, Reino Unido) usando un perfil estandarizado (desnaturalizacin inicial de 95 C durante 10 minutos, seguido de 40 ciclos de 15 segundos de desnaturalizacin a 95 C y 60 segundos de apareamiento/extensin a 60/65 C, dependiendo de los cebadores. Se aadio una etapa de disociacin despus de 40 ciclos para generar una curva de fusin. El anlisis se realiz usando el software de PCR en tiempo real Applied Biosystems QuantStudio v1.2.</span>Total RNA was extracted using the RNeasy mini kit (Qiagen, Manchester, JUK) according to the manufacturer's instructions, and RNA concentration was determined by absorbance at 260/280nm using a spectrophotometer (nano-Drop ND-1000; Thermo Scientific, Wilmington, DE). For mRNA expression analysis, cDNA was prepared from total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, UK) according to the manufacturer's instructions. Reverse transcription reactions were performed in a thermocycler (Biometra, Germany) at 25C for 10 min, 37C for 120 min, and 85C for 5 min, keeping at 4C. The resulting cDNA was amplified in duplicate. using the SYBR-Green PCR assay and the products were detected in the QuantStudio 6 flex real-time PCR machine (Applied  Biosystems, UK) using a standardized profile (initial denaturation at 95C for 10 minutes, followed by 40 cycles of 15 seconds denaturation at 95C and 60 seconds annealing/extension at 60/65C, depending on the primers.A cleavage step was added after 40 cycles to generate a melting curve.Analysis was performed using Applied Biosystems QuantStudio v1.2 real-time PCR software.</span>
  </p>
  <p id="p0664" num="0664" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0665" num="0665" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas HT29-mtx diferenciadas expuestas a forbol 12-miristato-13-acetato (PMA) secretaron una cantidad significativa de IL-8; por el contrario, el tratamiento durante 24 h con sobrenadantes bacterianos de MRx0029 indujo una secrecin incluso ms baja de IL-8 en comparacin con las clulas no tratadas y las tratadas con YCFA+ (Figura 14A).</span>Differentiated HT29-mtx cells exposed to phorbol 12-myristate-13-acetate (PMA) secreted a significant amount of IL-8; in contrast, treatment for 24 h with bacterial supernatants from MRx0029 induced even lower secretion of IL-8 compared to untreated and YCFA+ treated cells (FIG. 14A).</span>
  </p>
  <p id="p0666" num="0666" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Luego se investig la capacidad de MRx0029 para regular la permeabilidad epitelial mediante la modificacin de la transduccin de seales intracelulares implicadas en la expresin y localizacin de protenas implicadas en la formacin de la barrera intestinal.</span>The ability of MRx0029 to regulate epithelial permeability by modifying intracellular signal transduction involved in the expression and localization of proteins involved in intestinal barrier formation was then investigated.</span>
  </p>
  <p id="p0667" num="0667" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se aisl el ARN y se realiz un anlisis de RT-PCR cuantitativa (qRT-PCR) para caracterizar los cambios en la expresin gnica de las protenas de unin estrecha durante la incubacin con MRx0029. La administracin de MRx0029 mejor la expresin de ARNm de Ocludina, Vilina, Protena de Unin Estrecha 1 y 2 (respectivamente TJP1 y TJP2) despus de 2 horas de incubacin (Figura 14B).</span>RNA was isolated and quantitative RT-PCR (qRT-PCR) analysis was performed to characterize changes in gene expression of tight junction proteins during incubation with MRx0029. Administration of MRx0029 enhanced the expression of Occludin, Vilin, Tight Junction Protein 1 and 2 (respectively TJP1 and TJP2) mRNA expression after 2 hours of incubation (FIG. 14B).</span>
  </p>
  <p id="p0668" num="0668" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados in vitro se compararon con los datos del anlisis paralelo ex vivo en el intestino de ratones alimentados con MRx0029. La expresin gnica de TJP1 y Ocludina se cuantific en el colon y el leon. Los datos ex vivo reflejan perfectamente los datos in vitro ya que MRx0029 fue capaz de regular significativamente TJP1 y Ocludina (p=0,073) en la regin del colon del intestino murino (Figura 14C+14D). MRx0029 tambin pudo disminuir la funcin de permeabilidad en el colon de los mismos ratones (Figura 14F).</span>The in vitro results were compared with data from the parallel ex vivo analysis in the intestine of mice fed MRx0029. Gene expression of TJP1 and Ocludin was quantified in the colon and ileum. The ex vivo data perfectly mirrors the in vitro data as MRx0029 was able to significantly regulate TJP1 and Ocludin (p=0.073) in the colon region of the murine intestine (FIG. 14C+14D). MRx0029 was also able to decrease permeability function in the colon of the same mice (FIG. 14F).</span>
  </p>
  <p id="p0669" num="0669" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0670" num="0670" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 es capaz de regular la permeabilidad epitelial modificando la transduccin de seales intracelulares implicadas en la expresin y localizacin de protenas implicaas en la funcin de barrera intestinal (por ejemplo, Ocludina, Vilina, TJP1 y TJP2). Por lo tanto, los resultados muestran que MRx0029 funciona para aumentar la funcin de barrera intestinal y reducir la permeabilidad intestinal. Por lo tanto, las composiciones de la invencin son eficaces para el tratamiento o la prevencin de enfermedades o afecciones que se caracterizan por la reduccin de la funcin de barrera intestinal o el aumento de la permeabilidad intestinal.</span>The results show that MRx0029 is capable of regulating epithelial permeability by modifying the transduction of intracellular signals involved in the expression and localization of proteins involved in intestinal barrier function (for example, Ocludin, Vilin, TJP1 and TJP2). Therefore, the results show that MRx0029 works to increase intestinal barrier function and reduce intestinal permeability. Therefore, the compositions of the invention are effective for the treatment or prevention of diseases or conditions that are characterized by reduced intestinal barrier function or increased intestinal permeability.</span>
  </p>
  <p id="p0671" num="0671" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 12</span>Example 12</span>
      </i>
    </b>
  </p>
  <p id="p0672" num="0672" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0673" num="0673" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban analizar la expresin de genes para marcadores inflamatorios en tejido cerebral del hipocampo, la amgdala y la corteza prefrontal de ratones alimentados con MRx0029. Los inventores tambin exploraron los efectos sobre la produccin de citoquinas del bazo en los mismos ratones a los que se les administr MRx0029.</span>The inventors sought to analyze gene expression for inflammatory markers in brain tissue from the hippocampus, amygdala, and prefrontal cortex of mice fed MRx0029. The inventors also explored the effects on spleen cytokine production in the same mice administered MRx0029.</span>
  </p>
  <p id="p0674" num="0674" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0675" num="0675" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0676" num="0676" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodos</span>Methods</span>
    </i>
  </p>
  <p id="p0677" num="0677" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Animales</span>Animals</span>
    </i>
  </p>
  <p id="p0678" num="0678" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se alojaron en grupo ratones macho adultos BALBc (Envigo, Reino Unido) bajo un ciclo de luz-oscuridad de 12 h; La comida estndar para roedores y el agua estaban disponibles a voluntad. Todos los experimentos se realizaron de acuerdo con las pautas europeas luego de la aprobacin del Comit de Experimentacin de tica Animal del University College Cork. Los animales tenan 8 semanas de edad al comienzo del experimento.</span>Adult male BALBc mice (Envigo, UK) were group-housed under a 12-h light-dark cycle; Standard rodent food and water were available at will. All experiments were performed in accordance with European guidelines after approval by the University College Cork Animal Ethics Experimentation Committee. The animals were 8 weeks old at the beginning of the experiment.</span>
  </p>
  <p id="p0679" num="0679" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Diseo del estudio</span>Study design</span>
    </i>
  </p>
  <p id="p0680" num="0680" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se permiti que los animales se habituaran a su sala de espera durante una semana despus de su llegada a la unidad de animales. Reciben alimentacin forzada oral (dosis de 200 gl) de bioteraputicos vivos a una dosis de 1 X 109 UFC durante 6 das consecutivos entre las 15:00 y las 17:00. El da 7, los animales son decapitados y se recogen los tejidos para experimentacin. 
</span>Animals were allowed to habituate in their waiting room for one week after arrival at the animal unit. They receive oral force feeding (200 gl dose) of live biotherapeutics at a dose of 1 X 109 CFU for 6 consecutive days between 15:00 and 17:00. On day 7, the animals are decapitated and the tissues are collected for experimentation. </span>
  </p>
  <p id="p0681" num="0681" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Recogida de Tejidos</span>Tissue Collection</span>
    </i>
  </p>
  <p id="p0682" num="0682" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se sacrificaron de manera aleatoria segn el tratamiento y las condiciones de prueba; el muestreo se realiz entre las 9:00 am y las 2:30 pm. Se recogi sangre del tronco en tubos con EDTA de potasio (cido etilendiaminotetraactico) y se centrifug durante 15 min a 4000 g. El plasma se aisl y almacen a -80 C para su anlisis posterior. El cerebro se extirp rpidamente, se diseccion y cada regin del cerebro se congel al instante en hielo seco y se almacen a -80 C para su anlisis posterior. Se extrajo el bazo, se recogi en 5 ml de medio RPMI (con L-glutamina y bicarbonato de sodio, R8758 Sigma  FBS al 10% (F7524, Sigma)  Pen/Strep al 1% (P4333, Sigma)) y se proces inmediatamente despus de los sacrificios para la estimulacin inmune ex-vivo. Se mont tejido intestinal (se extirparon 2 segmentos de 3 cm de leon y colon ms cercanos al ciego, y se usaron los 1cm 2cm ms alejados del ciego) en las cmaras de Ussing para el ensayo de permeabilidad intestinal. Se extrajo el ciego, se pes y se almacen a -80 C para el anlisis de SCFA.</span>Animals were randomly sacrificed according to treatment and test conditions; Sampling was carried out between 9:00 am and 2:30 pm. Trunk blood was collected in potassium EDTA (ethylenediaminetetraacetic acid) tubes and centrifuged for 15 min at 4000 g. Plasma was isolated and stored at -80C for later analysis. The brain was rapidly excised, dissected, and each brain region snap-frozen on dry ice and stored at -80C for later analysis. The spleen was removed, collected in 5 mL RPMI medium (with L-glutamine and sodium bicarbonate, R8758 Sigma 10% FBS (F7524, Sigma) 1% Pen/Strep (P4333, Sigma)) and processed immediately. after sacrifices for ex-vivo immune stimulation. Intestinal tissue (2 3-cm segments of ileum and colon closest to the cecum were excised, and the furthest 1cm 2cm from the cecum used) was mounted in Ussing chambers for intestinal permeability testing. The cecum was removed, weighed and stored at -80C for SCFA analysis.</span>
  </p>
  <p id="p0683" num="0683" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo de citoquinas del bazo</span>Spleen cytokine assay</span>
    </i>
  </p>
  <p id="p0684" num="0684" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los bazos se recogieron inmediatamente en 5 ml de medio RPMI despus del sacrificio y se cultivaron inmediatamente. Primero se homogeneizaron las clulas de bazo en este medio RPMI, seguido de 5 min de incubacin con 1 ml de tampn de lisis de RBC (11814389001 ROCHE, Sigma). Se aadieron 10 ml adicionales de medio RPMI, seguido de centrifugacin a 200G durante 5 min. Luego, el sobrenadante se filtr a travs de un filtro de 40 um. Las clulas se contaron y sembraron (4.000.000/ml de medio). Despus de 2,5 h de adaptacin, las clulas se estimularon con lipopolisacrido (LPS-2 gg/ml) o concanavalina A (ConA-2,5 gg/ml) durante 24 h. Despus de la estimulacin, se recogieron los sobrenadantes para evaluar la liberacin de citoquinas usando el kit V-<sup class="style-scope patent-text">p</sup>L<sup class="style-scope patent-text">e</sup>X (Meso Scale Discovery, Maryland, USA) del Panel 1 (ratn) proinflamatorio para TNF-a, IL-10, IL-1 p, Interfern <sup class="style-scope patent-text">y</sup>, CXCL2 e IL6. Los anlisis se realizaron usando MESO QuickPlex SQ 120, SECTOR Imager 2400, SECTOR Imager 6000, SECTOR S 600.</span>Spleens were immediately harvested in 5 ml RPMI medium after sacrifice and cultured immediately. Spleen cells were first homogenized in this RPMI medium, followed by 5 min incubation with 1 ml RBC lysis buffer (11814389001 ROCHE, Sigma). An additional 10 ml of RPMI medium was added, followed by centrifugation at 200G for 5 min. The supernatant was then filtered through a 40 um filter. Cells were counted and seeded (4,000,000/ml medium). After 2.5 h adaptation, cells were stimulated with lipopolysaccharide (LPS-2 gg/ml) or concanavalin A (ConA-2.5 gg/ml) for 24 h. After stimulation, supernatants were collected to assess cytokine release using the proinflammatory Panel 1 (mouse) V- <sup class="style-scope patent-text">p</sup> L <sup class="style-scope patent-text">e</sup> X kit (Meso Scale Discovery, Maryland, USA) for TNF-a, IL-10, IL -1 p, Interferon <sup class="style-scope patent-text">and</sup> , CXCL2 and IL6. Analyzes were performed using MESO QuickPlex SQ 120, SECTOR Imager 2400, SECTOR Imager 6000, SECTOR S 600.</span>
  </p>
  <p id="p0685" num="0685" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis de expresin gnica</span>Gene expression analysis</span>
    </i>
  </p>
  <p id="p0686" num="0686" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El ARN total se extrajo con el kit de aislamiento de ARNmi mirVana (Ambion/Llife technologies, Paisley, Reino Unido) y se trat con DNasa (Turbo DNA-free, Ambion/life technologies) de acuerdo con las recomendaciones del fabricante. El ARN se cuantific usando el espectrofotmetro NanoDrop (Thermo Fisher Scientific Inc., Wilmington, Delaware, USA) de acuerdo con las instrucciones del fabricante. La calidad del ARN se evalu usando el Agilent Bioanalyzer (Agilent, Stockport, Reino Unido) de acuerdo con el procedimiento del fabricante y se calcul un nmero de integridad del ARN (RIN). Se us ARN con un valor RIN&gt;7 para experimentos posteriores. El ARN se transcribi inversamente a ADNc usando el kit de ADNc de capacidad de vuelo de Applied Biosystems (Applied Biosystems, Warrington, Reino Unido) de acuerdo con las instrucciones del fabricante. Brevemente, Se aadi transcriptasa inversa Multiscribe (50 U/gl) (1 )(2)(1 )(10) como parte de la mezcla maestra de RT, se incub a 25 C durante 10 min, 37 C durante 2 h, 85 C durante 5 min y se almacen a 4C. La PCR cuantitativa se llev a cabo usando sondas (6 carboxifluorescena-FAM) diseadas por Applied Biosystems para genes objetivo especficos de ratn, mientras se usaba p-actina como control endgeno. Las reacciones de amplificacin contenan 1 gl de ADNc, 5 gl de la mezcla maestra de PCR 2X (Roche), 900 nM de cada cebador y se llevaron a un total de 10 gl mediante la adicin de agua libre de RNasa. Todas las reacciones se realizaron por triplicado usando placas de 96 pocillos en el sistema LightCycler480. Las condiciones de los ciclado trmico fueron las recomendadas por el fabricante (Roche) para 55 ciclos. Para verificar la contaminacin por amplicones, cada serie no contena controles de plantilla por triplicado para cada sonda uszada. Se registraron los valores de umbral de ciclo (Ct). Los datos se normalizaron usando p-actina y se transformaron usando el mtodo 2-AACT y se presentaron como un cambio de veces frente al grupo de control.</span>Total RNA was extracted with the mirVana miRNA isolation kit (Ambion/Llife technologies, Paisley, UK) and treated with DNase (Turbo DNA-free, Ambion/life technologies) according to the manufacturer's recommendations. RNA was quantified using the NanoDrop spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, Delaware, USA) according to the manufacturer's instructions. RNA quality was assessed using the Agilent Bioanalyzer (Agilent, Stockport, UK) according to the manufacturer's procedure and an RNA integrity number (RIN) was calculated. RNA with an RIN value &gt;7 was used for further experiments. RNA was reverse transcribed to cDNA using the Applied Biosystems Flightability cDNA Kit (Applied Biosystems, Warrington, UK) according to the manufacturer's instructions. Briefly, Multiscribe reverse transcriptase (50 U/gl) (1)(2)(1)(10) was added as part of the RT master mix, incubated at 25C for 10 min, 37C for 2 h , 85C for 5 min and stored at 4C. Quantitative PCR was carried out using probes (6 carboxyfluorescein-FAM) designed by Applied Biosystems for mouse-specific target genes, while using p-actin as an endogenous control. Amplification reactions contained 1 l of cDNA, 5 l of 2X PCR master mix (Roche), 900 nM of each primer and brought to a total of 10 l by the addition of RNase-free water. All reactions were performed in triplicate using 96-well plates on the LightCycler480 system. Thermal cycling conditions were those recommended by the manufacturer (Roche) for 55 cycles. To check for amplicon contamination, each run did not contain triplicate template controls for each probe used. Cycle threshold (Ct) values were recorded. Data was normalized using p-actin and transformed using the 2-AACT method and presented as fold change versus control group.</span>
  </p>
  <p id="p0687" num="0687" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis estadstico</span>Statistic analysis</span>
    </i>
  </p>
  <p id="p0688" num="0688" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media  SEM; Los conjuntos de datos no paramtricos se presentan como mediana con rango intercuartlico. Se aplic la prueba t de dos colas no pareadas para analizar los datos paramtricos y la prueba de Mann-Whitney para los no paramtricos. Se emple el coeficiente de correlacin de rangos de Spearman para el anlisis de correlacin en los conjuntos de datos agrupados. Un valor de p&lt;0,05 se consider significativo en todos los casos.</span>Normally distributed data are presented as mean  SEM; Nonparametric data sets are presented as median with interquartile range. The unpaired two-tailed t-test was applied to analyze parametric data and the Mann-Whitney test for non-parametric data. Spearman's rank correlation coefficient was used for correlation analysis on pooled data sets. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0689" num="0689" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados - Expresin gnica</span>Results - Gene Expression</span>
    </i>
  </p>
  <p id="p0690" num="0690" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analiz la expresin de genes para marcadores inflamatorios [IL-1 p, IL6, CD11b, TNF-a y TLR-4] en tejido cerebral del hipocampo, la amgdala y la corteza prefrontal. Las Figuras 15-25 muestran los cambios en la expresin gnica despus del tratamiento con MRx0029 en el hipocampo, la amgdala y la corteza prefrontal. El tratamiento con MRx0029 aument significativamente la expresin de TLR-4 en la amgdala (Figura 20). El tratamiento con MRx0029 tambin aument la expresin de CD11b en la amgdala (Figura 21). 
</span>Gene expression for inflammatory markers [IL-1p, IL6, CD11b, TNF-a, and TLR-4] was analyzed in brain tissue from the hippocampus, amygdala, and prefrontal cortex. Figures 15-25 show changes in gene expression after MRx0029 treatment in the hippocampus, amygdala, and prefrontal cortex. MRx0029 treatment significantly increased TLR-4 expression in amygdala (FIG. 20). MRx0029 treatment also increased CD11b expression in tonsil (FIG. 21). </span>
  </p>
  <p id="p0691" num="0691" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados - Efecto sobre la expresin de citoquinas de los esplenocticos</span>Results - Effect on splenocytic cytokine expression</span>
    </i>
  </p>
  <p id="p0692" num="0692" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El ensayo de esplenocitos ex vivo implica desafiar los esplenocitos (clulas aisladas del bazo, un rgano principal implicado en la defensa inmunitaria), con un desafo mimtico bacteriolgico o viral.</span>The ex vivo splenocyte assay involves challenging splenocytes (cells isolated from the spleen, a major organ involved in immune defense), with a bacteriological or viral mimetic challenge.</span>
  </p>
  <p id="p0693" num="0693" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 llev a una reduccin de interfern-Y, iinterleucina-1 p e interleucina-6 despus de un desafo con LPS (Figuras 26, 27 y 28, respectivamente).</span>MRx0029 treatment led to a reduction in interferon-Y, interleukin-1p and interleukin-6 after LPS challenge (Figures 26, 27 and 28, respectively).</span>
  </p>
  <p id="p0694" num="0694" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 llev a un aumento en los niveles del quimioatrayente CXCL1 (Figura 30). <i class="style-scope patent-text">Anlisis</i> </span>Treatment with MRx0029 led to an increase in the levels of the chemoattractant CXCL1 (FIG. 30). <i class="style-scope patent-text">Analysis</i> </span>
  </p>
  <p id="p0695" num="0695" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 aument significativamente la expresin de las citoquinas proinflamatorias TLR-4 y CD11b en la amgdala. Por lo tanto, las composiciones de la invencin pueden ser tiles en el tratamiento de enfermedades, en particular enfermedades caracterizadas por una activacin inmunitaria reducida y enfermedades que pueden tratarse por una respuesta inmunitaria aumentada.</span>MRx0029 treatment significantly increased the expression of the proinflammatory cytokines TLR-4 and CD11b in the tonsil. Therefore, the compositions of the invention may be useful in the treatment of diseases, in particular diseases characterized by reduced immune activation and diseases that can be treated by an increased immune response.</span>
  </p>
  <p id="p0696" num="0696" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 13 - Prueba de estabilidad</span>Example 13 - Stability test</span>
      </i>
    </b>
  </p>
  <p id="p0697" num="0697" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composicin descrita en la presente que contiene por lo menos una cepa bacteriana descrita en la presente se almacena en un recipiente sellado a 25 C o 4 C y el recipiente se coloca en una atmsfera que tiene un 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90% o 95% de humedad relativa. Despus de 1 mes, 2 meses, 3 meses, 6 meses, 1 ao, 1,5 aos, 2 aos, 2,5 aos o 3 aos, deber quedar por lo menos el 50%, 60%, 70%, 80% o 90% de la cepa bacteriana medida en unidades formadoras de colonias determinadas por protocolos estndar.</span>A composition described herein containing at least one bacterial strain described herein is stored in a sealed container at 25C or 4C and the container is placed in an atmosphere that is 30%, 40%, 50% %, 60%, 70%, 75%, 80%, 90% or 95% relative humidity. After 1 month, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years, there must be at least 50%, 60%, 70%, 80% left or 90% of the bacterial strain measured in colony forming units determined by standard protocols.</span>
  </p>
  <p id="p0698" num="0698" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14 - anlisis del efecto de M. massiliensis sobre la va de sealizacin de ERK</span>Example 14 - Analysis of the effect of M. massiliensis on the ERK signaling pathway</span>
      </i>
    </b>
  </p>
  <p id="p0699" num="0699" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y mtodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0700" num="0700" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Extraccin de ARN y anlisis MAP2 qPCR</span>RNA extraction and MAP2 qPCR analysis</span>
    </i>
  </p>
  <p id="p0701" num="0701" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas se sembraron en placas de 12 pocillos a una densidad de 2 x 105 clulas/pocillo. Despus de 24 h, las clulas se trataron o con DMSO o con Vemurafenib (662005; EMD Millipore; VEMU; SKMEL28, SKMEL31, 451Lu, HT29 (1 pM) SKMEL2 (10 pM) o Azacitidina-C (A3656; Sigma Aldrich; AzaC; 5 pg/ml) o ambos frmacos (VEMU+Aza) juntos, en presencia de 10% de sobrenadantes de bacterias o ausencia de ellas (YCFA+). El ARN total se extrajo usando el mini kit RNeasy (Qiagen, Manchester, Reino Unido) de acuerdo con las instrucciones del fabricante, y la concentracin de ARN se determin mediante espectrofotmetro a 260/280 nm (NanoDrop ND-1000; Thermo Fisher Scientific, Loughborough). Para el anlisis de expresin de ARNm, se prepar ADNc a partir de 2000 ng de ARN total usando el kit de transcripcin inversa de ADNc de alta capacidad (Thermo Fisher, Loughborough) de acuerdo con las instrucciones del fabricante. Las reacciones de transcripcin inversa se realizaron en un termociclador (Biometra, Alemania) a 25 C durante 10 min, 37 C durante 120 min y 85 C durante 5 min. El ADNc resultante se amplific por duplicado mediante el ensayo de PCR SYBR-Green y los productos se detectaron en la mquina de PCR en tiempo real QuantStudio 6 flex (Applied Biosystems, Reino Unido) usando un perfil estandarizado (desnaturalizacin inicial de 95 C durante 10 minutos, seguido de 40 ciclos de 10 segundos de desnaturalizacin a 95 C y 30 segundos de apareamiento/extensin a 65 C). Se aadi una etapa de disociacin despus de los 40 ciclos para generar una curva de fusin. El anlisis se realiz usando el software de PCR en tiempo real QuantStudio v1.2 de Applied Biosystems. Las secuencias de los cebadores para GAPDH y MAP2 se muestran a continuacin.</span>Cells were seeded in 12-well plates at a density of 2 x 10 5 cells/well. After 24 h, cells were treated with either DMSO or Vemurafenib (662005; EMD Millipore; VEMU; SKMEL28, SKMEL31, 451Lu, HT29 (1 pM) SKMEL2 (10 pM) or Azacitidine-C (A3656; Sigma Aldrich; AzaC ; 5 pg/ml) or both drugs (VEMU+Aza) together, in the presence of 10% bacterial supernatants or absence of bacteria (YCFA+).Total RNA was extracted using the RNeasy mini kit (Qiagen, Manchester, UK). ) according to the manufacturer's instructions, and the RNA concentration was determined by spectrophotometer at 260/280 nm (NanoDrop ND-1000; Thermo Fisher Scientific, Loughborough).For mRNA expression analysis, cDNA was prepared from 2000 ng of total RNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Loughborough) according to the manufacturer's instructions Reverse transcription reactions were performed in a thermocycler (Biometra, Germany) at 25C for 10 min, 37C for 120 min and 85C for 5 min.The res cDNA The ultant was amplified in duplicate by the SYBR-Green PCR assay and the products were detected in the QuantStudio 6 flex real-time PCR machine (Applied Biosystems, UK) using a standardized profile (initial denaturation at 95C for 10 minutes). , followed by 40 cycles of 10 seconds denaturation at 95C and 30 seconds annealing/extension at 65C). A dissociation step was added after 40 cycles to generate a melting curve. Analysis was performed using QuantStudio v1.2 real-time PCR software from Applied Biosystems. The primer sequences for GAPDH and MAP2 are shown below.</span>
  </p>
  <p id="p0702" num="0702" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis de Transferencia Western</span>Western Blot Analysis</span>
    </i>
  </p>
  <p id="p0703" num="0703" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Despus de 24 horas de tratamiento con los frmacos apropiados en presencia o ausencia de sobrenadante bacteriano al 10% (YCFA+), se obtuvieron extractos de protena lisando las clulas en tampn RIPA (R0278; Sigma Aldrich) suplementado con inhibidores de proteasa (cOmplete Protease Inhibitor Cocktail Tablets; Roche, Suiza) y ortovanadato de sodio 1 mM/l, PMSF 0,5 mM/l. La cuantificacin de protenas se realiz mediante el ensayo de protenas BCA. Luego, se separaron cantidades iguales de protena total (20 pg/filal) mediante SDS-PAGE en gel con gradiente del 4-15% (BioRad) y se transfirieron a membranas de difluoruro de polivinilideno (PVDF) (Thermo Fisher Scientific, Loughborough). Despus de bloquear con BSA al 5% o leche en polvo desnatada en TBST (Tris 10 mM, pH 7,5, NaCl 150 mM, Tween 20 al 0,5%) durante 60 min, las membranas se probaron con anticuerpos primarios contra fosfo-ERK (9101S, 1:1000, Cell Signalling; New England Biolabs (Reino Unido)) o ERK total (4696S, 1:1000, Cell signalling; New England Biolabs (Reino Unido)).</span>After 24 hours of treatment with the appropriate drugs in the presence or absence of 10% bacterial supernatant (YCFA+), protein extracts were obtained by lysing cells in RIPA buffer (R0278; Sigma Aldrich) supplemented with protease inhibitors (complete Protease Inhibitor Cocktail Tablets; Roche, Switzerland) and sodium orthovanadate 1 mM/l, PMSF 0.5 mM/l. Protein quantification was performed using the BCA protein assay. Equal amounts of total protein (20 pg/filal) were then separated by 4-15% gradient gel SDS-PAGE (BioRad) and transferred to polyvinylidene difluoride (PVDF) membranes (Thermo Fisher Scientific, Loughborough). . After blocking with 5% BSA or nonfat dry milk in TBST (10 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Tween 20) for 60 min, membranes were probed with primary antibodies against phospho -ERK (9101S, 1:1000, Cell Signaling; New England Biolabs (UK)) or total ERK (4696S, 1:1000, Cell signaling; New England Biolabs (UK)).</span>
  </p>
  <p id="p0704" num="0704" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las protenas de inters se detectaron con el anticuerpo secundario conjugado con HRP adecuado (1: 10.000, Thermo Fisher Scientific, Loughborough), desarrollado con el sustrato de transferencia Western ECL Super Signal PicoPlus (34577; Thermo Fisher Scientific, Loughborough) y se visualizaron en Chemidoc XRS Imager 
(BioRad).</span>Proteins of interest were detected with the appropriate HRP-conjugated secondary antibody (1:10,000, Thermo Fisher Scientific, Loughborough), developed with ECL Super Signal PicoPlus Western blot substrate (34577; Thermo Fisher Scientific, Loughborough) and visualized on Chemidoc XRS Imager  (BioRad).</span>
  </p>
  <p id="p0705" num="0705" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Crecimiento independiente de anclaje </i>(<i class="style-scope patent-text">ensayo de crecimiento de agar suave) en placas de 96 pocilios</i> </span> <i class="style-scope patent-text">Anchorage-independent growth</i> ( <i class="style-scope patent-text">soft agar growth assay) in 96-well plates</i> </span>
  </p>
  <p id="p0706" num="0706" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sembraron en placas una mezcla de 25 pl precalentada (37 C) 2x de medio de crecimiento apropiado (EMEM para lneas celulares de melanoma; DMEM alto en glucosa para HT29) que contena FBS al 20%, L-Glu 4 mM, 2x NEAA, bicarbonato de sodio al 0,6%, 200 U/ml de penicilina/estreptomicina (Invitrogen) y 25 pl de agar noble al 1,2% precalentado (47 C) (A5431; Sigma Aldrich) en cada pocillo de una microplaca de 96 pocillos para servir como capa previa para el ensayo. Se mezclaron diez microlitros de suspensiones celulares que contenan 0-2 x 103 clulas con 25 pl de medio de cultivo 2x y 35 pl de agar noble al 0,8% en una microplaca de polipropileno de fondo redondo de 96 pocillos y se transfirieron a la microplaca de 96 pocillos que contena las capas previas solidificadas. Se permiti que las clulas crecieran durante 2 das y luego se alimentaron con medios que contenan frmacos en presencia de sobrenadantes bacterianos al 10% o YCFA+ cada tres das. Se dejaron crecer en la incubadora humidificada a 37 C con CO2 al 5% durante 1 o 2 semanas antes de puntuar el crecimiento en agar blando usando el ensayo de transformacin de clulas de 96 pocillos CytoSelect (CBA-130; Cell Biolabs) de acuerdo con el protocolo del fabricante. El crecimiento celular se midi usando un lector de placas de mltiples pocillos Tecan Infinite F200 Pro Series (Tecan Biosystems), con excitacin a 485 nm y emisin a 530 nm.</span>A 25 pl prewarmed (37C) 2x mixture of appropriate growth medium (EMEM for melanoma cell lines; high glucose DMEM for HT29) containing 20% FBS, 4 mM L-Glu, 2x NEAA, 0.6% sodium bicarbonate, 200 U/ml penicillin/streptomycin (Invitrogen), and 25 l prewarmed (47C) 1.2% noble agar (A5431; Sigma Aldrich) in each well of a 96-well microplate to serve as a prelayer for the assay. Ten microliters of cell suspensions containing 0-2 x 10 3 cells were mixed with 25 l of 2x culture medium and 35 l of 0.8% noble agar in a 96-well round bottom polypropylene microplate and transferred to the microplate. 96-well microplate containing solidified previous layers. Cells were allowed to grow for 2 days and then fed drug-containing media in the presence of 10% bacterial supernatants or YCFA+ every three days. They were allowed to grow in the humidified incubator at 37C with 5% CO2 for 1 or 2 weeks before scoring growth in soft agar using the CytoSelect 96-well cell transformation assay (CBA-130; Cell Biolabs) according to with the manufacturer's protocol. Cell growth was measured using a Tecan Infinite F200 Pro Series multiwell plate reader (Tecan Biosystems), with excitation at 485nm and emission at 530nm.</span>
  </p>
  <p id="p0707" num="0707" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Crecimiento independiente del anclaje </i>(<i class="style-scope patent-text">ensayo de crecimiento de asar suave) en una placa de 32 mm</i> </span> <i class="style-scope patent-text">Anchorage-independent growth</i> ( <i class="style-scope patent-text">gentle roast growth assay) in a 32 mm plate</i> </span>
  </p>
  <p id="p0708" num="0708" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se mezcl una mezcla de 1 ml de medio de cultivo 2x apropiado precalentado (37 C) (EMEM para lneas celulares de melanoma; DMEM alto en glucosa para HT29) y 1 ml de agar noble al 0,8% precalentado (47 C) por placa (agar final al 0,4%) con 1 ml de suspensin celular y se sembraron sobre una precapa de agar/crecimiento celular al 0,6% (2 ml) en una placa de 6 pocillos. Se permiti que las clulas crecieran en la incubadora humidificada a 37 C con CO2 al 5% durante 21-28 das. Se alimentaron con frmacos en ausencia (YCFA+) o presencia de sobrenadante bacteriano al 10% cada tres das. Las colonias se fotografiaron usando un microscopio Evos XL Core (Thermo Fisher Scientific, Loughborough).</span>A mixture of 1 mL of prewarmed (37C) appropriate 2x culture medium (EMEM for melanoma cell lines; DMEM high glucose for HT29) and 1 mL of prewarmed (47C) 0.8% noble agar was mixed. ) per plate (0.4% final agar) with 1 mL cell suspension and plated onto a 0.6% cell growth/agar prelayer (2 mL) in a 6-well plate. Cells were allowed to grow in the 37C humidified incubator with 5% CO2 for 21-28 days. They were fed drugs in the absence (YCFA+) or presence of 10% bacterial supernatant every three days. Colonies were photographed using an Evos XL Core microscope (Thermo Fisher Scientific, Loughborough).</span>
  </p>
  <p id="p0709" num="0709" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo clonognico</span>Clonogenic assay</span>
    </i>
  </p>
  <p id="p0710" num="0710" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas se tripsinizaron y se sembraron 200 clulas/pocillo en placas de 12 pocillos. Despus de 48 h, las clulas se trataron con los frmacos apropiados en ausencia (YCFA+) o presencia de sobrenadante bacteriano al 10% y se realimentaron cada tres das. El da 21 despus de la siembra, las clulas se fijaron en metanol enfriado con hielo y se tieron con azul cristal violeta. Se contaron las colonias (0,50 clulas) y se calcul la fraccin de supervivencia como el nmero de colonias dividido por el nmero de clulas sembradas (eficacia de sembrado) de las tratadas dividido por la eficacia de sembrado del control.</span>Cells were trypsinized and plated at 200 cells/well in 12-well plates. After 48 h, cells were treated with the appropriate drugs in the absence (YCFA+) or presence of 10% bacterial supernatant and re-fed every three days. On day 21 after seeding, cells were fixed in ice-cold methanol and stained with crystal blue violet. Colonies (0.50 cells) were counted and the survival fraction was calculated as the number of colonies divided by the number of cells seeded (seeding efficiency) of the treated divided by the seeding efficiency of the control.</span>
  </p>
  <p id="p0711" num="0711" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14A - Lnea celular de melanoma SKMEL2</span>Example 14A - Melanoma cell line SKMEL2</span>
      </i>
    </b>
  </p>
  <p id="p0712" num="0712" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos sobre la lnea celular de melanoma SKMEL2 (WT BRAF; mutacin oncognica N61R en Nras): (1) MRX0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRX029; (4) azacitidina-C (Aza-c) en medio Y<sup class="style-scope patent-text">f</sup>C<sup class="style-scope patent-text">a </sup>+; (5) Aza-c y MRX029; (6) VEMU, Aza-c y MRX0029.</span>The effects of the following treatments on the melanoma cell line SKMEL2 (WT BRAF; N61R oncogenic mutation in Nras) were evaluated: (1) MRX0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRX029; (4) azacitidine-C (Aza-c) in medium Y <sup class="style-scope patent-text">f</sup> C <sup class="style-scope patent-text">a</sup> +; (5) Aza-c and MRX029; (6) VEMU, Aza-c and MRX0029.</span>
  </p>
  <p id="p0713" num="0713" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresin del gen MAP2 en la lnea celular SKMEL2 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 31. Todos los tratamientos con MRX029 (solo o en combinacin con VEMU y/o Aza-c) aumentaron la expresin del gen MAP2 con respecto a ambos controles negativos (lnea celular solamente y YCFA+). La supervivencia clonognica de la lnea celular SKMEL2 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 32. El crecimiento en agar blando de la lnea celular SKMEL2 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 33. VEMU+Aza-c mejor la inhibicin del crecimiento en agar blando por MRX029. La sealizacin de ERK en la lnea celular SKMEL2 se evalu usando el protocolo en Materiales y Mtodos, y los resultados se muestran en la Figura 34 (no se evaluaron VEMU, Aza-c y MRX029).</span>MAP2 gene expression in the SKMEL2 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 31. All MRX029 treatments (alone or in combination with VEMU and/or Aza-c) increased MAP2 gene expression relative to both negative controls (cell line only and YCFA+). The clonogenic survival of the SKMEL2 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 32. The soft agar growth of the SKMEL2 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 32. results are shown in Figure 33. VEMU+Aza-c enhanced growth inhibition in soft agar by MRX029. ERK signaling in the SKMEL2 cell line was evaluated using the protocol in Materials and Methods, and the results are shown in Figure 34 (VEMU, Aza-c and MRX029 were not evaluated).</span>
  </p>
  <p id="p0714" num="0714" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRX0029 solo o en combinacin con Vemurafenib y/o Azacitidina-C puede tener los efectos de inducir la expresin del gen MAP2 en una lnea celular de melanoma (SKMEL2). Adems, Vemurafenib+Azacitidina-C mejor la inhibicin del crecimiento en agar blando por MRX0029. Sobre esta base, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de varios cnceres, en particular cnceres metastsicos, en particular melanoma metastsico.</span>These results indicate that MRX0029 alone or in combination with Vemurafenib and/or Azacitidine-C may have the effects of inducing MAP2 gene expression in a melanoma cell line (SKMEL2). In addition, Vemurafenib+Azacitidine-C improved growth inhibition in soft agar by MRX0029. On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of various cancers, in particular metastatic cancers, in particular metastatic melanoma.</span>
  </p>
  <p id="p0715" num="0715" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14B - Lnea celular de melanoma SKMEL28</span>Example 14B - Melanoma cell line SKMEL28</span>
      </i>
    </b>
  </p>
  <p id="p0716" num="0716" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos sobre la lnea celular de melanoma SKMEL28 (mutacin oncognica V600E en BRAF): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YCFA+; (3) VEMU y MRx0029; (4) azacitidina-C (Aza-c) en medio YCFA+; (5) Aza-c y MRX0029; (6) VEMU, Aza-c y MRx0029. 
</span>The effects of the following treatments on the melanoma cell line SKMEL28 (BRAF V600E oncogenic mutation) were evaluated: (1) MRx0029; (2) Vemurafenib (VEMU) in YCFA+ medium; (3) VEMU and MRx0029; (4) azacitidine-C (Aza-c) in YCFA+ medium; (5) Aza-c and MRX0029; (6) VEMU, Aza-c and MRx0029. </span>
  </p>
  <p id="p0717" num="0717" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresin del gen MAP2 en la lnea celular SKMEL28 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 35. La supervivencia clonognica de la lnea celular SKMEL28 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 36. MRx0029 en combinacin con VEMU y/o Aza-c disminuy la supervivencia clonognica con respecto a ambos controles negativos (YCFA+ y lnea celular solamente). El crecimiento en agar blando de la lnea celular SKMEE28 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 37. La sealizacin de ERK en la lnea celular SKMEL28 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 38 (VEMU, Aza-c y MRx0029 no fueron evaluados). Todos los tratamientos con MRx0029 (solo o en combinacin con VEMU o Aza-c) redujeron la sealizacin de ERK con respecto al control negativo (YFCA+).</span>The expression of the MAP2 gene in the SKMEL28 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 35. The clonogenic survival of the SKMEL28 cell line was evaluated using the Materials and Methods protocol, and the results results are shown in Figure 36. MRx0029 in combination with VEMU and/or Aza-c decreased clonogenic survival relative to both negative controls (YCFA+ and cell line only). Growth of the SKMEE28 cell line in soft agar was evaluated using the Materials and Methods protocol, and the results are shown in Figure 37. ERK signaling in the SKMEL28 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 38 (VEMU, Aza-c and MRx0029 were not evaluated). All MRx0029 treatments (alone or in combination with VEMU or Aza-c) reduced ERK signaling relative to the negative control (YFCA+).</span>
  </p>
  <p id="p0718" num="0718" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRx0029 solo o en combinacin con Vemurafenib y/o Azacitidina-C puede tener los efectos de inhibir la sealizacin de ERK y disminuir la supervivencia clonognica de una lnea celular de melanoma que comprende la mutacin BRAF V600E (SKMEL28). Sobre esta base, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de cnceres, en particular aquellos que comprenden sealizacin de ERK oncognica, especialmente melanomas. En particular, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de tales cnceres que comprenden una mutacin oncognica en BRAF, en particular en la posicin 600, y especialmente la mutacin BRAF V600E.</span>These results indicate that MRx0029 alone or in combination with Vemurafenib and/or Azacitidine-C may have the effects of inhibiting ERK signaling and decreasing clonogenic survival of a melanoma cell line comprising the BRAF V600E (SKMEL28) mutation. On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of cancers, in particular those that comprise oncogenic ERK signaling, especially melanomas. In particular, the compositions of the invention are expected to be useful in the treatment or prevention of such cancers that comprise an oncogenic mutation in BRAF, particularly at position 600, and especially the BRAF V600E mutation.</span>
  </p>
  <p id="p0719" num="0719" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14C - Lnea celular de melanoma SKMEL31</span>Example 14C - Melanoma cell line SKMEL31</span>
      </i>
    </b>
  </p>
  <p id="p0720" num="0720" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos en la lnea celular de melanoma SKMEL31 (heterocigota para BRAF V600E): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRx0029; (4) Azacitidina-C (Aza-c) en medio <sup class="style-scope patent-text">y </sup>F<sup class="style-scope patent-text">c</sup>A+; (5) Aza-c y MRx0029; (6) VEMU, Aza-c y MRx0029.</span>The effects of the following treatments on the melanoma cell line SKMEL31 (heterozygous for BRAF V600E) were evaluated: (1) MRx0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRx0029; (4) Azacitidine-C (Aza-c) in medium <sup class="style-scope patent-text">and</sup> F <sup class="style-scope patent-text">c</sup> A+; (5) Aza-c and MRx0029; (6) VEMU, Aza-c and MRx0029.</span>
  </p>
  <p id="p0721" num="0721" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresin del gen MAP2 en la lnea celular SKMEL31 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 39. La supervivencia clonognica de la lnea celular SKMEL31 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 40. El crecimiento en agar blando de la lnea celular SKMEL31 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 41. VEMU, Aza-c y VEMU+Aza-c mejoraron el crecimiento en agar blando y la inhibicin de la supervivencia clonognica mediante MRx0029. La sealizacin de ERK en la lnea celular SKMEL31 se evalu usando el protocolo en Materiales y Mtodos, y los resultados se muestran en la Figura 42 (VEMU, Aza-c y MRx0029 en combinacin no se evaluaron). Todos los tratamientos con MRx0029 (solo o en combinacin con VEMU o Aza-c) redujeron la sealizacin de ERK con respecto al control negativo (YFCA+).</span>The expression of the MAP2 gene in the SKMEL31 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 39. The clonogenic survival of the SKMEL31 cell line was evaluated using the Materials and Methods protocol, and the results The results are shown in Figure 40. Growth of the SKMEL31 cell line in soft agar was evaluated using the Materials and Methods protocol, and the results are shown in Figure 41. VEMU, Aza-c, and VEMU+Aza-c improved growth in soft agar and inhibition of clonogenic survival by MRx0029. ERK signaling in the SKMEL31 cell line was evaluated using the protocol in Materials and Methods, and the results are shown in Figure 42 (VEMU, Aza-c, and MRx0029 in combination were not evaluated). All MRx0029 treatments (alone or in combination with VEMU or Aza-c) reduced ERK signaling relative to the negative control (YFCA+).</span>
  </p>
  <p id="p0722" num="0722" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14D - Linea celular de melanoma 451Lu</span>Example 14D - Melanoma cell line 451Lu</span>
      </i>
    </b>
  </p>
  <p id="p0723" num="0723" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos en la lnea celular de melanoma 451Lu (mutacin oncognica V600E en BRAF): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRx0029; (4) Azacitidina-C (Aza-c) en medio YFCA+; (5) Aza-c y MRx0029; (6) VEMU, Aza-c y MRx0029.</span>The effects of the following treatments on the 451Lu melanoma cell line (BRAF V600E oncogenic mutation) were evaluated: (1) MRx0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRx0029; (4) Azacitidine-C (Aza-c) in YFCA+ medium; (5) Aza-c and MRx0029; (6) VEMU, Aza-c and MRx0029.</span>
  </p>
  <p id="p0724" num="0724" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresin del gen MAP2 en la lnea celular 451Lu se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 43. Todos los tratamientos con MRx0029 (solo o en combinacin con VEMU y/o Aza-c) aumentaron la expresin del gen MAP2 con respecto a la lnea celular slo con control negativo. La supervivencia clonognica de la lnea celular 451Lu se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 44. Todos los tratamientos con MRx0029 (solo o en combinacin con VEMU y/o Aza-c) redujeron la supervivencia clonognica con respecto a ambos controles negativos (lnea celular solamente y YCFA+ DMSO). El crecimiento en agar blando de la lnea celular 451Lu se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 45. La azacitidina C mejor la inhibicin del crecimiento en agar blando por MRx0029. La sealizacin de ERK en la lnea celular 451Lu se evalu usando el protocolo en Materiales y Mtodos, y los resultados se muestran en la Figura 46 (VEMU, Aza-c y MRx0029 en combinacin no se evaluaron). MRx0029 en combinacin con VEMU o Aza-c redujo la sealizacin de ERK con respecto al control negativo (YFCA+ DMSO).</span>MAP2 gene expression in the 451Lu cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 43. All MRx0029 treatments (alone or in combination with VEMU and/or Aza-c) increased the expression of the MAP2 gene with respect to the cell line only with negative control. The clonogenic survival of the 451Lu cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 44. All MRx0029 treatments (alone or in combination with VEMU and/or Aza-c) reduced survival. clonogenic relative to both negative controls (cell line only and YCFA+ DMSO). Soft agar growth of the 451Lu cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 45. Azacitidine C enhanced soft agar growth inhibition by MRx0029. ERK signaling in the 451Lu cell line was evaluated using the protocol in Materials and Methods, and the results are shown in Figure 46 (VEMU, Aza-c, and MRx0029 in combination were not evaluated). MRx0029 in combination with VEMU or Aza-c reduced ERK signaling relative to the negative control (YFCA+ DMSO).</span>
  </p>
  <p id="p0725" num="0725" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRx0029 solo o en combinacin con Vemurafenib y/o Azacitidina-C tiene los efectos de inducir la expresin del gen MAP2 y disminuir la supervivencia clonognica y el crecimiento de una lnea celular de melanoma portadora de una mutacin oncognica BRAF V600E (451Lu). Sobre esta base, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de cnceres, en particular aquellos que comprenden sealizacin de ERK oncognica, especialmente melanomas como melanomas metastsicos. En particular, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de dichos cnceres que comprenden una mutacin oncognica en BRAF, en particular en la posicin 600, y especialmente la mutacin BRAF V600E.</span>These results indicate that MRx0029 alone or in combination with Vemurafenib and/or Azacitidine-C has the effects of inducing MAP2 gene expression and decreasing clonogenic survival and growth of a melanoma cell line carrying an oncogenic mutation BRAF V600E (451Lu ). On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of cancers, in particular those that comprise oncogenic ERK signaling, especially melanomas such as metastatic melanomas. In particular, the compositions of the invention are expected to be useful in the treatment or prevention of such cancers that comprise an oncogenic mutation in BRAF, particularly at position 600, and especially the BRAF V600E mutation.</span>
  </p>
  <p id="p0726" num="0726" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14E - Lnea celular de cncer colorrectal HT29</span>Example 14E - Colorectal cancer cell line HT29</span>
      </i>
    </b>
  </p>
  <p id="p0727" num="0727" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos sobre la lnea celular de cncer colorrectal HT29 
(mutacin oncognica V600E en BRAF): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRx0029; (4) Azacitidina-C (Aza-c) en medio YCFA+; (5) Aza-c y MRx0029; (6) VEMU, Aza-c y MRx0029.</span>The effects of the following treatments on the HT29 colorectal cancer cell line were evaluated.  (BRAF V600E oncogenic mutation): (1) MRx0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRx0029; (4) Azacitidine-C (Aza-c) in YCFA+ medium; (5) Aza-c and MRx0029; (6) VEMU, Aza-c and MRx0029.</span>
  </p>
  <p id="p0729" num="0729" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresin del gen MAP2 en la lnea celular HT29 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 47. MRx0029 en combinacin con VEMU y/o Aza-c aument la expresin del gen MAP2 con respecto a ambos controles negativos (lnea celular solamente e YCFA+). La supervivencia clonognica de la lnea celular HT29 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 48. Todos los tratamientos con MRx0029 (solo o en combinacin con VEMU y/o Aza-c) disminuyeron la supervivencia clonognica con respecto a ambos controles negativos (lnea celular solamente y YCFA+ DMSO). Aza-c mejor los efectos de MRx0029 en la inhibicin de la supervivencia clonognica. El crecimiento en agar blando de la lnea celular HT29 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 49a y b. La sealizacin de ERK en la lnea celular HT29 se evalu usando el protocolo de Materiales y Mtodos, y los resultados se muestran en la Figura 50 (VEMU, Aza-c y MRx0029 en combinacin no se evaluaron). MRx0029 solo sealizacin de ERK con respecto al control negativo (YFCA+ DMSO).</span>MAP2 gene expression in the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 47. MRx0029 in combination with VEMU and/or Aza-c increased MAP2 gene expression relative to both negative controls (cell line only and YCFA+). Clonogenic survival of the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 48. All MRx0029 treatments (alone or in combination with VEMU and/or Aza-c) decreased survival. clonogenic relative to both negative controls (cell line only and YCFA+ DMSO). Aza-c enhanced the effects of MRx0029 in inhibiting clonogenic survival. Soft agar growth of the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 49a and b. ERK signaling in the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 50 (VEMU, Aza-c, and MRx0029 in combination were not evaluated). MRx0029 only ERK signaling relative to the negative control (YFCA+ DMSO).</span>
  </p>
  <p id="p0731" num="0731" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRx0029 solo o en combinacin con Vemurafenib y/o Azacitidina-C tiene los efectos de inducir la expresin del gen MAP2, disminuir la supervivencia clonognica e inhibir la sealizacin de ERK en una lnea celular portadora de la mutacin oncognica V600E (EEG29). Sobre esta base, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de cnceres, en particular aquellos que comprenden sealizacin de ERK oncognica, especialmente cnceres colorrectales como cncer colorrectal metastsico. En particular, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de dichos cnceres que comprenden una mutacin oncognica en BRAF, en particular en la posicin 600, y especialmente la mutacin BRAF V600E.</span>These results indicate that MRx0029 alone or in combination with Vemurafenib and/or Azacitidine-C has the effects of inducing MAP2 gene expression, decreasing clonogenic survival and inhibiting ERK signaling in a cell line carrying the V600E oncogenic mutation (EEG29). ). On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of cancers, in particular those that comprise oncogenic ERK signaling, especially colorectal cancers such as metastatic colorectal cancer. In particular, the compositions of the invention are expected to be useful in the treatment or prevention of such cancers that comprise an oncogenic mutation in BRAF, particularly at position 600, and especially the BRAF V600E mutation.</span>
  </p>
  <p id="p0733" num="0733" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 15 - Expresin de ARN de GPR109a en clulas Caco-2 diferenciadas</span>Example 15 - Expression of GPR109a RNA in Differentiated Caco-2 Cells</span>
      </i>
    </b>
  </p>
  <p id="p0735" num="0735" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GPR109a es un receptor acoplado a protena G expresado en la membrana apical orientada hacia el lumen de las clulas epiteliales intestinales y colnicas. El silenciamiento de la expresin de GPR109a se encuentra en lneas celulares de cncer de colon, y se ha informado que la induccin de su expresin induce la apoptosis de las clulas tumorales en presencia de productos de fermentacin bacteriana como el butirato [126].</span>GPR109a is a G protein-coupled receptor expressed on the lumen-facing apical membrane of intestinal and colonic epithelial cells. Silencing of GPR109a expression is found in colon cancer cell lines, and induction of its expression has been reported to induce apoptosis of tumor cells in the presence of bacterial fermentation products such as butyrate [126].</span>
  </p>
  <p id="p0737" num="0737" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sembraron clulas HT29mtx sembradas en placas de 12 pocillos y se diferenciaron durante 10 das; luego se privaron de suero durante 12 horas y posteriormente se expusieron a sobrenadante al 10% derivado de bacterias en fase estacionaria durante 24 horas. Se recogieron las clulas y se aisl el ARN total de acuerdo con el protocolo del RNeasy mini kit (Qiagen). El ADNc se prepar usando el kit de transcripcin inversa de ADNc de alta capacidad (Applied Biosystems). La expresin gnica se midi por qPCR. Se us p-actina como control interno. Se calcularon las veces de cambio de acuerdo con el mtodo 2A(-AAct) [127]. Las secuencias de los cebadores directo e inverso usados se proporcionan como las SEQ ID NO: 6 y 7, respectivamente.</span>Seed HT29mtx cells were plated in 12-well plates and differentiated for 10 days; they were then serum starved for 12 hours and subsequently exposed to 10% supernatant derived from bacteria in stationary phase for 24 hours. Cells were harvested and total RNA isolated according to the RNeasy mini kit (Qiagen) protocol. cDNA was prepared using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured by qPCR. p-actin was used as internal control. The fold change was calculated according to the 2A(-AAct) method [127]. The sequences of the forward and reverse primers used are provided as SEQ ID NOs: 6 and 7, respectively.</span>
  </p>
  <p id="p0739" num="0739" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las Caco-2 diferenciadas forman membranas apicales/mucosas y basolaterales/serosas polarizadas que son impermeables y estructural y funcionalmente similares a las clulas epiteliales del intestino delgado. El tratamiento de clulas Caco-2 con MRx0029 provoc un aumento de la expresin de GPR109a (Figura 52A). Adems, las Caco-2 tratadas con sobrenadante de forbol-12-miristato-13-acetato (PMA) mostraron una mayor expresin de ARN de GPR109a que el tratamiento con PMA solo (o PMA en medio YCFA+) - ver la Figura 52B. Por lo tanto, estos datos sugieren que las composiciones de la invencin pueden ser tiles en el tratamiento de cnceres, especialmente cnceres metastsicos, en particular cncer colorrectal metastsico o cncer de intestino delgado como adenocarcinoma de intestino delgado, y en particular aquellos que comprenden sealizacin de ERK oncognica. Estos datos tambin sugieren que las composiciones de la invencin pueden efectuar tal tratamiento a travs del mecanismo de induccin de apoptosis, como resultado de la expresin de GPR109a.</span>Differentiated Caco-2 form polarized apical/mucosal and basolateral/serous membranes that are impermeable and structurally and functionally similar to epithelial cells of the small intestine. Treatment of Caco-2 cells with MRx0029 caused an increase in the expression of GPR109a (FIG. 52A). In addition, Caco-2 treated with phorbol-12-myristate-13-acetate (PMA) supernatant showed higher GPR109a RNA expression than treatment with PMA alone (or PMA in YCFA+ medium) - see Figure 52B. Therefore, these data suggest that the compositions of the invention may be useful in the treatment of cancers, especially metastatic cancers, in particular metastatic colorectal cancer or cancer of the small intestine such as adenocarcinoma of the small intestine, and in particular those that comprise signaling of oncogenic ERK. These data also suggest that the compositions of the invention may effect such treatment through the mechanism of induction of apoptosis, as a result of the expression of GPR109a.</span>
  </p>
  <p id="p0741" num="0741" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 16 - Efecto de MRx0029 sobre la secrecin de IL-8 por la linea celular HT29</span>Example 16 - Effect of MRx0029 on IL-8 secretion by the HT29 cell line</span>
      </i>
    </b>
  </p>
  <p id="p0743" num="0743" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas HT29 diferenciadas forman membranas apicales/mucosas y basolaterales/serosas polarizadas que son impermeables y son estructural y funcionalmente similares a las clulas epiteliales del intestino delgado. Las clulas HT29 se sembraron en placas de 12 pocillos a una densidad de 200.000 clulas/pocillo. Las clulas se diferenciaron durante 10 das (cambio de medio cada 2 das). El da del experimento las clulas se colocaron en la campana anaerbica y se lavaron con solucin de HANKs equilibrada anaerbica. Luego se aadieron a las clulas 900 ul de medio de cultivo (sin FBS ni antibiticos). Las clulas bacterianas se volvieron a suspender en medio de crecimiento (sin FBS ni antibiticos) y luego se aadieron a 10A7 UFC en total en 100ul. Las clulas se coincubaron con bacterias durante 2 h en una campana anaerbica. Posteriormente, las clulas se lavaron en medios de crecimiento sin FBS pero que contenan antibiticos. Las clulas se dejaron reposar en 1 ml de medio de acondicionamiento de THP1 durante 24 h. Despus de 24 h de incubacin, se recogi el sobrenadante y se centrifug a 10.000 g durante 3 min y 4 C. Las muestras se congelaron a -80C hasta su uso posterior. 
</span>Differentiated HT29 cells form polarized apical/mucosal and basolateral/serous membranes that are impermeable and are structurally and functionally similar to epithelial cells of the small intestine. HT29 cells were seeded in 12-well plates at a density of 200,000 cells/well. Cells were differentiated for 10 days (medium change every 2 days). On the day of the experiment the cells were placed in the anaerobic hood and washed with anaerobic balanced HANKs solution. Then 900 ul of culture medium (without FBS and antibiotics) was added to the cells. Bacterial cells were resuspended in growth medium (without FBS or antibiotics) and then added to 10A7 CFU in total in 100ul. Cells were coincubated with bacteria for 2 h in an anaerobic hood. Cells were subsequently washed in growth media without FBS but containing antibiotics. Cells were allowed to stand in 1 ml of THP1 conditioning medium for 24 h. After 24 h of incubation, the supernatant was collected and centrifuged at 10,000 g for 3 min and 4C. Samples were frozen at -80C until further use. </span>
  </p>
  <p id="p0744" num="0744" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Medios de acondicionamiento de THP1: se sembraron THp1 en un matraz T25 a una densidad de 4310A6/matraz. Las clulas se trataron en medio RPMI (que contena L-glutamina 2 mM sin FBS) con LPS 1ug/ml o LPS  ATP 5 mM (ATP aadido 3 horas despus de LPS). Las clulas se dejaron reposar durante 24 horas. Posteriormente, se recogi el Medio de Acondicionamiento (CM) centrifugando las clulas a 250 g durante 5 min y a TA. Se usaron diferentes CM para tratar las clulas HT29. Se congel una pequea alcuota a 80 C para ELISA.</span>THP1 Conditioning Media: THp1 was seeded into a T25 flask at a density of 4310A6/flask. Cells were treated in RPMI medium (containing 2mM L-glutamine without FBS) with 1ug/ml LPS or 5mM LPS ATP (ATP added 3 hours after LPS). The cells were allowed to settle for 24 hours. Subsequently, the Conditioning Medium (CM) was collected by centrifuging the cells at 250 g for 5 min and at RT. Different CMs were used to treat HT29 cells. A small aliquot was frozen at 80C for ELISA.</span>
  </p>
  <p id="p0745" num="0745" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se recogieron los sobrenadantes de las diferentes muestras y se realiz el anlisis de citoquinas de acuerdo con las instrucciones del fabricante usando un kit ELISA de IL-8 humana de Peprotech. Se us GraphPad Prism7 para trazar y analizar los datos.</span>Supernatants from the different samples were collected and cytokine analysis was performed according to the manufacturer's instructions using a human IL-8 ELISA kit from Peprotech. GraphPad Prism7 was used to plot and analyze the data.</span>
  </p>
  <p id="p0746" num="0746" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 aument la secrecin de IL-8, que es una citoquina potente inmunoestimuladora (Figura 53). Estos datos demuestran la actividad inmunoestimuladora de MRx0029.</span>MRx0029 increased the secretion of IL-8, which is a potent immunostimulatory cytokine (FIG. 53). These data demonstrate the immunostimulatory activity of MRx0029.</span>
  </p>
  <p id="p0747" num="0747" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se ha indicado anteriormente, la secrecin de IL-8 aumenta la proliferacin de clulas B. Las clulas B se han implicado en la modulacin de la respuesta inmunitaria a los tumores. De hecho, la secrecin de anticuerpos antitumorales por parte de las clulas B es un potente mecanismo de control tumoral. Es bien sabido que la produccin de anticuerpos especficos de tumores puede desencadenar que las clulas asesinas naturales se unan al dominio constante de los anticuerpos, lo que da como resultado la lisis de las clulas tumorales a travs de la citotoxicidad mediada por clulas dependiente de anticuerpos (ADCC). Por lo tanto, las composiciones de la invencin pueden efectuar el tratamiento del cncer a travs de la modulacin apropiada de la respuesta de las clulas B asegurando respuestas inmunitarias antitumorales aumentadas.</span>As noted above, IL-8 secretion increases B cell proliferation. B cells have been implicated in modulating the immune response to tumors. In fact, the secretion of antitumor antibodies by B cells is a powerful mechanism of tumor control. It is well known that the production of tumor-specific antibodies can trigger natural killer cells to bind to the constant domain of antibodies, resulting in lysis of tumor cells through antibody-dependent cell-mediated cytotoxicity ( ADCC). Therefore, the compositions of the invention can effect the treatment of cancer through the appropriate modulation of the B cell response ensuring increased anti-tumor immune responses.</span>
  </p>
  <p id="p0748" num="0748" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En base al hecho de que el mecanismo patolgico de la mayora de los cnceres implica la evasin de la vigilancia por parte del sistema inmunitario del husped, cualquier mecanismo implicado en la estimulacin de la respuesta inmunitaria tendra un impacto teraputico beneficioso. Por lo tanto, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de varios tipos de cncer.</span>Based on the fact that the pathological mechanism of most cancers involves evasion of vigilance by the host's immune system, any mechanism involved in stimulating the immune response would have a beneficial therapeutic impact. Therefore, the compositions of the invention are expected to be useful in the treatment or prevention of various types of cancer.</span>
  </p>
  <p id="p0749" num="0749" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 17 - Anlisis de metabolitos</span>Example 17 - Analysis of metabolites</span>
      </i>
    </b>
  </p>
  <p id="p0750" num="0750" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0751" num="0751" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El microbiota intestinal, con su inmensa diversidad y capacidad metablica, representa un enorme depsito metablico para la produccin de una gran variedad de molculas. Los inventores buscaban determinar qu cidos grasos de cadena corta y cidos grasos de cadena media son producidos y consumidos por la cepa NCIMB 42787 de <i class="style-scope patent-text">M.massiliensis </i>y otras cepas de <i class="style-scope patent-text">M.massiliensis </i>identificadas en la presente como Ref 1, Ref 2 y Ref 3.</span>The gut microbiota, with its immense diversity and metabolic capacity, represents an enormous metabolic reservoir for the production of a wide variety of molecules. The inventors sought to determine which short chain fatty acids and medium chain fatty acids are produced and consumed by M.massiliensis strain NCIMB <i class="style-scope patent-text">42787</i> and other <i class="style-scope patent-text">M.massiliensis</i> strains identified herein as Ref 1, Ref 2 and Ref 3.</span>
  </p>
  <p id="p0752" num="0752" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Material y mtodos</span>Material and methods</span>
    </i>
  </p>
  <p id="p0753" num="0753" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cultivo bacteriano y recogida de sobrenadante libre de clulas</span>Bacterial culture and collection of cell-free supernatant</span>
    </i>
  </p>
  <p id="p0754" num="0754" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los cultivos puros de bacterias se cultivaron anaerbicamente en caldo YCFA+ hasta que alcanzaron su fase de crecimiento estacionario. Los cultivos se centrifugaron a 5000 x g durante 5 minutos y el sobrenadante libre de clulas (CFS) se filtr usando un filtro de 0,2 pM (Millipore, Reino Unido). Se almacenaron alcuotas de 1 ml de CFS a -80 C hasta su uso. El butirato de sodio, el cido hexanoico y el valrico se obtuvieron de Sigma Aldrich (Reino Unido) y se prepararon suspensiones en caldo YCFA+.</span>Pure cultures of bacteria were grown anaerobically in YCFA+ broth until they reached their stationary growth phase. Cultures were centrifuged at 5000 x g for 5 minutes and cell free supernatant (CFS) was filtered using a 0.2 pM filter (Millipore, UK). Aliquots of 1 ml of CFS were stored at -80C until use. Sodium butyrate, hexanoic acid and valeric acid were obtained from Sigma Aldrich (UK) and suspensions were prepared in YCFA+ broth.</span>
  </p>
  <p id="p0755" num="0755" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuantificacin de SCFA y MCFA de sobrenadantes bacterianos</span>SCFA and MCFA quantification of bacterial supernatants</span>
    </i>
  </p>
  <p id="p0756" num="0756" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizaron y cuantificaron los cidos grasos de cadena corta (SCFA) y los cidos grasos de cadena media (MCFA) de sobrenadantes bacterianos mediante MS Omics APS de la siguiente manera. Las muestras se acidificaron usando cido clorhdrico y se aadieron estndares internos marcados con deuterio. Todas las muestras se analizaron en un orden aleatorio. El anlisis se realiz usando una columna de alta polaridad (Zebron ZB-FFAP, GC Cap. 30 m x 0,25 mm x 0,25 pm) instalada en un GC (7890B, Agilent) acoplado a un detector de cuadropolo (59977B, Agilent). El sistema fue controlado por ChemStation (Agilent). Los datos sin procesar se convirtieron al formato netCDF usando Chemstation (Agilent), antes de que los datos fueran importados y procesados en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito en [128].</span>Short chain fatty acids (SCFA) and medium chain fatty acids (MCFA) of bacterial supernatants were analyzed and quantified by MS Omics APS as follows. Samples were acidified using hydrochloric acid and deuterium-labelled internal standards were added. All samples were analyzed in a random order. Analysis was performed using a high polarity column (Zebron ZB-FFAP, GC Cap. 30 m x 0.25 mm x 0.25 pm) installed on a GC (7890B, Agilent) coupled to a quadrupole detector (59977B, Agilent). The system was controlled by ChemStation (Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described in [128].</span>
  </p>
  <p id="p0757" num="0757" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0758" num="0758" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se muestra en las Figuras 54-56, la cepa 42787 produce cido valrico, butirato y cido hexanoico y consume propionato y acetato. Los inventores tambin descubrieron otras cepas de la especie <i class="style-scope patent-text">M. massiliensis </i>que producen niveles comparables de cido valrico, cido hexanoico y butirato y que consumen cantidades similares de acetato y propionato.</span>As shown in Figures 54-56, strain 42787 produces valeric acid, butyrate, and hexanoic acid and consumes propionate and acetate. The inventors also discovered other strains of the <i class="style-scope patent-text">M. massiliensis</i> species that produce comparable levels of valeric acid, hexanoic acid, and butyrate and that consume similar amounts of acetate and propionate.</span>
  </p>
  <p id="p0759" num="0759" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 18 - Supresin de enolasa 2 </span>Example 18 - Deletion of enolase 2</span>
      </i>
    </b>
    
  </p>
  <p id="p0760" num="0760" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 57 demuestra que MRx0029 tiene un efecto estadsticamente significativo que suprime la enolasa especfica de neuronas (NSE)/enolasa 2. Se cree que la NSE respalda las demandas metablicas de las clulas tumorales aumentadas, protege a las clulas tumorales de condiciones estresantes y promueve su invasin y migracin [129]. Tambin est implicado en la progresin del melanoma metastsico [130], la supervivencia y la progresin en el cncer de pulmn de clulas pequeas [131 ] y el pronstico del carcinoma de pulmn adenoescamoso [132]. Por lo tanto, se espera que las composiciones de la invencin sean eficaces para tratar y prevenir el cncer, en particular, melanoma metastsico, cncer de pulmn de clulas pequeas y carcinoma de pulmn adenoescamoso.</span>Figure 57 demonstrates that MRx0029 has a statistically significant effect in suppressing neuron-specific enolase (NSE)/enolase 2. NSE is believed to support increased tumor cell metabolic demands, protect tumor cells from stressful conditions, and promote their invasion and migration [129]. It is also implicated in metastatic melanoma progression [130], survival and progression in small cell lung cancer [131], and adenosquamous lung carcinoma prognosis [132]. Therefore, the compositions of the invention are expected to be effective in treating and preventing cancer, in particular, metastatic melanoma, small cell lung cancer, and adenosquamous lung carcinoma.</span>
  </p>
  <p id="p0761" num="0761" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 19 - Anlisis de metabolitos</span>Example 19 - Analysis of metabolites</span>
      </i>
    </b>
  </p>
  <p id="p0762" num="0762" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems de los datos proporcionados en el Ejemplo 17, la Figura 58 demuestra qu otros cidos grasos de cadena corta son producidos y consumidos por la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>y otras cepas depositadas con los nmeros de registro NCIMB 43385, Nc IMB 43388 y NCIMB 43389.</span>In addition to the data provided in Example 17, Figure 58 demonstrates what other short chain fatty acids are produced and consumed by <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 and other strains deposited under accession numbers NCIMB 43385, Nc IMB 43388 and NCIMB 43389.</span>
  </p>
  <p id="p0763" num="0763" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa de <i class="style-scope patent-text">M. massiliensis </i>NCIMB 42787 reduce el cido frmico a la vez que aumenta los niveles de cido 2-metil-propanoico y cido 3-metil-butanoico (Figura 58). Por lo tanto, la cepa NCIMB 42787 produce cido 2-metil-propanoico y cido 3-metil-butanoico y consume cido frmico. Los inventores tambin descubrieron que otras de las cepas depositadas producen niveles comparables de cido 2-metil-propanoico y cido 3-metil-butanoico y consumen cantidades similares de cido frmico.</span> <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 reduces formic acid while increasing levels of 2-methyl-propanoic acid and 3-methyl-butanoic acid (Figure 58). Therefore, the NCIMB 42787 strain produces 2-methyl-propanoic acid and 3-methyl-butanoic acid and consumes formic acid. The inventors also discovered that other of the deposited strains produce comparable levels of 2-methyl-propanoic acid and 3-methyl-butanoic acid and consume similar amounts of formic acid.</span>
  </p>
  <p id="p0764" num="0764" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 20 - Regulacin por incremento de IL-6</span>Example 20 - Upregulation of IL-6</span>
      </i>
    </b>
  </p>
  <p id="p0765" num="0765" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0766" num="0766" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investig la capacidad de las cepas bacterianas para desencadenar un aumento en la secrecin de IL-6 por la lnea celular de astrocitoma U373.</span>The ability of bacterial strains to trigger an increase in IL-6 secretion by the astrocytoma cell line U373 was investigated.</span>
  </p>
  <p id="p0767" num="0767" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Mtodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0768" num="0768" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lnea celular de astrocitoma de glioblastoma humana (U373), se mantuvieron en 25 ml de MEME 4,5 g/l de D-glucosa suplementada con 10% de FBS inactivado por calor, 4 mM de L-glutamina, 100 U/ml de penicilina, 100 gg/ml de estreptomicina y 5 gg/ml de ml de plasmocina, 1% de aminocidos no esenciales, 1% de piruvato de sodio (denominado medio de crecimiento completo).</span>Human glioblastoma astrocytoma cell line (U373), maintained in 25 ml MEME 4.5 g/l D-glucose supplemented with 10% heat-inactivated FBS, 4 mM L-glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin and 5 gg/ml plasmocin, 1% non-essential amino acids, 1% sodium pyruvate (referred to as complete growth medium).</span>
  </p>
  <p id="p0769" num="0769" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas se sembraron en placas de 24 pocillos a una densidad de 100.000 clulas/pocillo en 1ml de medio de cultivo completo y se dejaron reposar a 37C/5% de CO2 durante 72 h. El da del tratamiento, se retir el medio de cada pocillo, las clulas se enjuagaron con 0,5 ml de medio de lavado (MEME libre de suero), 0,9 ml de medio de estimulacin (medio MEME que contena FBS al 2%). Despus de una preincubacin de 1 h, las clulas se retiraron de la incubadora de CO2 y se trataron con 100 gl de sobrenadante de bacterias. Se us medio YCFA+ como control. Luego, las clulas se incubaron durante 24 h adicionales a 37 C/5% de CO2, despus de lo cual se recogieron los sobrenadantes libres de clulas y se centrifugaron a 10.000 g a 4 C durante 3 min. Las muestras se dividieron en alcuotas en microtubos de 1,5 ml y se almacenaron a -80 C para hIL-6 ELISA.</span>Cells were seeded in 24-well plates at a density of 100,000 cells/well in 1 ml of complete culture medium and left to stand at 37C/5% CO2 for 72 h. On the day of treatment, medium was removed from each well, cells were rinsed with 0.5 mL wash medium (MEME serum-free), 0.9 mL stimulation medium (MEME medium containing 2% FBS ). After a 1 h preincubation, cells were removed from the CO2 incubator and treated with 100 gl of bacterial supernatant. YCFA+ medium was used as a control. Cells were then incubated for an additional 24 h at 37C/5% CO2, after which cell-free supernatants were collected and centrifuged at 10,000 g at 4C for 3 min. Samples were aliquoted into 1.5 ml microtubes and stored at -80C for hIL-6 ELISA.</span>
  </p>
  <p id="p0770" num="0770" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados y conclusiones</span>Results and conclusions</span>
    </i>
  </p>
  <p id="p0771" num="0771" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 59 demuestra que la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>regula por incremento la secrecin de IL-6 en clulas U373 en comparacin con los controles de YCFA+ y sin tratar. Otras cepas depositadas, en particular la NCIMB 43389, tambin aumentaron la secrecin de IL-6. Las cepas depositadas adicionales son NCIMB 43385, NCIMB 43388, NCIMB 43386 y NCIMB 43387.</span>Figure 59 demonstrates that <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 up-regulates IL-6 secretion in U373 cells compared to YCFA+ and untreated controls. Other deposited strains, notably NCIMB 43389, also increased IL-6 secretion. Additional deposited strains are NCIMB 43385, NCIMB 43388, NCIMB 43386, and NCIMB 43387.</span>
  </p>
  <p id="p0772" num="0772" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La secrecin de IL-6 aumenta la proliferacin de clulas B. Como se ha descrito anteriormente, la proliferacin de clulas B aumentada puede actuar como un potente mecanismo para mejorar la respuesta inmunitaria contra un cncer (por ejemplo, a travs de la produccin de anticuerpos y la activacin de ADCC).</span>IL-6 secretion increases B-cell proliferation. As described above, increased B-cell proliferation may act as a potent mechanism to enhance the immune response against cancer (for example, through the production of antibodies). and ADCC activation).</span>
  </p>
  <p id="p0773" num="0773" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De hecho, la actividad inmunoestimuladora se demuestra, no slo por la cepa depositada, sino tambin por las cepas depositadas relacionadas. Por lo tanto, se espera que las composiciones de la invencin que comprenden cepas del gnero <i class="style-scope patent-text">Megasphaera, </i>o biotipos de las mismas, sean tiles en el tratamiento o prevencin de varios cnceres.</span>In fact, the immunostimulatory activity is demonstrated, not only by the deposited strain, but also by the related deposited strains. Therefore, compositions of the invention comprising strains of the genus <i class="style-scope patent-text">Megasphaera,</i> or biotypes thereof, are expected to be useful in the treatment or prevention of various cancers.</span>
  </p>
  <p id="p0774" num="0774" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 21 - Supresin de enolasa 2</span>Example 21 - Deletion of enolase 2</span>
      </i>
    </b>
  </p>
  <p id="p0775" num="0775" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Mtodos </span>Materials and methods</span>
    </i>
    
  </p>
  <p id="p0776" num="0776" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cultiv la lnea celular de neuroblastoma SH-SY5Y en medio MEM al 50% y mezcla de nutrientes F-12 Ham al 50% suplementado con L-glutamina 2 mM, FBS inactivado por calor al 10%, 100 U/ml de penicilina y 100 |jg/ml de estreptomicina. Las SH-SY5Y se sembraron en placas de 6 pocillos a una densidad de 0,5 x 106 clulas. Despus de 24 h, las clulas se trataron en medio de diferenciacin (medio de crecimiento que contena FBS al 1%) con sobrenadantes bacterianos al 10% o YCFA+ durante 17 h. Se recogieron las clulas y se aisl el ARN total de acuerdo con el protocolo del RNeasy mini kit (Qiagen). El ADNc se elabor usando el kit de transcripcin inversa de ADNc de alta capacidad (Applied Biosystems). La expresin gnica se midi por qPCR. Se us GAPDH como control interno. El cambio de veces se calcul de acuerdo con el mtodo 2(-ct). Los conjuntos de cebadores usados se enumeran como las SEQ ID NO: 2, 3, 13 y 14.</span>Neuroblastoma cell line SH-SY5Y was grown in 50% MEM medium and 50% F-12 Ham nutrient mix supplemented with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 U/ml penicillin and 100 |jg/ml of streptomycin. SH-SY5Ys were plated in 6-well plates at a density of 0.5 x 10 6 cells. After 24 h, cells were treated in differentiation medium (growth medium containing 1% FBS) with 10% bacterial supernatants or YCFA+ for 17 h. Cells were harvested and total RNA isolated according to the RNeasy mini kit (Qiagen) protocol. The cDNA was made using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured by qPCR. GAPDH was used as an internal control. The fold change was calculated according to the 2(-ct) method. The primer sets used are listed as SEQ ID NOs: 2, 3, 13 and 14.</span>
  </p>
  <p id="p0777" num="0777" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0778" num="0778" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 60 demuestra que la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>tiene un efecto estadsticamente significativo de supresin de la enolasa especfica de las neuronas (NSE)/enolasa 2. Adems, los inventores tambin descubrieron que las cepas de referencia depositadas desencadenan una reduccin estadsticamente significativa de la enolasa 2 en comparacin con el control de cultivo de YCFA+. En particular, las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43388, NCIMB 43389, NCI<sup class="style-scope patent-text">m </sup>B 43386 y NCI<sup class="style-scope patent-text">m </sup>B 43387 provocaron una supresin significativa de la enolasa 2.</span>Figure 60 demonstrates that <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 has a statistically significant effect of suppressing neuron-specific enolase (NSE)/enolase 2. In addition, the inventors also found that the deposited reference strains elicit a statistically significant reduction. significant increase in enolase 2 compared to the YCFA+ culture control. In particular, strains deposited under accession numbers NCIMB 43385, NCIMB 43388, NCIMB 43389, NCI <sup class="style-scope patent-text">m</sup> B 43386, and NCI <sup class="style-scope patent-text">m</sup> B 43387 caused significant suppression of enolase 2.</span>
  </p>
  <p id="p0779" num="0779" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Conclusin</span>conclusion</span>
    </i>
  </p>
  <p id="p0780" num="0780" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, de acuerdo con los comentarios del Ejemplo 18 anterior, se espera que las composiciones de la invencin, en ciertas realizaciones que comprenden las cepas de referencia ejemplares, sean eficaces para tratar y prevenir el cncer, en particular, el melanoma metastsico, el cncer de pulmn de clulas pequeas y el cncer de pulmn adenoescamoso.</span>Accordingly, based on the discussion of Example 18 above, the compositions of the invention, in certain embodiments comprising the exemplary reference strains, are expected to be effective in treating and preventing cancer, in particular, metastatic melanoma, small cell lung cancer and adenosquamous lung cancer.</span>
  </p>
  <p id="p0781" num="0781" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 22 - Regulacin por incremento de MAP2</span>Example 22 - Upregulation of MAP2</span>
      </i>
    </b>
  </p>
  <p id="p0782" num="0782" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Mtodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0783" num="0783" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La lnea celular de neuroblastoma SH-SY5Y se cultiv en medio MEM al 50% y mezcla de nutrientes F-12 Ham al 50% suplementado con L-glutamina 2 mM, FBS inactivado por calor al 10%, 100 U/ml de penicilina y 100 jg/ml de estreptomicina. Las SH-SY5Y se sembraron en placas de 6 pocillos a una densidad de 0,5 x 106 clulas. Despus de 24 h, las clulas se trataron en medio de diferenciacin (medio de crecimiento que contena FBS al 1%) con sobrenadantes bacterianos al 10% o YCFA+ durante 17 h. Se recogieron las clulas y se aisl el ARN total de acuerdo con el protocolo del RNeasy mini kit (Qiagen). El ADNc se elabor usando el kit de transcripcin inversa de ADNc de alta capacidad (Applied Biosystems). La expresin gnica se midi por qPCR. Se us GAPDH como control interno. El cambio de veces se calcul de acuerdo con el mtodo 2(-ct). Los conjuntos de cebadores usados se enumeran como las SEQ ID NO: 2, 3, 4 y 5.</span>The SH-SY5Y neuroblastoma cell line was grown in 50% MEM medium and 50% F-12 Ham nutrient mix supplemented with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 U/ml penicillin and 100 g/ml of streptomycin. SH-SY5Ys were plated in 6-well plates at a density of 0.5 x 10 6 cells. After 24 h, cells were treated in differentiation medium (growth medium containing 1% FBS) with 10% bacterial supernatants or YCFA+ for 17 h. Cells were harvested and total RNA isolated according to the RNeasy mini kit (Qiagen) protocol. The cDNA was made using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured by qPCR. GAPDH was used as an internal control. The fold change was calculated according to the 2(-ct) method. The primer sets used are listed as SEQ ID NOs: 2, 3, 4 and 5.</span>
  </p>
  <p id="p0784" num="0784" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0785" num="0785" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 61 A muestra que la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>y otras cepas depositadas desencadenan un aumento estadsticamente significativo de la expresin de MAP2 en comparacin con los controles (es decir, control negativo y control de medios). En particular, las cepas depositadas con los nmeros de registro NCIMB 43385, NCIMB 43388, NCIMB 43389, NCiMb 43386 y NCIMB 43387 provocaron un aumento significativo en la expresin de MAP2. Sobre esta base, se espera que las composiciones de la invencin sean tiles en el tratamiento o prevencin de varios tipos de cncer, en particular cnceres metastsicos, en particular melanoma metastsico.</span>Figure 61A shows that <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 and other deposited strains elicit a statistically significant increase in MAP2 expression compared to controls (ie, negative control and media control). In particular, strains deposited under accession numbers NCIMB 43385, NCIMB 43388, NCIMB 43389, NCiMb 43386, and NCIMB 43387 caused a significant increase in MAP2 expression. On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of various types of cancer, in particular metastatic cancers, in particular metastatic melanoma.</span>
  </p>
  <p id="p0786" num="0786" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 23 - Modulacin de la secrecin de citoquinas en clulas HMC3 expuestas a TNFa tras el tratamiento con la cepa NCIMB 42787 de M. massiliensis</span>Example 23 - Modulation of cytokine secretion in HMC3 cells exposed to TNFa after treatment with M. massiliensis strain NCIMB 42787</span>
      </i>
    </b>
  </p>
  <p id="p0787" num="0787" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0788" num="0788" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas HMC3 se trataron con TNFa y se midi la secrecin de IL-8 tras el tratamiento con sobrenadantes libres de clulas del cultivo en fase estacionaria de NCIMB 42787.</span>HMC3 cells were treated with TNFa and IL-8 secretion was measured after treatment with cell-free supernatants from the stationary phase culture of NCIMB 42787.</span>
  </p>
  <p id="p0789" num="0789" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Mtodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0790" num="0790" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cultivaron clulas HMC3 de microgla humana en medio EMEM suplementado con glutamina que contena FBS inactivado por calor al 15% y 100 |ug/ml de penicilina y 100 |ug/ml de estreptomicina. Las clulas HMC3 se sembraron en placas de 24 pocillos a una densidad de 50.000 clulas/pocillo. Las clulas se dejaron en una incubadora de CO2 en reposo durante 48 horas. Luego, las clulas se lavaron en EMEM en blanco y se pretrataron en medio de cultivo FBS al 2% con 10 ng/ml de TNF-a durante 1 h. Posteriormente, se aadieron sobrenadantes 
bacterianos libres de clulas al 10% para cultivos de crecimiento estacionarios de NCIMB 42787 (aislados como se ha descrito anteriormente) a pocillos tratados y no tratados con TNF-a y se incubaron en incubadora con CO2 a 37 C durante 24 h. Los sobrenadantes libres de clulas se recogieron y centrifugaron a 10.000 x g durante 3 minutos y 4 C. Las muestras se dividieron en alcuotas en microtubos de 1,5 ml y se almacenaron a -80 C para hIL-8 ELISA.</span>Human microglia HMC3 cells were cultured in glutamine-supplemented EMEM medium containing 15% heat-inactivated FBS and 100 g/ml penicillin and 100 g/ml streptomycin. HMC3 cells were seeded in 24-well plates at a density of 50,000 cells/well. Cells were left in a CO2 incubator at rest for 48 hours. Cells were then washed in blank EMEM and pretreated in 2% FBS culture medium with 10 ng/ml TNF- for 1 h. Subsequently, supernatants were added  10% cell-free bacterial cells for stationary growth cultures of NCIMB 42787 (isolated as described above) were added to TNF-a treated and untreated wells and incubated in a 37C CO 2 incubator for 24 h. Cell-free supernatants were collected and centrifuged at 10,000 xg for 3 minutes and 4C. Samples were aliquoted into 1.5 ml microtubes and stored at -80C for hIL-8 ELISA.</span>
  </p>
  <p id="p0791" num="0791" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La secrecin de IL-8 se analiz usando kits de ELISA estndar de hIL-8, de acuerdo con el protocolo del fabricante en los sobrenadantes libres de clulas de clulas HMC3 tratadas como se ha descrito anteriormente. Las muestras se midieron a 405 nm con una longitud de onda de correccin establecida a 655 nm en un lector de microplacas (iMark, Bio-Rad). Los datos sin procesar se trazaron y analizaron utilizando el software GraphPad Prism 7.</span>IL-8 secretion was assayed using standard hIL-8 ELISA kits according to the manufacturer's protocol on cell-free supernatants from HMC3 cells treated as described above. Samples were measured at 405nm with a correction wavelength set to 655nm in a microplate reader (iMark, Bio-Rad). Raw data was plotted and analyzed using GraphPad Prism 7 software.</span>
  </p>
  <p id="p0792" num="0792" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis estadstico</span>Statistic analysis</span>
  </p>
  <p id="p0793" num="0793" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media  SEM; Se us Anova unidireccional (prueba de comparacin mltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consider significativo en todos los casos.</span>Normally distributed data are presented as mean  SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0794" num="0794" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0795" num="0795" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NCIMB 42787 induce la secrecin de IL-8 en ausencia de estimulacin (Figura 61B). Como se ha indicado anteriormente, la IL-8 est implicada en la activacin del sistema inmunitario, en particular mediante la estimulacin de la proliferacin de clulas B.</span>NCIMB 42787 induces IL-8 secretion in the absence of stimulation (FIG. 61B). As indicated above, IL-8 is involved in the activation of the immune system, in particular by stimulating the proliferation of B cells.</span>
  </p>
  <p id="p0796" num="0796" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 24 - Activacin del promotor de NF-</span>Example 24 - Activation of the NF-promoter</span>
      </i>
    </b>
    <sup class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">k </span>k</span>
    </sup>
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">B en clulas HEK-TLR4 por M. massiliensis NCIMB 42787 </span>B in HEK-TLR4 cells by M. massiliensis NCIMB 42787</span>
      </i>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0797" num="0797" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para verificar si el tratamiento con NCIMB 42787 inducira la actividad del promotor NF-KB-Ap1 inducida por la participacin de TLR4, se trataron clulas F1EK-TLR4 con sobrenadantes bacterianos sin clulas para NCIMB 42787 solo o en combinacin con LPS.</span>To verify whether NCIMB 42787 treatment would induce TLR4-induced NF-KB-Ap1 promoter activity, F1EK-TLR4 cells were treated with cell-free bacterial supernatants for NCIMB 42787 alone or in combination with LPS.</span>
  </p>
  <p id="p0798" num="0798" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Mtodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0799" num="0799" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cultivaron clulas informadoras FlEK293-Blue que expresan de manera estable TLR4 humano (HEK-TLR4) de acuerdo con las instrucciones del fabricante. Brevemente, las clulas HEK-TLR4 se mantuvieron en DMEM 4,5 g/l de D-glucosa suplementada con FBS inactivado por calor al 10% (v/v), L-glutamina 4 mM, 100 U/ml de penicilina, 100 pg/ml de estreptomicina, 100 pg/ml de ml de normocina, medio de seleccin HEK-Blue 1X.</span>FlEK293-Blue reporter cells stably expressing human TLR4 (HEK-TLR4) were cultured according to the manufacturer's instructions. Briefly, HEK-TLR4 cells were maintained in DMEM with 4.5 g/l D-glucose supplemented with 10% (v/v) heat-inactivated FBS, 4 mM L-glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin, 100 pg/ml normocin ml, HEK-Blue 1X selection medium.</span>
  </p>
  <p id="p0800" num="0800" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Brevemente, las clulas se lavaron con PBS, se disociaron en PBS y se recogieron en medios de cultivo. Las clulas se sembraron en placas de 96 pocillos a una densidad de 25.000 clulas/pocillo. Para evaluar el efecto de las cepas bacterianas sobre el LPS que induce la activacin del promotor de NF-<sup class="style-scope patent-text">k</sup>B, las clulas se trataron con 10 ng/ml de LPS en presencia o ausencia de sobrenadantes al 10% (aislados como se ha descrito anteriormente) y se incubaron en una incubadora de CO2. Los tratamientos continuaron durante 22 h a 37 C y 5% de CO, despus de lo cual se realiz la deteccin de la actividad de la fosfatasa alcalina embrionaria secretada (SEAP) del sobrenadante del cultivo celular usando la solucin QUANTI-blue de acuerdo con las instrucciones del fabricante. Brevemente, se recogieron 20 pl de sobrenadante libre de clulas y se analiz la presencia de SEAP mezclndolo con 200 pl de medio de deteccin QUANTI-Blue filtrado estril. Despus de 2 h de incubacin a 37 C, se midi la densidad ptica a 655 nm en un lector de microplacas (microplaca iMark, Bio-Rad).</span>Briefly, cells were washed with PBS, dissociated in PBS and collected in culture media. Cells were seeded in 96-well plates at a density of 25,000 cells/well. To assess the effect of bacterial strains on LPS inducing NF- <sup class="style-scope patent-text">kB</sup> promoter activation, cells were treated with 10 ng/mL LPS in the presence or absence of 10% supernatants (isolated as described above). ) and incubated in a CO2 incubator. Treatments continued for 22 h at 37C and 5% CO, after which secreted embryonic alkaline phosphatase (SEAP) activity detection of cell culture supernatant was performed using QUANTI-blue solution according to the manufacturer's instructions. Briefly, 20 l of cell-free supernatant was collected and tested for the presence of SEAP by mixing with 200 l of sterile filtered QUANTI-Blue detection medium. After 2 h of incubation at 37C, the optical density at 655 nm was measured in a microplate reader (iMark microplate, Bio-Rad).</span>
  </p>
  <p id="p0801" num="0801" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis estadstico</span>Statistic analysis</span>
  </p>
  <p id="p0802" num="0802" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media  SEM; Se us Anova unidireccional (prueba de comparacin mltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consider significativo en todos los casos.</span>Normally distributed data are presented as mean  SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0803" num="0803" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0804" num="0804" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NCIMB 42787 indujo la activacin del promotor NF-KB-Ap1 por s mismo (Figura 61C).</span>NCIMB 42787 induced activation of the NF-KB-Ap1 promoter by itself (FIG. 61C).</span>
  </p>
  <p id="p0805" num="0805" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El NF-<sup class="style-scope patent-text">k</sup>B est implicado en la activacin de la respuesta inmunitaria, en particular estimulando la expresin de mediadores de la inflamacin y de citoquinas implicadas en la respuesta inmunitaria, por ejemplo, la IL-6. Como se ha indicado anteriormente, un aumento en la expresin de IL-6 ayuda a estimular el sistema inmunitario y, por lo tanto, la activacin de la va de NF-<sup class="style-scope patent-text">k</sup>B tiene actividad inmunoestimuladora. Por consiguiente, en ciertas realizaciones, las composiciones de la invencin activan la sealizacin de NF-kB y, por tanto, estimulan el sistema inmunitario. 
</span>NF- <sup class="style-scope patent-text">kB</sup> is involved in the activation of the immune response, in particular by stimulating the expression of inflammatory mediators and cytokines involved in the immune response, for example, IL-6. As noted above, an increase in IL-6 expression helps to stimulate the immune system, and thus activation of the NF- <sup class="style-scope patent-text">kB</sup> pathway has immunostimulatory activity. Accordingly, in certain embodiments, the compositions of the invention activate NF-kB signaling and thus stimulate the immune system. </span>
  </p>
  <p id="p0806" num="0806" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 25 - Las cepas de M. massiliensis producen cido butrico, valrico y hexanoico</span>Example 25 - M. massiliensis strains produce butyric, valeric and hexanoic acid</span>
      </i>
    </b>
  </p>
  <p id="p0807" num="0807" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Mtodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0808" num="0808" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La extraccin de SCFA de YCFA+, YCFA+ enriquecidos con una mezcla estndar de SCFA (cido actico 40 mM y cido frmico 20 mM, cido propinico, cido butrico, cido valrico y cido hexanoico) se realiz de acuerdo con el mtodo de De Baere et al.133.</span>SCFA extraction of YCFA+, YCFA+ spiked with SCFA standard mixture (40 mM acetic acid and 20 mM formic acid, propionic acid, butyric acid, valeric acid and hexanoic acid) was performed according to the method of De Baere et al. .133.</span>
  </p>
  <p id="p0809" num="0809" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis HPLC de SCFA</span>SCFA HPLC analysis</span>
  </p>
  <p id="p0810" num="0810" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La deteccin y cuantificacin de SCFA por HPLC se realiz de acuerdo con el mtodo de De Baere et al. 133 con ligeras modificaciones. Brevemente, el anlisis HPLC se realiz usando un sistema Waters e2695 HPLC equipado con un detector Waters Photodiode Array (PDA) 2998 (Waters Limited, Elstree, Reino Unido). El anlisis HPLC de los estndares de SCFA, SCFA extrados de los extractos de MRx0005 y MRx0029 BCFS y MRx0005 y MRx0029 hexano, ter dietlico, acetato de etilo, acetonitrilo y metanol se realizaron usando una columna LC Xselect HSS T33,5 qm 4,6 x 150 mm (Waters Limited, Elstree, Reino Unido).). El anlisis LC se realiz usando el conjunto de detectores de matriz de fotodiodos (PDA) para analizar longitudes de onda de 200-800 nm. La deteccin y cuantificacin de SCFA se realiz a 210 nm. La fase mvil consista de tampn de fosfato de sodio 25 mM en agua HPLC (pH ajustado a 3,0 usando cido fosfrico (A) y acetonitrilo (B). El mtodo de LC para la deteccin y cuantificacin de SCFA se llev a cabo usando el sistema de solventes con el siguiente gradiente: t0'A=95%, B=5%; t10' A=95%, B=5%; t30' A=30%, B=70%; t31' A=0%, B=100%; t36' A=0%, B=100%; t38' A=5%, B=95%; t60' A=5%, B=95%; caudal=lml/min.</span>Detection and quantification of SCFA by HPLC was performed according to the method of De Baere et al. 133 with slight modifications. Briefly, HPLC analysis was performed using a Waters e2695 HPLC system equipped with a Waters Photodiode Array (PDA) 2998 detector (Waters Limited, Elstree, UK). HPLC analysis of SCFA standards, SCFA extracted from MRx0005 and MRx0029 BCFS extracts and MRx0005 and MRx0029 hexane, diethyl ether, ethyl acetate, acetonitrile and methanol were performed using an Xselect HSS T33.5 qm 4 LC column, 6 x 150 mm (Waters Limited, Elstree, UK). LC analysis was performed using the photodiode array (PDA) detector array to analyze wavelengths of 200-800 nm. Detection and quantification of SCFA was performed at 210 nm. The mobile phase consisted of 25 mM sodium phosphate buffer in HPLC water (pH adjusted to 3.0 using phosphoric acid (A) and acetonitrile (B). The LC method for the detection and quantification of SCFA was carried out using the solvent system with the following gradient: t0'A=95%, B=5%; t10' A=95%, B=5%; t30' A=30%, B=70%; t31' A=0 %, B=100%, t36' A=0%, B=100%, t38' A=5%, B=95%, t60' A=5%, B=95%, flow rate=lml/min.</span>
  </p>
  <p id="p0811" num="0811" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se prepar una curva de calibracin de siete puntos para cada SCFA inyectando 20 |ul de una dilucin en serie doble de un SCFA (cido actico 40 mM y cido frmico 20 mM, cido propinico, cido butrico, cido valrico y cido hexanoico). La eficiencia de cuantificacin-extraccin se calcul mediante la siguiente frmula:</span>A seven-point calibration curve was prepared for each SCFA by injecting 20 l of a two-fold serial dilution of an SCFA (40 mM acetic acid and 20 mM formic acid, propionic acid, butyric acid, valeric acid, and hexanoic acid). The quantification-extraction efficiency was calculated using the following formula:</span>
  </p>
  <p id="p0812" num="0812" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[SCFA en YCFA+ enriquecido y extrado]/[SCFA en YCFA+ enriquecido no extrado]</span>[SCFA in YCFA+ enriched and extracted]/[SCFA in YCFA+ enriched non-extracted]</span>
  </p>
  <p id="p0813" num="0813" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se us la eficiencia de extraccin para determinar las concentraciones de SCFA individuales en cada muestra. La produccin de SCFA especficos se calcul restando la cantidad de SCFA correspondiente presente en el control de medios no enriquecidos.</span>Extraction efficiency was used to determine individual SCFA concentrations in each sample. Specific SCFA production was calculated by subtracting the amount of corresponding SCFA present in the non-enriched media control.</span>
  </p>
  <p id="p0814" num="0814" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metabolmica dirigida: metabolitos bacterianos y anlisis de cidos grasos</span>Targeted Metabolomics: Bacterial Metabolites and Fatty Acid Analysis</span>
  </p>
  <p id="p0815" num="0815" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El anlisis de las muestras se realiz por MS-Omics (Copenhague, Dinamarca). Se cre una muestra agrupada mixta (muestra QC) tomando una alcuota de cada muestra. Esta muestra se analiz con intervalos regulares a lo largo de la secuencia. Se probaron los efectos de la matriz para los compuestos cuantificados enriqueciendo la muestra QC en un mnimo de dos niveles.</span>Sample analysis was performed by MS-Omics (Copenhagen, Denmark). A mixed pooled sample (QC sample) was created by taking an aliquot of each sample. This sample was analyzed at regular intervals throughout the sequence. Matrix effects for quantified compounds were tested by spiking the QC sample by a minimum of two levels.</span>
  </p>
  <p id="p0816" num="0816" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el anlisis de metabolitos de GC, las muestras se derivatizaron con cloroformiato de metilo usando una versin ligeramente modificada del protocolo descrito por Smart et al.134. Todas las muestras se analizaron en un orden aleatorio. El anlisis se realiz usando GC (7890B, Agilent) acoplado con un detector de cuadrupolo (59977B, Agilent). Los datos sin procesar se convirtieron al formato netCDF usando Chemstation (Agilent), antes de que los datos se importaran y procesaran en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito por Johnsen et al.135.</span>For GC metabolite analysis, samples were derivatized with methyl chloroformate using a slightly modified version of the protocol described by Smart et al.134. All samples were analyzed in a random order. Analysis was performed using GC (7890B, Agilent) coupled with a quadrupole detector (59977B, Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described by Johnsen et al.135.</span>
  </p>
  <p id="p0817" num="0817" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el anlisis SCFA, las muestras se acidificaron usando cido clorhdrico y se aadieron estndares internos marcados con deuterio. El anlisis se realiz usando una columna de alta polaridad (Columna Zebron ZB-FFAP, GC Cap. 30mx0,25mmx0,25qm) instalada en un GC (7890B, Agilent) acoplado a un detector de cuadrupolo (59977B, Agilent). Los datos sin procesar se convirtieron a formato netCDF usando Chemstation (Agilent), antes de que los datos se importaran y procesaran en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito por Johnsen et al.135.</span>For SCFA analysis, samples were acidified using hydrochloric acid and deuterium-labeled internal standards were added. Analysis was performed using a high polarity column (Zebron ZB-FFAP Column, GC Cap. 30mx0.25mmx0.25qm) installed on a GC (7890B, Agilent) coupled to a quadrupole detector (59977B, Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described by Johnsen et al.135.</span>
  </p>
  <p id="p0818" num="0818" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0819" num="0819" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El anlisis de cidos grasos, usando metabolmica dirigida, demostr que NCIMB 42787 produce cido butanoico (butrico), pentanoico (valrico) y hexanoico (caproico), tanto en forma lineal como ramificada (C4-C6) (Figura 62A). Adems, la proporcin de cido 4-hidroxi-fenilactico:medio aument en el sobrenadante libre de clulas NCIMB 42787. Se us anlisis HPLC de sobrenadantes libres de clulas para monitorizar la produccin de cido frmico, actico, propinico, butrico, valrico y hexanoico (en base al tiempo de retencin y el espectro de absorbancia de SCFA relevantes) por NCIMB 42787. En la Figura 62C se informa de cromatogramas representativos para estndares de SCFA superpuestos a sobrenadantes libres de clulas NCIMB 42787 extrados para SCFA. El anlisis HPLC confirm la produccin de cido butrico, valrico y hexanoico por NCIMB 42787. 
</span>Fatty acid analysis, using directed metabolomics, showed that NCIMB 42787 produces butanoic (butyric), pentanoic (valeric), and hexanoic (caproic) acids, both in linear and branched (C4-C6) forms (FIG. 62A). In addition, the ratio of 4-hydroxy-phenylacetic acid:medium was increased in the NCIMB 42787 cell-free supernatant. HPLC analysis of cell-free supernatants was used to monitor the production of formic, acetic, propionic, butyric, valeric, and hexanoic acid ( based on relevant SCFA retention time and absorbance spectrum) by NCIMB 42787. Representative chromatograms for SCFA standards overlaid on extracted NCIMB 42787 cell-free supernatants for SCFA are reported in Figure 62C. HPLC analysis confirmed the production of butyric, valeric and hexanoic acid per NCIMB 42787. </span>
  </p>
  <p id="p0820" num="0820" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 26 - Las fracciones metanlicas de M. massiliensis que contienen butirato y valerato muestran actividad inmunoestimuladora en clulas U373</span>Example 26 - M. massiliensis Methanolic Fractions Containing Butyrate and Valerate Show Immunostimulatory Activity in U373 Cells</span>
      </i>
    </b>
  </p>
  <p id="p0821" num="0821" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para investigar la funcin de los SCFA en la reduccin de la secrecin de IL-8, se trataron clulas U373 con concentraciones crecientes de butirato de sodio (SB), valerato de sodio (SV) y cido hexanoico (HA).</span>To investigate the role of SCFAs in reducing IL-8 secretion, U373 cells were treated with increasing concentrations of sodium butyrate (SB), sodium valerate (SV), and hexanoic acid (HA).</span>
  </p>
  <p id="p0822" num="0822" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodos</span>Methods</span>
    </i>
  </p>
  <p id="p0823" num="0823" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas U373 se prepararon como se ha descrito anteriormente. Las clulas se pretrataron durante 1 h con 1 gg/ml de LPS indicado anteriormente y se incubaron a 37 C y CO2 al 5%. Despus de una preincubacin de 1 h, las clulas se retiraron de la incubadora con CO2 y se trataron con una concentracin creciente de butirato de sodio (SB), valerato de sodio (SV) y cido hexanoico (HA) recin preparados.</span>U373 cells were prepared as described above. Cells were pretreated for 1 h with 1 gg/ml LPS indicated above and incubated at 37C and 5% CO2. After a 1 h preincubation, cells were removed from the CO 2 incubator and treated with increasing concentrations of freshly prepared sodium butyrate (SB), sodium valerate (SV), and hexanoic acid (HA).</span>
  </p>
  <p id="p0824" num="0824" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis estadstico</span>Statistic analysis</span>
  </p>
  <p id="p0825" num="0825" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media  SEM; Se us Anova unidireccional (prueba de comparacin mltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consider significativo en todos los casos.</span>Normally distributed data are presented as mean  SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0826" num="0826" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados y conclusiones</span>Results and conclusions</span>
    </i>
  </p>
  <p id="p0827" num="0827" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las concentraciones probadas cubrieron el intervalo de concentraciones medidas en los sobrenadantes libres de clulas para los diferentes cidos grasos y tuvieron en cuenta el hecho de que solo se us el 10% de los sobrenadantes mencionados anteriormente en los ensayos basados en clulas. Tanto SB como SV aumentaron la secrecin de IL-8 inducida por LPS en las mismas clulas (Figura 63), lo que sugiere que la presencia de ambos SCFA probablemente contribuy a la induccin de IL-8 cuando se aade NCIMB 42787 al cultivo. HA no inhiba la secrecin de IL-8 despus del desafo con LPS. Ninguno de los SFCA probados indujo per se la secrecin de IL-8 por encima del nivel de referencia (control de clulas sin tratar). La mezcla reconstituida de los tres SCFA reprodujo la actividad biolgica del sobrenadante libre de clulas NCIMB 42787, tanto en presencia como en ausencia de LPS.</span>The concentrations tested covered the range of concentrations measured in the cell-free supernatants for the different fatty acids and took into account the fact that only 10% of the aforementioned supernatants were used in the cell-based assays. Both SB and SV increased LPS-induced IL-8 secretion in the same cells (FIG. 63), suggesting that the presence of both SCFAs likely contributed to IL-8 induction when NCIMB 42787 is added to culture. HA did not inhibit IL-8 secretion after LPS challenge. None of the SFCAs tested per se induced IL-8 secretion above the baseline level (untreated cell control). The reconstituted mixture of the three SCFAs reproduced the biological activity of the NCIMB 42787 cell-free supernatant, both in the presence and absence of LPS.</span>
  </p>
  <p id="p0828" num="0828" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, en ciertas realizaciones, el cido butrico y/o valrico estn implicados en la generacin de IL-8 y, por lo tanto, son importantes para estimular el sistema inmunitario, por ejemplo mediante la proliferacin de clulas B. Por lo tanto, en ciertas realizaciones, las cepas bacterianas de la invencin estimulan el sistema inmunitario a travs de la produccin de cido butrico y/o valrico.</span>Accordingly, in certain embodiments, butyric and/or valeric acid are involved in the generation of IL-8 and thus are important in stimulating the immune system, for example, by proliferation of B cells. Therefore, In certain embodiments, the bacterial strains of the invention stimulate the immune system through the production of butyric and/or valeric acid.</span>
  </p>
  <p id="p0829" num="0829" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 27 - Los SCFA generados por NCIMB 42787 son por lo menos parcialmente responsables de la actividad inmunoestimuladora</span>Example 27 - SCFAs generated by NCIMB 42787 are at least partially responsible for immunostimulatory activity</span>
      </i>
    </b>
  </p>
  <p id="p0830" num="0830" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introduccin</span>Introduction</span>
    </i>
  </p>
  <p id="p0831" num="0831" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para confirmar an ms si la actividad de NCIMB 42787 se deba por lo menos en parte a los SCFA, se fraccion el sobrenadante bacteriano libre de clulas con diferentes solventes de polaridad creciente. Se realiz un anlisis HPLC de los extractos brutos desproteinizados (hexano, F5; ter dietlico, F4; acetato de etilo, F3; acetonitrilo, F4; metanol, F1) de los sobrenadantes de esta cepa para analizar la complejidad bioqumica de los sobrenadantes de fase estacionaria libres de clulas de NCIMB 42787, as como para subfraccionar compuestos en base a la polaridad y la solubilidad.</span>To further confirm whether the activity of NCIMB 42787 was at least in part due to SCFAs, cell-free bacterial supernatant was fractionated with different solvents of increasing polarity. HPLC analysis of the crude deproteinized extracts (hexane, F5; diethyl ether, F4; ethyl acetate, F3; acetonitrile, F4; methanol, F1) of the supernatants of this strain was performed to analyze the biochemical complexity of phase supernatants. cell-free stationary enzyme of NCIMB 42787, as well as to subfractionate compounds based on polarity and solubility.</span>
  </p>
  <p id="p0832" num="0832" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mtodos</span>Methods</span>
    </i>
  </p>
  <p id="p0833" num="0833" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Extracciones secuenciales con solventes - preparacin de extractos brutos</span>Sequential solvent extractions - preparation of crude extracts</span>
    </i>
  </p>
  <p id="p0834" num="0834" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se extrajeron tres rplicas biolgicas de BCFS de la cepa NCIMB 42787 y YCFA+ (control de medio) secuencialmente con hexano de grado HPLC (HEX), ter dietlico (DE), acetato de etilo (EtOAc), acetonitrilo (ACN) y metanol (MeOFl). Brevemente, se colocaron 20 ml de BCFS en viales de vidrio y se extrajeron a temperatura ambiente (TA) en 20 ml de HEX en un agitador rotatorio (70 rpm) durante 30 min. Se realizaron un total de tres extracciones en cada BCFS y control de medio YCFA+. Luego, las capas acuosas restantes se extrajeron a TA en 20 ml de DE, EtOAc en un agitador rotatorio MX-RD-Pro (70 rpm) durante 30 min un total de tres veces. Los extractos combinados de cada muestra se secaron a presin reducida en un evaporador rotatorio R-300 equipado con una bomba de vaco V-300 (Bchi, Flawil, Suiza) a una temperatura que no exceda los 30 C. Los extractos resultantes se volvieron a solubilizar en 2 ml del solvente correspondiente y se dividieron en alcuotas en cuatro tubos Eppendorf de 1,5 ml (500 ml cada uno correspondiente a 5 ml de muestra original). Luego, las capas acuosas restantes se extrajeron a TA en 20 ml de DE, EtOAc en un agitador rotatorio MX-RD-Pro (70 rpm) durante 30 min un total de tres veces. Los extractos combinados de cada muestra se secaron a presin reducida en un evaporador rotatorio R-300 equipado con una bomba de vaco V-300 (Bchi, Flawil, Suiza) a una temperatura que no exceda los 
30 C. Los extractos resultantes se volvieron a solubilizar en 2 ml del solvente correspondiente y se dividieron en alcuotas en cuatro tubos Eppendorf de 1,5 ml (500 ml cada uno correspondiente a 5 ml de muestra original).</span>Three biological replicates of BCFS from strain NCIMB 42787 and YCFA+ (medium control) were extracted sequentially with HPLC-grade hexane (HEX), diethyl ether (DE), ethyl acetate (EtOAc), acetonitrile (ACN), and methanol (MeOFl). ). Briefly, 20 ml BCFS was placed in glass vials and extracted at room temperature (RT) into 20 ml HEX on a rotary shaker (70 rpm) for 30 min. A total of three extractions were performed on each BCFS and YCFA+ medium control. The remaining aqueous layers were then extracted at RT into 20 mL DE, EtOAc on MX-RD-Pro rotary shaker (70 rpm) for 30 min for a total of three times. The combined extracts of each sample were dried under reduced pressure in an R-300 rotary evaporator equipped with a V-300 vacuum pump (Bchi, Flawil, Switzerland) at a temperature not exceeding 30C. The resulting extracts were turned to be solubilized in 2 ml of the corresponding solvent and divided into aliquots in four 1.5 ml Eppendorf tubes (500 ml each corresponding to 5 ml of original sample). The remaining aqueous layers were then extracted at RT into 20 mL DE, EtOAc on MX-RD-Pro rotary shaker (70 rpm) for 30 min for a total of three times. The combined extracts of each sample were dried under reduced pressure in an R-300 rotary evaporator equipped with a V-300 vacuum pump (Bchi, Flawil, Switzerland) at a temperature not exceeding  30C. The resulting extracts were resolubilized in 2 ml of the corresponding solvent and aliquoted into four 1.5 ml Eppendorf tubes (500 ml each corresponding to 5 ml of original sample).</span>
  </p>
  <p id="p0835" num="0835" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las capas acuosas restantes se evaporaron hasta la sequedad usando un evaporador rotatorio R-300. Los extractos secos resultantes se extrajeron durante 30 min en 20 ml de ACN un total de tres veces. Los extractos de ACN se combinaron, se evaporaron hasta la sequedad usando un evaporador rotatorio, se volvieron a solubilizar en 2 ml de ACN y se dividieron en alcuotas en cuatro tubos Eppendorf de 1,5 ml (500 pl cada uno). Los extractos secos restantes (porcin insoluble en ACN de los extractos) se extrajeron luego durante 30 min en 20 ml de MeOH un total de tres veces. Los extractos de MeOH se combinaron, se evaporaron hasta la sequedad usando un evaporador rotatorio R-300, se volvieron a solubilizar en 2 ml de MeOH y se dividieron en alcuotas en cuatro tubos Eppendorf de 1,5 ml (500 ml cada uno).</span>The remaining aqueous layers were evaporated to dryness using an R-300 rotary evaporator. The resulting dry extracts were extracted for 30 min into 20 ml ACN a total of three times. The ACN extracts were combined, evaporated to dryness using a rotary evaporator, resolubilized in 2 ml ACN and aliquoted into four 1.5 ml Eppendorf tubes (500 l each). The remaining dry extracts (ACN-insoluble portion of the extracts) were then extracted for 30 min into 20 mL MeOH a total of three times. The MeOH extracts were combined, evaporated to dryness using an R-300 rotary evaporator, resolubilized in 2 mL MeOH, and aliquoted into four 1.5 mL Eppendorf tubes (500 mL each).</span>
  </p>
  <p id="p0836" num="0836" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se mantuvieron alcuotas de los extractos brutos durante la noche a -20 C induciendo la precipitacin de los componentes proteicos. Despus de la precipitacin durante la noche, cada alcuota se centrifug a 10.000 xg durante 6 min y se transfiri a un tubo nuevo de 2 ml. La precipitacin durante la noche se repiti tres veces, despus de lo cual los extractos se secaron en un RVC 2-18 CDPlus speedvac (Christ, Osterode am Harz, Alemania) y se pesaron. Todas las alcuotas secas de cada extracto se almacenaron a -80 C hasta su uso posterior. Tratamiento</span>Aliquots of crude extracts were kept overnight at -20C inducing precipitation of protein components. After overnight precipitation, each aliquot was centrifuged at 10,000 xg for 6 min and transferred to a fresh 2 ml tube. The overnight precipitation was repeated three times, after which the extracts were dried on a RVC 2-18 CDPlus speedvac (Christ, Osterode am Harz, Germany) and weighed. All dry aliquots of each extract were stored at -80C until further use. Treatment</span>
  </p>
  <p id="p0837" num="0837" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las clulas U373 se prepararon como se ha descrito anteriormente. Las clulas se pretrataron durante 1 h con 1 pg/ml de LPS como se ha indicado anteriormente. Posteriormente, las clulas se retiraron de la incubadora de CO2 y se trataron con 100 ml de las diferentes fracciones. Las fracciones de los medios se usaron como controles. Los sobrenadantes libres de clulas se recogieron 24 horas despus del tratamiento y se analizaron mediante ELISA para determinar la secrecin de IL-8 (como se ha descrito anteriormente).</span>U373 cells were prepared as described above. Cells were pretreated for 1 h with 1 pg/ml LPS as above. Subsequently, the cells were removed from the CO2 incubator and treated with 100 ml of the different fractions. Media fractions were used as controls. Cell-free supernatants were collected 24 hours after treatment and analyzed by ELISA for IL-8 secretion (as described above).</span>
  </p>
  <p id="p0838" num="0838" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anlisis estadstico</span>Statistic analysis</span>
  </p>
  <p id="p0839" num="0839" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media  SEM; Se us Anova unidireccional (prueba de comparacin mltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consider significativo en todos los casos.</span>Normally distributed data are presented as mean  SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0840" num="0840" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0841" num="0841" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El anlisis por HPLC confirm la extraccin selectiva y el fraccionamiento bruto de los compuestos presentes en los sobrenadantes desproteinizados. El NCIMB 42787 no fraccionado indujo la secrecin de IL-8 en clulas U373 tanto en presencia como en ausencia de LPS, y la misma actividad fue producida por la fraccin metanlica F1, reiterando por tanto la importante funcin de los cidos butrico y valrico en la produccin de IL-8 por estos tipos de clulas (Figura 64A y B).</span>HPLC analysis confirmed the selective extraction and crude fractionation of compounds present in the deproteinized supernatants. Unfractionated NCIMB 42787 induced IL-8 secretion in U373 cells both in the presence and absence of LPS, and the same activity was produced by the F1 methanolic moiety, thus reiterating the important role of butyric and valeric acids in the IL-8 production by these cell types (FIG. 64A and B).</span>
  </p>
  <p id="p0842" num="0842" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, como se ha descrito anteriormente, en ciertas realizaciones, la produccin de cido butrico y/o valrico estimul el sistema inmunitario. Por consiguiente, en ciertas realizaciones, las cepas bacterianas de la invencin estimulan el sistema inmunitario a travs de la produccin de cido butrico y/o valrico.</span>Therefore, as described above, in certain embodiments, the production of butyric and/or valeric acid stimulated the immune system. Accordingly, in certain embodiments, the bacterial strains of the invention stimulate the immune system through the production of butyric and/or valeric acid.</span>
  </p>
  <p id="p0843" num="0843" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 28 - La cepa de referencia de Megasphaera NCIMB 43387 reduce significativamente la expresin de ARNm de IDO-1 colnico en ratones BALB/c</span>Example 28 - Megasphaera Reference Strain NCIMB 43387 Significantly Reduces Colonic IDO-1 mRNA Expression in BALB/c Mice</span>
      </i>
    </b>
  </p>
  <p id="p0844" num="0844" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 65 demuestra que NCIMB 43387 provoca una reduccin significativa (cuantificada por qPCR normalizada a p-actina) en la expresin de ARNm de IDO-1 en el colon de ratones BALB/c en comparacin con el control del vehculo.</span>Figure 65 demonstrates that NCIMB 43387 causes a significant reduction (measured by qPCR normalized to p-actin) in IDO-1 mRNA expression in the colon of BALB/c mice compared to vehicle control.</span>
  </p>
  <p id="p0845" num="0845" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha implicado a IDO-1 en la promocin de la inmunosupresin en respuesta a la inflamacin o infeccin. Por consiguiente, impulsar una disminucin en la expresin de IDO-1 est asociada con la inmunoestimulacin. Adems, las reducciones en IDO-1 reducen la capacidad proliferativa y migratoria de las clulas cancerosas y mejoran la vigilancia inmunitaria contra los tumores. Por lo tanto, en ciertas realizaciones, las cepas bacterianas de la invencin sirven para reducir la expresin de IDO-1. En ciertas realizaciones, la inmunoestimulacin est asociada con la reduccin de la expresin de IDO-1. Adems, en ciertas realizaciones, las composiciones de la presente invencin previenen el crecimiento del cncer metastsico. En ciertas realizaciones, las composiciones de la presente invencin son eficaces para tratar y prevenir el cncer, en particular, el melanoma metastsico, cncer de pulmn de clulas pequeas y carcinoma de pulmn adenoescamoso a la luz de su actividad contra la metstasis <b class="style-scope patent-text"> <i class="style-scope patent-text">Ejemplo 29 - Las cepas de Megasphaera depositadas con los nmeros de registro NCIMB 43385 y NCIMB 43387 reducen la expresin del ARNm de Tph-1 colnico en ratones BALB/c</i> </b> </span>IDO-1 has been implicated in promoting immunosuppression in response to inflammation or infection. Therefore, driving a decrease in IDO-1 expression is associated with immunostimulation. In addition, reductions in IDO-1 reduce the proliferative and migratory capacity of cancer cells and improve immune surveillance against tumors. Therefore, in certain embodiments, the bacterial strains of the invention serve to reduce the expression of IDO-1. In certain embodiments, the immunostimulation is associated with the reduction of IDO-1 expression. Furthermore, in certain embodiments, the compositions of the present invention prevent the growth of metastatic cancer. In certain embodiments, the compositions of the present invention are effective in treating and preventing cancer, in particular, metastatic melanoma, small cell lung cancer, and adenosquamous lung carcinoma in light of their anti-metastatic activity. <b class="style-scope patent-text"> <i class="style-scope patent-text">Example 29 - The Megasphaera strains deposited under accession numbers NCIMB 43385 and NCIMB 43387 reduce colonic Tph-1 mRNA expression in BALB/c mice</i> </b> </span>
  </p>
  <p id="p0846" num="0846" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones BALB/c se les administr bioteraputico vivo y los tejidos se aislaron para el anlisis de la 
expresin gnica usando qPCR.</span>BALB/c mice were administered live biotherapeutic and tissues were isolated for analysis of the  gene expression using qPCR.</span>
  </p>
  <p id="p0847" num="0847" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 66 demuestra la capacidad de las composiciones de la invencin para reducir la expresin de ARNm de Tph-1 (usando la cuantificacin por qPCR normalizada a p-actina) en comparacin con el control del vehculo.</span>Figure 66 demonstrates the ability of compositions of the invention to reduce Tph-1 mRNA expression (using qPCR quantification normalized to p-actin) compared to vehicle control.</span>
  </p>
  <p id="p0848" num="0848" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sabe que las disminuciones en Tph-1 estn asociadas con una mayor resistencia al cncer y un crecimiento reducido de clulas cancerosas. Adems, una disminucin en la actividad de Tph-1 estimula el sistema inmunitario proporcionando niveles suficientes del aminocido esencial triptfano para que los mastocitos impulsen la inmunidad antitumoral. Por consiguiente, en ciertas realizaciones, las composiciones de la invencin disminuyen los niveles de expresin de Tph-1. En ciertas realizaciones, las composiciones de la invencin desencadenan la inmunoestimulacin y tratan y/o previenen las enfermedades divulgadas en el presente reduciendo los niveles de Tph-1.</span>Decreases in Tph-1 are known to be associated with increased cancer resistance and reduced cancer cell growth. Additionally, a decrease in Tph-1 activity stimulates the immune system by providing sufficient levels of the essential amino acid tryptophan for mast cells to boost antitumor immunity. Accordingly, in certain embodiments, the compositions of the invention decrease the expression levels of Tph-1. In certain embodiments, the compositions of the invention trigger immunostimulation and treat and/or prevent the diseases disclosed herein by reducing Tph-1 levels.</span>
  </p>
  <p id="p0850" num="0850" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejem plo 30 - La cepa M egasphaera depositada con e l nm ero de registro N C IM B 43385 aum enta la produccin de IF N <sup class="style-scope patent-text">y </sup>e IL -6 tras la estim ulacin con ConA de esplenocitos de ratones BALB/c</span>Example 30 - Strain M egasphaera deposited under NC registry number IM B 43385 increases IFN <sup class="style-scope patent-text">and</sup> IL-6 production after ConA stimulation of splenocytes from BALB/c mice</span>
      </i>
    </b>
  </p>
  <p id="p0851" num="0851" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas bioteraputicas vivas se seleccionaron ex vivo en cuanto a la eficacia de la produccin de marcadores inmunitarios en esplenocitos aislados de ratones BALB/c y estimulados con ConA.</span>Live biotherapeutic strains were screened ex vivo for the efficacy of production of immune markers in splenocytes isolated from BALB/c and ConA-stimulated mice.</span>
  </p>
  <p id="p0852" num="0852" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 67 muestra la capacidad de las composiciones de la invencin para aumentar significativamente la produccin de las citoquinas proinflamatorias IFNy e IL-6. Como se ha descrito anteriormente, ambas citoquinas estn implicadas en la estimulacin de la respuesta inmunitaria. Adems, IFNy tiene actividad tumoricida significativa.</span>Figure 67 shows the ability of the compositions of the invention to significantly increase the production of the proinflammatory cytokines IFN and IL-6. As described above, both cytokines are involved in the stimulation of the immune response. In addition, IFN has significant tumoricidal activity.</span>
  </p>
  <p id="p0853" num="0853" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, como se ha descrito anteriormente, en ciertas realizaciones, las composiciones de la invencin aumentan la produccin de y/o IL-6 y, por lo tanto, impulsan la estimulacin de la respuesta inmunitaria. Por consiguiente, en ciertas realizaciones, el beneficio teraputico de las composiciones de la presente invencin est relacionado con un aumento en la produccin de IFNy y/o IL-6.</span>Accordingly, as described above, in certain embodiments, the compositions of the invention increase the production of and/or IL-6 and thereby drive the stimulation of the immune response. Accordingly, in certain embodiments, the therapeutic benefit of the compositions of the present invention is related to an increase in IFN[gamma] and/or IL-6 production.</span>
  </p>
  <p id="p0855" num="0855" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejem plo 30 - La cepa de referencia de M egasphaera depositada con e l nm ero de registro N C IM B 43385 aum enta s ignificativam ente la expresin de IL -6 y CD11b</span>Example 30 - Reference strain of Megasphaera deposited under registry number NCIM B 43385 significantly increases the expression of IL-6 and CD11b</span>
      </i>
    </b>
  </p>
  <p id="p0856" num="0856" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones B ALB/c se les administr bioteraputico vivo y los tejidos se aislaron para el anlisis de la expresin gnica usando qPCR.</span>B ALB/c mice were administered live biotherapeutic and tissues were isolated for gene expression analysis using qPCR.</span>
  </p>
  <p id="p0857" num="0857" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 68 demuestra la capacidad de NCIMB 43385 para aumentar significativamente la expresin de IL-6 y CD11b en el hipocampo de ratones BALB/c en comparacin con el control del vehculo.</span>Figure 68 demonstrates the ability of NCIMB 43385 to significantly increase IL-6 and CD11b expression in the hippocampus of BALB/c mice compared to vehicle control.</span>
  </p>
  <p id="p0858" num="0858" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, como se ha descrito anteriormente, las composiciones de la presente invencin, en ciertas realizaciones, aumentan la expresin de citoquinas proinflamatorias implicadas en la estimulacin de la respuesta inmunitaria, en particular IL-6 y CD11b. En ciertas realizaciones, las composiciones de la invencin son teraputicamente eficaces a la luz del aumento en la expresin de IL-6 y CD11b.</span>Accordingly, as described above, the compositions of the present invention, in certain embodiments, increase the expression of proinflammatory cytokines involved in the stimulation of the immune response, in particular IL-6 and CD11b. In certain embodiments, the compositions of the invention are therapeutically effective in light of increased expression of IL-6 and CD11b.</span>
  </p>
  <p id="p0860" num="0860" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 31 - N C IM B 42787 aum enta la expresin de TLR4</span>Example 31 - N CIM B 42787 increases the expression of TLR4</span>
      </i>
    </b>
  </p>
  <p id="p0861" num="0861" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones BALB/c se les administr bioteraputico vivo y los tejidos se aislaron para el anlisis de la expresin gnica usando qPCR.</span>BALB/c mice were administered live biotherapeutic and tissues were isolated for gene expression analysis using qPCR.</span>
  </p>
  <p id="p0862" num="0862" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 69 demuestra la capacidad de NCIMB 42787 para aumentar significativamente la expresin de TLR4 en la amgdala de ratones BALB/c en comparacin con el control del vehculo.</span>Figure 69 demonstrates the ability of NCIMB 42787 to significantly increase TLR4 expression in the amygdala of BALB/c mice compared to vehicle control.</span>
  </p>
  <p id="p0863" num="0863" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TLR4 est asociado con la activacin de la respuesta inmunitaria. Por consiguiente, aumentar la expresin de TLR4 mejorar la inmunoestimulacin. En ciertas realizaciones, las composiciones de la invencin aumentan la expresin de TLR4. En ciertas realizaciones, el aumento de la expresin de TLR4 aumenta la respuesta inmunitaria. En ciertas realizaciones, las composiciones de la presente invencin aumentan la respuesta inmunitaria y tienen un efecto teraputico en el tratamiento de las enfermedades divulgadas en la presente a travs del aumento de la expresin de TLR4.</span>TLR4 is associated with the activation of the immune response. Therefore, increasing the expression of TLR4 will improve immunostimulation. In certain embodiments, the compositions of the invention increase the expression of TLR4. In certain embodiments, increased expression of TLR4 enhances the immune response. In certain embodiments, the compositions of the present invention enhance the immune response and have a therapeutic effect in the treatment of the diseases disclosed herein through increased expression of TLR4.</span>
  </p>
  <p id="p0864" num="0864" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Secuencias</span>sequences</span>
    </b>
  </p>
  <p id="p0865" num="0865" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 1 (secuencia de ARNr 16S de consenso para la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis) </i>
TGAGAAGCTTGCTTCTTATCGATTCTAGTGGCAAACGGGTGAGTAACGCGTAAGCAACC TGCCCTTCAGATGGGGACAACAGCTGGAAACGGCTGCTAATACCGAATACGTTCTTTCC GCCGCATGACGGGAAGAAGAAAGGGAGGCCTTCGGGCTTTCGCTGGAGGAGGGGCTTG CGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGTC TGAGAGGATGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCA GCAGTGGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAACGCCGCGTGAACGA T GAC GGC C TTCGGGTT GT A AAGTTCTGTT AT AT GGGAC GA AC AGGAC AT C GGTT AAT AC CCGGTGTCTTTGACGGTACCGTAAGAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGC GGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCGCGCAGGC GGCATCGCAAGTCGGTCTTAAAAGTGCGGGGCTTAACCCCGTGAGGGGACCGAAACTGT GA AGCTC GAGT GT C GGAGAGGA AAGC GG A ATT C CT AGT GT AGC GGT GA AAT GC GT AGA TATTAGGAGGAACACCAGTGGCGAAAGCGGCTTTCTGGACGACAACTGACGCTGAGGC GCGAAAGCCAGGGGAGCAAACGGGATTAGATACCCCGGTAGTCCTGGCCGTAAACGAT GGATACTAGGTGTAGGAGGTATCGACTCCTTCTGTGCCGGAGTTAACGCAATAAGTATC CCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCAC AAGCGGTGGAGTATGTGGTTTAATTCGACGCAACGCGAAGAACCTTACCAAGCCTTGAC ATTGATTGCTACGGAAAGAGATTTCCGGTTCTTCTTCGGAAGACAAGAAAACAGGTGGT GCACGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAA CCCCTATCTTCTGTTGCCAGCACCTCGGGTGGGGACTCAGAAGAGACTGCCGCAGACAA TGCGGAGGAAGGCGGGGATGACGTCAAGTCATCATGCCCCTTATGGCTTGGGCTACACA CGTACTACAATGGCTCTTAATAGAGGGAAGCGAAGGAGCGATCCGGAGCAAACCCCAA AAACAGAGTCCCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGCAGGAATCGCT AGTAATCGCAGGTCAGCATACTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC GTCACACCACGAAAGTCATTCACACCCGAAGCCGGTGAGGCAACCGCAAG</span>SEQ ID NO: 1 (consensus 16S rRNA sequence for <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029)</i>  TGAGAAGCTTGCTTCTTATCGATTCTAGTGGCAAACGGGTGAGTAACGCGTAAGCAACC TGCCCTTCAGATGGGGACAACAGCTGGAAACGGCTGCTAATACCGAATACGTTCTTTCC GCCGCATGACGGGAAGAAGAAAGGGAGGCCTTCGGGCTTTCGCTGGAGGAGGGGCTTG CGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGTC TGAGAGGATGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCA GCAGTGGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAACGCCGCGTGAACGA T GAC GGC C TTCGGGTT GT A AAGTTCTGTT AT AT GGGAC GA AC AGGAC AT C GGTT AAT AC CCGGTGTCTTTGACGGTACCGTAAGAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGC GGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCGCGCAGGC GGCATCGCAAGTCGGTCTTAAAAGTGCGGGGCTTAACCCCGTGAGGGGACCGAAACTGT GA AGCTC GAGT GT C GGAGAGGA AAGC GG A ATT C CT AGT GT AGC GGT GA AAT GC GT AGA TATTAGGAGGAACACCAGTGGCGAAAGCGGCTTTCTGGACGACAACTGACGCTGAGGC GCGAAAGCCAGGGGAGCAAACGGGATTAGATACCCCGGTAGTCCTGGCCGTAAACGAT GGATACTAGGTGTAGGAGGTATCGACTCCTTCTGTGCCGGAGTTAACGCAATAAGTATC CCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCAC AAGCGGTGGAGTATGTGGTTTAATTCGACGCAACGCGAAGAACCTTACCAAGCCTTGAC ATTGATTGCT ACGGAAAGAGATTTCCGGTTCTTCTTCGGAAGACAAGAAAACAGGTGGT GCACGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAA CCCCTATCTTCTGTTGCCAGCACCTCGGGTGGGGACTCAGAAGAGACTGCCGCAGACAA TGCGGAGGAAGGCGGGGATGACGTCAAGTCATCATGCCCCTTATGGCTTGGGCTACACA CGTACTACAATGGCTCTTAATAGAGGGAAGCGAAGGAGCGATCCGGAGCAAACCCCAA AAACAGAGTCCCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGCAGGAATCGCT AGTAATCGCAGGTCAGCATACTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC GTCACACCACGAAAGTCATTCACACCCGAAGCCGGTGAGGCAACCGCAAG</span>
  </p>
  <p id="p0866" num="0866" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cebadores usados para qPCR</span>Primers used for qPCR</span>
  </p>
  <p id="p0868" num="0868" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000066_0001" he="104" wi="1954" file="imgf000066_0001.tif" img-format="tif" width="7816" height="416" alt="Figure imgf000066_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000066_0001" he="104" wi="1954" file="imgf000066_0001.tif" img-format="tif" width="7816" height="416" alt="Figure imgf000066_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0870" num="0870" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 8 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el nmero de registro NCIMB43385) </span>SEQ ID NO: 8 (consensus 16S rRNA sequence for <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB43385)</span>
  </p>
  <p id="p0871" num="0871" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC 
TGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC C T GTTTT C TTGTCTTC C G A A G A A G A A C C GG A A A TC TC TTTC C GT A GC A AT C A A TGT CA A G GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG TTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTATCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCA GCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTT TGCCACTCGAATTGATAAGAAGCAAGCTTCTCATC </span>GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC  TGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC CT GTTTT C TTGTCTTC CGAAGAAGAACC GG AAA TC TC TTTC C GT A GC A AT CAA TGT CA AG GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG TTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTATCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCT CCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCA GCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTT TGCCACTCGAATTGATAAGAAGCAAGCTTCTCATC</span>
  </p>
  <p id="p0872" num="0872" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 9 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el nmero de registro NCIMB43388) GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC TGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC CTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTCAAG GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG 
TTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGTCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCAG CCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTTT GCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCT SEQ ID NO: 10 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera massilliensis </i>depositada con el nmero de registro NCIMB43389) CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGT TGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCA CCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGT CAAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTG CGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATAC TTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTT TACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGC GTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATT TCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTC CCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCT TTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCAC GTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGCC CTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTT GCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCT GGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGC CTTGGTGGGCCGTTACCCCTCCAACCAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAA AGCCCGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTA GCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCC GTTTGCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCTCGTTCGACTTGCAT SEQ ID NO: 11 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el nmero de registro NCIMB43386) 
</span>SEQ ID NO: 9 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera</i> depositada con el nmero de registro NCIMB43388) GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC TGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC CTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTCAAG GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTT AAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG  TTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGTCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCAG CCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTTT GCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCT SEQ ID NO: 10 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera massilliensis</i> depositada con el nmero de registro NCIMB43389) CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGT TGCGCTCGTTGCGGGACTTAACCCAACAT CTCACGACACGAGCTGACGACAGCCGTGCA CCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGT CAAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTG CGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATAC TTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTT TACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGC GTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATT TCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTC CCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCT TTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCAC GTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGCC CTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTT GCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCT GGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGC CTTGGTGGGCCGTTACCCCTCCAACCAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAA AGCCCGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTA GCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTC ACCC GTTTGCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCTCGTTCGACTTGCAT SEQ ID NO: 11 (consensus 16S rRNA sequence for <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB43386) </span>
  </p>
  <p id="p0873" num="0873" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTT GCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCAC CACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTC AAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGC GGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACT TATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTT ACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCG TCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTT CACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCC CCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTT TACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACG TAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTATCC TGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTG CTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTG GGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCC TTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAA GCCCGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAG CAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCG TTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTGCA SEQ ID NO: 12 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el nmero de registro NCIMB43387) TCGAACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGT GTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGA TTACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCT GTTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTAC GTGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGC ATTGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGG GTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTG CACCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAAT GTCAAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTG TGCGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGAT ACTTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCG 
TTTACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCA </span>CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTT GCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCAC CACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTC AAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGC GGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACT TATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTT ACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCG TCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTT CACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCC CCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTT TACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACG TAGTTAGCCGTGGCTTTCTCTTACGGT ACCGTCAGGGATAACGGGTATTGACCGCTATCC TGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTG CTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTG GGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCC TTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAA GCCCGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAG CAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCG TTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTGCA SEQ ID NO: 12 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera</i> depositada con el nmero de registro NCIMB43387) TCGAACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGT GTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGA TTACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCT GTTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTAC GTGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGC ATTGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGG GTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGC CGTG CACCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAAT GTCAAGGCTTGGTAAGGTTCTTCGTTGCGTCGAATTAAACCACATACTCCACCGCTTG TGCGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGAAT ACTTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCG  TTTACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCA</span>
  </p>
  <p id="p0874" num="0874" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GCGTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCA </span>GGCGTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCA</span>
  </p>
  <p id="p0875" num="0875" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TTTCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGG </span>TTTCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGG</span>
  </p>
  <p id="p0876" num="0876" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TCCCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCC </span>TCCCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCC</span>
  </p>
  <p id="p0877" num="0877" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CTTTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCA </span>CTTTAGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGCGTGCTGGCA</span>
  </p>
  <p id="p0878" num="0878" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CGTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTAT </span>CGTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTAT</span>
  </p>
  <p id="p0879" num="0879" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CCTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGT </span>CCTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGT</span>
  </p>
  <p id="p0880" num="0880" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TGCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTC </span>TGCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTC</span>
  </p>
  <p id="p0881" num="0881" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TGGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCG </span>TGGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCG</span>
  </p>
  <p id="p0882" num="0882" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CCTTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGA </span>CCTTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGA</span>
  </p>
  <p id="p0883" num="0883" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AAGCCCGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATT </span>AAGCCCGAAGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATT</span>
  </p>
  <p id="p0884" num="0884" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AGCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACC </span>AGCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACC</span>
  </p>
  <p id="p0885" num="0885" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CGTTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTTGCA</span>CGTTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTTGCA</span>
  </p>
  <p id="p0887" num="0887" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cebadores usados para qPCR de endolasa</span>Primers used for endolase qPCR</span>
  </p>
  <p id="p0889" num="0889" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000070_0001" he="52" wi="1954" file="imgf000070_0001.tif" img-format="tif" width="7816" height="208" alt="Figure imgf000070_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000070_0001" he="52" wi="1954" file="imgf000070_0001.tif" img-format="tif" width="7816" height="208" alt="Figure imgf000070_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0892" num="0892" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REFERENCIAS</span>REFERENCES</span>
    </b>
  </p>
  <p id="p0894" num="0894" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[1] Spor et al. (2011) Nat Rev Microbiol. 9(4):279-90.</span>[1] Spor et al. (2011) Nat Rev Microbiol. 9(4):279-90.</span>
  </p>
  <p id="p0895" num="0895" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[2] Eckburg et al. (2005) Science. 10;308(5728):1635-8.</span>[2] Eckburg et al. (2005) Science. 10;308(5728):1635-8.</span>
  </p>
  <p id="p0896" num="0896" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[3] Macpherson et al. (2001) Microbes Infect. 3(12):1021-35</span>[3] Macpherson et al. (2001) Microbes Infect. 3(12):1021-35</span>
  </p>
  <p id="p0897" num="0897" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[4] Macpherson et al. (2002) Cell Mol Life Sci. 59(12):2088-96.</span>[4] Macpherson et al. (2002) Cell Mol Life Sci. 59(12):2088-96.</span>
  </p>
  <p id="p0898" num="0898" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[5] Mazmanian et al. (2005) Cell 15;122(1 ):107-18.</span>[5] Mazmanian et al. (2005) Cell 15;122(1):107-18.</span>
  </p>
  <p id="p0899" num="0899" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[6] Frank et al. (2007) PNAS 104(34):13780-5.</span>[6] Frank et al. (2007) PNAS 104(34):13780-5.</span>
  </p>
  <p id="p0900" num="0900" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[7] Scanlan et al. (2006) J Clin Microbiol. 44(11 ):3980-8.</span>[7] Scanlan et al. (2006) J Clin Microbiol. 44(11):3980-8.</span>
  </p>
  <p id="p0901" num="0901" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[8] Kang et al. (2010) Inflamm Bowel Dis. 16(12):2034-42.</span>[8] Kang et al. (2010) Inflamm Bowel Dis. 16(12):2034-42.</span>
  </p>
  <p id="p0902" num="0902" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[9] Machiels et al. (2013) Gut. 63(8):1275-83.</span>[9] Machiels et al. (2013) Gut. 63(8):1275-83.</span>
  </p>
  <p id="p0903" num="0903" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[10] WO 2013/050792</span>[10] WO 2013/050792</span>
  </p>
  <p id="p0904" num="0904" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[11 ] WO 03/046580</span>[11] WO 03/046580</span>
  </p>
  <p id="p0905" num="0905" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[12] WO 2013/008039</span>[12] WO 2013/008039</span>
  </p>
  <p id="p0906" num="0906" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[13] WO 2014/167338</span>[13] WO 2014/167338</span>
  </p>
  <p id="p0907" num="0907" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[14] Goldin and Gorbach (2008) Clin Infect Dis. 46 Suppl 2:S96-100.</span>[14] Goldin and Gorbach (2008) Clin Infect Dis. 46 Suppl 2:S96-100.</span>
  </p>
  <p id="p0908" num="0908" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[15] Azad et al. (2013) BMJ. 347:f6471.</span>[15] Azad et al. (2013) BMJ. 347:f6471.</span>
  </p>
  <p id="p0909" num="0909" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[16] Padmanabhan et al. (2013) Standards in Genomic Sciences 8:525-538</span>[16] Padmanabhan et al. (2013) Standards in Genomic Sciences 8:525-538</span>
  </p>
  <p id="p0910" num="0910" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[17] Masco et al. (2003) Systematic and Applied Microbiology, 26:557-563.</span>[17] Masco et al. (2003) Systematic and Applied Microbiology, 26:557-563.</span>
  </p>
  <p id="p0911" num="0911" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[18] Srutkov et al. (2011) J. Microbiol. Methods, 87(1):10-6.</span>[18] Srutkov et al. (2011) J. Microbiol. Methods, 87(1):10-6.</span>
  </p>
  <p id="p0912" num="0912" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[19] Kondelkov et al. (2010) Acta Medica (Hradec Kralove).;53(2):73-7.</span>[19] Kondelkov et al. (2010) Acta Medica (Hradec Kralove).;53(2):73-7.</span>
  </p>
  <p id="p0913" num="0913" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[20] Zhang et al. (2016) BMC Gastroenterol.; 16: 84.</span>[20] Zhang et al. (2016). BMC Gastroenterol.; 16:84.</span>
  </p>
  <p id="p0914" num="0914" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[21] Ren and Torres (2009) Brain Res Rev.;60(1):57-64</span>[21] Ren and Torres (2009) Brain Res Rev.;60(1):57-64</span>
  </p>
  <p id="p0915" num="0915" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[22] Martinon et al. (2002) Mol Cell.;10(2):417-26.</span>[22] Martinon et al. (2002) MolCell.;10(2):417-26.</span>
  </p>
  <p id="p0916" num="0916" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[23] Murphy et al. (2003) J Exp Med. 2003; 198(12): 1951-1957.</span>[23] Murphy et al. (2003) J Exp Med. 2003; 198(12): 1951-1957.</span>
  </p>
  <p id="p0917" num="0917" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[24] Chan et al. (2006) J Exp Med.; 203(12): 2577-2587.</span>[24] Chan et al. (2006) J Exp Med.; 203(12): 2577-2587.</span>
  </p>
  <p id="p0918" num="0918" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">[25] </i>The Immune Response Basic and Clinical Principles, 1a Edicin (2006)</span> <i class="style-scope patent-text">[25]</i> The Immune Response Basic and Clinical Principles, 1st Edition (2006)</span>
  </p>
  <p id="p0919" num="0919" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[26] Hoover et al. (2002) J Biol Chem. 277(40):37647-54.</span>[26] Hoover et al. (2002) J Biol Chem. 277(40):37647-54.</span>
  </p>
  <p id="p0920" num="0920" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[27] Kaser et al. (2004) J Clin Immunol.;24(1):74-85.</span>[27] Kaser et al. (2004) J Clin Immunol.;24(1):74-85.</span>
  </p>
  <p id="p0921" num="0921" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[28] Gaur and Aggarwal (2003). Biochem Pharmacol.;66(8):1403-8.</span>[28] Gaur and Aggarwal (2003). Biochem Pharmacol.;66(8):1403-8.</span>
  </p>
  <p id="p0922" num="0922" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[29] Wang and Lin (2008) Acta Pharmacol Sin.; 29(11): 1275-1288.</span>[29] Wang and Lin (2008) Acta Pharmacol Sin.; 29(11): 1275-1288.</span>
  </p>
  <p id="p0923" num="0923" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[30] Tanaka et al. (2014) Cold Spring Harb Perspect Biol.; 6(10): a016295.</span>[30] Tanaka et al. (2014) Cold Spring Harb Perspective Biol.; 6(10): a016295.</span>
  </p>
  <p id="p0924" num="0924" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[31] Bettelli et al. (2006) Nature 441:235-238</span>[31] Bettelli et al. (2006) Nature 441:235-238</span>
  </p>
  <p id="p0925" num="0925" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[32] Menezes and Luskin (1994) Journal of Neuroscience, 14 (9) 5399-5416;</span>[32] Menezes and Luskin (1994) Journal of Neuroscience, 14 (9) 5399-5416;</span>
  </p>
  <p id="p0926" num="0926" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[33] Bhat et al. (2006) Nucleic Acids Res.;34(13):3819-32. 
</span>[33] Bhat et al. (2006) Nucleic Acids Res.;34(13):3819-32. </span>
  </p>
  <p id="p0927" num="0927" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[34] Andreeff et al. (2003), Holland-Frei Cncer Medicine. 6a edicin.</span>[34] Andreeff et al. (2003), Holland-Frei Cancer Medicine. 6th edition.</span>
  </p>
  <p id="p0928" num="0928" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[35] Soltani MH et al, (2005) Am J Pathol;166:1841 -50</span>[35] Soltani MH et al, (2005) Am J Pathol;166:1841-50</span>
  </p>
  <p id="p0929" num="0929" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[36] Jandaghi et al. (2016) Gastroenterology;151 (6):1218-1231.</span>[36] Jandaghi et al. (2016) Gastroenterology;151(6):1218-1231.</span>
  </p>
  <p id="p0930" num="0930" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[37] Pornour et al. (2015) Recent Pat Anticancer Drug Discov.;10(2):214-23.</span>[37] Pornour et al. (2015) Recent Pat Anticancer Drug Disc.;10(2):214-23.</span>
  </p>
  <p id="p0931" num="0931" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[38] Sachlos et al. (2012) Cell.;149(6):1284-97</span>[38] Sachlos et al. (2012) Cell.;149(6):1284-97</span>
  </p>
  <p id="p0932" num="0932" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[39] Li et al. (2014), Oncotarget.;5(4):882-93.</span>[39] Li et al. (2014), Oncotarget.;5(4):882-93.</span>
  </p>
  <p id="p0933" num="0933" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[40] Visnyei et al. (2011) Mol Cancer Ther.;10(10):1818-28.</span>[40] Visnyei et al. (2011) Mol Cancer Ther.;10(10):1818-28.</span>
  </p>
  <p id="p0934" num="0934" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[41] Cheng et al. (2015) Cell Death Dis.;6:e1753</span>[41] Cheng et al. (2015) Cell Death Dis.;6:e1753</span>
  </p>
  <p id="p0935" num="0935" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[42] Shin et al. (2012) Biol Pharm Bull. ;35(7):1069-75.</span>[42] Shin et al. (2012) BiolPharm Bull. ;35(7):1069-75.</span>
  </p>
  <p id="p0936" num="0936" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[43] Chen et al. (2011) PLoS One.;6(11):e27186</span>[43] Chen et al. (2011) PLoS One.;6(11):e27186</span>
  </p>
  <p id="p0937" num="0937" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[44] Arvigo et al. (2010) J Endocrinol. ;207(3):309-17.</span>[44] Arvigo et al. (2010) J Endocrinol. ;207(3):309-17.</span>
  </p>
  <p id="p0938" num="0938" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[45] Mao et al. (2015) J Obstet Gynaecol Res.;41(8):1240-5</span>[45] Mao et al. (2015) J Obstet Gynaecol Res.;41(8):1240-5</span>
  </p>
  <p id="p0939" num="0939" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[46] Park et al. (2014) Oncotarget.;5(13):4929-34.</span>[46] Park et al. (2014) Oncotarget.;5(13):4929-34.</span>
  </p>
  <p id="p0940" num="0940" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[47] Spengler et al. (2011) Anticancer Res.;31(12):4201-5.</span>[47] Spengler et al. (2011) Anticancer Res.;31(12):4201-5.</span>
  </p>
  <p id="p0941" num="0941" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[48] Mu et al. (2014) Oncol Rep.;31(5):2107-14.</span>[48] Mu et al. (2014) Oncol Rep.;31(5):2107-14.</span>
  </p>
  <p id="p0942" num="0942" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[49] Prabhu et al. (2017) Neuro-Oncology, 19(6) vi60</span>[49] Prabhu et al. (2017) Neuro-Oncology, 19(6) vi60</span>
  </p>
  <p id="p0943" num="0943" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[50] Devarajan et al. (2002) Oncogene. 12;21(57):8843-51.</span>[50] Devarajan et al. (2002) Oncogene. 12;21(57):8843-51.</span>
  </p>
  <p id="p0944" num="0944" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[51] Bell and Megeney (2017) Cell Death Differ. ;24(8):1359-1368.</span>[51] Bell and Megeney (2017) Cell Death Differ. ;24(8):1359-1368.</span>
  </p>
  <p id="p0945" num="0945" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[52] Gerl and Vaux (2005) Carcinogenesis. 2005 Feb;26(2):263-70.</span>[52] Gerl and Vaux (2005) Carcinogenesis. 2005 Feb;26(2):263-70.</span>
  </p>
  <p id="p0946" num="0946" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[53] Barnes et al. (2005) Eur Respir J. 25:552-563.</span>[53] Barnes et al. (2005) Eur Respir J. 25:552-563.</span>
  </p>
  <p id="p0947" num="0947" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[54] Gray SG, Dangond F. (2006) Epigenetics. 1:67-75.</span>[54] Gray SG, Dangond F. (2006) Epigenetics. 1:67-75.</span>
  </p>
  <p id="p0948" num="0948" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[55] Grabiec et al. (2008) Arthritis Res Ther. 10:226.</span>[55] Grabiec et al. (2008) Arthritis Res Ther. 10:226.</span>
  </p>
  <p id="p0949" num="0949" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[56] Saito et al. (1999) Proc Natl Acad Sci USA. 96:4592-4597.</span>[56] Saito et al. (1999) Proc Natl Acad Sci USA. 96:4592-4597.</span>
  </p>
  <p id="p0950" num="0950" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[57] Butler et al. (2000) Cancer Res. 60:5165-5170.</span>[57] Butler et al. (2000) Cancer Res. 60:5165-5170.</span>
  </p>
  <p id="p0951" num="0951" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[58] Mwakwari et al. (2010) Curr Top Med Chem. 10 (14): 1423-40.</span>[58] Mwakwari et al. (2010) Curr Top Med Chem. 10(14): 1423-40.</span>
  </p>
  <p id="p0952" num="0952" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[59] Monneret C. (2007) Anti-Cancer Drugs. 18 (4): 363-70.</span>[59] Monneret C. (2007) Anti-Cancer Drugs. 18 (4): 363-70.</span>
  </p>
  <p id="p0953" num="0953" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[60] Chun, (2015) Arch Pharm Res. 38(6):933-49.</span>[60] Chun, (2015) Arch Pharm Res. 38(6):933-49.</span>
  </p>
  <p id="p0954" num="0954" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[61] Abel and Zukin (2008) Curr Opin Pharmacol, 2008. 8(1): 57-64.</span>[61] Abel and Zukin (2008) Curr Opin Pharmacol, 2008. 8(1): 57-64.</span>
  </p>
  <p id="p0955" num="0955" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[62] PCT/EP2018/065858</span>[62] PCT/EP2018/065858</span>
  </p>
  <p id="p0956" num="0956" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[63] Toshkov et al. (2017) Radiat Res. 187(5):570-580</span>[63] Toshkov et al. (2017) Radiat Res. 187(5):570-580</span>
  </p>
  <p id="p0957" num="0957" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[64] Tanaka and Sakaguchi (2017) Cell Res.;27(1):109-118.</span>[64] Tanaka and Sakaguchi (2017) Cell Res.;27(1):109-118.</span>
  </p>
  <p id="p0958" num="0958" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[65] Allen et al. (2010) J Exp Med.;207(5):1045-56.</span>[65] Allen et al. (2010) J Exp Med.;207(5):1045-56.</span>
  </p>
  <p id="p0959" num="0959" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[66] Haabeth et al. (2012) Oncolmmunology 1 (1):1146-1152.</span>[66] Haabeth et al. (2012) Oncolmmunology 1(1):1146-1152.</span>
  </p>
  <p id="p0960" num="0960" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[67] Lejeune et al. (2006) Cancer Immun. 6:6</span>[67] Lejeune et al. (2006) Cancer Immun. 6:6</span>
  </p>
  <p id="p0961" num="0961" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[68] Pace et al. (1983) PNAS. 80:8782-6.</span>[68] Pace et al. (1983) PNAS. 80:8782-6.</span>
  </p>
  <p id="p0962" num="0962" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[69] Sgadari et al. (1996) PNAS. 93:13791-6.</span>[69] Sgadari et al. (1996) PNAS. 93:13791-6.</span>
  </p>
  <p id="p0963" num="0963" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[70] Arenberg et al. (1996) J. Exp. Med. 184:981-92.</span>[70] Arenberg et al. (1996) J. Exp. Med. 184:981-92.</span>
  </p>
  <p id="p0964" num="0964" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[71] Sgadari et al. (1997) Blood. 89:2635-43.</span>[71] Sgadari et al. (1997) Blood. 89:2635-43.</span>
  </p>
  <p id="p0965" num="0965" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[72] Liu et al., (2018) Acta Pharmaceutica Sinica B; 8, 4; 552-562</span>[72] Liu et al., (2018) Acta Pharmaceutica Sinica B; 8, 4; 552-562</span>
  </p>
  <p id="p0966" num="0966" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[73] Jones et al. (2017). J Clin Oncol. 2017 Aug 10; 35(23): 2624-2630</span>[73] Jones et al. (2017). J Clin Oncol. 2017 Aug 10; 35(23): 2624-2630</span>
  </p>
  <p id="p0967" num="0967" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[74] Ascierto et al. (2012) Journal of Translational Medicine. 10, 85</span>[74] Ascerto et al. (2012) Journal of Translational Medicine. 10, 85</span>
  </p>
  <p id="p0968" num="0968" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[75] https://www.uniprot.org/uniprot/P15056</span>[75] https://www.uniprot.org/uniprot/P15056</span>
  </p>
  <p id="p0969" num="0969" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[76] Soltani MH et al, (2005) Am J Pathol;166:1841-50</span>[76] Soltani MH et al, (2005) Am J Pathol;166:1841-50</span>
  </p>
  <p id="p0970" num="0970" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[77] Xie (2016); Med Res Rev; 36,2: 300-312</span>[77] Xie (2016); Med Res Rev; 36.2: 300-312</span>
  </p>
  <p id="p0971" num="0971" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[78] Bloch et al. (2016) Eur Cytokine Netw.;27(3):63-67</span>[78] Bloch et al. (2016) Eur Cytokine Netw.;27(3):63-67</span>
  </p>
  <p id="p0972" num="0972" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[79] Mohanty et al. (2015) J Infect Dis, 211(7) 1174-1184.</span>[79] Mohanty et al. (2015) J Infect Dis, 211(7) 1174-1184.</span>
  </p>
  <p id="p0973" num="0973" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[80] Fernandez-Ruiz et al.,(2015) Vaccine 201533(51)</span>[80] Fernandez-Ruiz et al.,(2015) Vaccine 201533(51)</span>
  </p>
  <p id="p0974" num="0974" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[81] Morel et al., (2011) Vaccine, 29(13) 2461-2473.</span>[81] Morel et al., (2011) Vaccine, 29(13) 2461-2473.</span>
  </p>
  <p id="p0975" num="0975" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[82] Leal et al.,(2001) Immunol 103(3) 375-381</span>[82] Leal et al.,(2001) Immunol 103(3) 375-381</span>
  </p>
  <p id="p0976" num="0976" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[83] Knudsen et al. (2016), Sci Reps, 6 (19570).</span>[83] Knudsen et al. (2016), Sci Reps, 6 (19570).</span>
  </p>
  <p id="p0977" num="0977" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[84] Su et al.,(2008) Vaccine 26(40), 5111 -22</span>[84] Su et al.,(2008) Vaccine 26(40), 5111-22</span>
  </p>
  <p id="p0978" num="0978" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[85] Song, Mol Ther 2007</span>[85] Song, Mol Ther 2007</span>
  </p>
  <p id="p0979" num="0979" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[86] Li et al, (2007) J Immunol, 178(8), 5271-5276</span>[86] Li et al, (2007) J Immunol, 178(8), 5271-5276</span>
  </p>
  <p id="p0980" num="0980" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[87] Coffman et al.,(2012) Immunity 33(4) 492-503</span>[87] Coffman et al.,(2012) Immunity 33(4) 492-503</span>
  </p>
  <p id="p0981" num="0981" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[88] Ruan et al. (2014) Acta Virol. 58(4):356-8</span>[88] Ruan et al. (2014) Act Virol. 58(4):356-8</span>
  </p>
  <p id="p0982" num="0982" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[89] Wang et al. (2016) Oncotarget. 20; 7(51)</span>[89] Wang et al. (2016) Oncotarget. twenty; 7(51)</span>
  </p>
  <p id="p0983" num="0983" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[90] Fraietta, Nat Med 2018</span>[90] Fraietta, NatMed 2018</span>
  </p>
  <p id="p0984" num="0984" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[91] Zhou, Blood 2010</span>[91] Zhou, Blood 2010</span>
  </p>
  <p id="p0985" num="0985" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[92] Glenn and Whartenby (2014) World J Stem Cells.; 6(5): 526-539.</span>[92] Glenn and Whartenby (2014) World J Stem Cells.; 6(5): 526-539.</span>
  </p>
  <p id="p0986" num="0986" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[93] Heng et al. (2004) Cardiovasc Res. 2004 Apr 1 ;62(1):34-42.</span>[93] Heng et al. (2004) Cardiovasc Res. 2004 Apr 1;62(1):34-42.</span>
  </p>
  <p id="p0987" num="0987" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[94] Fulop et al</span>[94] Fulop et al</span>
  </p>
  <p id="p0988" num="0988" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[95] Bektas et al. (2017) J Leukoc Biol.;102(4):977-988.</span>[95] Bektas et al. (2017) J Leukoc Biol.;102(4):977-988.</span>
  </p>
  <p id="p0989" num="0989" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[96] Fulop et al (2016) Rev Invest Clin.;68(2):84-91.</span>[96] Fulop et al (2016) Rev Invest Clin.;68(2):84-91.</span>
  </p>
  <p id="p0990" num="0990" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[97] Fulop et al. (2018) Front lmmunol.;8:1960.</span>[97] Fulop et al. (2018) Front immunol.;8:1960.</span>
  </p>
  <p id="p0991" num="0991" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[98] Miyamoto-Shinohara et al. (2008) J. Gen. Appl. Microbiol., 54, 9-24. 
</span>[98] Miyamoto-Shinohara et al. (2008) J. Gen. Appl. Microbiol., 54, 9-24.
</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(16)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Spanish</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM330793482" lang="EN" load-source="google" class="style-scope patent-text">
  <claim-statement class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REIVINDICACIONES
  </span></span></claim-statement>
  <claim id="clm-0001" num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera</i>, para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16S que es por lo menos un 97% idntica a la SEQ ID NO: 1.</span>1. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO: 1.</span>
    </claim-text>
  </claim>
  <claim id="clm-0002" num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Una composicin que comprende una cepa bacteriana del gnero <i class="style-scope patent-text">Megasphaera</i>, en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 95% idntica a la SEQ ID NO: 1; (a) para su uso en el tratamiento o prevencin del cncer, (b) para su uso en el tratamiento, prevencin o retraso de la inmunosenescencia, (c) para su uso como adyuvante de vacunas, o (d) para su uso en terapia con clulas T con receptores de antgenos quimricos (CAR-T), terapia de clulas madre mesenquimales (MSC), o terapia de trasplante de clulas madre; en un sujeto humano.</span>2. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1; (a) for use in the treatment or prevention of cancer, (b) for use in the treatment, prevention, or delay of immunosenescence, (c) for use as an adjuvant to vaccines, or (d) for use in chimeric antigen receptor T cell (CAR-T) therapy, mesenchymal stem cell (MSC) therapy, or stem cell transplant therapy; in a human subject.</span>
    </claim-text>
  </claim>
  <claim id="clm-0003" num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. La composicin para el uso de la reivindicacin 1 o 2, para su uso en el tratamiento o prevencin del cncer, como melanoma metastsico, cncer de mama, cncer de ovario, cncer de cuello uterino, glioblastoma, carcinoma, cncer de pulmn, leucemia linfoctica crnica, cncer de prstata, linfoma, cncer gstrico, cncer colorrectal y/o enfermedades malignas hematolgicas.</span>3. The composition for the use of claim 1 or 2, for use in the treatment or prevention of cancer, such as metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
    </claim-text>
  </claim>
  <claim id="clm-0004" num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. La composicin para el uso de acuerdo con la reivindicacin 3, en donde la composicin tiene actividad inhibidora de histona deacetilasas, y/o en donde la composicin regula por incremento citoquinas proinflamatorias.</span>4. The composition for use according to claim 3, wherein the composition has histone deacetylases inhibitory activity, and/or wherein the composition up-regulates pro-inflammatory cytokines.</span>
    </claim-text>
  </claim>
  <claim id="clm-0005" num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. La composicin para el uso de la reivindicacin 1 o 2, para su uso en el tratamiento, prevencin o retraso de la inmunosenescencia.</span>5. The composition for use of claim 1 or 2, for use in the treatment, prevention or delay of immunosenescence.</span>
    </claim-text>
  </claim>
  <claim id="clm-0006" num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. La composicin para el uso de la reivindicacin 1 o 2, para su uso como adyuvante de vacunas.</span>6. The composition for use of claim 1 or 2, for use as a vaccine adjuvant.</span>
    </claim-text>
  </claim>
  <claim id="clm-0007" num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. La composicin para el uso de la reivindicacin 1 o 2, para su uso en terapia con CAR-T, terapia con MSC o terapia de trasplante de clulas madre.</span>7. The composition for the use of claim 1 or 2, for use in CAR-T therapy, MSC therapy or stem cell transplant therapy.</span>
    </claim-text>
  </claim>
  <claim id="clm-0008" num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. La composicin para el uso de cualquier reivindicacin anterior, en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 98%, 99%, 99,5% o 99,9% idntica a cualquiera de las SEQ ID NO: 8, 9. 10, 11 o 12 o en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s representada por cualquiera de las SEQ ID NO: 8, 9, 10, 11 o 12.</span>8. The composition for the use of any preceding claim, wherein the bacterial strain has a 16s rRNA gene sequence that is at least 98%, 99%, 99.5% or 99.9% identical to any of the SEQ ID NO: 8, 9. 10, 11 or 12 or where the bacterial strain has a 16s rRNA gene sequence represented by any of SEQ ID NO: 8, 9, 10, 11 or 12.</span>
    </claim-text>
  </claim>
  <claim id="clm-0009" num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. La composicin para el uso de cualquier reivindicacin anterior, en donde la cepa bacteriana es de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>9. The composition for use of any preceding claim, wherein the bacterial strain is <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
    </claim-text>
  </claim>
  <claim id="clm-0010" num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. La composicin para el uso de cualquier reivindicacin anterior, en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s que es por lo menos un 98%, 99%, 99,5% o 99,9% idntica a la SEQ ID NO: 1 o en donde la cepa bacteriana tiene una secuencia gnica de ARNr 16s representada por la SEQ ID NO: 1; opcionalmente en donde la cepa bacteriana es la cepa depositada con el nmero de registro 42787 en el NCIMB.</span>10. The composition for the use of any preceding claim, wherein the bacterial strain has a 16s rRNA gene sequence that is at least 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: 1 or wherein the bacterial strain has a 16s rRNA gene sequence represented by SEQ ID NO: 1; optionally wherein the bacterial strain is the strain deposited under accession number 42787 with the NCIMB.</span>
    </claim-text>
  </claim>
  <claim id="clm-0011" num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. La composicin para el uso de cualquier reivindicacin anterior, en donde la composicin es para administracin oral, y/o en donde la composicin comprende uno o ms excipientes o portadores farmacuticamente aceptables, y/o en donde la cepa bacteriana est liofilizada; o un producto alimenticio que comprende dicha composicin, para el uso de cualquier reivindicacin anterior.</span>11. The composition for use of any preceding claim, wherein the composition is for oral administration, and/or wherein the composition comprises one or more pharmaceutically acceptable excipients or carriers, and/or wherein the bacterial strain is lyophilized; or a food product comprising said composition, for the use of any preceding claim.</span>
    </claim-text>
  </claim>
  <claim id="clm-0012" num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. Una composicin que comprende una clula de la cepa bacteriana definida en cualquiera de las reivindicaciones 1, 2 o 8-10 en donde la clula expresa uno o ms antgenos heterlogos; para su uso como vacuna; opcionalmente en donde la clula presenta el uno o ms antgenos heterlogos.</span>12. A composition comprising a cell of the bacterial strain defined in any of claims 1, 2 or 8-10, wherein the cell expresses one or more heterologous antigens; for use as a vaccine; optionally wherein the cell presents the one or more heterologous antigens.</span>
    </claim-text>
  </claim>
  <claim id="clm-0013" num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Una clula de la cepa bacteriana definida en cualquiera de las reivindicaciones 1, 2, o 8-10, en donde la clula expresa uno o ms antgenos heterlogos; para su como vacuna; opcionalmente en donde la clula presenta el uno o ms antgenos heterlogos.</span>13. A cell of the bacterial strain defined in any of claims 1, 2, or 8-10, wherein the cell expresses one or more heterologous antigens; for your as a vaccine; optionally wherein the cell presents the one or more heterologous antigens.</span>
    </claim-text>
  </claim>
  <claim id="clm-0014" num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Una cepa bacteriana para su uso en terapia, en donde la cepa bacteriana tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idntica a cualquiera de las SEQ ID NO: 8, 11 o 12.</span>14. A bacterial strain for use in therapy, wherein the bacterial strain has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to any one of SEQ ID NO: 8, 11 or 12.</span>
    </claim-text>
  </claim>
  <claim id="clm-0015" num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Una cepa bacteriana que tiene la secuencia de ARNr 16S representada por cualquiera de las SEQ ID NO: 8, 10, 11 o 12 para su uso en terapia.</span>15. A bacterial strain having the 16S rRNA sequence represented by any one of SEQ ID NO: 8, 10, 11 or 12 for use in therapy.</span>
    </claim-text>
  </claim>
  <claim id="clm-0016" num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. La cepa bacteriana depositada con el nmero de registro NCIMB. 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, o NCIMB 43389, para su uso en terapia. 
</span>16. The bacterial strain deposited with the registry number NCIMB. 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, or NCIMB 43389, for use in therapy.
</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (36)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPS5557520A/en"><a id="link" href="#" class="style-scope state-modifier">JPS5557520A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1978-10-26</span>
                    <span class="td style-scope patent-result">1980-04-28</span>
                    <span class="td style-scope patent-result">Nisshin Flour Milling Co Ltd</span>
                    <span class="td style-scope patent-result">Preparation of carcinostatic substance 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002080947A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002080947A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-06</span>
                    <span class="td style-scope patent-result">2002-10-17</span>
                    <span class="td style-scope patent-result">Kyodoken Institute For Animal Science Research &amp; Development</span>
                    <span class="td style-scope patent-result">Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0127916D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0127916D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-21</span>
                    <span class="td style-scope patent-result">2002-01-16</span>
                    <span class="td style-scope patent-result">Rowett Res Inst</span>
                    <span class="td style-scope patent-result">Method 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040005304A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040005304A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-08</span>
                    <span class="td style-scope patent-result">2004-01-08</span>
                    <span class="td style-scope patent-result">Mak Wood, Inc.</span>
                    <span class="td style-scope patent-result">Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0307026D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0307026D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">2003-04-30</span>
                    <span class="td style-scope patent-result">Rowett Res Inst</span>
                    <span class="td style-scope patent-result">Bacterial supplement 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN101856348A/en"><a id="link" href="#" class="style-scope state-modifier">CN101856348A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-08-29</span>
                    <span class="td style-scope patent-result">2010-10-13</span>
                    <span class="td style-scope patent-result">-</span>
                    <span class="td style-scope patent-result">The therapeutic alliance method for cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201112091D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201112091D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-07-14</span>
                    <span class="td style-scope patent-result">2011-08-31</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Bacterial strains isolated from pigs 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201117313D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201117313D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-07</span>
                    <span class="td style-scope patent-result">2011-11-16</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Bacterium for use in medicine 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112015011933A8/en"><a id="link" href="#" class="style-scope state-modifier">BR112015011933A8</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-23</span>
                    <span class="td style-scope patent-result">2022-09-20</span>
                    <span class="td style-scope patent-result">Seres Therapeutics Inc</span>
                    <span class="td style-scope patent-result">
  SYNERGIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2951283A4/en"><a id="link" href="#" class="style-scope state-modifier">EP2951283A4</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-02-04</span>
                    <span class="td style-scope patent-result">2017-01-25</span>
                    <span class="td style-scope patent-result">Seres Therapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201306536D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201306536D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-04-10</span>
                    <span class="td style-scope patent-result">2013-05-22</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Polypeptide and immune modulation 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6585041B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6585041B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-07-18</span>
                    <span class="td style-scope patent-result">2019-10-02</span>
                    <span class="td style-scope patent-result">      </span>
                    <span class="td style-scope patent-result">
  Methods for enhancing the capacity of immune cells
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN104415060A/en"><a id="link" href="#" class="style-scope state-modifier">CN104415060A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-08-30</span>
                    <span class="td style-scope patent-result">2015-03-18</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Edible composition as well as preparation method and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015038731A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015038731A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-09-12</span>
                    <span class="td style-scope patent-result">2015-03-19</span>
                    <span class="td style-scope patent-result">The Johns Hopkins University</span>
                    <span class="td style-scope patent-result">Biofilm formation to define risk for colon cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116370507A/en"><a id="link" href="#" class="style-scope state-modifier">CN116370507A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-11-25</span>
                    <span class="td style-scope patent-result">2023-07-04</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Synergistic bacterial compositions, methods of manufacture and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9650654B2/en"><a id="link" href="#" class="style-scope state-modifier">US9650654B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-06-25</span>
                    <span class="td style-scope patent-result">2017-05-16</span>
                    <span class="td style-scope patent-result">William Marsh Rice University</span>
                    <span class="td style-scope patent-result">Making C4+ products in bacteria 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10366793B2/en"><a id="link" href="#" class="style-scope state-modifier">US10366793B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-21</span>
                    <span class="td style-scope patent-result">2019-07-30</span>
                    <span class="td style-scope patent-result">uBiome, Inc.</span>
                    <span class="td style-scope patent-result">Method and system for characterizing microorganism-related conditions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10688166B2/en"><a id="link" href="#" class="style-scope state-modifier">US10688166B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-11-03</span>
                    <span class="td style-scope patent-result">2020-06-23</span>
                    <span class="td style-scope patent-result">Cerus Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for improved car-T cell therapies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MA41020A/en"><a id="link" href="#" class="style-scope state-modifier">MA41020A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-11-25</span>
                    <span class="td style-scope patent-result">2017-10-03</span>
                    <span class="td style-scope patent-result">Evelo Biosciences Inc</span>
                    <span class="td style-scope patent-result">
  PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6783247B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6783247B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-01-23</span>
                    <span class="td style-scope patent-result">2020-11-11</span>
                    <span class="td style-scope patent-result">         </span>
                    <span class="td style-scope patent-result">
  Use of short-chain fatty acids in cancer prevention
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016149449A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016149449A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-03-18</span>
                    <span class="td style-scope patent-result">2016-09-22</span>
                    <span class="td style-scope patent-result">Tufts University</span>
                    <span class="td style-scope patent-result">Compositions and methods for preventing colorectal cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MA41060B1/en"><a id="link" href="#" class="style-scope state-modifier">MA41060B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-15</span>
                    <span class="td style-scope patent-result">2019-11-29</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">
  Compositions comprising bacterial strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ME03003B/en"><a id="link" href="#" class="style-scope state-modifier">ME03003B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-11-20</span>
                    <span class="td style-scope patent-result">2018-10-20</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20180083894A/en"><a id="link" href="#" class="style-scope state-modifier">KR20180083894A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-11-24</span>
                    <span class="td style-scope patent-result">2018-07-23</span>
                    <span class="td style-scope patent-result"> , </span>
                    <span class="td style-scope patent-result">
  Designed bacterial composition
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2018008523A/en"><a id="link" href="#" class="style-scope state-modifier">MX2018008523A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-01-11</span>
                    <span class="td style-scope patent-result">2019-05-15</span>
                    <span class="td style-scope patent-result">3Plw Ltd</span>
                    <span class="td style-scope patent-result">Lactic acid-utilizing bacteria genetically modified to secrete polysaccharide-degrading enzymes. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN107028985A/en"><a id="link" href="#" class="style-scope state-modifier">CN107028985A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-02-04</span>
                    <span class="td style-scope patent-result">2017-08-11</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Application of the heavy wall mushroom probiotics in preventing and/or treating diabetes and its relevant disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20190125808A1/en"><a id="link" href="#" class="style-scope state-modifier">US20190125808A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-03-30</span>
                    <span class="td style-scope patent-result">2019-05-02</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Methods of preventing, treating and detecting colorectal cancer using butyrate producing bacteria 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9999641B2/en"><a id="link" href="#" class="style-scope state-modifier">US9999641B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-06-14</span>
                    <span class="td style-scope patent-result">2018-06-19</span>
                    <span class="td style-scope patent-result">Vedanta Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Treatment of clostridium difficile infection 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116196425A/en"><a id="link" href="#" class="style-scope state-modifier">CN116196425A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-09-27</span>
                    <span class="td style-scope patent-result">2023-06-02</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Methods of enhancing immune checkpoint blocking therapies by modulating microbiome 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018094190A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2018094190A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-11-18</span>
                    <span class="td style-scope patent-result">2018-05-24</span>
                    <span class="td style-scope patent-result">Sanford Burnham Prebys Medical Discovery Institute</span>
                    <span class="td style-scope patent-result">Gut microbiota and treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018112365A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2018112365A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-12-16</span>
                    <span class="td style-scope patent-result">2018-06-21</span>
                    <span class="td style-scope patent-result">Evelo Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018112363A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2018112363A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-12-16</span>
                    <span class="td style-scope patent-result">2018-06-21</span>
                    <span class="td style-scope patent-result">Evelo Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Methods of treating cancer using parabacteroides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RS61367B1/en"><a id="link" href="#" class="style-scope state-modifier">RS61367B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-14</span>
                    <span class="td style-scope patent-result">2021-02-26</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20200015575A/en"><a id="link" href="#" class="style-scope state-modifier">KR20200015575A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-14</span>
                    <span class="td style-scope patent-result">2020-02-12</span>
                    <span class="td style-scope patent-result">4   </span>
                    <span class="td style-scope patent-result">
  Compositions Containing Bacterial Strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202014513A/en"><a id="link" href="#" class="style-scope state-modifier">TW202014513A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-05-11</span>
                    <span class="td style-scope patent-result">2020-04-16</span>
                    <span class="td style-scope patent-result">4D</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/SG11202106230XA/en"><a id="link" href="#" class="style-scope state-modifier">SG11202106230XA</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">2021-07-29</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (10)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11492587B2/en"><a id="link" href="#" class="style-scope state-modifier">US11492587B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-01-31</span>
                    <span class="td style-scope patent-result">2022-11-08</span>
                    <span class="td style-scope patent-result">Kansas State University Research Foundation</span>
                    <span class="td style-scope patent-result">Microbial cells, methods of producing the same, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20200015575A/en"><a id="link" href="#" class="style-scope state-modifier">KR20200015575A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-14</span>
                    <span class="td style-scope patent-result">2020-02-12</span>
                    <span class="td style-scope patent-result">4   </span>
                    <span class="td style-scope patent-result">
  Compositions Containing Bacterial Strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2020004078A/en"><a id="link" href="#" class="style-scope state-modifier">MX2020004078A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-10-20</span>
                    <span class="td style-scope patent-result">2020-09-25</span>
                    <span class="td style-scope patent-result">Ms Biotech Inc</span>
                    <span class="td style-scope patent-result">Methods of producing ensiled plant materials using megasphaera elsdenii. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202014513A/en"><a id="link" href="#" class="style-scope state-modifier">TW202014513A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-05-11</span>
                    <span class="td style-scope patent-result">2020-04-16</span>
                    <span class="td style-scope patent-result">4D</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11541105B2/en"><a id="link" href="#" class="style-scope state-modifier">US11541105B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-06-01</span>
                    <span class="td style-scope patent-result">2023-01-03</span>
                    <span class="td style-scope patent-result">The Research Foundation For The State University Of New York</span>
                    <span class="td style-scope patent-result">Compositions and methods for disrupting biofilm formation and maintenance 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3893906A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3893906A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">2021-10-20</span>
                    <span class="td style-scope patent-result">4D Pharma Research Limited</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2021252861A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2021252861A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-06-11</span>
                    <span class="td style-scope patent-result">2021-12-16</span>
                    <span class="td style-scope patent-result">Evelo Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for treating diseases and disorders using megasphaera sp 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN112877275B/en"><a id="link" href="#" class="style-scope state-modifier">CN112877275B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-04</span>
                    <span class="td style-scope patent-result">2023-03-31</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">HDAC2 gene knockout BHK-21 cell line and construction method and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN112980878B/en"><a id="link" href="#" class="style-scope state-modifier">CN112980878B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-04</span>
                    <span class="td style-scope patent-result">2023-03-31</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">HDAC8 gene knockout BHK-21 cell line and construction method and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR102551061B1/en"><a id="link" href="#" class="style-scope state-modifier">KR102551061B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-05-26</span>
                    <span class="td style-scope patent-result">2023-07-03</span>
                    <span class="td style-scope patent-result"> </span>
                    <span class="td style-scope patent-result">A composition comprising SAHA as an active ingredient for inhibiting the formation of biofilm generated by Salmonella spp. 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2916601T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2916601T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-07-04</span>
                    <span class="td style-scope patent-result">
  Compositions comprising bacterial strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230173001A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230173001A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-06-08</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2988686C/en"><a id="link" href="#" class="style-scope state-modifier">CA2988686C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-01-24</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2705157T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2705157T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-03-22</span>
                    <span class="td style-scope patent-result">
  Compositions comprising bacterial strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2016278066B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2016278066B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-09-23</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3970733A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3970733A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-03-23</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210283194A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210283194A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-09-16</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/OA20345A/en"><a id="link" href="#" class="style-scope state-modifier">OA20345A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-06-02</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains. 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/OA18810A/en"><a id="link" href="#" class="style-scope state-modifier">OA18810A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-07-19</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains. 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (8)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        EP18171893<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-05-11</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        EP18178136<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-06-15</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201810386D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1810386.1A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-06-25</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201813460D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1813460.1A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-08-17</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201817642D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1817642.0A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-10-29</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201820256D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1820256.4A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201820264D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1820264.8A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2019215346A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/EP2019/062238</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2019-05-13</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu"></span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Anatomy</div>
          
            <div class="item style-scope dropdown-menu">Chemical class</div>
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          
            <div class="item style-scope dropdown-menu">Chemical group</div>
          
            <div class="item style-scope dropdown-menu">Diseases</div>
          
            <div class="item style-scope dropdown-menu">Drugs</div>
          
            <div class="item style-scope dropdown-menu">Effects</div>
          
            <div class="item style-scope dropdown-menu">Human genes</div>
          
            <div class="item style-scope dropdown-menu">Inorganic materials</div>
          
            <div class="item style-scope dropdown-menu">Methods</div>
          
            <div class="item style-scope dropdown-menu">Natural products</div>
          
            <div class="item style-scope dropdown-menu">Nutrition</div>
          
            <div class="item style-scope dropdown-menu">Polymers</div>
          
            <div class="item style-scope dropdown-menu">Proteins</div>
          
            <div class="item style-scope dropdown-menu">Species</div>
          
            <div class="item style-scope dropdown-menu">Substances</div>
          
            <div class="item style-scope dropdown-menu">Toxicity</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mixture</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">644</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bacterial effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">338</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">diseases, disorders, signs and symptoms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">119</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">116</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Megasphaera</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">71</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">16S ribosomal RNA</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">45</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">proteins and genes</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">42</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">immune system</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">33</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">stimulating effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">21</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">300</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">treatment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">295</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">204</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">187</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Megasphaera massiliensis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">173</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">prevention</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">116</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigen</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">66</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">66</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">66</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Histone deacetylase</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">61</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Histone deacetylase</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">61</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Colon cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">54</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Colorectal Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">43</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">therapeutic procedure</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">40</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Hematologic Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">35</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vaccine adjuvant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">32</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vaccine adjuvant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">32</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Ovarian neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">30</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">inhibitory effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">30</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lymphocytic Chronic B-Cell Leukemia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Ovarian cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Breast cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Breast neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cervix carcinoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Prostate cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Prostatic Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Uterine Cervical Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cervical cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">glioblastoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Stomach Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gastric cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">stomach cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lung neoplasm malignant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">24</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">B-cell chronic lymphocytic leukemia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Carcinoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chronic lymphocytic leukemia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lung cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lung neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lymphomas</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">22</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">proinflammatory effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">22</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Metastatic malignant melanoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">20</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">metastatic melanoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">20</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vaccine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pharmaceutical excipient</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">T-lymphocyte</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">14</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug carrier</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">13</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mesenchymal stem cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">stem cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Nutrition style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">food</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">adjuvant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Chimeric Antigen Receptors</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.32482061" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.32482061" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=874337561" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>